thalidomide has been researched along with Recrudescence in 543 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Thalidomide has been evaluated for the treatment of recurrent bleeding due to small-intestinal angiodysplasia (SIA), but confirmatory trials are lacking." | 9.69 | Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia. ( Chen, H; Dai, Z; Du, Y; Gao, Y; Ge, Z; Gong, S; Li, X; Li, Z; Liu, S; Lu, H; Lu, L; Shen, X; Shen, Y; Tang, M; Wu, S; Xiong, H; Xu, L; Xue, H; Yang, A; Yang, S; Zhang, Q; Zhao, R; Zhong, J; Zhong, L, 2023) |
| "Isatuximab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone for relapsed or refractory multiple myeloma." | 9.41 | Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. ( Asset, G; Baker, R; Capra, M; Dimopoulos, MA; Facon, T; Hajek, R; Kim, K; Koh, Y; Leleu, X; Macé, S; Martin, T; Martinez, G; Mikhael, J; Min, CK; Moreau, P; Oriol, A; Pour, L; Risse, ML; Špička, I; Suzuki, K; Yong, K, 2021) |
| "Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed." | 9.30 | Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. ( Avivi, I; Benyamini, N; Blacklock, H; Chanan-Khan, A; Farooqui, M; George, A; Goldschmidt, H; Iida, S; Jagannath, S; Kher, U; Larocca, A; Liao, J; Lonial, S; Marinello, P; Mateos, MV; Matsumoto, M; Ocio, EM; Oriol, A; Ribrag, V; Rodriguez-Otero, P; San Miguel, J; Schjesvold, F; Sherbenou, D; Simpson, D; Suzuki, K; Usmani, SZ, 2019) |
| "This phase 1 study investigated the safety of the anthracycline amrubicin combined with lenalidomide and dexamethasone in adults with relapsed or refractory multiple myeloma." | 9.27 | A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. ( Berube, C; Coutré, SE; Dinner, S; Dunn, TJ; Gotlib, J; Kaufman, GP; Liedtke, M; Medeiros, BC; Price, E, 2018) |
| "Circularly permuted TRAIL (CPT) has exhibited promising efficacy as a mono-therapy or in combination with thalidomide for patients with multiple myeloma (MM)." | 9.24 | Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. ( Chang, N; Chen, W; Hou, J; Jiang, B; Jiang, H; Jin, J; Ke, X; Leng, Y; Li, J; Li, W; Liu, J; Liu, L; Liu, Y; Meng, H; Pan, L; Pang, H; Qiu, L; Shen, Z; Wang, J; Wang, Z; Wei, P; Yang, L; Yang, S; Zhang, M; Zheng, X; Zhou, F, 2017) |
| "Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients with relapsed/refractory multiple myeloma with ≥2 prior lines of therapy who were refractory to their last treatment." | 9.24 | Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. ( Ahmadi, T; Arnulf, B; Chari, A; Chiu, C; Comenzo, R; Fay, JW; Ifthikharuddin, JJ; Kaufman, JL; Khokhar, NZ; Krishnan, A; Lentzsch, S; Lonial, S; Nottage, K; Suvannasankha, A; Wang, J; Weiss, BM, 2017) |
| "The randomized phase III ELOQUENT-2 study (NCT01239797) evaluated the efficacy and safety of elotuzumab + lenalidomide/dexamethasone (ELd) versus lenalidomide/dexamethasone (Ld) in relapsed/refractory multiple myeloma." | 9.24 | Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. ( Anderson, K; Beksac, M; Belch, A; Bleickardt, E; Dimopoulos, MA; Grosicki, S; Katz, J; Lonial, S; Magen, H; Mateos, MV; Moreau, P; Palumbo, A; Poulart, V; Reece, D; Richardson, P; San-Miguel, J; Sheng, J; Shpilberg, O; Singhal, A; Spicka, I; Sy, O; Walter-Croneck, A; White, D, 2017) |
| " We report a phase 1 study (NCT01241292) in which we evaluated the safety, efficacy and pharmacokinetics of elotuzumab combined with lenalidomide and dexamethasone in Japanese patients with relapsed/refractory multiple myeloma (RRMM)." | 9.24 | Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. ( Bleickardt, E; Chou, T; Iida, S; Kinoshita, G; Miyoshi, M; Nagai, H; Pandya, D; Robbins, M, 2017) |
| "We report the first clinical investigation conducted in Japan to confirm the safety, tolerability, and pharmacokinetics of ixazomib alone and combined with lenalidomide-dexamethasone (Rd) in Japanese patients with relapsed/refractory multiple myeloma." | 9.24 | Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. ( Chou, T; Handa, H; Ishizawa, K; Kase, Y; Suzuki, K; Takubo, T, 2017) |
| "The combination of lenalidomide and dexamethasone is an established treatment for patients with multiple myeloma (MM)." | 9.24 | Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. ( Baker, B; Blacklock, H; Browett, P; Cannell, P; Corbett, G; Cowan, L; Dimopoulos, MA; Fernyhough, L; Forsyth, C; Harrison, S; Henderson, R; Link, E; Miles Prince, H; Neylon, A; Quach, H; Swern, A; Trotman, J; Underhill, C, 2017) |
| "A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression-free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in patients with relapsed multiple myeloma (RMM)." | 9.24 | Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. ( Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Obreja, M; Oriol, A; Palumbo, A; Rajnics, P; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A, 2017) |
| " Of 13 assessable patients (nine with adult T-cell leukaemia-lymphoma, four with other peripheral T-cell lymphomas) receiving lenalidomide, dose-limiting toxic effects were reported in three patients during cycle 1 (one grade 4 thrombocytopenia [cohort 2], one grade 3 QT prolongation on electrocardiogram [cohort 3], and one grade 3 fatigue and grade 4 thrombocytopenia [cohort 3])." | 9.22 | Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. ( Aoki, T; Asou, N; Chen, N; Choi, I; Imaizumi, Y; Maruyama, D; Midorikawa, S; Nosaka, K; Ogura, M; Ohtsu, T; Taguchi, J; Tobinai, K; Tsukasaki, K; Uchida, T; Uike, N; Utsunomiya, A, 2016) |
| "Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM)." | 9.22 | Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. ( Anderson, KC; Chanan-Khan, AA; Chauhan, D; Hofmeister, CC; Jakubowiak, AJ; Kaufman, JL; Laubach, JP; Reich, S; Richardson, PG; Talpaz, M; Trikha, M; Zimmerman, TM, 2016) |
| " We evaluated the safety and tolerability of elotuzumab 10 mg/kg combined with thalidomide 50-200 mg and dexamethasone 40 mg (with/without cyclophosphamide 50 mg) in patients with relapsed/refractory multiple myeloma (RRMM)." | 9.22 | Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. ( Blade, J; Bleickardt, E; Gironella, M; Granell, M; Hernandez, MT; Lynch, M; Martín, J; Martinez-Lopez, J; Mateos, MV; Oriol, A; Paliwal, P; San-Miguel, J; Singhal, A, 2016) |
| "Purpose To determine the effects of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) on health-related quality of life (HR-QoL) in the Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone for the Treatment of Patients With Relapsed Multiple Myeloma (ASPIRE) trial." | 9.22 | Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. ( Buchanan, J; Cocks, K; Dimopoulos, MA; Hájek, R; Jakubowiak, AJ; Ludwig, H; Masszi, T; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Tonda, M; Xing, B; Yang, X; Zojwalla, N, 2016) |
| "Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma." | 9.22 | Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. ( Ahmadi, T; Bahlis, NJ; Ben Yehuda, D; Chiu, C; Dimopoulos, MA; Goldschmidt, H; Guckert, M; Khokhar, NZ; Komarnicki, M; Lisby, S; Moreau, P; Nahi, H; O'Rourke, L; Oriol, A; Orlowski, RZ; Plesner, T; Qin, X; Rabin, N; Reece, D; Richardson, PG; San-Miguel, J; Suzuki, K; Usmani, SZ; Yoon, SS, 2016) |
| "In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone (POM+LoDEX) improved overall survival (OS) versus high-dose dexamethasone (HiDEX) in 455 patients with relapsed and refractory multiple myeloma (RRMM) after treatment with bortezomib and lenalidomide." | 9.20 | Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. ( Akehurst, R; Delforge, M; Dhanasiri, S; Dimopoulos, MA; Facon, T; Jacques, C; Lee, D; Morgan, G; Offner, F; Oriol, A; Palumbo, A; Sternas, L; Weisel, K; Yu, X; Zaki, M, 2015) |
| "Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma." | 9.20 | Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. ( Ben-Yehuda, D; Bensinger, WI; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, AJ; Kukreti, V; Ludwig, H; Maisnar, V; Masszi, T; Mateos, MV; Mihaylov, GG; Minarik, J; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajkumar, SV; Rajnics, P; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Suvorov, A; Tonda, ME; Wang, M; Xing, B; Yang, X; Zojwalla, N, 2015) |
| "Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, has been studied in multiple myeloma (MM) but lacks significant single agent activity." | 9.19 | Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. ( Anderson, KC; Burke, JN; Cirstea, DD; Ghobrial, IM; Hari, P; Hideshima, T; Laubach, JP; Mahindra, AK; Marcheselli, R; Munshi, NC; Raje, NS; Richardson, PG; Rodig, SJ; Schlossman, RL; Scullen, TA; Weller, EA; Yee, AJ, 2014) |
| "Data from two randomized pivotal, phase 3 trials evaluating the combination of lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM) were pooled to characterize the subset of patients who achieved long-term benefit of therapy (progression-free survival ⩾ 3 years)." | 9.19 | Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. ( Baz, R; Dimopoulos, MA; Hussein, M; Li, JS; Nagarwala, Y; Swern, AS; Weiss, L, 2014) |
| "Lenalidomide (LEN) has been shown to yield red blood cell (RBC) transfusion independence in about 25% of lower risk myelodysplastic syndromes (MDS) without del(5q), but its efficacy in patients clearly refractory to erythropoiesis-stimulating agents (ESA) is not known." | 9.16 | Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. ( Banos, A; Baracco, F; Besson, C; Blanc, M; Cannas, G; Corm, S; Fenaux, P; Perrier, H; Prebet, T; Sibon, D; Slama, B; Vey, N; Wattel, E, 2012) |
| "Here we report the efficacy, safety and health-related quality-of-life (HRQoL) associated with long-term lenalidomide and dexamethasone (Len + Dex) treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the Spanish cohort of the MM-018 study." | 9.16 | Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. ( Aguado, B; Alegre, A; Cibeira, MT; Garcia-Larana, J; Knight, R; Martinez-Chamorro, C; Mateos, MV; Oriol-Rocafiguera, A; Rosettani, B; Sureda, A, 2012) |
| "The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM)." | 9.16 | Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. ( Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S, 2012) |
| "This multicenter phase 1/2 trial investigated the combination of bendamustine, lenalidomide, and dexamethasone in repeating 4-week cycles as treatment for relapsed refractory multiple myeloma (MM)." | 9.16 | Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. ( Abbas, M; Agha, M; Boyiadzis, M; Burt, S; Dai, L; Kennedy, RC; Lentzsch, S; Mapara, MY; Normolle, D; O'Sullivan, A; Pregja, SL; Roodman, GD; Shuai, Y; Waas, J; Zonder, JA, 2012) |
| "This phase I study evaluated elotuzumab, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (MM)." | 9.16 | Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. ( Facon, T; Harousseau, JL; Jagannath, S; Kaufman, JL; Leleu, X; Lonial, S; Mazumder, A; Moreau, P; Singhal, AK; Tsao, LC; Vij, R; Westland, C, 2012) |
| "Lenalidomide is effective in low-risk myelodysplastic syndromes (MDS) with deletion 5q." | 9.16 | A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. ( Borthakur, G; Chen, Y; Cortes, J; Estrov, Z; Faderl, S; Kantarjian, H; Ravandi, F; Rey, K, 2012) |
| "This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT)." | 9.16 | Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomi ( Cakana, A; Casassus, P; Chaleteix, C; de Witte, T; Dib, M; Doyen, C; Fontan, J; Gahrton, G; Garderet, L; Gorin, NC; Gratwohl, A; Hajek, R; Harousseau, JL; Hertenstein, B; Iacobelli, S; Ketterer, N; Koenecke, C; Kolb, B; Lafon, I; Ludwig, H; Masszi, T; Michallet, M; Milone, G; Mohty, M; Moreau, P; Morris, C; Niederwieser, D; Onida, F; Pegourie, B; van Os, M, 2012) |
| "The combination of lenalidomide-dexamethasone is active in multiple myeloma (MM)." | 9.16 | Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. ( Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T, 2012) |
| "We evaluated the clinical results of lenalidomide (Len) as a compassionate salvage therapy in refractory/relapsed multiple myeloma (MM) patients." | 9.15 | Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. ( Aguado, B; Alegre, A; Calvo, JM; Cánovas, A; Castillo, I; de la Serna, J; García, FL; Giraldo, P; Hernández, MT; Ibáñez, Á; Lahuerta, JJ; Martínez-Chamorro, C; Oriol, A; Palomera, L; Ríos, E; Rodríguez, JN, 2011) |
| "Single nucleotide polymorphisms (SNPs) in 12 genes involving multidrug resistance, drug metabolic pathways, DNA repair systems and cytokines were examined in 28 patients with relapsed/refractory multiple myeloma (MM) treated with single agent thalidomide and the results were correlated with response, toxicity and overall survival (OS)." | 9.15 | Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. ( Bladé, J; Cibeira, MT; de Larrea, CF; Díaz, T; Fuster, D; Monzó, M; Navarro, A; Rosiñol, L; Tovar, N, 2011) |
| "Maintenance therapy was explored in multiple myeloma (MM) patients after conventional thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD)." | 9.14 | Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Catarini, M; Centurioni, R; Corvatta, L; Ferranti, M; Galieni, P; Gentili, S; Giuliodori, L; Leoni, P; Marconi, M; Mele, A; Offidani, M; Piersantelli, MN; Polloni, C; Samori, A; Visani, G, 2009) |
| "This subset analysis of data from two phase III studies in patients with relapsed or refractory multiple myeloma (MM) evaluated the benefit of initiating lenalidomide plus dexamethasone at first relapse." | 9.14 | Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. ( Belch, A; Dimopoulos, MA; Facon, T; Knight, RD; Niesvizky, R; Olesnyckyj, M; Prince, MH; San Miguel, JF; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB, 2009) |
| "Lenalidomide plus dexamethasone is effective for the treatment of relapsed and refractory multiple myeloma (MM); however, toxicities from dexamethasone can be dose limiting." | 9.14 | Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. ( Anderson, KC; Badros, AZ; Bensinger, W; Berenson, J; Hussein, M; Irwin, D; Jagannath, S; Kenvin, L; Knight, R; Olesnyckyj, M; Richardson, P; Singhal, S; Vescio, R; Williams, SF; Yu, Z; Zeldis, J, 2009) |
| "Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM)." | 9.14 | Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. ( Alsina, M; Anderson, KC; Avigan, DE; Dalton, W; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Knight, R; Lunde, LE; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL; Warren, DL; Weller, E, 2009) |
| "The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported." | 9.14 | Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. ( Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U, 2010) |
| "The results from this study indicated that, with careful monitoring of the CLCr level and adverse events as well as appropriate dose adjustments, lenalidomide plus dexamethasone is an effective and well tolerated treatment option for patients with multiple myeloma who have RI." | 9.14 | The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. ( Alegre, A; de Castro, CM; Dimopoulos, M; Goldschmidt, H; Masliak, Z; Olesnyckyj, M; Reece, D; Stadtmauer, EA; Weber, DM; Yu, Z; Zonder, JA, 2010) |
| "Thalidomide is an effective agent for advanced refractory or relapsed multiple myeloma (MM), although dose-limiting toxicity (DLT) may limit its use." | 9.13 | Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. ( Boldt, T; Goldschmidt, H; Haas, A; Hoffmann, FA; Kreibich, U; Niederwieser, D; Pönisch, W; Ritter, U; Rohrberg, R; Rozanski, M; Schirmer, V; Schwalbe, E; Schwarzer, A; Uhlig, J; Zehrfeld, T, 2008) |
| "Thalidomide has been estimated as a useful drug in therapy of refractory or relapsed multiple myeloma." | 9.13 | Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma. ( Adam, Z; Bacovsky, J; Gregora, E; Minarik, J; Pavlicek, P; Pika, T; Pour, L; Scudla, V; Zemanova, M, 2008) |
| "High-dose therapy with melphalan can prolong survival among patients with multiple myeloma." | 9.12 | Thalidomide and hematopoietic-cell transplantation for multiple myeloma. ( Anaissie, E; Barlogie, B; Crowley, J; Fassas, A; Fox, M; Hollmig, K; Kiwan, E; Krishna, S; Lee, C; Pineda-Roman, M; Rasmussen, E; Shaughnessy, J; Talamo, G; Thertulien, R; Tricot, G; van Rhee, F; Zangari, M, 2006) |
| "Lenalidomide is active and well tolerated in relapsed and refractory multiple myeloma." | 9.12 | Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. ( Andresen, S; Baz, R; Brand, C; Bruening, K; Choueiri, TK; Ellis, Y; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Knight, R; Reed, J; Srkalovic, G; Walker, E; Zeldis, J, 2006) |
| "In multiple myeloma (MM), the addition of thalidomide or bortezomib to the standard oral melphalan/prednisone combination significantly increased response rate and event-free survival." | 9.12 | Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. ( Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P, 2007) |
| "Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma." | 9.12 | Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. ( Attal, M; Corso, A; Dimopoulos, M; Dmoszynska, A; Facon, T; Foà, R; Harousseau, JL; Hellmann, A; Knight, RD; Masliak, Z; Olesnyckyj, M; Patin, J; Prince, HM; San Miguel, J; Spencer, A; Yu, Z; Zeldis, JB, 2007) |
| "Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma." | 9.12 | Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. ( Belch, A; Borrello, I; Chanan-Khan, AA; Chen, C; Knight, RD; Lonial, S; Niesvizky, R; Olesnyckyj, M; Patin, J; Rajkumar, SV; Siegel, D; Stadtmauer, EA; Wang, M; Weber, DM; Yu, Z; Zeldis, JB, 2007) |
| "To determine the progression-free survival at 12 weeks, to evaluate the toxic effects, and to analyze the biological activity of thalidomide in patients with relapsed multiple myeloma (MM) after high-dose chemotherapy and stem cell transplantation." | 9.11 | Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. ( Alsina, M; Anderson, K; Blood, E; Bosch, J; Dalton, W; Davies, F; Desikan, R; Doss, D; Freeman, A; Hideshima, T; Jagannath, S; Knight, R; Mitsiades, C; Patin, J; Richardson, P; Schlossman, R; Weller, E; Zeldis, J, 2004) |
| "To evaluate safety and efficacy of thalidomide in the treatment of prurigo nodularis in a group of human immunodeficiency virus (HIV)-infected patients whose condition was recalcitrant to standard treatment." | 9.11 | Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. ( Berger, T; Maurer, T; Poncelet, A, 2004) |
| "Based on the efficacy of thalidomide in multiple myeloma and on its synergy with dexamethasone on myeloma plasma cells, we evaluated the combination of thalidomide (100 mg/d, with 100-mg increments every 2 weeks, up to 400 mg) and dexamethasone (20 mg on days 1-4) every 21 days in 31 patients with primary amyloidosis (AL) whose disease was refractory to or had relapsed after first-line therapy." | 9.11 | The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). ( Caccialanza, R; Comotti, B; Invernizzi, R; Lavatelli, F; Merlini, G; Obici, L; Palladini, G; Perfetti, V; Perlini, S, 2005) |
| "Thalidomide is an effective agent for patients with refractory multiple myeloma (MM) with a response rate of 30-40% at doses of 200-800 mg but with considerable side effects." | 9.11 | Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. ( Daenen, SM; de Wolf, JT; Hovenga, S; Kluin-Nelemans, HC; Sluiter, WJ; van Imhoff, GW; Vellenga, E, 2005) |
| "G3139, dexamethasone, and thalidomide are well tolerated and result in encouraging clinical responses in relapsed multiple myeloma patients." | 9.11 | Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. ( Badros, AZ; Fenton, RG; Flaws, JA; Gahres, N; Gocke, CD; Goloubeva, O; Heyman, M; Meisenberg, B; Rapoport, AP; Ratterree, B; Streicher, H; Takebe, N; Tomic, D; Zhang, B; Zwiebel, J, 2005) |
| "The feasibility and efficacy of a triple regimen of oral weekly cyclophosphamide, monthly pulsed dexamethasone and low-dose Thalidomide (CDT) was studied in 52 patients with relapsed or refractory multiple myeloma (MM)." | 9.11 | Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. ( D'Sa, S; Flory, A; Goldstone, AH; Hanslip, J; Kyriakou, C; Thomson, K; Yong, KL, 2005) |
| "The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma." | 9.11 | Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma. ( Ashihara, E; Fuchida, S; Hatsuse, M; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R; Yamada, N, 2005) |
| "Although thalidomide (Thal) was introduced successfully in the treatment of multiple myeloma (MM), the optimal Thal dosage and schedule are still controversial." | 9.10 | Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2002) |
| "Though thalidomide in a dosage of 100 mg/day is the standard treatment for recurrent oral and genital ulcers (OGU), its toxicity would be less important with lower dosage, while its efficacy would be identical." | 9.09 | [Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients]. ( Berthier, S; de Wazières, B; Dupond, JL; Gil, H; Magy, N; Vuitton, DA, 1999) |
| "Thalidomide is currently used as a very promising drug in patients with recurrent multiple myeloma or those refractory to chemotherapy." | 9.09 | Thalidomide treatment of resistant or relapsed multiple myeloma patients. ( Ciepnuch, H; Dmoszynska, A; Hellmann, A; Hus, M; Jawniak, D; Legiec, W; Manko, J; Skotnicki, A; Soroka-Wojtaszko, M; Wolska-Smolen, T, 2001) |
| "Thalidomide is effective for treating the oral and genital ulcers and follicular lesions of the Behçet syndrome." | 9.08 | Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. ( Hamuryudan, V; Mat, C; Ozyazgan, Y; Saip, S; Siva, A; Yazici, H; Yurdakul, S; Zwingenberger, K, 1998) |
| "Sequential combined therapy with thalidomide and narrow-band UVB therapy could improve the management of prurigo nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age." | 9.08 | Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. ( Bielsa, I; Carrascosa, JM; Ferrándiz, C; Just, M; Ribera, M, 1997) |
| "Thalidomide was given to 15 patients with severe orogenital ulceration (OGU)." | 9.05 | Thalidomide in severe orogenital ulceration. ( Allen, BR; Jenkins, JS; Littlewood, SM; Maurice, PD; Powell, RJ; Smith, NJ, 1984) |
| "We sought to evaluate the activity and safety of carfilzomib-/ixazomib-containing combinations for patients with relapsed/refractory multiple myeloma (RRMM)." | 8.98 | Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma. ( Guo, H; Sun, X; Wang, B; Xu, W, 2018) |
| " Thalidomide has been used as a therapeutic strategy for refractory epistaxis in hereditary haemorrhagic telangiectasia patients." | 8.98 | The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. ( Harrison, L; Jervis, P; Kundra, A, 2018) |
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 8.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| "Oral pomalidomide (Imnovid® [EU]; Pomalyst® [USA]) in combination with dexamethasone (in the EU), is approved in several countries for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy (or progression within the last 60 days in the USA)." | 8.90 | Pomalidomide: a review of its use in patients with recurrent multiple myeloma. ( Scott, LJ, 2014) |
| "In several countries, including the US and in Europe, oral lenalidomide in combination with oral dexamethasone is approved for the treatment of multiple myeloma patients (aged ≥ 18 years) who have received at least one prior antimyeloma therapy." | 8.87 | Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. ( Lyseng-Williamson, KA; Scott, LJ, 2011) |
| "To estimate the cost-effectiveness of bortezomib (BTZ) compared with dexamethasone (DEX) and lenalidomide plus dexamethasone (LEN/DEX) for the treatment of relapsed/refractory multiple myeloma in Sweden." | 8.86 | The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. ( Aschan, J; Dhawan, R; Hornberger, J; Liwing, J; Löthgren, M; Rickert, J, 2010) |
| "Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%." | 8.84 | A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. ( Bargou, R; Cook, G; Furkert, K; Glasmacher, A; Hahn-Ast, C; Hoffmann, F; Naumann, R; von Lilienfeld-Toal, M, 2008) |
| "Given that the efficacy/safety of thalidomide for relapsed or refractory multiple myeloma have not been well characterized in a randomized, controlled setting, an analysis of larger, single-agent trials was conducted." | 8.84 | An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. ( Mileshkin, L; Prince, HM; Schenkel, B, 2007) |
| "Thalidomide has been demonstrated to be active as a first-line and salvage therapy in patients with multiple myeloma." | 8.83 | The role of thalidomide in multiple myeloma. ( Jagannath, S; Schwab, C, 2006) |
| "To evaluate the literature regarding the dosing of thalidomide in multiple myeloma." | 8.82 | Thalidomide dosing in patients with relapsed or refractory multiple myeloma. ( Hansen, LA; Thompson, JL, 2003) |
| "Thalidomide is the first drug in over 20 years to demonstrate clinically significant activity in patients with multiple myeloma." | 8.81 | Thalidomide for the treatment of relapsed and refractory multiple myeloma. ( Cool, RM; Herrington, JD, 2002) |
| "Lenalidomide is an important component of initial therapy in newly diagnosed multiple myeloma, either as maintenance therapy post-autologous stem cell transplantation (ASCT) or as first-line therapy with dexamethasone for patients' ineligible for ASCT (non-ASCT)." | 8.02 | Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. ( Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D, 2021) |
| "Pomalidomide demonstrated activity in the treatment of AL amyloidosis in three phase II clinical trials." | 7.96 | Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. ( Basset, M; Foli, A; Hegenbart, U; Kimmich, C; Mahmood, S; Merlini, G; Milani, P; Nuvolone, M; Palladini, G; Sachchithanantham, S; Schönland, SO; Sharpley, F; Wechalekar, A, 2020) |
| "We analyzed gene expression levels of CRBN, cMYC, IRF4, BLIMP1, and XBP1 in 224 patients with multiple myeloma treated with pomalidomide and low-dose dexamethasone in the STRATUS study (ClinicalTrials." | 7.91 | Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. ( Amatangelo, M; Bjorklund, C; Dimopoulos, MA; Flynt, E; Moreau, P; Ocio, EM; Peluso, T; Qian, X; Sternas, L; Thakurta, A; Towfic, F; Weisel, KC; Yu, X; Zaki, M, 2019) |
| "Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI)." | 7.91 | Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. ( Blin, N; Bonnet, A; Chevallier, P; Dubruille, V; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Trudel, S, 2019) |
| "Determinants of the efficacy and safety of pomalidomide (POM) monotherapy or POM plus dexamethasone (DEX) (POM/DEX) for relapsed and refractory multiple myeloma (RRMM) were examined retrospectively in a real-world clinical practice setting in Japan." | 7.88 | Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. ( Fuchida, SI; Hino, M; Iida, M; Imada, K; Ishikawa, J; Kamitsuji, Y; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsuda, M; Matsui, T; Matsumura, I; Matsumura-Kimoto, Y; Nakaya, A; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Uchiyama, H; Uoshima, N; Wada, K; Yagi, H; Yokota, I, 2018) |
| "To investigate the efficacy, safety, and cost of a pomalidomide-dexamethasone regimen in patients with relapsed and refractory multiple myeloma (RRMM)." | 7.88 | Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma. ( Aho, LS; Boulin, M; Caillot, D; Chretien, ML; Cransac-Miet, A; Favennec, C; Gueneau, P; Guy, J; Lafon, I, 2018) |
| "Pomalidomide plus low-dose dexamethasone (POM-d), daratumumab monotherapy (DARA), and carfilzomib monotherapy (CAR) have been approved for use in the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma (RRMM) in the US, based on findings from the MM-002, SIRIUS, and PX-171-003-A1 studies, respectively." | 7.85 | Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States. ( Abouzaid, S; Ailawadhi, S; Chandler, C; Guo, S; Mouro, J; Parikh, K; Pelligra, CG, 2017) |
| "In the UK, the standard of care for patients with multiple myeloma who received ≥2 prior treatments is lenalidomide plus dexamethasone (LEN + DEX) and pomalidomide plus DEX (POM + DEX) (in Wales only)." | 7.85 | Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data. ( Gray, E; Krishna, A; Majer, I; Polanyi, Z; Roy, A; van de Wetering, G, 2017) |
| "On November 30, 2015, the FDA approved elotuzumab (Empliciti; Bristol-Myers Squibb) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who received one to three prior therapies." | 7.85 | FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma. ( Deisseroth, A; Farrell, AT; Goldberg, KB; Gormley, NJ; Kaminskas, E; Ko, CW; Kormanik, N; Nie, L; Pazdur, R, 2017) |
| "Multiple myeloma (MM) patients who have progressed following treatment with both bortezomib and lenalidomide have a poor prognosis." | 7.83 | Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. ( Borg, S; Elvidge, J; Hansson, M; Lee, D; Nahi, H; Persson, U, 2016) |
| "To assess the economic value of carfilzomib (Kyprolis), this study developed the Kyprolis Global Economic Model (K-GEM), which examined from a United States (US) payer perspective the cost-effectiveness of carfilzomib-lenalidomide-dexamethasone (KRd) versus lenalidomide-dexamethasone (Rd) in relapsed multiple myeloma (RMM; 1-3 prior therapies) based on results from the phase III ASPIRE trial that directly compared these regimens." | 7.83 | Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. ( Aggarwal, SK; Barber, BL; Benedict, Á; Campioni, M; Giannopoulou, A; Houisse, I; Jakubowiak, AJ; Panjabi, S; Tichy, E, 2016) |
| "Circulating vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and selectins were prospectively measured in 145 newly-diagnosed patients with symptomatic myeloma (NDMM), 61 patients with asymptomatic/smoldering myeloma (SMM), 47 with monoclonal gammopathy of undetermined significance (MGUS) and 87 multiple myeloma (MM) patients at first relapse who received lenalidomide- or bortezomib-based treatment (RD, n=47; or VD, n=40)." | 7.83 | Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. ( Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Iakovaki, M; Kanellias, N; Kastritis, E; Migkou, M; Panagiotidis, I; Terpos, E; Ziogas, DC, 2016) |
| "Thalidomide has been successful use in patients with refractory Crohn disease (CD) in recent years." | 7.83 | Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review. ( Hu, H; Liu, S; Wang, X, 2016) |
| "This is a retrospective chart review to evaluate the efficacy of the addition of vorinostat to lenalidomide and dexamethasone in patients with multiple myeloma relapsed/refractory to lenalidomide and dexamethasone." | 7.83 | Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. ( Bednarz, U; Bilotti, E; Gao, Z; Gilani, M; Graef, T; Mato, A; McBride, L; McNeill, A; Richter, J; Schmidt, L; Siegel, DS; Vesole, DH, 2016) |
| "In 12 patients with relapsed or refractory acute myelogenous leukemia (AML), the efficacy and safety of a novel regimen, namely thalidomide combined with interferon and interleukin 2 (IL-2), were initially explored." | 7.83 | [Thalidomide combined with interferon and interleukin-2 in treatment of relapsed or refractory acute myelogenous leukemia]. ( Ai, H; Chen, L; Hao, QM; Mi, RH; Song, YP; Wang, P; Wei, XD; Yin, QS; Yuan, FF, 2016) |
| "Lenalidomide was approved for the treatment of relapsed and refractory multiple myeloma (rrMM) based on MM009 and MM010 clinical trials." | 7.81 | Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center. ( Coelho, I; Costa, C; Esteves, S; João, C; Lucio, P, 2015) |
| "We retrospectively investigated the prognostic factor of lenalidomide plus low-dose dexamethasone (Rd) in Japanese patients with refractory or relapsed multiple myeloma (RRMM) registered in the Kansai Myeloma Forum from January 2006 to December 2013." | 7.81 | Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma. ( Adachi, Y; Fuchida, S; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kobayashi, T; Kosugi, S; Kuroda, J; Matsuda, M; Matsumura, I; Nakatani, E; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uchiyama, H; Uoshima, N; Yagi, H, 2015) |
| "The introduction of immunomodulatory drugs such as lenalidomide combined with dexamethasone (Len/Dex) has improved the outcome of patients with relapsed/refractory multiple myeloma (RRMM)." | 7.81 | Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. ( Bacchiarri, F; Bosi, A; Donnini, I; Guarrera, A; Longo, G; Nozzoli, C; Staderini, M; Veltroni, A, 2015) |
| "In the past decade, the introduction of bortezomib, thalidomide, and lenalidomide has changed the treatment of multiple myeloma (MM) dramatically." | 7.81 | [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy]. ( Nakaseko, C; Sakaida, E; Takeda, Y, 2015) |
| "In this retrospective real-life study in relapsed/refractory multiple myeloma patients, we analyzed clinical and biologic features distinguishing patients with rapidly progressing disease while receiving lenalidomide therapy from those without progression." | 7.81 | Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. ( Battistutta, C; Berno, T; Bonaldi, L; Branca, A; Briani, C; Cavraro, M; De March, E; Gurrieri, C; Lico, A; Martines, A; Minotto, C; Piazza, F; Sechettin, E; Semenzato, G; Temporin, F; Trentin, L; Zambello, R, 2015) |
| "Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition." | 7.80 | "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. ( Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P, 2014) |
| "Lenalidomide in combination with dexamethasone is an effective and well-established treatment of relapsed or refractory multiple myeloma (rrMM) disease." | 7.80 | Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. ( Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M, 2014) |
| "A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants." | 7.80 | Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. ( Hobeika, L; Self, SE; Velez, JC, 2014) |
| "A lenalidomide-based regimen was highly effective in this patient with diffuse large B-cell lymphoma." | 7.80 | Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report. ( Gałązka, K; Gruchała, A; Jurczak, W; Krawczyk, K; Skotnicki, AB, 2014) |
| " In this report, we presented a Chinese patient with recurrent melena due to gastric angiodysplasia in HHT treated successfully with thalidomide." | 7.79 | Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia. ( Chen, Y; Du, Q; Wang, XY, 2013) |
| "The combination of lenalidomide, bortezomib and dexamethasone (RVD) has shown excellent efficacy in patients with relapsed or refractory multiple myeloma (RRMM)." | 7.79 | Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. ( Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S, 2013) |
| "Few data are available on the efficacy of the combination of lenalidomide plus dexamethasone (Len/Dex) in very elderly patients above 75 years of age with relapsed multiple myeloma (MM)." | 7.78 | Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. ( Blin, N; Clavert, A; Dubruille, V; Le Gouill, S; Loirat, M; Mahe, B; Malard, F; Mohty, M; Moreau, P; Pennetier, M; Peterlin, P; Planche, L; Roland, V; Tessoulin, B; Touzeau, C, 2012) |
| "del(17p13)(TP53) seems to be an independent poor prognostic factor in patients with relapsed/refractory multiple myeloma (MM) receiving lenalidomide." | 7.78 | p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide. ( Chang, H; Chen, MH; Qi, CX; Saha, MN, 2012) |
| "Retrospective multicenter analysis of 26 patients with multiple myeloma to assess the efficacy and toxicity of relapse treatment with lenalidomide/dexamethasone in renal-function impairment." | 7.78 | Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers. ( Hahn-Ast, C; Kuhn, S; Langer, C; Oehrlein, K; Pönisch, W; Sturm, I; Weisel, KC, 2012) |
| "Two pivotal, phase III, randomised, placebo-controlled, registration trials (MM-009 and MM-010) showed that lenalidomide plus dexamethasone was more effective than placebo plus dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma." | 7.78 | Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. ( Borrello, I; Chanan-Khan, AA; Dimopoulos, M; Foà, R; Hellmann, A; Knight, R; Lonial, S; Swern, AS; Weber, D, 2012) |
| "In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM)." | 7.77 | Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. ( Goldschmidt, H; Hielscher, T; Hillengass, J; Ho, AD; Hose, D; Jauch, A; Klein, U; Neben, K; Raab, MS; Seckinger, A, 2011) |
| "Evidence of long-term response to lenalidomide in heavily pretreated patients with multiple myeloma is lacking." | 7.77 | Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. ( Citro, A; Corradini, P; Crippa, C; De Muro, M; Falcone, AP; Galli, M; Gentili, S; Grasso, M; Guglielmelli, T; Montefusco, V; Olivero, B; Patriarca, F; Rossi, D; Sammassimo, S; Spina, F, 2011) |
| "Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients." | 7.76 | Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand. ( Atichartakarn, V; Aungchaisuksiri, P; Chuncharunee, S; Jootar, S; Niparuck, P; Puavilai, T; Sorakhunpipitkul, L; Ungkanont, A, 2010) |
| "Thalidomide is now recognized as an important agent for multiple myeloma." | 7.76 | [Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma]. ( Akagi, T; Goto, K; Ikebe, T; Ikewaki, J; Imamura, T; Kadota, J; Kohno, K; Miyazaki, M; Miyazaki, Y; Ogata, M; Ohtsuka, E; Saburi, Y; Uno, N, 2010) |
| "Previous literature suggests that cytogenetics may be used for risk-adapted therapy in patients with relapsed/refractory multiple myeloma (MM) treated with lenalidomide and dexamethasone." | 7.76 | Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. ( Chang, H; Chen, C; Jiang, A; Qi, C; Reece, D; Trieu, Y, 2010) |
| "The immunomodulatory drugs thalidomide and lenalidomide have enhanced activity in patients with multiple myeloma (MM)." | 7.75 | Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. ( Goldschmidt, H; Hegenbart, U; Hillengass, J; Ho, AD; Hundemer, M; Klein, U; Kosely, F; Moehler, T; Neben, K; Schmitt, S, 2009) |
| "A prospective subgroup analysis of two prospective, randomized, double-blind, placebo-controlled phase III clinical trials showed that the combination of lenalidomide plus dexamethasone is superior to dexamethasone alone in patients with relapsed or refractory multiple myeloma who had been previously treated with thalidomide; the implications for clinical practice are discussed." | 7.75 | Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma. ( Meijer, E; Sonneveld, P, 2009) |
| "Lenalidomide gained Food and Drug Administration (FDA) approval for treatment of patients with relapsed or refractory multiple myeloma (MM) in combination with dexamethasone in June 2006." | 7.75 | Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. ( Abonour, R; Alsina, M; Bahlis, NJ; Boccia, RV; Chen, C; Coutre, SE; Knight, RD; Kumar, S; Matous, J; Niesvizky, R; Pietronigro, D; Rajkumar, V; Reece, DE; Richardson, P; Siegel, D; Stadtmauer, EA; Vescio, R; Zeldis, JB, 2009) |
| "We present a pooled update of two large, multicenter MM-009 and MM-010 placebo-controlled randomized phase III trials that included 704 patients and assessed lenalidomide plus dexamethasone versus dexamethasone plus placebo in patients with relapsed/refractory multiple myeloma (MM)." | 7.75 | Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. ( Attal, M; Chen, C; Dimopoulos, MA; Knight, RD; Niesvizky, R; Olesnyckyj, M; Petrucci, MT; Spencer, A; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB, 2009) |
| "This analysis assessed the efficacy and safety of lenalidomide + dexamethasone in patients with relapsed or refractory multiple myeloma (MM) previously treated with thalidomide." | 7.74 | Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. ( Attal, M; Chen, C; Cibeira, MT; Dimopoulos, MA; Knight, RD; Olesnyckyj, M; Rajkumar, SV; Spencer, A; Wang, M; Weber, DM; Yu, Z; Zeldis, JB, 2008) |
| "Thalidomide is one of the drugs which are newly used in the therapy of multiple myeloma." | 7.74 | [Low-dose thalidomide in refractory and relapsing multiple myeloma]. ( Maisnar, V; Radocha, J, 2007) |
| "Thalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmune diseases due to its anti-angiogenic, immunomodulatory and anti-inflammatory effects." | 7.74 | Leukocytoclastic vasculitis due to thalidomide in multiple myeloma. ( Alpay, N; Ayer, M; Küçükkaya, RD; Mete, O; Nalçaci, M; Yavuz, AS; Yenerel, MN; Yildirim, ND, 2007) |
| "Thalidomide is an immunomodulatory drug used in the treatment of relapsed or refractory multiple myeloma (MM)." | 7.74 | Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. ( Bláha, V; Büchler, T; Hájek, R; Maisnar, V; Malý, J; Radocha, J, 2007) |
| "We report preliminary observations on the efficacy of bortezomib in 20 patients with AL amyloidosis whose clonal disease was active despite treatment with a median of 3 lines of prior chemotherapy, including a thalidomide combination in all cases." | 7.74 | Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. ( Gillmore, JD; Hawkins, PN; Lachmann, HJ; Offer, M; Wechalekar, AD, 2008) |
| "Thalidomide and its analogs have been extensively studied in patients with multiple myeloma." | 7.73 | Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. ( Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P, 2005) |
| "The use of the proteasome inhibitor bortezomib has been recently introduced into the treatment of relapsed, refractory multiple myeloma (MM)." | 7.73 | Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. ( Graeven, U; König, M; Schmiegel, W; Schmielau, J; Teschendorf, C, 2005) |
| "To investigate the effect of the combination of thalidomide, cyclophosphamide and dexamethasone for the treatment of relapsed/refractory multiple myeloma." | 7.73 | [The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma]. ( An, N; Chen, SL; Gao, W, 2006) |
| "Thalidomide administered as a single agent produces a response rate of about 40% in patients with refractory or relapsed multiple myeloma (MM)." | 7.73 | Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. ( Bladé, J; Cibeira, MT; Esteve, J; Ramiro, L; Rosiñol, L; Torrebadell, M, 2006) |
| "We studied the effect of thalidomide on the macroscopic appearance of angiodysplasias in three patients with bleeding due to multiple angiodysplasias of the small intestine." | 7.73 | Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. ( Bauditz, J; Lochs, H; Voderholzer, W, 2006) |
| "To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma." | 7.72 | Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Hayman, SR; Iturria, NL; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2003) |
| "Fifty Taiwanese patients with relapsed and/or refractory multiple myeloma (MM) were treated with thalidomide on a dose-escalation schedule, commencing with 100 mg/d nightly and incremented either to the maximally tolerated dose or 800 mg/d." | 7.72 | Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. ( Chen, YC; Hong, RL; Huang, SY; Ko, BS; Shen, MC; Tang, JL; Tien, HF; Tsai, W; Wang, CH; Yao, M, 2003) |
| "The current study suggests that thalidomide has limited single-agent activity in heavily pretreated patients with recurrent or refractory lymphoma." | 7.72 | Thalidomide for patients with recurrent lymphoma. ( Albitar, M; Cabanillas, F; Clemons, M; Dang, NH; Hagemeister, FB; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Samaniego, F; Younes, A, 2004) |
| "Thalidomide has shown efficacy in relapsed or refractory patients of multiple myeloma (MM)." | 7.71 | The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. ( Grover, JK; Raina, V; Uppal, G, 2002) |
| "Thalidomide seems to be an effective and safe treatment in patients with refractory Crohn disease." | 7.71 | Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. ( Candusso, M; Facchini, S; Liubich, M; Martelossi, S; Panfili, E; Ventura, A, 2001) |
| "The feasibility and efficacy of a combination of thalidomide, cyclophosphamide, etoposide, and dexamethasone were studied in 56 patients with poor-prognosis multiple myeloma." | 7.71 | Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. ( Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Krasniqi, F; Moehler, TM; Neben, K, 2001) |
| " We present a case of coinfection with disseminated HSV and VZV infection in a patient taking thalidomide for relapsed multiple myeloma." | 7.71 | Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. ( Curley, MJ; Hassoun, PM; Hussein, SA, 2002) |
| "To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma." | 7.70 | Thalidomide in the treatment of relapsed multiple myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2000) |
| "Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells." | 6.94 | OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. ( Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P, 2020) |
| "Proteasome inhibitors (PIs) in combination with immunomodulatory drugs (IMiDs) have been shown to be effective against relapsed/refractory multiple myeloma (RRMM)." | 6.82 | Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma. ( Hagiwara, S; Iida, S; Ishida, T; Ito, A; Kanamori, T; Kato, C; Kinoshita, S; Komatsu, H; Kusumoto, S; Masuda, A; Murakami, S; Nakashima, T; Narita, T; Ri, M; Suzuki, N; Totani, H; Yoshida, T, 2016) |
| "Relapsed/refractory multiple myeloma (RRMM) patients have poor overall survival (OS)." | 6.82 | Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). ( Dimopoulos, MA; Gibson, CJ; Hong, K; Moreau, P; Saunders, O; Song, KW; Sternas, LA; Weisel, KC; Zaki, MH, 2016) |
| " Dosing was based on the lenalidomide label." | 6.82 | Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. ( Abraham, J; Arnulf, B; Bridoux, F; Chen, N; Desport, E; Fermand, JP; Jaccard, A; Moreau, S; Moumas, E, 2016) |
| "Pomalidomide is a distinct oral IMiD(®) immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects." | 6.80 | Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. ( Alegre, A; Bahlis, NJ; Banos, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, MA; Garderet, L; Goldschmidt, H; Ivanova, V; Jacques, C; Karlin, L; Martinez-Lopez, J; Moreau, P; Oriol, A; Renner, C; San Miguel, JF; Song, KW; Sternas, L; Teasdale, T; Weisel, KC; Yu, X; Zaki, MH, 2015) |
| "Lenalidomide was given orally 21/28 days per cycle for 1 year, at escalated dose of 15 to 20 mg during phase 1 to determine the MTD; the phase 2 part was conducted at the MTD." | 6.80 | Lenalidomide is safe and active in Waldenström macroglobulinemia. ( Arnulf, B; Bakala, J; Banos, A; Bories, C; Brice, P; Choquet, S; Demarquette, H; Dib, M; Fouquet, G; Guidez, S; Herbaux, C; Karlin, L; Leblond, V; LeGouill, S; Leleu, X; Louni, C; Martin, A; Morel, P; Nudel, M; Ohyba, B; Petillon, MO; Poulain, S; Salles, G; Thielemans, B; Tournilhac, O, 2015) |
| "Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 6.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
| "Pomalidomide was given at 1 to 2." | 6.78 | Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. ( Baldi, I; Boccadoro, M; Bringhen, S; Carella, AM; Corradini, P; Crippa, C; Galli, M; Giuliani, N; Guglielmelli, T; La Verde, G; Larocca, A; Magarotto, V; Marcatti, M; Mina, R; Montefusco, V; Omedé, P; Palumbo, A; Rossi, D; Rota-Scalabrini, D; Santagostino, A, 2013) |
| "Thrombocytopenia was the most common grade ≥ 3 AE (35%)." | 6.78 | A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. ( Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A, 2013) |
| "In newly diagnosed multiple myeloma (MM), three/four-drug combinations as induction therapy seem to be more effective compared with two-drug associations in terms of response rate and duration of remission." | 6.76 | Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. ( Blasi, N; Brunori, M; Caraffa, P; Catarini, M; Corvatta, L; Ferranti, M; Gentili, S; Leoni, P; Malerba, L; Mele, A; Offidani, M; Polloni, C; Rizzi, R; Samori, A, 2011) |
| "Thalidomide has direct antimyeloma and immunomodulatory effects." | 6.73 | Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. ( Abonour, R; Ansari, RH; Cripe, LD; Fausel, C; Fisher, WB; Juliar, BE; Smith, GG; Suvannasankha, A; Wood, LL; Yiannoutsos, CT, 2007) |
| "Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%." | 6.72 | A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ( Alsina, M; Anderson, KC; Blood, E; Dalton, WS; Desikan, KR; Doss, D; Freeman, A; Gorelik, S; Hideshima, T; Jagannath, S; Kelly-Colson, K; Knight, R; McKenney, ML; Mitsiades, CS; Munshi, NC; Olesnyckyj, M; Rajkumar, SV; Rich, R; Richardson, PG; Schlossman, RL; Warren, D; Weller, E; Wride, K; Wu, A; Zeldenrust, SR; Zeldis, J, 2006) |
| "Thalidomide is an effective maintenance therapy in patients with multiple myeloma." | 6.72 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Bourhis, JH; Caillot, D; Doyen, C; Dumontet, C; Facon, T; Garderet, L; Grobois, B; Harousseau, JL; Hulin, C; Leyvraz, S; Marit, G; Monconduit, M; Moreau, P; Pegourie, B; Renaud, M; Voillat, L; Yakoub Agha, I, 2006) |
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 6.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| "We treated with thalidomide 17 patients (12 males, 5 females), average age 51 (range 42-73 years), mean time since diagnosis to the start of thalidomide treatment was 24 months (range 5-48)." | 6.71 | [Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma]. ( Helbig, G; Hołowiecki, J; Kyrcz-Krzemień, S; Stella-Hołowiecka, B, 2003) |
| " The patients received PTX at the initiating dosage until complete clinical cure." | 6.71 | [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. ( Achirafi, A; de Carsalade, GY; Flageul, B, 2003) |
| "Pomalidomide (Pom) has demonstrated synergistic antiproliferative activity in combination regimens as a result of its distinct anticancer, antiangiogenic, and immunomodulatory effects." | 6.61 | Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials. ( Ali, Z; Anwer, F; Hassan, H; Hassan, SF; Iftikhar, A; Kamal, A; Lakhani, M; Mushtaq, A; Raychaudhuri, S; Razzaq, F; Safdar, A; Sagar, F; Zahid, U; Zar, MA, 2019) |
| "Pomalidomide is a distinct IMiD agent recently approved in the US and Europe." | 6.50 | Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. ( Coleman, M; Mark, TM; Niesvizky, R, 2014) |
| "Although multiple myeloma remains an essentially incurable disease, treatment options and patients' quality of life have improved over the last years with the introduction of more effective and less toxic agents." | 6.48 | Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies. ( Figueiredo, A; João, C; Martins, HF, 2012) |
| "Lenalidomide is an immunomodulatory drug, which has anti-myeloma activity in vitro." | 6.45 | United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma. ( Behrens, J; Bird, J; Cavenagh, J; Cook, G; Davies, F; Morgan, G; Morris, C; Schey, S; Tighe, J; Williams, C, 2009) |
| "Bortezomib was associated with a significantly higher response rate and complete remission rate using both M-protein and EBMT criteria." | 6.44 | Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison. ( Adena, M; Hertel, J; Prince, HM; Smith, DK, 2007) |
| " Thalidomide has been evaluated for the treatment of recurrent bleeding due to small-intestinal angiodysplasia (SIA), but confirmatory trials are lacking." | 5.69 | Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia. ( Chen, H; Dai, Z; Du, Y; Gao, Y; Ge, Z; Gong, S; Li, X; Li, Z; Liu, S; Lu, H; Lu, L; Shen, X; Shen, Y; Tang, M; Wu, S; Xiong, H; Xu, L; Xue, H; Yang, A; Yang, S; Zhang, Q; Zhao, R; Zhong, J; Zhong, L, 2023) |
| "Pomalidomide is a second-generation immunomodulatory drug that has shown activity in lenalidomide-refractory disease in the setting of different combinations." | 5.62 | Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience. ( Anguita, M; Arguiñano, JM; Arnao, M; Bladé, J; Blanchard, MJ; Cabañas, V; Casado, F; de Cabo, E; de Coca, AG; Encinas, C; García, R; González-Rodríguez, AP; Hernández-Rivas, JÁ; Iñigo, B; Lafuente, AP; Lahuerta, JJ; Lavilla, E; López, A; Maldonado, R; Martí, JM; Mateos, MV; Motlló, C; Murillo, I; Pérez-Persona, E; Ribas, P; Rodriguez-Otero, P; Sampol, A; San Miguel, JF; Sirvent, M, 2021) |
| "We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse." | 5.51 | Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics. ( Anderson, LD; Beksac, M; Corso, A; Dimopoulos, M; Dürig, J; Engelhardt, M; Galli, M; Grote, L; Jenner, M; Jiang, R; Kanate, AS; Larocca, A; Liberati, AM; Lindsay, J; Moreau, P; Oriol, A; Pavic, M; Peluso, T; Richardson, PG; Robak, P; Rodriguez-Otero, P; Salomo, M; Schjesvold, F; Sonneveld, P; Vural, F; Weisel, K; White, D; Yagci, M, 2022) |
| "During maintenance medication at the fourth and eighth weekend, the two doses (50 and 25 mg/d) of thalidomide were equivalent in reducing the incidence of ulcers, ulcer number, and ulcer pain, respectively (all p > 0." | 5.51 | A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis. ( Deng, Y; Du, G; Pan, L; Tang, G; Wang, Y; Wei, W; Yao, H, 2022) |
| "Pomalidomide is an immunomodulatory compound that has demonstrated activity in MM patients with disease refractory to lenalidomide and bortezomib." | 5.48 | The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience. ( Bernatowicz, P; Charlinski, G; Dmoszynska, A; Grzasko, N; Guzicka-Kazimierczak, R; Janczarski, M; Jurczyszyn, A; Lech-Maranda, E; Swiderska, A; Szczepaniak, A; Szeremet, A; Waszczuk-Gajda, A; Wichary, R, 2018) |
| " Adverse events (AEs) occurred in 69 (57." | 5.48 | Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/\ refractory multiple myeloma: a real-life experience ( Duran, M; Durusoy, R; Patır, P; Şahin, F; Saydam, G; Soyer, N; Töbü, M; Tombuloğlu, M; Ünal, HD; Uysal, A; Vural, F, 2018) |
| "Lenalidomide can be a good treatment option for AL amyloidosis in HIV-infected patients on antiretroviral therapy." | 5.46 | Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient. ( Cook, M; Denman, J; Manavi, K, 2017) |
| "Pomalidomide has shown improved survival and good tolerability in this patient cohort in clinical trials, but real world data are scarce." | 5.46 | Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. ( Benjamin, R; Cerner, A; Cheesman, S; D'sa, S; Jenner, M; Maciocia, N; Maciocia, P; Melville, A; Popat, R; Rabin, N; Ramasamy, K; Rismani, A; Schey, S; Sharpley, F; Streetly, M; Yong, K, 2017) |
| "Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies." | 5.46 | Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment. ( Arnould, B; Bacon, P; Gilet, H; Kyriakou, C; Leleu, X; Lewis, P; Murphy, P; Petrucci, MT; Vande Broek, I, 2017) |
| " The dosing and safety profile of POM + LoDEX was similar across RI subgroups." | 5.43 | Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. ( Baz, R; Cavo, M; Delforge, M; Dimopoulos, MA; Goldschmidt, H; Hong, K; Jagannath, S; Moreau, P; Palumbo, A; Richardson, P; San Miguel, JF; Siegel, DS; Song, KW; Sternas, L; Weisel, KC; Yu, X; Zaki, M, 2016) |
| " In conclusion, low-dose lenalidomide plus dexamethasone therapy is an effective and safe regimen for patients with relapsed or refractory POEMS syndrome." | 5.42 | Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome. ( Cai, H; Cai, QQ; Cao, XX; Li, J; Wang, C; Zhou, DB, 2015) |
| "Isatuximab is an anti-CD38 monoclonal antibody approved in combination with pomalidomide-dexamethasone and carfilzomib-dexamethasone for relapsed or refractory multiple myeloma." | 5.41 | Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. ( Asset, G; Baker, R; Capra, M; Dimopoulos, MA; Facon, T; Hajek, R; Kim, K; Koh, Y; Leleu, X; Macé, S; Martin, T; Martinez, G; Mikhael, J; Min, CK; Moreau, P; Oriol, A; Pour, L; Risse, ML; Špička, I; Suzuki, K; Yong, K, 2021) |
| "We conclude that RD reduces bone resorption only in responding patients with relapsed/refractory myeloma but has no effect on bone formation." | 5.40 | The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. ( Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Koulieris, E; Kyrtsonis, MC; Michalis, E; Papanikolaou, X; Papatheodorou, A; Pouli, A; Terpos, E; Zervas, K, 2014) |
| "Treatment options for multiple myeloma dwindle with each relapse." | 5.40 | Pomalidomide. A last-line treatment option for multiple myeloma. ( , 2014) |
| "Optimal salvage treatment for multiple myeloma relapsing after allogeneic stem cell transplantation remains to be determined." | 5.39 | Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. ( Bachy, E; Bourhis, JH; Brebion, A; Coman, T; François, S; Hermine, O; Huynh, A; Lapusan, S; Lioure, B; Maury, S; Michallet, M; Milpied, N; Mohty, M; Rubio, MT; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I, 2013) |
| "Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described." | 5.39 | Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. ( Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R, 2013) |
| "POEMS syndrome is a rare disorder characterized by polyneuropathy, monoclonal gammopathy, multiorgan involvement, and elevated vascular endothelial growth factor levels." | 5.39 | Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. ( Abraham, J; Asli, B; Banos, A; Brisseau, JM; Choquet, S; Decaux, O; Deplanque, G; Facon, T; Fermand, JP; Galicier, L; Godmer, P; Guichard, I; Haroche, J; Hermine, O; Jaccard, A; Leblond, V; Leleu, X; Marolleau, JP; Merlusca, L; Musset, L; Recher, C; Roussel, M; Royer, B; Sebban, C, 2013) |
| "Lenalidomide was well tolerated in intensively pretreated and elderly MM patients, including those with RI." | 5.38 | Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. ( Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R, 2012) |
| "POEMS syndrome is a rare paraneoplastic condition associated to an underlying plasmacellular dyscrasia." | 5.38 | Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation. ( Balducci, M; Chiusolo, P; De Stefano, V; Giannotta, C; Laurenti, L; Leone, G; Luigetti, M; Sabatelli, M; Sica, S; Sorà, F; Vannata, B, 2012) |
| "Lenalidomide was previously shown to induce an overall response rate (ORR) of 28% in patients with relapsed/refractory DLBCL." | 5.37 | Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. ( Czuczman, MS; Deeb, G; Goy, A; Hernandez-Ilizaliturri, FJ; Macon, WR; Malik, F; Pileri, SA; Witzig, TE; Zinzani, PL, 2011) |
| "Patients with relapsed or refractory multiple myeloma (RRMM) who received lenalidomide plus dexamethasone in the MM-009 and MM-010 trials were pooled and those who had not progressed and were still receiving lenalidomide at 12 months were included." | 5.37 | Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. ( Dimopoulos, MA; Hussein, M; Swern, AS; Weber, D, 2011) |
| "Thalidomide is an effective and safe treatment agent for GIVM and its associated bleeding." | 5.37 | The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study. ( Chen, HM; Chen, HY; Fang, JY; Gao, YJ; Ge, ZZ; Liu, WZ; Tan, HH; Xiao, SD, 2011) |
| "Lenalidomide was given at a dose of 15 mg (n=4), or 25 mg (n=20), orally once daily on day 1 to day 1 every 28 days, with (n=20) or without (n=4) DHAP." | 5.36 | Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. ( Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Blaise, D; El-Cheikh, J; Fehse, B; Hildebrandt, Y; Hoffmann, F; Kröger, N; Lioznov, M; Mohty, M; Schilling, G; Wolschke, C; Zander, AR, 2010) |
| "Thalidomide was reduced for toxicity in 68 patients (24%) and permanently discontinued in 36 (12%)." | 5.35 | Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. ( Barbarano, L; Cafro, AM; Caravita, T; Corso, A; Gay, F; Lazzarino, M; Mangiacavalli, S; Morra, E; Palumbo, A; Petrucci, MT; Varettoni, M; Zappasodi, P, 2009) |
| "Angiodysplasias are a major cause of lower gastrointestinal bleeding in patients over the age of 60 years." | 5.35 | A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias. ( Dabak, V; Kamboj, G; Kuriakose, P; Shurafa, M, 2008) |
| "Nearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy." | 5.34 | Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. ( Avonto, I; Boccadoro, M; Bringhen, S; Corvatta, L; Falco, P; Leoni, P; Marconi, M; Offidani, M; Palumbo, A; Piersantelli, MN; Polloni, C, 2007) |
| "An 80-year-old man with von Willebrand's disease was admitted with severe melaena." | 5.33 | Thalidomide as treatment for digestive tract angiodysplasias. ( Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ, 2006) |
| "Thalidomide was used to treat acute (n=21) or chronic (n=59) graft-vs-host disease (GVHD) in 80 haematopoietic stem cell allograft recipients after failure to respond to the combination of cyclosporine and corticosteroids with or without other agents." | 5.32 | Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. ( Atra, A; Goyal, S; Horton, C; Kulkarni, S; Mehta, J; Meller, S; Ortin, M; Pinkerton, CR; Powles, R; Rudin, C; Sankpal, S; Saso, R; Singhal, S; Sirohi, B; Treleaven, J, 2003) |
| "Thalidomide has antiangiogenic and immunomodulatory effects, mediated by several cytokines such as vascular endothelial growth factor (VEGF), fibroblastic growth factor (FGF-2), hepatocyte growth factor (HGF), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha)." | 5.32 | Response to thalidomide in multiple myeloma: impact of angiogenic factors. ( Arenillas, L; Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004) |
| "Thalidomide was administered at relatively high doses (escalated up to 700 mg daily and continued for 4 months)." | 5.31 | Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. ( Anagnostopoulos, N; Dimopoulos, MA; Zomas, A, 2000) |
| "Thalidomide has been used to treat many inflammatory dermatologic conditions and has been reintroduced in the United States to treat immune-modulated diseases such as pyoderma gangrenosum." | 5.31 | Recalcitrant pyoderma gangrenosum treated with thalidomide. ( Federman, DG; Federman, GL, 2000) |
| "Pomalidomide and dexamethasone is a standard of care for patients with multiple myeloma in whom bortezomib and lenalidomide treatment has failed." | 5.30 | Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. ( Avivi, I; Benyamini, N; Blacklock, H; Chanan-Khan, A; Farooqui, M; George, A; Goldschmidt, H; Iida, S; Jagannath, S; Kher, U; Larocca, A; Liao, J; Lonial, S; Marinello, P; Mateos, MV; Matsumoto, M; Ocio, EM; Oriol, A; Ribrag, V; Rodriguez-Otero, P; San Miguel, J; Schjesvold, F; Sherbenou, D; Simpson, D; Suzuki, K; Usmani, SZ, 2019) |
| "This phase 1 study investigated the safety of the anthracycline amrubicin combined with lenalidomide and dexamethasone in adults with relapsed or refractory multiple myeloma." | 5.27 | A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. ( Berube, C; Coutré, SE; Dinner, S; Dunn, TJ; Gotlib, J; Kaufman, GP; Liedtke, M; Medeiros, BC; Price, E, 2018) |
| "Cases of neuritis responded much more satisfactorily and there was no change in the muscle deficity before or after treatment with thalidomide." | 5.26 | Treatment with thalidomide in steroid dependency and neuritis. ( Theophilus, S, 1980) |
| "Circularly permuted TRAIL (CPT) has exhibited promising efficacy as a mono-therapy or in combination with thalidomide for patients with multiple myeloma (MM)." | 5.24 | Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study. ( Chang, N; Chen, W; Hou, J; Jiang, B; Jiang, H; Jin, J; Ke, X; Leng, Y; Li, J; Li, W; Liu, J; Liu, L; Liu, Y; Meng, H; Pan, L; Pang, H; Qiu, L; Shen, Z; Wang, J; Wang, Z; Wei, P; Yang, L; Yang, S; Zhang, M; Zheng, X; Zhou, F, 2017) |
| "Daratumumab plus pomalidomide and dexamethasone (pom-dex) was evaluated in patients with relapsed/refractory multiple myeloma with ≥2 prior lines of therapy who were refractory to their last treatment." | 5.24 | Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. ( Ahmadi, T; Arnulf, B; Chari, A; Chiu, C; Comenzo, R; Fay, JW; Ifthikharuddin, JJ; Kaufman, JL; Khokhar, NZ; Krishnan, A; Lentzsch, S; Lonial, S; Nottage, K; Suvannasankha, A; Wang, J; Weiss, BM, 2017) |
| "The randomized phase III ELOQUENT-2 study (NCT01239797) evaluated the efficacy and safety of elotuzumab + lenalidomide/dexamethasone (ELd) versus lenalidomide/dexamethasone (Ld) in relapsed/refractory multiple myeloma." | 5.24 | Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. ( Anderson, K; Beksac, M; Belch, A; Bleickardt, E; Dimopoulos, MA; Grosicki, S; Katz, J; Lonial, S; Magen, H; Mateos, MV; Moreau, P; Palumbo, A; Poulart, V; Reece, D; Richardson, P; San-Miguel, J; Sheng, J; Shpilberg, O; Singhal, A; Spicka, I; Sy, O; Walter-Croneck, A; White, D, 2017) |
| " We report a phase 1 study (NCT01241292) in which we evaluated the safety, efficacy and pharmacokinetics of elotuzumab combined with lenalidomide and dexamethasone in Japanese patients with relapsed/refractory multiple myeloma (RRMM)." | 5.24 | Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study. ( Bleickardt, E; Chou, T; Iida, S; Kinoshita, G; Miyoshi, M; Nagai, H; Pandya, D; Robbins, M, 2017) |
| "We report the first clinical investigation conducted in Japan to confirm the safety, tolerability, and pharmacokinetics of ixazomib alone and combined with lenalidomide-dexamethasone (Rd) in Japanese patients with relapsed/refractory multiple myeloma." | 5.24 | Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma. ( Chou, T; Handa, H; Ishizawa, K; Kase, Y; Suzuki, K; Takubo, T, 2017) |
| "The combination of lenalidomide and dexamethasone is an established treatment for patients with multiple myeloma (MM)." | 5.24 | Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study. ( Baker, B; Blacklock, H; Browett, P; Cannell, P; Corbett, G; Cowan, L; Dimopoulos, MA; Fernyhough, L; Forsyth, C; Harrison, S; Henderson, R; Link, E; Miles Prince, H; Neylon, A; Quach, H; Swern, A; Trotman, J; Underhill, C, 2017) |
| "A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression-free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in patients with relapsed multiple myeloma (RMM)." | 5.24 | Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. ( Aggarwal, S; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, A; Ludwig, H; Masszi, T; Mihaylov, GG; Moreau, P; Niesvizky, R; Obreja, M; Oriol, A; Palumbo, A; Rajnics, P; Rosiñol, L; San-Miguel, J; Siegel, D; Špička, I; Stewart, AK; Suvorov, A, 2017) |
| " Of 13 assessable patients (nine with adult T-cell leukaemia-lymphoma, four with other peripheral T-cell lymphomas) receiving lenalidomide, dose-limiting toxic effects were reported in three patients during cycle 1 (one grade 4 thrombocytopenia [cohort 2], one grade 3 QT prolongation on electrocardiogram [cohort 3], and one grade 3 fatigue and grade 4 thrombocytopenia [cohort 3])." | 5.22 | Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. ( Aoki, T; Asou, N; Chen, N; Choi, I; Imaizumi, Y; Maruyama, D; Midorikawa, S; Nosaka, K; Ogura, M; Ohtsu, T; Taguchi, J; Tobinai, K; Tsukasaki, K; Uchida, T; Uike, N; Utsunomiya, A, 2016) |
| "Marizomib (MRZ) is a novel, irreversible proteasome inhibitor in clinical development for the treatment of relapsed or relapsed and refractory multiple myeloma (RRMM)." | 5.22 | Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. ( Anderson, KC; Chanan-Khan, AA; Chauhan, D; Hofmeister, CC; Jakubowiak, AJ; Kaufman, JL; Laubach, JP; Reich, S; Richardson, PG; Talpaz, M; Trikha, M; Zimmerman, TM, 2016) |
| " We evaluated the safety and tolerability of elotuzumab 10 mg/kg combined with thalidomide 50-200 mg and dexamethasone 40 mg (with/without cyclophosphamide 50 mg) in patients with relapsed/refractory multiple myeloma (RRMM)." | 5.22 | Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. ( Blade, J; Bleickardt, E; Gironella, M; Granell, M; Hernandez, MT; Lynch, M; Martín, J; Martinez-Lopez, J; Mateos, MV; Oriol, A; Paliwal, P; San-Miguel, J; Singhal, A, 2016) |
| "Purpose To determine the effects of carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) on health-related quality of life (HR-QoL) in the Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone for the Treatment of Patients With Relapsed Multiple Myeloma (ASPIRE) trial." | 5.22 | Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. ( Buchanan, J; Cocks, K; Dimopoulos, MA; Hájek, R; Jakubowiak, AJ; Ludwig, H; Masszi, T; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Tonda, M; Xing, B; Yang, X; Zojwalla, N, 2016) |
| "Daratumumab showed promising efficacy alone and with lenalidomide and dexamethasone in a phase 1-2 study involving patients with relapsed or refractory multiple myeloma." | 5.22 | Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. ( Ahmadi, T; Bahlis, NJ; Ben Yehuda, D; Chiu, C; Dimopoulos, MA; Goldschmidt, H; Guckert, M; Khokhar, NZ; Komarnicki, M; Lisby, S; Moreau, P; Nahi, H; O'Rourke, L; Oriol, A; Orlowski, RZ; Plesner, T; Qin, X; Rabin, N; Reece, D; Richardson, PG; San-Miguel, J; Suzuki, K; Usmani, SZ; Yoon, SS, 2016) |
| "In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone (POM+LoDEX) improved overall survival (OS) versus high-dose dexamethasone (HiDEX) in 455 patients with relapsed and refractory multiple myeloma (RRMM) after treatment with bortezomib and lenalidomide." | 5.20 | Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone. ( Akehurst, R; Delforge, M; Dhanasiri, S; Dimopoulos, MA; Facon, T; Jacques, C; Lee, D; Morgan, G; Offner, F; Oriol, A; Palumbo, A; Sternas, L; Weisel, K; Yu, X; Zaki, M, 2015) |
| "Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma." | 5.20 | Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. ( Ben-Yehuda, D; Bensinger, WI; Dimopoulos, MA; Goranova-Marinova, V; Hájek, R; Jakubowiak, AJ; Kukreti, V; Ludwig, H; Maisnar, V; Masszi, T; Mateos, MV; Mihaylov, GG; Minarik, J; Moreau, P; Niesvizky, R; Oriol, A; Palumbo, A; Rajkumar, SV; Rajnics, P; Rosiñol, L; San-Miguel, JF; Siegel, DS; Špička, I; Stewart, AK; Suvorov, A; Tonda, ME; Wang, M; Xing, B; Yang, X; Zojwalla, N, 2015) |
| "Elotuzumab, an immunostimulatory monoclonal antibody targeting signaling lymphocytic activation molecule F7 (SLAMF7), showed activity in combination with lenalidomide and dexamethasone in a phase 1b-2 study in patients with relapsed or refractory multiple myeloma." | 5.20 | Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. ( Anderson, KC; Beksac, M; Belch, A; Bleickardt, E; Dimopoulos, M; Einsele, H; Grosicki, S; Katz, J; Lonial, S; Magen, H; Mateos, MV; Matsumoto, M; Moreau, P; Oakervee, H; Orlowski, RZ; Palumbo, A; Poulart, V; Reece, D; Richardson, P; Röllig, C; San-Miguel, J; Singhal, A; Spencer, A; Spicka, I; Taniwaki, M; Walter-Croneck, A; White, D; Wu, KL, 2015) |
| "The oral proteasome inhibitor ixazomib is under phase 3 clinical investigation in multiple myeloma (MM) in combination with lenalidomide-dexamethasone." | 5.20 | Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. ( Chim, CS; Chng, WJ; Esseltine, DL; Goh, YT; Gupta, N; Hanley, MJ; Hui, AM; Kim, K; Lee, JH; Min, CK; Venkatakrishnan, K; Wong, RS; Yang, H, 2015) |
| "In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of bortezomib 1." | 5.19 | A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. ( Alsina, M; Anderson, KC; Colson, K; Esseltine, DL; Feather, J; Francis, D; Ghobrial, IM; Hideshima, T; Jagannath, S; Jakubowiak, A; Kaufman, JL; Knight, R; Lonial, S; Lunde, LE; Maglio, ME; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Raje, NS; Richardson, PG; Schlossman, RL; Vesole, DH; Warren, D; Weller, E; Xie, W, 2014) |
| "Everolimus, an oral mammalian target of rapamycin (mTOR) inhibitor, has been studied in multiple myeloma (MM) but lacks significant single agent activity." | 5.19 | Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. ( Anderson, KC; Burke, JN; Cirstea, DD; Ghobrial, IM; Hari, P; Hideshima, T; Laubach, JP; Mahindra, AK; Marcheselli, R; Munshi, NC; Raje, NS; Richardson, PG; Rodig, SJ; Schlossman, RL; Scullen, TA; Weller, EA; Yee, AJ, 2014) |
| "Data from two randomized pivotal, phase 3 trials evaluating the combination of lenalidomide and dexamethasone in relapsed/refractory multiple myeloma (RRMM) were pooled to characterize the subset of patients who achieved long-term benefit of therapy (progression-free survival ⩾ 3 years)." | 5.19 | Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma. ( Baz, R; Dimopoulos, MA; Hussein, M; Li, JS; Nagarwala, Y; Swern, AS; Weiss, L, 2014) |
| "Lenalidomide-rituximab therapy is effective in grade 1-2 follicular and mantle cell lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL), transformed large cell lymphoma (TL) and grade 3 follicular lymphoma (FLG3) is unknown." | 5.17 | Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. ( Badillo, M; Bejarano, M; Champlin, R; Chen, Y; Cheng, N; Desai, M; Fanale, M; Fayad, L; Feng, L; Fowler, N; Hagemeister, F; Hosing, C; Kwak, L; Neelapu, SS; Newberry, KJ; Oki, Y; Pro, B; Romaguera, J; Shah, J; Thomas, S; Wagner-Bartak, N; Wang, M; Younes, A; Young, KH; Zhang, L, 2013) |
| " BU and CY followed by lenalidomide maintenance therapy in 33 patients with multiple myeloma (MM) who relapsed following an autograft after a median of 12 months." | 5.17 | Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients. ( Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Burchert, A; Hansen, T; Hildebrandt, Y; Klyuchnikov, E; Kröger, N; Kropff, M; Pflüger, KH; Schilling, G; Stübig, T; Wolschke, C; Zabelina, T; Zander, AR, 2013) |
| "Lenalidomide (LEN) has been shown to yield red blood cell (RBC) transfusion independence in about 25% of lower risk myelodysplastic syndromes (MDS) without del(5q), but its efficacy in patients clearly refractory to erythropoiesis-stimulating agents (ESA) is not known." | 5.16 | Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents. ( Banos, A; Baracco, F; Besson, C; Blanc, M; Cannas, G; Corm, S; Fenaux, P; Perrier, H; Prebet, T; Sibon, D; Slama, B; Vey, N; Wattel, E, 2012) |
| "Here we report the efficacy, safety and health-related quality-of-life (HRQoL) associated with long-term lenalidomide and dexamethasone (Len + Dex) treatment in patients with relapsed or refractory multiple myeloma (RRMM) enrolled in the Spanish cohort of the MM-018 study." | 5.16 | Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience. ( Aguado, B; Alegre, A; Cibeira, MT; Garcia-Larana, J; Knight, R; Martinez-Chamorro, C; Mateos, MV; Oriol-Rocafiguera, A; Rosettani, B; Sureda, A, 2012) |
| "The combination of melphalan, prednisone and thalidomide (MPT) has demonstrated efficacy and acceptable toxicity in newly diagnosed and relapsed/refractory patients with multiple myeloma (MM)." | 5.16 | Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma. ( Alesiani, F; Ballanti, S; Boccadoro, M; Caraffa, P; Catarini, M; Cavallo, F; Corvatta, L; Gentili, S; Leoni, P; Liberati, AM; Offidani, M; Palumbo, A; Polloni, C; Pulini, S, 2012) |
| "This multicenter phase 1/2 trial investigated the combination of bendamustine, lenalidomide, and dexamethasone in repeating 4-week cycles as treatment for relapsed refractory multiple myeloma (MM)." | 5.16 | Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. ( Abbas, M; Agha, M; Boyiadzis, M; Burt, S; Dai, L; Kennedy, RC; Lentzsch, S; Mapara, MY; Normolle, D; O'Sullivan, A; Pregja, SL; Roodman, GD; Shuai, Y; Waas, J; Zonder, JA, 2012) |
| "This phase I study evaluated elotuzumab, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (MM)." | 5.16 | Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. ( Facon, T; Harousseau, JL; Jagannath, S; Kaufman, JL; Leleu, X; Lonial, S; Mazumder, A; Moreau, P; Singhal, AK; Tsao, LC; Vij, R; Westland, C, 2012) |
| "Lenalidomide is effective in low-risk myelodysplastic syndromes (MDS) with deletion 5q." | 5.16 | A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities. ( Borthakur, G; Chen, Y; Cortes, J; Estrov, Z; Faderl, S; Kantarjian, H; Ravandi, F; Rey, K, 2012) |
| "This prospective multicenter phase III study compared the efficacy and safety of a triple combination (bortezomib-thalidomide-dexamethasone [VTD]) versus a dual combination (thalidomide-dexamethasone [TD]) in patients with multiple myeloma (MM) progressing or relapsing after autologous stem-cell transplantation (ASCT)." | 5.16 | Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomi ( Cakana, A; Casassus, P; Chaleteix, C; de Witte, T; Dib, M; Doyen, C; Fontan, J; Gahrton, G; Garderet, L; Gorin, NC; Gratwohl, A; Hajek, R; Harousseau, JL; Hertenstein, B; Iacobelli, S; Ketterer, N; Koenecke, C; Kolb, B; Lafon, I; Ludwig, H; Masszi, T; Michallet, M; Milone, G; Mohty, M; Moreau, P; Morris, C; Niederwieser, D; Onida, F; Pegourie, B; van Os, M, 2012) |
| "The combination of lenalidomide-dexamethasone is active in multiple myeloma (MM)." | 5.16 | Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. ( Alsina, M; Anderson, KC; Gardner, L; Giusti, K; Harvey, C; Hideshima, T; Jakubowiak, AJ; Kandarpa, M; Kaufman, JL; Kraftson, S; Poradosu, E; Richardson, PG; Ross, CW; Sportelli, P; Zimmerman, T, 2012) |
| "We evaluated the clinical results of lenalidomide (Len) as a compassionate salvage therapy in refractory/relapsed multiple myeloma (MM) patients." | 5.15 | Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients. ( Aguado, B; Alegre, A; Calvo, JM; Cánovas, A; Castillo, I; de la Serna, J; García, FL; Giraldo, P; Hernández, MT; Ibáñez, Á; Lahuerta, JJ; Martínez-Chamorro, C; Oriol, A; Palomera, L; Ríos, E; Rodríguez, JN, 2011) |
| "Single nucleotide polymorphisms (SNPs) in 12 genes involving multidrug resistance, drug metabolic pathways, DNA repair systems and cytokines were examined in 28 patients with relapsed/refractory multiple myeloma (MM) treated with single agent thalidomide and the results were correlated with response, toxicity and overall survival (OS)." | 5.15 | Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide. ( Bladé, J; Cibeira, MT; de Larrea, CF; Díaz, T; Fuster, D; Monzó, M; Navarro, A; Rosiñol, L; Tovar, N, 2011) |
| "Maintenance therapy was explored in multiple myeloma (MM) patients after conventional thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD)." | 5.14 | Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. ( Alesiani, F; Brunori, M; Burattini, M; Candela, M; Catarini, M; Centurioni, R; Corvatta, L; Ferranti, M; Galieni, P; Gentili, S; Giuliodori, L; Leoni, P; Marconi, M; Mele, A; Offidani, M; Piersantelli, MN; Polloni, C; Samori, A; Visani, G, 2009) |
| "This subset analysis of data from two phase III studies in patients with relapsed or refractory multiple myeloma (MM) evaluated the benefit of initiating lenalidomide plus dexamethasone at first relapse." | 5.14 | Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. ( Belch, A; Dimopoulos, MA; Facon, T; Knight, RD; Niesvizky, R; Olesnyckyj, M; Prince, MH; San Miguel, JF; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB, 2009) |
| "Lenalidomide plus dexamethasone is effective for the treatment of relapsed and refractory multiple myeloma (MM); however, toxicities from dexamethasone can be dose limiting." | 5.14 | Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. ( Anderson, KC; Badros, AZ; Bensinger, W; Berenson, J; Hussein, M; Irwin, D; Jagannath, S; Kenvin, L; Knight, R; Olesnyckyj, M; Richardson, P; Singhal, S; Vescio, R; Williams, SF; Yu, Z; Zeldis, J, 2009) |
| "Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM)." | 5.14 | Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. ( Alsina, M; Anderson, KC; Avigan, DE; Dalton, W; Delaney, C; Doss, D; Esseltine, DL; Ghobrial, IM; Hideshima, T; Jagannath, S; Knight, R; Lunde, LE; Mazumder, A; McKenney, M; Mitsiades, CS; Munshi, NC; Richardson, PG; Schlossman, RL; Warren, DL; Weller, E, 2009) |
| "The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported." | 5.14 | Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. ( Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U, 2010) |
| "The results from this study indicated that, with careful monitoring of the CLCr level and adverse events as well as appropriate dose adjustments, lenalidomide plus dexamethasone is an effective and well tolerated treatment option for patients with multiple myeloma who have RI." | 5.14 | The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. ( Alegre, A; de Castro, CM; Dimopoulos, M; Goldschmidt, H; Masliak, Z; Olesnyckyj, M; Reece, D; Stadtmauer, EA; Weber, DM; Yu, Z; Zonder, JA, 2010) |
| "Patients with recurrent and refractory T-cell lymphomas other than mycosis fungoides and untreated patients ineligible for combination chemotherapy were prescribed oral lenalidomide (25 mg daily) on Days 1 to 21 of each 28-day cycle until disease progression, death, or unacceptable toxicity." | 5.14 | Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma. ( Belch, A; Chua, N; Dueck, G; Finch, D; Johnston, J; Prasad, A; Reiman, T; Stewart, D; van der Jagt, R; White, D, 2010) |
| "Thalidomide is an effective agent for advanced refractory or relapsed multiple myeloma (MM), although dose-limiting toxicity (DLT) may limit its use." | 5.13 | Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial. ( Boldt, T; Goldschmidt, H; Haas, A; Hoffmann, FA; Kreibich, U; Niederwieser, D; Pönisch, W; Ritter, U; Rohrberg, R; Rozanski, M; Schirmer, V; Schwalbe, E; Schwarzer, A; Uhlig, J; Zehrfeld, T, 2008) |
| "Thalidomide has been estimated as a useful drug in therapy of refractory or relapsed multiple myeloma." | 5.13 | Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma. ( Adam, Z; Bacovsky, J; Gregora, E; Minarik, J; Pavlicek, P; Pika, T; Pour, L; Scudla, V; Zemanova, M, 2008) |
| "Twenty-one patients with multiple myeloma, all relapsed after frontline autologous stem cell transplantation and all relapsed again after or resistant to thalidomide (employed as second line treatment) received bortezomib (1." | 5.12 | Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. ( Balleari, E; Boccadoro, M; Bodenizza, C; Carella, AM; Cascavilla, N; Catalano, L; Cavallo, F; Dell'Olio, M; Falcone, A; Greco, MM; Guglielmelli, T; La Sala, A; Mantuano, S; Melillo, L; Merla, E; Musto, P; Nobile, M; Palumbo, A; Sanpaolo, G; Scalzulli, PR; Spriano, M; Zambello, R, 2006) |
| "High-dose therapy with melphalan can prolong survival among patients with multiple myeloma." | 5.12 | Thalidomide and hematopoietic-cell transplantation for multiple myeloma. ( Anaissie, E; Barlogie, B; Crowley, J; Fassas, A; Fox, M; Hollmig, K; Kiwan, E; Krishna, S; Lee, C; Pineda-Roman, M; Rasmussen, E; Shaughnessy, J; Talamo, G; Thertulien, R; Tricot, G; van Rhee, F; Zangari, M, 2006) |
| "Lenalidomide is active and well tolerated in relapsed and refractory multiple myeloma." | 5.12 | Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. ( Andresen, S; Baz, R; Brand, C; Bruening, K; Choueiri, TK; Ellis, Y; Faiman, B; Hussein, MA; Jawde, RA; Karam, MA; Knight, R; Reed, J; Srkalovic, G; Walker, E; Zeldis, J, 2006) |
| "In multiple myeloma (MM), the addition of thalidomide or bortezomib to the standard oral melphalan/prednisone combination significantly increased response rate and event-free survival." | 5.12 | Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. ( Ambrosini, MT; Avonto, I; Benevolo, G; Boccadoro, M; Bringhen, S; Callea, V; Cangialosi, C; Caravita, T; Cavallo, F; Falco, P; Morabito, F; Musto, P; Palumbo, A; Pescosta, N; Pregno, P, 2007) |
| "Lenalidomide plus dexamethasone is more effective than high-dose dexamethasone alone in relapsed or refractory multiple myeloma." | 5.12 | Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. ( Attal, M; Corso, A; Dimopoulos, M; Dmoszynska, A; Facon, T; Foà, R; Harousseau, JL; Hellmann, A; Knight, RD; Masliak, Z; Olesnyckyj, M; Patin, J; Prince, HM; San Miguel, J; Spencer, A; Yu, Z; Zeldis, JB, 2007) |
| "Lenalidomide, an oral immunomodulatory drug that is similar to thalidomide but has a different safety profile, has clinical activity in relapsed or refractory multiple myeloma." | 5.12 | Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. ( Belch, A; Borrello, I; Chanan-Khan, AA; Chen, C; Knight, RD; Lonial, S; Niesvizky, R; Olesnyckyj, M; Patin, J; Rajkumar, SV; Siegel, D; Stadtmauer, EA; Wang, M; Weber, DM; Yu, Z; Zeldis, JB, 2007) |
| "To determine the progression-free survival at 12 weeks, to evaluate the toxic effects, and to analyze the biological activity of thalidomide in patients with relapsed multiple myeloma (MM) after high-dose chemotherapy and stem cell transplantation." | 5.11 | Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. ( Alsina, M; Anderson, K; Blood, E; Bosch, J; Dalton, W; Davies, F; Desikan, R; Doss, D; Freeman, A; Hideshima, T; Jagannath, S; Knight, R; Mitsiades, C; Patin, J; Richardson, P; Schlossman, R; Weller, E; Zeldis, J, 2004) |
| "To evaluate safety and efficacy of thalidomide in the treatment of prurigo nodularis in a group of human immunodeficiency virus (HIV)-infected patients whose condition was recalcitrant to standard treatment." | 5.11 | Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy. ( Berger, T; Maurer, T; Poncelet, A, 2004) |
| "Based on the efficacy of thalidomide in multiple myeloma and on its synergy with dexamethasone on myeloma plasma cells, we evaluated the combination of thalidomide (100 mg/d, with 100-mg increments every 2 weeks, up to 400 mg) and dexamethasone (20 mg on days 1-4) every 21 days in 31 patients with primary amyloidosis (AL) whose disease was refractory to or had relapsed after first-line therapy." | 5.11 | The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). ( Caccialanza, R; Comotti, B; Invernizzi, R; Lavatelli, F; Merlini, G; Obici, L; Palladini, G; Perfetti, V; Perlini, S, 2005) |
| "Thalidomide is an effective agent for patients with refractory multiple myeloma (MM) with a response rate of 30-40% at doses of 200-800 mg but with considerable side effects." | 5.11 | Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. ( Daenen, SM; de Wolf, JT; Hovenga, S; Kluin-Nelemans, HC; Sluiter, WJ; van Imhoff, GW; Vellenga, E, 2005) |
| "G3139, dexamethasone, and thalidomide are well tolerated and result in encouraging clinical responses in relapsed multiple myeloma patients." | 5.11 | Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. ( Badros, AZ; Fenton, RG; Flaws, JA; Gahres, N; Gocke, CD; Goloubeva, O; Heyman, M; Meisenberg, B; Rapoport, AP; Ratterree, B; Streicher, H; Takebe, N; Tomic, D; Zhang, B; Zwiebel, J, 2005) |
| "The feasibility and efficacy of a triple regimen of oral weekly cyclophosphamide, monthly pulsed dexamethasone and low-dose Thalidomide (CDT) was studied in 52 patients with relapsed or refractory multiple myeloma (MM)." | 5.11 | Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. ( D'Sa, S; Flory, A; Goldstone, AH; Hanslip, J; Kyriakou, C; Thomson, K; Yong, KL, 2005) |
| "The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma." | 5.11 | Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma. ( Ashihara, E; Fuchida, S; Hatsuse, M; Ochiai, N; Okamoto, M; Okano, A; Shimazaki, C; Uchida, R; Yamada, N, 2005) |
| "Although thalidomide (Thal) was introduced successfully in the treatment of multiple myeloma (MM), the optimal Thal dosage and schedule are still controversial." | 5.10 | Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. ( Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Kraemer, A; Moehler, T; Neben, K, 2002) |
| "Though thalidomide in a dosage of 100 mg/day is the standard treatment for recurrent oral and genital ulcers (OGU), its toxicity would be less important with lower dosage, while its efficacy would be identical." | 5.09 | [Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients]. ( Berthier, S; de Wazières, B; Dupond, JL; Gil, H; Magy, N; Vuitton, DA, 1999) |
| "Thalidomide is currently used as a very promising drug in patients with recurrent multiple myeloma or those refractory to chemotherapy." | 5.09 | Thalidomide treatment of resistant or relapsed multiple myeloma patients. ( Ciepnuch, H; Dmoszynska, A; Hellmann, A; Hus, M; Jawniak, D; Legiec, W; Manko, J; Skotnicki, A; Soroka-Wojtaszko, M; Wolska-Smolen, T, 2001) |
| "Thalidomide is effective for treating the oral and genital ulcers and follicular lesions of the Behçet syndrome." | 5.08 | Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial. ( Hamuryudan, V; Mat, C; Ozyazgan, Y; Saip, S; Siva, A; Yazici, H; Yurdakul, S; Zwingenberger, K, 1998) |
| "Sequential combined therapy with thalidomide and narrow-band UVB therapy could improve the management of prurigo nodularis with minimal side effects, although it should probably be reserved to men and women over 50 years of age." | 5.08 | Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis. ( Bielsa, I; Carrascosa, JM; Ferrándiz, C; Just, M; Ribera, M, 1997) |
| "Thalidomide was given to 15 patients with severe orogenital ulceration (OGU)." | 5.05 | Thalidomide in severe orogenital ulceration. ( Allen, BR; Jenkins, JS; Littlewood, SM; Maurice, PD; Powell, RJ; Smith, NJ, 1984) |
| "We sought to evaluate the activity and safety of carfilzomib-/ixazomib-containing combinations for patients with relapsed/refractory multiple myeloma (RRMM)." | 4.98 | Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma. ( Guo, H; Sun, X; Wang, B; Xu, W, 2018) |
| " In a few small studies, thalidomide was shown to consistently improve severity and frequency of epistaxis and improve hemoglobin concentrations while decreasing the need for transfusion." | 4.98 | Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review. ( Clark, C; Halderman, AA; Invernizzi, R; Marple, BF; Poetker, DM; Reh, DD; Ryan, MW; Sindwani, R, 2018) |
| " Thalidomide has been used as a therapeutic strategy for refractory epistaxis in hereditary haemorrhagic telangiectasia patients." | 4.98 | The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review. ( Harrison, L; Jervis, P; Kundra, A, 2018) |
| "The aim of this study was to present a new case on the successful use of thalidomide in a patient with acquired von Willebrand syndrome and recurrent angiodysplasia-related GI bleedings, and to conduct a literature review on the use of thalidomide in patients with GI angiodysplasia." | 4.91 | Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature. ( Engelen, ET; Schutgens, RE; van Galen, KP, 2015) |
| "Oral pomalidomide (Imnovid® [EU]; Pomalyst® [USA]) in combination with dexamethasone (in the EU), is approved in several countries for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy (or progression within the last 60 days in the USA)." | 4.90 | Pomalidomide: a review of its use in patients with recurrent multiple myeloma. ( Scott, LJ, 2014) |
| "The outcomes and management of multiple myeloma (MM) in the United States have changed dramatically over the past 15 years with the approval by the US Food and Drug Administration (FDA) of 6 new drugs (thalidomide, lenalidomide, bortezomib, pegylated liposomal doxorubicin [Doxil], carfilzomib, and pomalidomide)." | 4.90 | Novel drug combinations for the management of relapsed/refractory multiple myeloma. ( Lonial, S; Usmani, SZ, 2014) |
| "Mantle cell lymphoma (MCL), which accounts for about 6% of non-Hodgkin lymphoma (NHL), is characterized by the chromosomal translocation t(11;14)(q13;q32), resulting in de-regulated expression of cyclin D1." | 4.89 | Therapies for mantle cell lymphoma: current challenges and a brighter future. ( Skarbnik, AP; Smith, MR, 2013) |
| "Widespread use of the novel agents bortezomib and lenalidomide has improved outcomes in multiple myeloma (MM)." | 4.89 | Management of double-refractory multiple myeloma. ( Mark, TM; Meadows, JP, 2013) |
| "Novel agents such as thalidomide, bortezomib, and lenalidomide have improved outcomes and extended survival in patients with relapsed and/or refractory multiple myeloma (RRMM)." | 4.88 | Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy? ( Ludwig, H; Sonneveld, P, 2012) |
| "In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin." | 4.87 | Treatment-related adverse events in patients with relapsed/refractory multiple myeloma. ( Vij, R, 2011) |
| "In several countries, including the US and in Europe, oral lenalidomide in combination with oral dexamethasone is approved for the treatment of multiple myeloma patients (aged ≥ 18 years) who have received at least one prior antimyeloma therapy." | 4.87 | Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma. ( Lyseng-Williamson, KA; Scott, LJ, 2011) |
| "To estimate the cost-effectiveness of bortezomib (BTZ) compared with dexamethasone (DEX) and lenalidomide plus dexamethasone (LEN/DEX) for the treatment of relapsed/refractory multiple myeloma in Sweden." | 4.86 | The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. ( Aschan, J; Dhawan, R; Hornberger, J; Liwing, J; Löthgren, M; Rickert, J, 2010) |
| "Thalidomide monotherapy in relapsed/refractory multiple myeloma (MM) has a response rate of 30%." | 4.84 | A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. ( Bargou, R; Cook, G; Furkert, K; Glasmacher, A; Hahn-Ast, C; Hoffmann, F; Naumann, R; von Lilienfeld-Toal, M, 2008) |
| "Given that the efficacy/safety of thalidomide for relapsed or refractory multiple myeloma have not been well characterized in a randomized, controlled setting, an analysis of larger, single-agent trials was conducted." | 4.84 | An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma. ( Mileshkin, L; Prince, HM; Schenkel, B, 2007) |
| "Thalidomide has been demonstrated to be active as a first-line and salvage therapy in patients with multiple myeloma." | 4.83 | The role of thalidomide in multiple myeloma. ( Jagannath, S; Schwab, C, 2006) |
| "To evaluate the literature regarding the dosing of thalidomide in multiple myeloma." | 4.82 | Thalidomide dosing in patients with relapsed or refractory multiple myeloma. ( Hansen, LA; Thompson, JL, 2003) |
| "Thalidomide is the first drug in over 20 years to demonstrate clinically significant activity in patients with multiple myeloma." | 4.81 | Thalidomide for the treatment of relapsed and refractory multiple myeloma. ( Cool, RM; Herrington, JD, 2002) |
| "Lenalidomide is an important component of initial therapy in newly diagnosed multiple myeloma, either as maintenance therapy post-autologous stem cell transplantation (ASCT) or as first-line therapy with dexamethasone for patients' ineligible for ASCT (non-ASCT)." | 4.02 | Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada. ( Aslam, M; Atenafu, EG; Cherniawsky, H; Gul, E; Jimenez-Zepeda, VH; Kotb, R; LeBlanc, R; Louzada, ML; Masih-Khan, E; McCurdy, A; Reece, DE; Reiman, A; Sebag, M; Song, K; Stakiw, J; Venner, CP; White, D, 2021) |
| "Pomalidomide demonstrated activity in the treatment of AL amyloidosis in three phase II clinical trials." | 3.96 | Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients. ( Basset, M; Foli, A; Hegenbart, U; Kimmich, C; Mahmood, S; Merlini, G; Milani, P; Nuvolone, M; Palladini, G; Sachchithanantham, S; Schönland, SO; Sharpley, F; Wechalekar, A, 2020) |
| "To evaluate the efficacy and safety of apremilast in treating oral ulcers (OUs), the cardinal and high-disabling feature of Behçet's disease (BD)." | 3.96 | Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience. ( Boffini, N; Campochiaro, C; Cariddi, A; Cavalli, G; Dagna, L; De Luca, G; Tomelleri, A; Vanni, D, 2020) |
| "We analyzed gene expression levels of CRBN, cMYC, IRF4, BLIMP1, and XBP1 in 224 patients with multiple myeloma treated with pomalidomide and low-dose dexamethasone in the STRATUS study (ClinicalTrials." | 3.91 | Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. ( Amatangelo, M; Bjorklund, C; Dimopoulos, MA; Flynt, E; Moreau, P; Ocio, EM; Peluso, T; Qian, X; Sternas, L; Thakurta, A; Towfic, F; Weisel, KC; Yu, X; Zaki, M, 2019) |
| "Pomalidomide dexamethasone is a standard of care for relapsed multiple myeloma (MM) patients who received at least two prior lines of therapy, including both lenalidomide and proteasome inhibitors (PI)." | 3.91 | Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study. ( Blin, N; Bonnet, A; Chevallier, P; Dubruille, V; Garnier, A; Gastinne, T; Guillaume, T; Jullien, M; Le Bourgeois, A; Le Gouill, S; Lok, A; Mahé, B; Moreau, P; Peterlin, P; Tessoulin, B; Touzeau, C; Trudel, S, 2019) |
| "The combination of pomalidomide and low-dose dexamethasone (Pom-Dex) has proved effective and safe in patients with end-stage relapsed/refractory multiple myeloma (RRMM), otherwise characterized by a very poor outcome." | 3.88 | Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma. ( Araujo, C; Arnulf, B; Attal, M; Avet-Loiseau, H; Benboubker, L; Brechiniac, S; Caillot, D; Decaux, O; Dib, M; Escoffre-Barbe, M; Facon, T; Fermand, JP; Fouquet, G; Garderet, L; Hulin, C; Karlin, L; Kolb, B; Leleu, X; Macro, M; Mathiot, C; Moreau, P; Pegourie, B; Perrot, A; Petillon, MO; Richez, V; Rodon, P; Roussel, M; Royer, B; Stoppa, AM; Tiab, M; Wetterwald, M, 2018) |
| "Determinants of the efficacy and safety of pomalidomide (POM) monotherapy or POM plus dexamethasone (DEX) (POM/DEX) for relapsed and refractory multiple myeloma (RRMM) were examined retrospectively in a real-world clinical practice setting in Japan." | 3.88 | Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum. ( Fuchida, SI; Hino, M; Iida, M; Imada, K; Ishikawa, J; Kamitsuji, Y; Kanakura, Y; Kaneko, H; Kobayashi, M; Kosugi, S; Kuroda, J; Matsuda, M; Matsui, T; Matsumura, I; Matsumura-Kimoto, Y; Nakaya, A; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Uchiyama, H; Uoshima, N; Wada, K; Yagi, H; Yokota, I, 2018) |
| "To investigate the efficacy, safety, and cost of a pomalidomide-dexamethasone regimen in patients with relapsed and refractory multiple myeloma (RRMM)." | 3.88 | Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma. ( Aho, LS; Boulin, M; Caillot, D; Chretien, ML; Cransac-Miet, A; Favennec, C; Gueneau, P; Guy, J; Lafon, I, 2018) |
| "Pomalidomide plus low-dose dexamethasone (POM-d), daratumumab monotherapy (DARA), and carfilzomib monotherapy (CAR) have been approved for use in the treatment of patients with heavily pretreated relapsed-refractory multiple myeloma (RRMM) in the US, based on findings from the MM-002, SIRIUS, and PX-171-003-A1 studies, respectively." | 3.85 | Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States. ( Abouzaid, S; Ailawadhi, S; Chandler, C; Guo, S; Mouro, J; Parikh, K; Pelligra, CG, 2017) |
| "In the UK, the standard of care for patients with multiple myeloma who received ≥2 prior treatments is lenalidomide plus dexamethasone (LEN + DEX) and pomalidomide plus DEX (POM + DEX) (in Wales only)." | 3.85 | Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data. ( Gray, E; Krishna, A; Majer, I; Polanyi, Z; Roy, A; van de Wetering, G, 2017) |
| "On November 30, 2015, the FDA approved elotuzumab (Empliciti; Bristol-Myers Squibb) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who received one to three prior therapies." | 3.85 | FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma. ( Deisseroth, A; Farrell, AT; Goldberg, KB; Gormley, NJ; Kaminskas, E; Ko, CW; Kormanik, N; Nie, L; Pazdur, R, 2017) |
| "Multiple myeloma (MM) patients who have progressed following treatment with both bortezomib and lenalidomide have a poor prognosis." | 3.83 | Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden. ( Borg, S; Elvidge, J; Hansson, M; Lee, D; Nahi, H; Persson, U, 2016) |
| "To assess the economic value of carfilzomib (Kyprolis), this study developed the Kyprolis Global Economic Model (K-GEM), which examined from a United States (US) payer perspective the cost-effectiveness of carfilzomib-lenalidomide-dexamethasone (KRd) versus lenalidomide-dexamethasone (Rd) in relapsed multiple myeloma (RMM; 1-3 prior therapies) based on results from the phase III ASPIRE trial that directly compared these regimens." | 3.83 | Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. ( Aggarwal, SK; Barber, BL; Benedict, Á; Campioni, M; Giannopoulou, A; Houisse, I; Jakubowiak, AJ; Panjabi, S; Tichy, E, 2016) |
| "Circulating vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and selectins were prospectively measured in 145 newly-diagnosed patients with symptomatic myeloma (NDMM), 61 patients with asymptomatic/smoldering myeloma (SMM), 47 with monoclonal gammopathy of undetermined significance (MGUS) and 87 multiple myeloma (MM) patients at first relapse who received lenalidomide- or bortezomib-based treatment (RD, n=47; or VD, n=40)." | 3.83 | Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment. ( Christoulas, D; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Iakovaki, M; Kanellias, N; Kastritis, E; Migkou, M; Panagiotidis, I; Terpos, E; Ziogas, DC, 2016) |
| "2 years) underwent clinical and neurophysiologic assessment at baseline and at 2 (8 patients, group A) or 5 years (11 patients, group B) after starting lenalidomide therapy for relapsed/refractory multiple myeloma." | 3.83 | Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study. ( Barilà, G; Berno, T; Briani, C; Cacciavillani, M; Campagnolo, M; Dalla Torre, C; De March, E; Ermani, M; Lico, A; Lucchetta, M; Salvalaggio, A; Zambello, R, 2016) |
| "Thalidomide has been successful use in patients with refractory Crohn disease (CD) in recent years." | 3.83 | Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review. ( Hu, H; Liu, S; Wang, X, 2016) |
| "This is a retrospective chart review to evaluate the efficacy of the addition of vorinostat to lenalidomide and dexamethasone in patients with multiple myeloma relapsed/refractory to lenalidomide and dexamethasone." | 3.83 | Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma. ( Bednarz, U; Bilotti, E; Gao, Z; Gilani, M; Graef, T; Mato, A; McBride, L; McNeill, A; Richter, J; Schmidt, L; Siegel, DS; Vesole, DH, 2016) |
| "In 12 patients with relapsed or refractory acute myelogenous leukemia (AML), the efficacy and safety of a novel regimen, namely thalidomide combined with interferon and interleukin 2 (IL-2), were initially explored." | 3.83 | [Thalidomide combined with interferon and interleukin-2 in treatment of relapsed or refractory acute myelogenous leukemia]. ( Ai, H; Chen, L; Hao, QM; Mi, RH; Song, YP; Wang, P; Wei, XD; Yin, QS; Yuan, FF, 2016) |
| "Lenalidomide was approved for the treatment of relapsed and refractory multiple myeloma (rrMM) based on MM009 and MM010 clinical trials." | 3.81 | Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center. ( Coelho, I; Costa, C; Esteves, S; João, C; Lucio, P, 2015) |
| "Treatment options are limited in myeloma relapsed or refractory to both bortezomib and lenalidomide (double-relapsed/refractory multiple myeloma; DRMM)." | 3.81 | Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. ( Aitchison, R; Blesing, N; Lau, IJ; Peniket, A; Rabin, N; Ramasamy, K; Roberts, P; Smith, D; Yong, K, 2015) |
| "We retrospectively investigated the prognostic factor of lenalidomide plus low-dose dexamethasone (Rd) in Japanese patients with refractory or relapsed multiple myeloma (RRMM) registered in the Kansai Myeloma Forum from January 2006 to December 2013." | 3.81 | Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma. ( Adachi, Y; Fuchida, S; Ishii, K; Kanakura, Y; Kaneko, H; Kobayashi, M; Kobayashi, T; Kosugi, S; Kuroda, J; Matsuda, M; Matsumura, I; Nakatani, E; Nomura, S; Ohta, K; Shibayama, H; Shimazaki, C; Takaori-Kondo, A; Tanaka, H; Taniwaki, M; Tsudo, M; Uchiyama, H; Uoshima, N; Yagi, H, 2015) |
| "The introduction of immunomodulatory drugs such as lenalidomide combined with dexamethasone (Len/Dex) has improved the outcome of patients with relapsed/refractory multiple myeloma (RRMM)." | 3.81 | Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. ( Bacchiarri, F; Bosi, A; Donnini, I; Guarrera, A; Longo, G; Nozzoli, C; Staderini, M; Veltroni, A, 2015) |
| "In the past decade, the introduction of bortezomib, thalidomide, and lenalidomide has changed the treatment of multiple myeloma (MM) dramatically." | 3.81 | [Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy]. ( Nakaseko, C; Sakaida, E; Takeda, Y, 2015) |
| "In this retrospective real-life study in relapsed/refractory multiple myeloma patients, we analyzed clinical and biologic features distinguishing patients with rapidly progressing disease while receiving lenalidomide therapy from those without progression." | 3.81 | Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation. ( Battistutta, C; Berno, T; Bonaldi, L; Branca, A; Briani, C; Cavraro, M; De March, E; Gurrieri, C; Lico, A; Martines, A; Minotto, C; Piazza, F; Sechettin, E; Semenzato, G; Temporin, F; Trentin, L; Zambello, R, 2015) |
| "Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis." | 3.81 | Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs. ( Bullement, A; Dickens, E; Elvidge, J; Gooding, S; Lau, IJ; Lee, D; Ramasamy, K; Roberts, P; Sheikh, M; Wong, J, 2015) |
| "Lenalidomide and dexamethasone (RD) is a standard of care for relapsed/refractory multiple myeloma (RRMM), but there is limited published data on its efficacy and safety in the "real world" (RW), according to the International Society of Pharmacoeconomics and Outcomes Research definition." | 3.80 | "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. ( Anagnostopoulos, N; Anargyrou, K; Briasoulis, E; Giannakoulas, N; Hatzimichael, E; Karras, G; Katodritou, E; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Lalagianni, C; Maniatis, A; Matsouka, P; Michali, E; Papageorgiou, G; Spanoudakis, E; Symeonidis, A; Terpos, E; Tsakiridou, A; Tsionos, K; Vadikolia, C; Zikos, P, 2014) |
| "Lenalidomide in combination with dexamethasone is an effective and well-established treatment of relapsed or refractory multiple myeloma (rrMM) disease." | 3.80 | Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. ( Hahn-Ast, C; Kanz, L; Oehrlein, K; Rendl, C; Weisel, K; Zago, M, 2014) |
| "A 62 year-old Caucasian man with hypertension and a 4-year history of multiple myeloma, had been previously treated with lenalidomide, bortezomib and two autologous hematopoietic stem cell transplants." | 3.80 | Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. ( Hobeika, L; Self, SE; Velez, JC, 2014) |
| "A lenalidomide-based regimen was highly effective in this patient with diffuse large B-cell lymphoma." | 3.80 | Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report. ( Gałązka, K; Gruchała, A; Jurczak, W; Krawczyk, K; Skotnicki, AB, 2014) |
| " In this report, we presented a Chinese patient with recurrent melena due to gastric angiodysplasia in HHT treated successfully with thalidomide." | 3.79 | Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia. ( Chen, Y; Du, Q; Wang, XY, 2013) |
| "The introduction of autologous stem cell transplantation as well as novel agents such as proteasome inhibitors (bortezomib) and immunomodulatory drugs (IMiDs; thalidomide and lenalidomide) have significantly improved long-term outcome of multiple myeloma patients." | 3.79 | New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. ( Lokhorst, HM; van de Donk, NW, 2013) |
| "The combination of lenalidomide, bortezomib and dexamethasone (RVD) has shown excellent efficacy in patients with relapsed or refractory multiple myeloma (RRMM)." | 3.79 | Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma. ( Chen, C; Jimenez-Zepeda, VH; Kukreti, V; Reece, DE; Tiedemann, R; Trudel, S, 2013) |
| "Few data are available on the efficacy of the combination of lenalidomide plus dexamethasone (Len/Dex) in very elderly patients above 75 years of age with relapsed multiple myeloma (MM)." | 3.78 | Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma. ( Blin, N; Clavert, A; Dubruille, V; Le Gouill, S; Loirat, M; Mahe, B; Malard, F; Mohty, M; Moreau, P; Pennetier, M; Peterlin, P; Planche, L; Roland, V; Tessoulin, B; Touzeau, C, 2012) |
| "del(17p13)(TP53) seems to be an independent poor prognostic factor in patients with relapsed/refractory multiple myeloma (MM) receiving lenalidomide." | 3.78 | p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide. ( Chang, H; Chen, MH; Qi, CX; Saha, MN, 2012) |
| "Retrospective multicenter analysis of 26 patients with multiple myeloma to assess the efficacy and toxicity of relapse treatment with lenalidomide/dexamethasone in renal-function impairment." | 3.78 | Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers. ( Hahn-Ast, C; Kuhn, S; Langer, C; Oehrlein, K; Pönisch, W; Sturm, I; Weisel, KC, 2012) |
| "Two pivotal, phase III, randomised, placebo-controlled, registration trials (MM-009 and MM-010) showed that lenalidomide plus dexamethasone was more effective than placebo plus dexamethasone in the treatment of patients with relapsed or refractory multiple myeloma." | 3.78 | Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. ( Borrello, I; Chanan-Khan, AA; Dimopoulos, M; Foà, R; Hellmann, A; Knight, R; Lonial, S; Swern, AS; Weber, D, 2012) |
| " For relapsed or refractory multiple myeloma (RRMM), a series of novel agents (thalidomide, bortezomib and lenalidomide) has emerged during the latest decade, but their use in routine clinical practice is not well documented as well as the cost of RRMM." | 3.77 | Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study. ( Armoiry, X; Aulagner, G; Benboubker, L; Facon, T; Fagnani, F; Fermand, JP; Hulin, C; Moreau, P, 2011) |
| "In the era of novel agents such as lenalidomide and bortezomib, risk stratification by chromosomal abnormalities may enable a more rational selection of therapeutic approaches in patients with multiple myeloma (MM)." | 3.77 | Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone. ( Goldschmidt, H; Hielscher, T; Hillengass, J; Ho, AD; Hose, D; Jauch, A; Klein, U; Neben, K; Raab, MS; Seckinger, A, 2011) |
| "Evidence of long-term response to lenalidomide in heavily pretreated patients with multiple myeloma is lacking." | 3.77 | Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant. ( Citro, A; Corradini, P; Crippa, C; De Muro, M; Falcone, AP; Galli, M; Gentili, S; Grasso, M; Guglielmelli, T; Montefusco, V; Olivero, B; Patriarca, F; Rossi, D; Sammassimo, S; Spina, F, 2011) |
| "Thalidomide based regimen is an effective and well tolerated therapy in multiple myeloma (MM) patients, however, there were a small number of studies written about the results of thalidomide therapy in non-transplant MM patients." | 3.76 | Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand. ( Atichartakarn, V; Aungchaisuksiri, P; Chuncharunee, S; Jootar, S; Niparuck, P; Puavilai, T; Sorakhunpipitkul, L; Ungkanont, A, 2010) |
| "To obtain efficacy and safety data on lenalidomide treatment outside of clinical trials, we analyzed the clinical data of 114 patients with refractory or relapsed multiple myeloma treated with lenalidomide on a compassionate use basis." | 3.76 | Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program. ( Eeltink, CM; Huls, G; Kersten, MJ; Kneppers, E; Koedam, J; Lokhorst, HM; Minnema, MC; Raymakers, RA; Schaafsma, MR; Sonneveld, P; van Oers, MH; Vellenga, E; Wijermans, PW; Wittebol, S; Zweegman, S, 2010) |
| "Thalidomide is now recognized as an important agent for multiple myeloma." | 3.76 | [Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma]. ( Akagi, T; Goto, K; Ikebe, T; Ikewaki, J; Imamura, T; Kadota, J; Kohno, K; Miyazaki, M; Miyazaki, Y; Ogata, M; Ohtsuka, E; Saburi, Y; Uno, N, 2010) |
| "Previous literature suggests that cytogenetics may be used for risk-adapted therapy in patients with relapsed/refractory multiple myeloma (MM) treated with lenalidomide and dexamethasone." | 3.76 | Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. ( Chang, H; Chen, C; Jiang, A; Qi, C; Reece, D; Trieu, Y, 2010) |
| "The immunomodulatory drugs thalidomide and lenalidomide have enhanced activity in patients with multiple myeloma (MM)." | 3.75 | Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone. ( Goldschmidt, H; Hegenbart, U; Hillengass, J; Ho, AD; Hundemer, M; Klein, U; Kosely, F; Moehler, T; Neben, K; Schmitt, S, 2009) |
| "A prospective subgroup analysis of two prospective, randomized, double-blind, placebo-controlled phase III clinical trials showed that the combination of lenalidomide plus dexamethasone is superior to dexamethasone alone in patients with relapsed or refractory multiple myeloma who had been previously treated with thalidomide; the implications for clinical practice are discussed." | 3.75 | Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma. ( Meijer, E; Sonneveld, P, 2009) |
| "Lenalidomide gained Food and Drug Administration (FDA) approval for treatment of patients with relapsed or refractory multiple myeloma (MM) in combination with dexamethasone in June 2006." | 3.75 | Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma. ( Abonour, R; Alsina, M; Bahlis, NJ; Boccia, RV; Chen, C; Coutre, SE; Knight, RD; Kumar, S; Matous, J; Niesvizky, R; Pietronigro, D; Rajkumar, V; Reece, DE; Richardson, P; Siegel, D; Stadtmauer, EA; Vescio, R; Zeldis, JB, 2009) |
| "We present a pooled update of two large, multicenter MM-009 and MM-010 placebo-controlled randomized phase III trials that included 704 patients and assessed lenalidomide plus dexamethasone versus dexamethasone plus placebo in patients with relapsed/refractory multiple myeloma (MM)." | 3.75 | Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. ( Attal, M; Chen, C; Dimopoulos, MA; Knight, RD; Niesvizky, R; Olesnyckyj, M; Petrucci, MT; Spencer, A; Stadtmauer, EA; Weber, DM; Yu, Z; Zeldis, JB, 2009) |
| "This analysis assessed the efficacy and safety of lenalidomide + dexamethasone in patients with relapsed or refractory multiple myeloma (MM) previously treated with thalidomide." | 3.74 | Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. ( Attal, M; Chen, C; Cibeira, MT; Dimopoulos, MA; Knight, RD; Olesnyckyj, M; Rajkumar, SV; Spencer, A; Wang, M; Weber, DM; Yu, Z; Zeldis, JB, 2008) |
| "Thalidomide is one of the drugs which are newly used in the therapy of multiple myeloma." | 3.74 | [Low-dose thalidomide in refractory and relapsing multiple myeloma]. ( Maisnar, V; Radocha, J, 2007) |
| "Thalidomide is successfully used in the treatment of multiple myeloma, leprosy and various autoimmune diseases due to its anti-angiogenic, immunomodulatory and anti-inflammatory effects." | 3.74 | Leukocytoclastic vasculitis due to thalidomide in multiple myeloma. ( Alpay, N; Ayer, M; Küçükkaya, RD; Mete, O; Nalçaci, M; Yavuz, AS; Yenerel, MN; Yildirim, ND, 2007) |
| "Thalidomide is an immunomodulatory drug used in the treatment of relapsed or refractory multiple myeloma (MM)." | 3.74 | Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment. ( Bláha, V; Büchler, T; Hájek, R; Maisnar, V; Malý, J; Radocha, J, 2007) |
| "We report preliminary observations on the efficacy of bortezomib in 20 patients with AL amyloidosis whose clonal disease was active despite treatment with a median of 3 lines of prior chemotherapy, including a thalidomide combination in all cases." | 3.74 | Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. ( Gillmore, JD; Hawkins, PN; Lachmann, HJ; Offer, M; Wechalekar, AD, 2008) |
| "Thalidomide and its analogs have been extensively studied in patients with multiple myeloma." | 3.73 | Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide. ( Carbonell, AL; del Giglio, A; Manhani, AR; Mitteldorf, CA; Weinschenker, P, 2005) |
| "The use of the proteasome inhibitor bortezomib has been recently introduced into the treatment of relapsed, refractory multiple myeloma (MM)." | 3.73 | Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. ( Graeven, U; König, M; Schmiegel, W; Schmielau, J; Teschendorf, C, 2005) |
| "To investigate the effect of the combination of thalidomide, cyclophosphamide and dexamethasone for the treatment of relapsed/refractory multiple myeloma." | 3.73 | [The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma]. ( An, N; Chen, SL; Gao, W, 2006) |
| "We evaluated the combination of thalidomide, pulsed dexamethasone and weekly cyclophosphamide (CTD) for the treatment of patients with newly diagnosed, relapsed or VAD-refractory multiple myeloma." | 3.73 | Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. ( Byrne, JL; Myers, B; Russell, NH; Sidra, G; Williams, CD; Zaman, S, 2006) |
| "Thalidomide administered as a single agent produces a response rate of about 40% in patients with refractory or relapsed multiple myeloma (MM)." | 3.73 | Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. ( Bladé, J; Cibeira, MT; Esteve, J; Ramiro, L; Rosiñol, L; Torrebadell, M, 2006) |
| "We studied the effect of thalidomide on the macroscopic appearance of angiodysplasias in three patients with bleeding due to multiple angiodysplasias of the small intestine." | 3.73 | Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. ( Bauditz, J; Lochs, H; Voderholzer, W, 2006) |
| "To assess response rate, duration of response, progression-free survival, and toxicity of thalidomide in patients with relapsed multiple myeloma." | 3.72 | Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Geyer, SM; Greipp, PR; Hayman, SR; Iturria, NL; Kumar, S; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2003) |
| "Fifty Taiwanese patients with relapsed and/or refractory multiple myeloma (MM) were treated with thalidomide on a dose-escalation schedule, commencing with 100 mg/d nightly and incremented either to the maximally tolerated dose or 800 mg/d." | 3.72 | Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma. ( Chen, YC; Hong, RL; Huang, SY; Ko, BS; Shen, MC; Tang, JL; Tien, HF; Tsai, W; Wang, CH; Yao, M, 2003) |
| "The current study suggests that thalidomide has limited single-agent activity in heavily pretreated patients with recurrent or refractory lymphoma." | 3.72 | Thalidomide for patients with recurrent lymphoma. ( Albitar, M; Cabanillas, F; Clemons, M; Dang, NH; Hagemeister, FB; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Samaniego, F; Younes, A, 2004) |
| "Thalidomide has shown efficacy in relapsed or refractory patients of multiple myeloma (MM)." | 3.71 | The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. ( Grover, JK; Raina, V; Uppal, G, 2002) |
| "Thalidomide seems to be an effective and safe treatment in patients with refractory Crohn disease." | 3.71 | Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. ( Candusso, M; Facchini, S; Liubich, M; Martelossi, S; Panfili, E; Ventura, A, 2001) |
| "The feasibility and efficacy of a combination of thalidomide, cyclophosphamide, etoposide, and dexamethasone were studied in 56 patients with poor-prognosis multiple myeloma." | 3.71 | Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. ( Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Krasniqi, F; Moehler, TM; Neben, K, 2001) |
| " Thalidomide, an antineoplastic agent, has been shown to be effective in multiple myeloma through proposed mechanisms that may include angiogenesis inhibition." | 3.71 | Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation. ( Biagi, JJ; Grigg, AP; Mileshkin, L; Prince, HM; Westerman, DW, 2001) |
| " We present a case of coinfection with disseminated HSV and VZV infection in a patient taking thalidomide for relapsed multiple myeloma." | 3.71 | Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. ( Curley, MJ; Hassoun, PM; Hussein, SA, 2002) |
| "To describe the efficacy of therapy with thalidomide, a drug that has antiangiogenic properties, in patients with relapsed multiple myeloma." | 3.70 | Thalidomide in the treatment of relapsed multiple myeloma. ( Dispenzieri, A; Fonseca, R; Gertz, MA; Greipp, PR; Kyle, RA; Lacy, MQ; Lust, JA; Rajkumar, SV; Witzig, TE, 2000) |
| "The objective of this study was to evaluate the efficacy of thalidomide in the treatment of chronic erythema multiforme unresponsive to usual treatments." | 3.69 | [Treatment by thalidomide of chronic multiforme erythema: its recurrent and continuous variants. A retrospective study of 26 patients]. ( Cambazard, F; Cherouati, K; Claudy, A; Crickx, B; Lamorelle, A; Morel, P; Moulin, G; Revuz, J; Souteyrand, P; Vaillant, L, 1996) |
| " Reactive episodes continue to be a serious complication, but the availability of thalidomide to control erythema nodosum leprosum has markedly improved the prognosis." | 3.65 | The diagnosis and treatment of leprosy. ( Jacobson, RR; Trautman, JR, 1976) |
| " Adverse reactions were recorded." | 2.94 | The efficacy and safety of thalidomide on the recurrence interval of continuous recurrent aphthous ulceration: A randomized controlled clinical trial. ( Shi, J; Shi, X; Yang, J; Yang, M; Zeng, Q; Zhao, W; Zhao, X; Zhou, H, 2020) |
| "Melflufen is a novel peptide-drug conjugate that rapidly delivers a cytotoxic payload into tumor cells." | 2.94 | OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma. ( Aschan, J; Pour, L; Robak, P; Schjesvold, F; Sonneveld, P, 2020) |
| "Pomalidomide is a next-generation immunomodulatory agent with activity in relapsed light chain (AL) amyloidosis, but real world outcomes are lacking." | 2.87 | Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis. ( Gilmore, J; Hawkins, P; Lachmann, H; Mahmood, S; Manwani, R; Sachchithanantham, S; Sharpley, FA; Wechalekar, A; Whelan, C, 2018) |
| "Lenalidomide is an immunomodulatory agent approved in the US for patients with relapsed/refractory MCL following bortezomib based on results from 3 multicenter phase II studies (2 including relapsed/refractory aggressive NHL and 1 focusing on MCL post-bortezomib)." | 2.84 | Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma. ( Casadebaig Bravo, ML; Drach, J; Fu, T; Goy, A; Habermann, TM; Kalayoglu Besisik, S; Luigi Zinzani, P; Ramchandren, R; Takeshita, K; Tuscano, JM; Witzig, TE; Zhang, L, 2017) |
| "Proteasome inhibitors (PIs) in combination with immunomodulatory drugs (IMiDs) have been shown to be effective against relapsed/refractory multiple myeloma (RRMM)." | 2.82 | Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma. ( Hagiwara, S; Iida, S; Ishida, T; Ito, A; Kanamori, T; Kato, C; Kinoshita, S; Komatsu, H; Kusumoto, S; Masuda, A; Murakami, S; Nakashima, T; Narita, T; Ri, M; Suzuki, N; Totani, H; Yoshida, T, 2016) |
| " The most common grade ≥3 adverse events (AEs) were neutropenia and thrombocytopenia." | 2.82 | Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. ( Buhler, A; Chanan-Khan, A; De Bedout, S; Dürig, J; Fraser, GA; Gribben, JG; Hallek, M; Hillmen, P; Kalaycio, M; Kipps, TJ; Mei, J; Michallet, AS; Purse, B; Stilgenbauer, S; Wendtner, CM; Zhang, J, 2016) |
| "Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse." | 2.82 | Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantatio ( Baertsch, MA; Fenk, R; Goerner, M; Goldschmidt, H; Graeven, U; Haenel, M; Hielscher, T; Hillengaß, J; Ho, AD; Hose, D; Jauch, A; Klein, S; Kunz, C; Lindemann, HW; Luntz, S; Mai, EK; Martin, H; Merz, M; Nogai, A; Noppeney, R; Raab, MS; Reimer, P; Salwender, H; Scheid, C; Schlenzka, J; Schmidt-Hieber, M; Schmidt-Wolf, IG; Weisel, K; Wuchter, P, 2016) |
| "Relapsed/refractory multiple myeloma (RRMM) patients have poor overall survival (OS)." | 2.82 | Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). ( Dimopoulos, MA; Gibson, CJ; Hong, K; Moreau, P; Saunders, O; Song, KW; Sternas, LA; Weisel, KC; Zaki, MH, 2016) |
| " Dosing was based on the lenalidomide label." | 2.82 | Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment. ( Abraham, J; Arnulf, B; Bridoux, F; Chen, N; Desport, E; Fermand, JP; Jaccard, A; Moreau, S; Moumas, E, 2016) |
| "Polymerase chain reaction (PCR)-based minimal residual disease (MRD) analysis is a useful prognostic tool in multiple myeloma (MM), although its long-term impact still needs to be addressed." | 2.80 | Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival. ( Boccadoro, M; Callea, V; Caltagirone, S; Cangialosi, C; Carovita, T; Cavallo, F; Crippa, C; De Rosa, L; Drandi, D; Falcone, AP; Ferrero, S; Genuardi, E; Grasso, M; Guglielmelli, T; Ladetto, M; Liberati, AM; Musto, P; Oliva, S; Palumbo, A; Passera, R; Pisani, F; Pregno, P; Rossini, F; Terragna, C; Urbano, M, 2015) |
| "Lenalidomide was administered at 20 mg/day for 21 days and cyclophosphamide at 50 mg/day for 28 days (cycles every 28 days)." | 2.80 | A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma. ( Casanova, M; García-Sanz, R; Labrador, J; Pastor, M; Provencio, M; Quero-Blanco, C; Rueda, A; Salar, A, 2015) |
| "Pomalidomide is a distinct oral IMiD(®) immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects." | 2.80 | Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma. ( Alegre, A; Bahlis, NJ; Banos, A; Cavo, M; Chen, C; Delforge, M; Dimopoulos, MA; Garderet, L; Goldschmidt, H; Ivanova, V; Jacques, C; Karlin, L; Martinez-Lopez, J; Moreau, P; Oriol, A; Renner, C; San Miguel, JF; Song, KW; Sternas, L; Teasdale, T; Weisel, KC; Yu, X; Zaki, MH, 2015) |
| "Lenalidomide was given orally 21/28 days per cycle for 1 year, at escalated dose of 15 to 20 mg during phase 1 to determine the MTD; the phase 2 part was conducted at the MTD." | 2.80 | Lenalidomide is safe and active in Waldenström macroglobulinemia. ( Arnulf, B; Bakala, J; Banos, A; Bories, C; Brice, P; Choquet, S; Demarquette, H; Dib, M; Fouquet, G; Guidez, S; Herbaux, C; Karlin, L; Leblond, V; LeGouill, S; Leleu, X; Louni, C; Martin, A; Morel, P; Nudel, M; Ohyba, B; Petillon, MO; Poulain, S; Salles, G; Thielemans, B; Tournilhac, O, 2015) |
| " In conclusion, the poor results obtained with lenalidomide in combination with vorinostat and dexamethasone provide no arguments that could justify further investigation of this drug combination for the treatment of relapsed PTCL." | 2.79 | Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. ( Egle, A; Greil, R; Hopfinger, G; Lang, A; Linkesch, W; Melchardt, T; Nösslinger, T; Weiss, L, 2014) |
| "Adequate dosing of lenalidomide in Chronic Lymphocytic Leukemia (CLL) remains unclear." | 2.79 | A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia. ( Andritsos, LA; Browning, R; Byrd, JC; Flynn, J; Gao, Y; Harper, E; Jiang, Y; Johnson, AJ; Jones, J; Kefauver, C; Maddocks, K; Phelps, MA; Poi, M; Rozewski, DM; Ruppert, AS, 2014) |
| "Sorafenib treatment was effective in two patients who achieved a partial response and a continuous stable disease with duration of 24." | 2.78 | Sorafenib in patients with refractory or recurrent multiple myeloma. ( Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A, 2013) |
| "Pomalidomide was given at 1 to 2." | 2.78 | Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study. ( Baldi, I; Boccadoro, M; Bringhen, S; Carella, AM; Corradini, P; Crippa, C; Galli, M; Giuliani, N; Guglielmelli, T; La Verde, G; Larocca, A; Magarotto, V; Marcatti, M; Mina, R; Montefusco, V; Omedé, P; Palumbo, A; Rossi, D; Rota-Scalabrini, D; Santagostino, A, 2013) |
| "Lenalidomide is an immunomodulatory agent with proven tumoricidal and antiproliferative activity in MCL." | 2.78 | Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. ( Cicero, S; Drach, J; Fu, T; Goy, A; Kalayoglu Besisik, S; Ramchandren, R; Sinha, R; Williams, ME; Witzig, TE; Zhang, L, 2013) |
| "Lenalidomide is an immunomodulatory agent demonstrating antitumor and antiproliferative effects in MCL." | 2.78 | Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. ( Czuczman, MS; Haioun, C; Li, J; Polikoff, J; Prandi, K; Reeder, CB; Tilly, H; Vose, JM; Witzig, TE; Zhang, L; Zinzani, PL, 2013) |
| "How to reduce recurrence following discontinuation of etanercept should be further researched." | 2.78 | Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept. ( Deng, X; Huang, F; Zhang, J, 2013) |
| "Lenalidomide is an immunomodulatory drug active as salvage therapy for chronic lymphocytic leukemia (CLL)." | 2.78 | Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia. ( Badoux, XC; Burger, JA; Faderl, S; Ferrajoli, A; Keating, MJ; O'Brien, SM; Sargent, R; Wen, S; Wierda, WG, 2013) |
| "Thrombocytopenia was the most common grade ≥ 3 AE (35%)." | 2.78 | A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. ( Allietta, N; Angermund, R; Bladé, J; Blau, IW; Broer, E; Corradini, P; Dimopoulos, MA; Drach, J; Giraldo, P; Mitchell, V; Petrucci, MT; Teixeira, A, 2013) |
| "Lenalidomide was safely titrated to 20 mg/day; the MTDEL was not reached." | 2.77 | Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. ( Bloor, A; Bosch, F; Bühler, A; Chanan-Khan, AA; Coutré, S; Dreisbach, L; Ferrajoli, A; Frankfurt, O; Furman, RR; Gobbi, M; Gribben, JG; Hallek, M; Heerema, NA; Hillmen, P; Hurd, DD; Kimby, E; Mahadevan, D; Moutouh-de Parseval, L; Sekeres, MA; Shah, S; Stilgenbauer, S; Uharek, L; Wendtner, CM; Zhang, J, 2012) |
| " We aimed to identify the maximum tolerated dose (MTD) of lenalidomide when combined with rituximab in a phase 1 trial and to assess the efficacy and safety of this combination in a phase 2 trial in patients with relapsed or refractory MCL." | 2.77 | Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. ( Badillo, M; Bejarano, M; Bell, N; Byrne, C; Cabanillas, F; Champlin, R; Chen, W; Chen, Y; Fanale, M; Fayad, L; Feng, L; Fowler, N; Hagemeister, F; Hartig, K; Kwak, L; McLaughlin, P; Neelapu, SS; Newberry, KJ; Romaguera, J; Samaniego, F; Sun, L; Wagner-Bartak, N; Wang, M; Younes, A; Young, KH; Zeldis, J; Zhang, L, 2012) |
| "Thalidomide has proven its efficacy in refractory cutaneous lupus disease, although it is not exempt from significant side effects and frequent relapses after withdrawal." | 2.77 | Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. ( Ávila, G; Cortés-Hernández, J; Ordi-Ros, J; Vilardell-Tarrés, M, 2012) |
| "Lenalidomide was administered by mouth daily for 21 days, repeated every 28 days." | 2.76 | Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. ( Blaney, SM; Boyett, JM; Fangusaro, J; Goldman, S; Jakacki, R; Kun, LE; Macdonald, T; Packer, R; Pollack, IF; Schaiquevich, P; Stewart, CF; Wallace, D; Warren, KE, 2011) |
| "Cohorts of children with solid tumors received lenalidomide once daily for 21 days, every 28 days at dose levels of 15 to 70 mg/m(2)/dose." | 2.76 | Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. ( Adamson, PC; Ayello, J; Berg, SL; Blaney, SM; Cairo, MS; Chen, N; Ingle, AM; Lau, H; Russell, H, 2011) |
| "In newly diagnosed multiple myeloma (MM), three/four-drug combinations as induction therapy seem to be more effective compared with two-drug associations in terms of response rate and duration of remission." | 2.76 | Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. ( Blasi, N; Brunori, M; Caraffa, P; Catarini, M; Corvatta, L; Ferranti, M; Gentili, S; Leoni, P; Malerba, L; Mele, A; Offidani, M; Polloni, C; Rizzi, R; Samori, A, 2011) |
| "Patients with chronic lymphocytic lymphoma (CLL) with high-risk cytogenetics [del(11q)(q22." | 2.75 | Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. ( Bilgrami, SA; Block, AW; Chanan-Khan, AA; Czuczman, MS; Hernandez-Ilizaliturri, F; Lawrence, D; Lawrence, W; Lee, K; Miller, A; Miller, KC; Sher, T; Sood, R; Whitworth, A; Wood, MT, 2010) |
| "Lenalidomide was given orally at escalating doses of 25 to 75 mg daily on days 1 through 21 of 28-day cycles to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD), as well as to provide pharmacokinetic and preliminary efficacy data." | 2.75 | Dose escalation of lenalidomide in relapsed or refractory acute leukemias. ( Becker, H; Blum, W; Byrd, JC; Chandler, JC; Curfman, J; Devine, SM; Garzon, R; Grever, MR; Kefauver, C; Klisovic, RB; Liu, S; Marcucci, G; Mickle, J; Phelps, MA; Rozewski, DM; Schaaf, L; Walker, A; Whitman, SP; Yang, X, 2010) |
| "Lenalidomide has acceptable toxicity and is associated with long-term disease stabilization and PSA declines." | 2.75 | Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study. ( Antonarakis, ES; Carducci, M; Denmeade, S; Drake, C; Eisenberger, M; Hudock, S; Keizman, D; Pili, R; Sinibaldi, V; Zahurak, M, 2010) |
| "Oral lenalidomide 25 mg was self-administered once daily on days 1-21 every 28 d for up to 52 weeks, according to tolerability or until disease progression." | 2.74 | Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. ( Ervin-Haynes, A; Habermann, TM; Justice, G; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB, 2009) |
| "Dapsone was prescribed for a total of nine patients, of whom eight (89%) showed improvement in their symptoms, while five showed complete remission." | 2.74 | Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial. ( Hirota, SK; Migliari, DA; Mimura, MA; Sanches, JA; Sugaya, NN, 2009) |
| "Lenalidomide is a novel immunomodulatory agent with antiproliferative activities." | 2.74 | Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. ( Cole, C; Ervin-Haynes, A; Justice, G; Kaplan, H; Moore, T; Pietronigro, D; Reeder, C; Takeshita, K; Voralia, M; Vose, JM; Wiernik, PH; Witzig, TE; Zeldis, JB, 2009) |
| " Eight patients had permitted escalation of thalidomide dosage up to 200 mg daily." | 2.73 | Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma. ( Boyd, K; Clarke, P; Drake, M; Hull, DR; Jones, FC; Kettle, PJ; Morris, TC; Morrison, A; O'Reilly, P; Quinn, J, 2008) |
| "Bortezomib (1." | 2.73 | The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. ( Anagnostopoulos, N; Christoulas, D; Croucher, P; Dimopoulos, MA; Eleftherakis-Papaiakovou, E; Heath, D; Kastritis, E; Roussou, M; Terpos, E; Tsionos, K, 2008) |
| "Thalidomide has direct antimyeloma and immunomodulatory effects." | 2.73 | Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. ( Abonour, R; Ansari, RH; Cripe, LD; Fausel, C; Fisher, WB; Juliar, BE; Smith, GG; Suvannasankha, A; Wood, LL; Yiannoutsos, CT, 2007) |
| "Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma, mantle cell lymphoma and lymphoplasmacytic lymphoma." | 2.73 | Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. ( Bartlett, NL; Cheson, BD; Grinblatt, D; Johnson, JL; Niedzwiecki, D; Rizzieri, D; Smith, SM, 2008) |
| "Significant peripheral neuropathy and deep vein thrombosis each occurred in only 3%." | 2.72 | A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. ( Alsina, M; Anderson, KC; Blood, E; Dalton, WS; Desikan, KR; Doss, D; Freeman, A; Gorelik, S; Hideshima, T; Jagannath, S; Kelly-Colson, K; Knight, R; McKenney, ML; Mitsiades, CS; Munshi, NC; Olesnyckyj, M; Rajkumar, SV; Rich, R; Richardson, PG; Schlossman, RL; Warren, D; Weller, E; Wride, K; Wu, A; Zeldenrust, SR; Zeldis, J, 2006) |
| "Thalidomide is an effective maintenance therapy in patients with multiple myeloma." | 2.72 | Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. ( Attal, M; Avet-Loiseau, H; Benboubker, L; Berthou, C; Bourhis, JH; Caillot, D; Doyen, C; Dumontet, C; Facon, T; Garderet, L; Grobois, B; Harousseau, JL; Hulin, C; Leyvraz, S; Marit, G; Monconduit, M; Moreau, P; Pegourie, B; Renaud, M; Voillat, L; Yakoub Agha, I, 2006) |
| "Sixty patients with advanced multiple myeloma received 2-6 monthly treatment courses combining hyperfractionated cyclophosphamide (300 mg/m2 i." | 2.71 | Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. ( Berdel, WE; Bisping, G; Dominé, N; Fenk, R; Heinecke, A; Hentrich, M; Innig, G; Kienast, J; Koch, OM; Kropff, MH; Lang, N; Mitterer, M; Ostermann, H; Straka, C; Südhoff, T, 2003) |
| "We treated with thalidomide 17 patients (12 males, 5 females), average age 51 (range 42-73 years), mean time since diagnosis to the start of thalidomide treatment was 24 months (range 5-48)." | 2.71 | [Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma]. ( Helbig, G; Hołowiecki, J; Kyrcz-Krzemień, S; Stella-Hołowiecka, B, 2003) |
| " The patients received PTX at the initiating dosage until complete clinical cure." | 2.71 | [Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study]. ( Achirafi, A; de Carsalade, GY; Flageul, B, 2003) |
| "Thalidomide in lower intermittent doses is ineffective at preventing recurrence of aphthous ulcers in HIV-infected persons." | 2.70 | Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers. ( Chernoff, M; Fahey, JL; Fox, L; Greenspan, JS; Hooton, TM; Jackson, JB; Jacobson, JM; Pulvirenti, JJ; Shikuma, C; Spritzler, J; Wohl, DA, 2001) |
| "Thalidomide was first developed and marketed in Germany in the 1950s as a sedative." | 2.68 | Thalidomide: an alternative therapy for treatment of apthous ulcers (canker sores). ( Manesis, DA, 1995) |
| " We concluded that thalidomide in a dosage of 100 mg/d is an effective treatment of severe aphthous stomatitis but is not without some risk." | 2.67 | Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. ( Bonnetblanc, JM; Claudy, A; Dallac, S; Guillaume, JC; Hans, P; Janier, M; Klene, C; Marchand, C; Revuz, J; Souteyrand, P, 1990) |
| "Thalidomide therapy was initiated." | 2.61 | Nonresectable Thoracic Rosai-Dorfman Disease: A Case Report and Review of the Literature. ( Lin, CK; Tsai, YD, 2019) |
| "Pomalidomide (Pom) has demonstrated synergistic antiproliferative activity in combination regimens as a result of its distinct anticancer, antiangiogenic, and immunomodulatory effects." | 2.61 | Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials. ( Ali, Z; Anwer, F; Hassan, H; Hassan, SF; Iftikhar, A; Kamal, A; Lakhani, M; Mushtaq, A; Raychaudhuri, S; Razzaq, F; Safdar, A; Sagar, F; Zahid, U; Zar, MA, 2019) |
| "Lenalidomide is FDA-approved for treatment of relapsed/refractory mantle cell lymphoma as a single agent, as well as in combination with rituximab for R/R follicular lymphoma and marginal zone lymphoma." | 2.61 | IMiDs New and Old. ( Ruan, J; Yamshon, S, 2019) |
| "Thalidomide has shown excellent results for severe cutaneous lupus erythematosus (CLE), but its prescription is limited by potentially severe adverse events." | 2.58 | Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis. ( Arnaud, L; Barbaud, A; Cesbron, E; Chasset, F; Francès, C; Tounsi, T, 2018) |
| "Thalidomide has a rapid action but its use is limited due the teratogenicity and neurotoxicity." | 2.58 | Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition. ( Costa, PDSS; Daxbacher, ELR; Fraga, LR; Kowalski, TW; Schuler-Faccini, L; Vianna, FSL, 2018) |
| "Lenalidomide is an immunomodulatory drug (IMiD) with a unique mode of action (MOA) that may vary across disease-type." | 2.55 | Lenalidomide in the treatment of chronic lymphocytic leukemia. ( Brown, JR; Itchaki, G, 2017) |
| "Lenalidomide has been proved to be effective for relapsed/refractory CLL as a single agent or in combination with various chemo-immunotherapeutic regimens." | 2.53 | Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis. ( Hu, X; Liang, L; Liu, H; Yang, LP; Zhao, M; Zhu, YC, 2016) |
| "We report the cases of 3 patients with hematological malignancies and complex karyotypes involving der(5; 17) (p10;q10), which results in the loss of 5q and 17p." | 2.50 | der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases. ( Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T, 2014) |
| "Multiple myeloma is still an incurable disease with pattern of regression and remission followed by multiple relapses raising from the residual myeloma cells surviving even in the patients who achieve complete clinical response to treatment." | 2.50 | New approaches to management of multiple myeloma. ( Cavallo, F; Genadieva-Stavric, S; Palumbo, A, 2014) |
| "Pomalidomide is a distinct IMiD agent recently approved in the US and Europe." | 2.50 | Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma. ( Coleman, M; Mark, TM; Niesvizky, R, 2014) |
| "Multiple myeloma is caused by the expansion of monoclonal plasma cells and secretion of M-protein (immunoglobulins, Bence Jones protein and free light chain)." | 2.49 | Current therapeutic strategy for multiple myeloma. ( Suzuki, K, 2013) |
| "Although multiple myeloma remains an essentially incurable disease, treatment options and patients' quality of life have improved over the last years with the introduction of more effective and less toxic agents." | 2.48 | Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies. ( Figueiredo, A; João, C; Martins, HF, 2012) |
| "The follicular lymphomas are indolent diseases that are highly responsive to various combinations of standard chemotherapy drugs." | 2.47 | New agents in follicular lymphoma. ( Cheson, BD, 2011) |
| "Recent advances in the treatment of multiple myeloma have resulted in improved response rates and overall survival in patients with multiple myeloma." | 2.46 | Advances in treatment for relapses and refractory multiple myeloma. ( Richards, T; Weber, D, 2010) |
| "Lenalidomide is an immunomodulatory drug, which has anti-myeloma activity in vitro." | 2.45 | United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma. ( Behrens, J; Bird, J; Cavenagh, J; Cook, G; Davies, F; Morgan, G; Morris, C; Schey, S; Tighe, J; Williams, C, 2009) |
| "Thalidomide has been extensively studied alone and in combination in patients with relapsed myeloma, demonstrating substantial efficacy, and is therefore widely used in this setting." | 2.44 | The emerging role of novel therapies for the treatment of relapsed myeloma. ( Anderson, KC; Hideshima, T; Mitsiades, C; Richardson, PG, 2007) |
| " This article provides the clinical rationale for the use of PLD in combination with immunomodulatory drugs to treat patients with MM and summarizes the clinical experience with these combinations to date." | 2.44 | Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience. ( Chanan-Khan, AA; Lee, K, 2007) |
| "Bortezomib was associated with a significantly higher response rate and complete remission rate using both M-protein and EBMT criteria." | 2.44 | Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison. ( Adena, M; Hertel, J; Prince, HM; Smith, DK, 2007) |
| "Relapsed and refractory multiple myeloma (MM) constitutes a specific and unmet medical need." | 2.44 | The treatment of relapsed and refractory multiple myeloma. ( Anderson, K; Chauhan, D; Ghobrial, I; Hideshima, T; Mitsiades, C; Munshi, N; Richardson, P; Schlossman, R, 2007) |
| "Multiple myeloma is the second most common haematological malignancy." | 2.44 | An update on drug combinations for treatment of myeloma. ( Davies, FE; Morgan, GJ; Srikanth, M, 2008) |
| "Despite advances in treatment relapses are still frequent, and systemic disease remains associated with an adverse prognosis." | 2.44 | [Adamantiades-Behçet's disease. Clinical review]. ( Angermann, CE; Bröcker, EB; Ertl, G; Hoyer, C; Kneitz, C; Störk, S, 2008) |
| "Recurrent aphthous stomatitis is a common problem with 20% to 50% of the population having experienced simple aphthous lesions (ie, canker sores)." | 2.43 | Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide. ( Jorizzo, JL; Letsinger, JA; McCarty, MA, 2005) |
| "In most cases multiple myeloma is an incurable plasma cell malignancy." | 2.43 | Current treatment options for myeloma. ( Dimopoulos, MA; Rahemtulla, A; Terpos, E, 2005) |
| "For patients with relapsed/refractory multiple myeloma, the MM-007 study has shown that lenalidomide alone or in combination with dexamethasone provides response rates between 37% and 41%." | 2.43 | Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. ( Richardson, P, 2005) |
| "Treatment options for patients with multiple myeloma are a rapidly progressing area of clinical and scientific development." | 2.43 | Novel treatment approaches for patients with multiple myeloma. ( Kaufman, JL; Lonial, S; Sinha, R, 2006) |
| "Multiple myeloma is an incurable plasma cell malignancy that accounts for 10% of all hematologic cancers." | 2.41 | Current therapy for multiple myeloma. ( Gertz, MA; Greipp, PR; Kyle, RA; Rajkumar, SV, 2002) |
| "Pomalidomide combinations were well tolerated, no patient discontinued treatment due to adverse events." | 1.91 | Pomalidomide combinations are a safe and effective option after daratumumab failure. ( Binder, M; Brioli, A; Engelhardt, M; Ernst, T; Gengenbach, L; Heidel, FH; Hilgendorf, I; Hochhaus, A; Mancuso, K; Stauch, T; von Lilienfeld-Toal, M; Zamagni, E, 2023) |
| "Pomalidomide is a second-generation immunomodulatory drug that has shown activity in lenalidomide-refractory disease in the setting of different combinations." | 1.62 | Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience. ( Anguita, M; Arguiñano, JM; Arnao, M; Bladé, J; Blanchard, MJ; Cabañas, V; Casado, F; de Cabo, E; de Coca, AG; Encinas, C; García, R; González-Rodríguez, AP; Hernández-Rivas, JÁ; Iñigo, B; Lafuente, AP; Lahuerta, JJ; Lavilla, E; López, A; Maldonado, R; Martí, JM; Mateos, MV; Motlló, C; Murillo, I; Pérez-Persona, E; Ribas, P; Rodriguez-Otero, P; Sampol, A; San Miguel, JF; Sirvent, M, 2021) |
| "Treatment benefit in multiple myeloma (MM) patients with high-risk cytogenetics remains suboptimal." | 1.62 | Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics. ( Alegre, A; Campana, F; Delimpasi, S; Facon, T; Harrison, SJ; Hulin, C; Inchauspé, M; Macé, S; Perrot, A; Richardson, P; Risse, ML; Simpson, D; Spencer, A; Sunami, K; van de Velde, H; Vlummens, P; Wang, MC; Yong, K, 2021) |
| "Thalidomide was clinically efficacious and safe among pediatric CD." | 1.56 | Long-term outcomes of thalidomide in pediatric Crohn's disease. ( Huang, Y; Wang, L; Wang, Y; Xue, A; Zheng, C; Zhou, Y, 2020) |
| "Isatuximab is used to treat multiple myeloma (MM), characterized by the excessive production of abnormal "myeloma proteins" (M-proteins) that may interact with therapeutic IgG mAb on the neonatal Fc receptor (FcRn)-mediated recycling pathway." | 1.56 | Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients. ( Brillac, C; Campana, F; El-Cheikh, R; Fau, JB; Koiwai, K; Mace, N; Nguyen, L; Semiond, D, 2020) |
| "Multiple myeloma is a malignancy of antibody-secreting plasma cells." | 1.51 | Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. ( Auclair, D; Bahlis, NJ; Barwick, BG; Boise, LH; Dhodapkar, MV; Gupta, VA; Hofmeister, CC; Jaye, DL; Kaufman, JL; Keats, JJ; Lonial, S; Neri, P; Nooka, AK; Vertino, PM, 2019) |
| "Patients with AL amyloidosis who need second-line therapy after response to up-front treatment generally have a good outcome." | 1.48 | Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies. ( Basset, M; Foli, A; Merlini, G; Milani, P; Palladini, G; Perlini, S; Russo, F, 2018) |
| "Since then, the patient has had two recurrences, coinciding with the reduction of thalidomide dosages, which were controlled by increasing the dose of the immunomodulator." | 1.48 | A Dramatic Case of Odynophagia. ( Diniz-Freitas, M; Diz, P; García-Caballero, L; Limeres, J; Seoane, J; Sopeña, B, 2018) |
| "13." | 1.48 | Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival. ( Adamopoulos, I; Aktypi, A; Anagnostopoulos, A; Briasoulis, E; Delimpasi, S; Douka, V; Fotiou, D; Giannakoulas, N; Giannopoulou, E; Gogos, D; Hatzimichael, E; Katodritou, E; Kioumi, A; Kokoviadou, K; Kotsopoulou, M; Kyriakou, D; Kyrtsonis, MC; Megalakaki, A; Nikolaou, E; Papadaki, E; Pappa, V; Repousis, P; Spanoudakis, E; Symeonidis, A; Terpos, E; Timotheatou, D; Vasilopoulos, G; Zikos, P, 2018) |
| "Pomalidomide is an immunomodulatory compound that has demonstrated activity in MM patients with disease refractory to lenalidomide and bortezomib." | 1.48 | The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience. ( Bernatowicz, P; Charlinski, G; Dmoszynska, A; Grzasko, N; Guzicka-Kazimierczak, R; Janczarski, M; Jurczyszyn, A; Lech-Maranda, E; Swiderska, A; Szczepaniak, A; Szeremet, A; Waszczuk-Gajda, A; Wichary, R, 2018) |
| "Postoperative pathology confirmed Crohn's disease." | 1.48 | [The 465th case: intestinal obstruction, gastrointestinal hemorrhage and duodenal fistula]. ( Guo, F; Li, JN; Li, XQ; Ma, ZQ; Qian, JM; Wang, YN; Xue, HD; Yang, AM; Zhou, WX, 2018) |
| " Adverse events (AEs) occurred in 69 (57." | 1.48 | Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/\ refractory multiple myeloma: a real-life experience ( Duran, M; Durusoy, R; Patır, P; Şahin, F; Saydam, G; Soyer, N; Töbü, M; Tombuloğlu, M; Ünal, HD; Uysal, A; Vural, F, 2018) |
| "Lenalidomide can be a good treatment option for AL amyloidosis in HIV-infected patients on antiretroviral therapy." | 1.46 | Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient. ( Cook, M; Denman, J; Manavi, K, 2017) |
| "Lenalidomide-based treatment showed clinical activity, with no unexpected toxicities, in patients with relapsed/refractory mantle cell lymphoma who previously failed ibrutinib therapy." | 1.46 | Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). ( Barnett, E; Bravo, MC; Ghosh, N; Goy, A; Hamadani, M; Lossos, IS; Martin, P; Phillips, T; Reeder, CB; Rule, S; Schuster, SJ; Wang, M, 2017) |
| " All four children completed the protocol without any significant adverse effects and remain in complete and durable remission 15-18 months posttreatment." | 1.46 | Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children. ( Bakane, A; Raj, R; Ramachandrakurup, S; Subburaj, D; Uppuluri, R, 2017) |
| "Pomalidomide has shown improved survival and good tolerability in this patient cohort in clinical trials, but real world data are scarce." | 1.46 | Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. ( Benjamin, R; Cerner, A; Cheesman, S; D'sa, S; Jenner, M; Maciocia, N; Maciocia, P; Melville, A; Popat, R; Rabin, N; Ramasamy, K; Rismani, A; Schey, S; Sharpley, F; Streetly, M; Yong, K, 2017) |
| "Treatment advances for multiple myeloma (MM) that have prolonged survival emphasise the importance of measuring patients' health-related quality of life (HRQoL) in clinical studies." | 1.46 | Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment. ( Arnould, B; Bacon, P; Gilet, H; Kyriakou, C; Leleu, X; Lewis, P; Murphy, P; Petrucci, MT; Vande Broek, I, 2017) |
| "We analyzed the overall survival of 347 multiple myeloma patients in Austria by means of a national registry (AMR), focused on results from 3rd and later lines of therapy." | 1.43 | Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics. ( Rochau, U; Siebert, U; Weger, R; Willenbacher, E; Willenbacher, W, 2016) |
| " The dosing and safety profile of POM + LoDEX was similar across RI subgroups." | 1.43 | Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. ( Baz, R; Cavo, M; Delforge, M; Dimopoulos, MA; Goldschmidt, H; Hong, K; Jagannath, S; Moreau, P; Palumbo, A; Richardson, P; San Miguel, JF; Siegel, DS; Song, KW; Sternas, L; Weisel, KC; Yu, X; Zaki, M, 2016) |
| "Clinical relapse was frequent (73%) and occurred between 3 and 24 weeks after withdrawal of thalidomide." | 1.42 | Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus? ( Baret, I; De Haes, P, 2015) |
| " In conclusion, low-dose lenalidomide plus dexamethasone therapy is an effective and safe regimen for patients with relapsed or refractory POEMS syndrome." | 1.42 | Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome. ( Cai, H; Cai, QQ; Cao, XX; Li, J; Wang, C; Zhou, DB, 2015) |
| "We conclude that RD reduces bone resorption only in responding patients with relapsed/refractory myeloma but has no effect on bone formation." | 1.40 | The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. ( Christoulas, D; Dimopoulos, MA; Gavriatopoulou, M; Gkotzamanidou, M; Kastritis, E; Katodritou, E; Koulieris, E; Kyrtsonis, MC; Michalis, E; Papanikolaou, X; Papatheodorou, A; Pouli, A; Terpos, E; Zervas, K, 2014) |
| "Treatment options for multiple myeloma dwindle with each relapse." | 1.40 | Pomalidomide. A last-line treatment option for multiple myeloma. ( , 2014) |
| "A total of 200 patients with multiple myeloma who developed disease recurrence after treatment with upfront ASCT and received an autologous retransplantation as salvage therapy at the study center over a period of 15 years were retrospectively reviewed." | 1.39 | Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients. ( Benner, A; Egerer, G; Goldschmidt, H; Heiss, C; Hillengass, J; Ho, AD; Hose, D; Lehners, N; Neben, K; Raab, MS; Sellner, L, 2013) |
| "Real-world costs during treatment of relapsed/refractory multiple myeloma vary greatly." | 1.39 | Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. ( Franken, MG; Gaultney, JG; Huijgens, PC; Redekop, WK; Sonneveld, P; Tan, SS; Uyl-de Groot, CA, 2013) |
| "Optimal salvage treatment for multiple myeloma relapsing after allogeneic stem cell transplantation remains to be determined." | 1.39 | Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy. ( Bachy, E; Bourhis, JH; Brebion, A; Coman, T; François, S; Hermine, O; Huynh, A; Lapusan, S; Lioure, B; Maury, S; Michallet, M; Milpied, N; Mohty, M; Rubio, MT; Socié, G; Uzunov, M; Vigouroux, S; Yakoub-Agha, I, 2013) |
| "Minimal residual disease was assessed by nested polymerase chain reaction on bone marrow samples with patient-specific primers." | 1.39 | Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia. ( Corradini, P; Farina, L; Rezzonico, F; Spina, F, 2013) |
| "Prognostic impact of specific chromosomal aberrations in patients with relapsed multiple myeloma (MM) treated with the novel agents is briefly described." | 1.39 | Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib. ( Adam, Z; Almasi, M; Berankova, K; Frohlich, J; Greslikova, H; Hajek, R; Jarkovsky, J; Jurczyszyn, A; Kaisarova, P; Krejci, M; Kuglik, P; Kupska, R; Melicharova, H; Mikulasova, A; Nemec, P; Penka, M; Sandecka, V; Sevcikova, S; Smetana, J; Zahradova, L; Zaoralova, R, 2013) |
| "POEMS syndrome is a rare disorder characterized by polyneuropathy, monoclonal gammopathy, multiorgan involvement, and elevated vascular endothelial growth factor levels." | 1.39 | Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. ( Abraham, J; Asli, B; Banos, A; Brisseau, JM; Choquet, S; Decaux, O; Deplanque, G; Facon, T; Fermand, JP; Galicier, L; Godmer, P; Guichard, I; Haroche, J; Hermine, O; Jaccard, A; Leblond, V; Leleu, X; Marolleau, JP; Merlusca, L; Musset, L; Recher, C; Roussel, M; Royer, B; Sebban, C, 2013) |
| "Clinical relapse was frequent (70%) and usually occurred 5 months after withdrawal or reduction of thalidomide." | 1.38 | Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. ( Castro-Marrero, J; Cortés-Hernández, J; Ordi-Ros, J; Torres-Salido, M; Vilardell-Tarres, M, 2012) |
| "Lenalidomide was well tolerated in intensively pretreated and elderly MM patients, including those with RI." | 1.38 | Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal. ( Engelhardt, M; Ihorst, G; Kleber, M; Koch, B; Udi, J; Wäsch, R, 2012) |
| "Adult Langerhans cell histiocytosis (LCH) usually follows a favorable course." | 1.38 | [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp ( Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "POEMS syndrome is a rare paraneoplastic condition associated to an underlying plasmacellular dyscrasia." | 1.38 | Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation. ( Balducci, M; Chiusolo, P; De Stefano, V; Giannotta, C; Laurenti, L; Leone, G; Luigetti, M; Sabatelli, M; Sica, S; Sorà, F; Vannata, B, 2012) |
| "Management of relapsing or refractory immune reconstitution inflammatory syndromes (IRISs) despite corticosteroid therapy is yet to be defined." | 1.38 | Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS. ( Brunel, AS; Le Moing, V; Lortholary, O; Makinson, A; Montes, B; Reynes, J; Rubbo, PA; Tuaillon, E, 2012) |
| "Lenalidomide was previously shown to induce an overall response rate (ORR) of 28% in patients with relapsed/refractory DLBCL." | 1.37 | Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. ( Czuczman, MS; Deeb, G; Goy, A; Hernandez-Ilizaliturri, FJ; Macon, WR; Malik, F; Pileri, SA; Witzig, TE; Zinzani, PL, 2011) |
| "Patients with relapsed or refractory multiple myeloma (RRMM) who received lenalidomide plus dexamethasone in the MM-009 and MM-010 trials were pooled and those who had not progressed and were still receiving lenalidomide at 12 months were included." | 1.37 | Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. ( Dimopoulos, MA; Hussein, M; Swern, AS; Weber, D, 2011) |
| "Thalidomide is an effective and safe treatment agent for GIVM and its associated bleeding." | 1.37 | The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study. ( Chen, HM; Chen, HY; Fang, JY; Gao, YJ; Ge, ZZ; Liu, WZ; Tan, HH; Xiao, SD, 2011) |
| "Pyoderma gangrenosum is a rare neutrophilic dermatosis that affects 4% of children." | 1.37 | [Pyoderma gangrenosum and Behçet's disease: a study of two pediatric cases]. ( Benchikhi, H; Bouayad, K; Chiheb, S; Hali, F; Khadir, K; Mikou, N, 2011) |
| "Lenalidomide was given at a dose of 15 mg (n=4), or 25 mg (n=20), orally once daily on day 1 to day 1 every 28 days, with (n=20) or without (n=4) DHAP." | 1.36 | Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells. ( Atanackovic, D; Ayuk, F; Bacher, U; Badbaran, A; Blaise, D; El-Cheikh, J; Fehse, B; Hildebrandt, Y; Hoffmann, F; Kröger, N; Lioznov, M; Mohty, M; Schilling, G; Wolschke, C; Zander, AR, 2010) |
| "Thalidomide is an effective treatment for recurrent aphthosis but its effectiveness at low dose has been rarely assessed." | 1.36 | [Recurrent aphthosis: safety of low dose thalidomide]. ( Dupond, JL; Gil, H; Hafsaoui, C; Limat, S; Magy-Bertrand, N; Meaux-Ruault, N; Perrin, S, 2010) |
| "Thalidomide is an effective second-line therapy for SRAS, but is suppressive rather than curative, and adverse events limit its use." | 1.36 | Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis. ( Barbarot, S; Bastuji-Garin, S; Chosidow, O; Hello, M; Revuz, J, 2010) |
| "Lenalidomide-based treatment is effective across the spectrum of MM disease phases, allowing for the long-term management of myeloma." | 1.36 | Lenalidomide: an update on evidence from clinical trials. ( Dimopoulos, MA; Terpos, E, 2010) |
| "Scleromyxedema is a rare disorder characterized by mucin deposits in the dermis and monoclonal gammopathy." | 1.35 | Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema. ( Arpaci, F; Ataergin, S; Demiriz, M; Ozet, A, 2008) |
| "Thalidomide was reduced for toxicity in 68 patients (24%) and permanently discontinued in 36 (12%)." | 1.35 | Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects. ( Barbarano, L; Cafro, AM; Caravita, T; Corso, A; Gay, F; Lazzarino, M; Mangiacavalli, S; Morra, E; Palumbo, A; Petrucci, MT; Varettoni, M; Zappasodi, P, 2009) |
| "Angiodysplasias are a major cause of lower gastrointestinal bleeding in patients over the age of 60 years." | 1.35 | A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias. ( Dabak, V; Kamboj, G; Kuriakose, P; Shurafa, M, 2008) |
| "Nearly all patients with multiple myeloma (MM) relapse or become refractory to front-line therapy." | 1.34 | Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. ( Avonto, I; Boccadoro, M; Bringhen, S; Corvatta, L; Falco, P; Leoni, P; Marconi, M; Offidani, M; Palumbo, A; Piersantelli, MN; Polloni, C, 2007) |
| "These cases of unconventional disease recurrence are likely to be seen due to sub-clinical seeding of tumour cells suggestive of the presence of an extramedullary (EM) clone of plasma cells with a high degree of chemoresistance." | 1.33 | Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma. ( Apperley, JF; Basu, S; Milne, AE; Rahemtulla, A; Rezvani, K; Rose, PE; Samson, D; Scott, GL; Terpos, E, 2005) |
| "An 80-year-old man with von Willebrand's disease was admitted with severe melaena." | 1.33 | Thalidomide as treatment for digestive tract angiodysplasias. ( Brouwer, RE; Heidt, J; Langers, AM; van der Meer, FJ, 2006) |
| "Serous effusions in multiple myeloma are uncommon but a myelomatous pleural effusion occurring in these patients is extremely rare." | 1.33 | Myelomatous pleural effusion. ( Advani, SH; Ghosh, S; Gopal, R, 2006) |
| "Thalidomide was used to treat acute (n=21) or chronic (n=59) graft-vs-host disease (GVHD) in 80 haematopoietic stem cell allograft recipients after failure to respond to the combination of cyclosporine and corticosteroids with or without other agents." | 1.32 | Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. ( Atra, A; Goyal, S; Horton, C; Kulkarni, S; Mehta, J; Meller, S; Ortin, M; Pinkerton, CR; Powles, R; Rudin, C; Sankpal, S; Saso, R; Singhal, S; Sirohi, B; Treleaven, J, 2003) |
| "Thalidomide is a putative anti-angiogenesis agent that has significant anti-tumour activity in haematological malignancies with increased bone marrow angiogenesis, including multiple myeloma (MM) and myelodysplastic syndromes (MDS)." | 1.32 | Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. ( Albitar, M; Cortes, J; Estey, E; Faderl, S; Giles, FJ; Kantarjian, H; Keating, M; O'Brien, S; Thomas, DA, 2003) |
| "Thalidomide 100 mg/day was then started, and the symptoms disappeared within 2 weeks." | 1.32 | Treatment of recurrent perforating intestinal ulcers with thalidomide in Behçet's disease. ( Arslanturk, H; Bayram, I; Gul, A; Kotan, MC; Sayarlioglu, M; Topcu, N, 2004) |
| "Thalidomide has antiangiogenic and immunomodulatory effects, mediated by several cytokines such as vascular endothelial growth factor (VEGF), fibroblastic growth factor (FGF-2), hepatocyte growth factor (HGF), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha)." | 1.32 | Response to thalidomide in multiple myeloma: impact of angiogenic factors. ( Arenillas, L; Aymerich, M; Bladé, J; Cibeira, MT; Cid, MC; Esteve, J; Filella, X; Montserrat, E; Rosiñol, L; Rozman, M; Segarra, M, 2004) |
| "Thalidomide was administered at relatively high doses (escalated up to 700 mg daily and continued for 4 months)." | 1.31 | Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent. ( Anagnostopoulos, N; Dimopoulos, MA; Zomas, A, 2000) |
| "Thalidomide has been used to treat many inflammatory dermatologic conditions and has been reintroduced in the United States to treat immune-modulated diseases such as pyoderma gangrenosum." | 1.31 | Recalcitrant pyoderma gangrenosum treated with thalidomide. ( Federman, DG; Federman, GL, 2000) |
| "We report one case of Langerhans cell histiocytosis in a 33-year-old woman with resistant vulvar involvement whose cutaneous lesions improved with thalidomide." | 1.30 | [Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide]. ( Blot, E; Boullié, MC; Cailleux, N; Courtois, H; Courville, P; Lair, G; Lauret, P; Lévesque, H; Marie, I, 1998) |
| "The patient had a recurrence of the choroidal neovascular membrane eight months after the start of thalidomide therapy." | 1.29 | Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide. ( Gorin, MB; Ip, M, 1996) |
| "Thalidomide appears to be an effective agent for the treatment of severe RAS unresponsive to traditional therapies." | 1.28 | Thalidomide: treatment of severe recurrent aphthous stomatitis in patients with AIDS. ( Nicolau, DP; West, TE, 1990) |
| "Thalidomide is a very effective drug in CDLE, but in most cases it exerts its effect only whilst treatment is continued." | 1.27 | Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. ( Bonsmann, G; Happle, R; Knop, J; Ludolph, A; Macher, E; Matz, DR; Mifsud, EJ, 1983) |
| "Cases of neuritis responded much more satisfactorily and there was no change in the muscle deficity before or after treatment with thalidomide." | 1.26 | Treatment with thalidomide in steroid dependency and neuritis. ( Theophilus, S, 1980) |
| " The initial dosage of either of the drugs was 300 mg daily administered in divided doses of 100 mg three times a day." | 1.26 | Treatment of steroid dependant cases of recurrent lepra reaction with a combination of thalidomide and clofazimine. ( Girdhar, A; Ramu, G, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (3.87) | 18.7374 |
| 1990's | 20 (3.68) | 18.2507 |
| 2000's | 164 (30.20) | 29.6817 |
| 2010's | 317 (58.38) | 24.3611 |
| 2020's | 21 (3.87) | 2.80 |
| Authors | Studies |
|---|---|
| Chim, CS | 2 |
| Kumar, S | 4 |
| Wong, VKC | 1 |
| Ngai, C | 1 |
| Kwong, YL | 1 |
| Richardson, PG | 14 |
| Schjesvold, F | 3 |
| Weisel, K | 4 |
| Moreau, P | 25 |
| Anderson, LD | 1 |
| White, D | 5 |
| Rodriguez-Otero, P | 3 |
| Sonneveld, P | 11 |
| Engelhardt, M | 4 |
| Jenner, M | 2 |
| Corso, A | 5 |
| Dürig, J | 3 |
| Pavic, M | 1 |
| Salomo, M | 1 |
| Beksac, M | 3 |
| Oriol, A | 13 |
| Lindsay, J | 1 |
| Liberati, AM | 5 |
| Galli, M | 3 |
| Robak, P | 2 |
| Larocca, A | 3 |
| Yagci, M | 1 |
| Vural, F | 2 |
| Kanate, AS | 1 |
| Jiang, R | 1 |
| Grote, L | 1 |
| Peluso, T | 2 |
| Dimopoulos, M | 5 |
| Deng, Y | 1 |
| Wei, W | 1 |
| Wang, Y | 3 |
| Pan, L | 2 |
| Du, G | 1 |
| Yao, H | 1 |
| Tang, G | 1 |
| Brioli, A | 2 |
| Gengenbach, L | 1 |
| Mancuso, K | 2 |
| Binder, M | 1 |
| Ernst, T | 1 |
| Heidel, FH | 1 |
| Stauch, T | 1 |
| Zamagni, E | 4 |
| Hilgendorf, I | 1 |
| Hochhaus, A | 1 |
| von Lilienfeld-Toal, M | 2 |
| Chen, H | 2 |
| Wu, S | 1 |
| Tang, M | 1 |
| Zhao, R | 1 |
| Zhang, Q | 3 |
| Dai, Z | 1 |
| Gao, Y | 2 |
| Yang, S | 3 |
| Li, Z | 3 |
| Du, Y | 1 |
| Yang, A | 1 |
| Zhong, L | 1 |
| Lu, L | 1 |
| Xu, L | 1 |
| Shen, X | 1 |
| Liu, S | 3 |
| Zhong, J | 1 |
| Li, X | 1 |
| Lu, H | 1 |
| Xiong, H | 1 |
| Shen, Y | 1 |
| Gong, S | 1 |
| Xue, H | 1 |
| Ge, Z | 1 |
| Zheng, F | 1 |
| Li, Q | 1 |
| Zhou, Z | 1 |
| Zeng, Q | 2 |
| Liu, K | 1 |
| Lee, HC | 1 |
| Shah, JJ | 2 |
| Feng, L | 4 |
| Morphey, A | 1 |
| Johnson, RJ | 1 |
| Wesson, ET | 1 |
| Wang, ML | 1 |
| Alexanian, R | 1 |
| Thomas, SK | 1 |
| Orlowski, RZ | 5 |
| Weber, DM | 6 |
| Shi, X | 1 |
| Yang, J | 1 |
| Yang, M | 1 |
| Zhao, W | 1 |
| Zhao, X | 1 |
| Shi, J | 1 |
| Zhou, H | 1 |
| Lin, CK | 1 |
| Tsai, YD | 1 |
| Leotta, S | 1 |
| Pirosa, MC | 1 |
| Markovic, U | 1 |
| Scalise, L | 1 |
| Bulla, A | 1 |
| Sapienza, G | 1 |
| Di Giorgio, MA | 1 |
| Martino, EA | 1 |
| Curto Pelle, A | 1 |
| Leotta, V | 1 |
| Milone, G | 3 |
| Cupri, A | 1 |
| Vaddinelli, D | 1 |
| Villari, L | 1 |
| Conticello, C | 1 |
| Wang, L | 1 |
| Xue, A | 1 |
| Zheng, C | 1 |
| Zhou, Y | 1 |
| Huang, Y | 1 |
| Lee, HS | 1 |
| Kim, K | 4 |
| Kim, SJ | 1 |
| Lee, JJ | 2 |
| Kim, I | 1 |
| Kim, JS | 1 |
| Eom, HS | 1 |
| Yoon, DH | 1 |
| Suh, C | 1 |
| Shin, HJ | 1 |
| Mun, YC | 1 |
| Kim, MK | 1 |
| Lim, SN | 1 |
| Choi, CW | 1 |
| Kang, HJ | 1 |
| Yoon, SS | 2 |
| Min, CK | 4 |
| Hagihara, M | 1 |
| Ide, S | 1 |
| Ohara, S | 1 |
| Uchida, T | 2 |
| Inoue, M | 1 |
| Hua, J | 1 |
| Wudhikarn, K | 1 |
| Wills, B | 1 |
| Lesokhin, AM | 1 |
| Pour, L | 6 |
| Aschan, J | 2 |
| Manasanch, EE | 1 |
| Jain, P | 1 |
| Chen, W | 3 |
| Oriabure, O | 1 |
| Badillo, M | 3 |
| Berkova, Z | 1 |
| Wang, M | 8 |
| Milani, P | 3 |
| Sharpley, F | 2 |
| Schönland, SO | 1 |
| Basset, M | 2 |
| Mahmood, S | 3 |
| Nuvolone, M | 2 |
| Kimmich, C | 1 |
| Foli, A | 3 |
| Sachchithanantham, S | 3 |
| Merlini, G | 4 |
| Wechalekar, A | 2 |
| Palladini, G | 4 |
| Hegenbart, U | 2 |
| Xu, S | 1 |
| Zu, XM | 1 |
| Feng, R | 1 |
| Zhang, SH | 1 |
| Qiu, Y | 1 |
| Chen, BL | 1 |
| Zeng, ZR | 1 |
| Chen, MH | 2 |
| He, Y | 1 |
| Fau, JB | 1 |
| El-Cheikh, R | 1 |
| Brillac, C | 1 |
| Koiwai, K | 1 |
| Mace, N | 1 |
| Campana, F | 2 |
| Semiond, D | 1 |
| Nguyen, L | 1 |
| Sirvent, M | 1 |
| González-Rodríguez, AP | 1 |
| Lavilla, E | 1 |
| de Coca, AG | 1 |
| Arguiñano, JM | 1 |
| Martí, JM | 1 |
| Cabañas, V | 1 |
| Motlló, C | 1 |
| de Cabo, E | 1 |
| Encinas, C | 1 |
| Murillo, I | 1 |
| Hernández-Rivas, JÁ | 1 |
| Pérez-Persona, E | 1 |
| Casado, F | 1 |
| Sampol, A | 1 |
| García, R | 1 |
| Blanchard, MJ | 1 |
| Anguita, M | 1 |
| Lafuente, AP | 1 |
| Iñigo, B | 1 |
| López, A | 1 |
| Ribas, P | 1 |
| Arnao, M | 1 |
| Maldonado, R | 1 |
| Bladé, J | 6 |
| Mateos, MV | 10 |
| Lahuerta, JJ | 2 |
| San Miguel, JF | 8 |
| Harrison, SJ | 1 |
| Perrot, A | 3 |
| Alegre, A | 6 |
| Simpson, D | 2 |
| Wang, MC | 1 |
| Spencer, A | 6 |
| Delimpasi, S | 2 |
| Hulin, C | 5 |
| Sunami, K | 1 |
| Facon, T | 14 |
| Vlummens, P | 1 |
| Yong, K | 5 |
| Inchauspé, M | 1 |
| Macé, S | 2 |
| Risse, ML | 2 |
| van de Velde, H | 1 |
| Richardson, P | 10 |
| Dimopoulos, MA | 30 |
| Mikhael, J | 2 |
| Capra, M | 1 |
| Hajek, R | 11 |
| Špička, I | 7 |
| Baker, R | 1 |
| Martinez, G | 1 |
| Leleu, X | 9 |
| Koh, Y | 1 |
| Suzuki, K | 6 |
| Asset, G | 1 |
| Martin, T | 1 |
| Reece, DE | 6 |
| Masih-Khan, E | 2 |
| Atenafu, EG | 1 |
| Jimenez-Zepeda, VH | 2 |
| McCurdy, A | 1 |
| Song, K | 1 |
| LeBlanc, R | 1 |
| Sebag, M | 1 |
| Cherniawsky, H | 1 |
| Reiman, A | 1 |
| Stakiw, J | 1 |
| Louzada, ML | 1 |
| Kotb, R | 1 |
| Aslam, M | 1 |
| Gul, E | 1 |
| Venner, CP | 2 |
| Chen, T | 1 |
| Levitt, J | 1 |
| Geller, L | 1 |
| Loyal, J | 1 |
| Flores, S | 1 |
| Alikhan, A | 1 |
| Park, S | 1 |
| Hamel, JF | 1 |
| Toma, A | 1 |
| Kelaidi, C | 1 |
| Thépot, S | 1 |
| Campelo, MD | 1 |
| Santini, V | 1 |
| Sekeres, MA | 2 |
| Balleari, E | 3 |
| Kaivers, J | 1 |
| Sapena, R | 1 |
| Götze, K | 1 |
| Müller-Thomas, C | 1 |
| Beyne-Rauzy, O | 1 |
| Stamatoullas, A | 1 |
| Kotsianidis, I | 1 |
| Komrokji, R | 1 |
| Steensma, DP | 2 |
| Fensterl, J | 1 |
| Roboz, GJ | 1 |
| Bernal, T | 1 |
| Ramos, F | 1 |
| Calabuig, M | 1 |
| Guerci-Bresler, A | 1 |
| Bordessoule, D | 1 |
| Cony-Makhoul, P | 1 |
| Cheze, S | 1 |
| Wattel, E | 2 |
| Rose, C | 1 |
| Vey, N | 2 |
| Gioia, D | 1 |
| Ferrero, D | 1 |
| Gaidano, G | 1 |
| Cametti, G | 1 |
| Pane, F | 1 |
| Sanna, A | 1 |
| Germing, U | 1 |
| Sanz, GF | 1 |
| Dreyfus, F | 1 |
| Fenaux, P | 2 |
| Itchaki, G | 1 |
| Brown, JR | 1 |
| Leng, Y | 1 |
| Hou, J | 1 |
| Jin, J | 1 |
| Zhang, M | 1 |
| Ke, X | 1 |
| Jiang, B | 1 |
| Yang, L | 1 |
| Zhou, F | 1 |
| Wang, J | 4 |
| Wang, Z | 1 |
| Liu, L | 1 |
| Li, W | 1 |
| Shen, Z | 1 |
| Qiu, L | 1 |
| Chang, N | 1 |
| Li, J | 5 |
| Liu, J | 1 |
| Pang, H | 1 |
| Meng, H | 1 |
| Wei, P | 1 |
| Jiang, H | 2 |
| Liu, Y | 1 |
| Zheng, X | 1 |
| de Wit, E | 1 |
| Tian, C | 1 |
| Yang, H | 2 |
| Zhu, L | 1 |
| Cao, Z | 1 |
| Zhang, Y | 3 |
| Randall, K | 1 |
| Kaparou, M | 1 |
| Xenou, E | 1 |
| Paneesha, S | 1 |
| Kishore, B | 2 |
| Kanellopoulos, A | 1 |
| Lovell, R | 1 |
| Holder, K | 1 |
| Suhr, J | 1 |
| Baker, L | 1 |
| Ryan, L | 1 |
| Nikolousis, E | 1 |
| Denman, J | 1 |
| Manavi, K | 1 |
| Cook, M | 1 |
| Chari, A | 1 |
| Suvannasankha, A | 2 |
| Fay, JW | 1 |
| Arnulf, B | 4 |
| Kaufman, JL | 8 |
| Ifthikharuddin, JJ | 1 |
| Weiss, BM | 1 |
| Krishnan, A | 1 |
| Lentzsch, S | 3 |
| Comenzo, R | 1 |
| Nottage, K | 1 |
| Chiu, C | 2 |
| Khokhar, NZ | 3 |
| Ahmadi, T | 3 |
| Lonial, S | 14 |
| Palumbo, A | 27 |
| San-Miguel, J | 5 |
| Shpilberg, O | 1 |
| Anderson, K | 4 |
| Grosicki, S | 2 |
| Walter-Croneck, A | 2 |
| Magen, H | 2 |
| Belch, A | 5 |
| Reece, D | 5 |
| Bleickardt, E | 4 |
| Poulart, V | 2 |
| Sheng, J | 1 |
| Sy, O | 1 |
| Katz, J | 2 |
| Singhal, A | 3 |
| Witzig, TE | 9 |
| Luigi Zinzani, P | 1 |
| Habermann, TM | 3 |
| Tuscano, JM | 4 |
| Drach, J | 4 |
| Ramchandren, R | 3 |
| Kalayoglu Besisik, S | 2 |
| Takeshita, K | 3 |
| Casadebaig Bravo, ML | 2 |
| Zhang, L | 6 |
| Fu, T | 2 |
| Goy, A | 6 |
| Jung, SH | 4 |
| Lee, SE | 1 |
| Lee, M | 1 |
| Kim, SH | 1 |
| Yim, SH | 1 |
| Kim, TW | 1 |
| Chung, YJ | 1 |
| Pelligra, CG | 1 |
| Parikh, K | 1 |
| Guo, S | 1 |
| Chandler, C | 1 |
| Mouro, J | 1 |
| Abouzaid, S | 1 |
| Ailawadhi, S | 1 |
| Chasset, F | 1 |
| Tounsi, T | 1 |
| Cesbron, E | 1 |
| Barbaud, A | 1 |
| Francès, C | 1 |
| Arnaud, L | 1 |
| Scott, A | 1 |
| Weber, N | 1 |
| Tiley, C | 1 |
| Taylor, K | 1 |
| Taper, J | 1 |
| Harrison, S | 3 |
| Chan, KL | 1 |
| Stark, R | 1 |
| Lee, C | 2 |
| Morris, K | 1 |
| Ho, PJ | 1 |
| Dodds, A | 1 |
| Ramanathan, S | 1 |
| Ramakrishna, R | 1 |
| Watson, AM | 1 |
| Auguston, B | 1 |
| Kwok, F | 1 |
| Quach, H | 3 |
| Warburton, P | 1 |
| Rowlings, P | 1 |
| Mollee, P | 1 |
| Büyükkaramikli, NC | 1 |
| de Groot, S | 1 |
| Fayter, D | 1 |
| Wolff, R | 1 |
| Armstrong, N | 1 |
| Stirk, L | 1 |
| Worthy, G | 1 |
| Albuquerque de Almeida, F | 1 |
| Kleijnen, J | 1 |
| Al, MJ | 1 |
| Schuster, SJ | 1 |
| Phillips, T | 1 |
| Lossos, IS | 3 |
| Rule, S | 2 |
| Hamadani, M | 1 |
| Ghosh, N | 1 |
| Reeder, CB | 4 |
| Barnett, E | 1 |
| Bravo, MC | 1 |
| Martin, P | 2 |
| Russo, F | 1 |
| Perlini, S | 2 |
| Hoy, SM | 1 |
| Blair, HA | 1 |
| Sopeña, B | 1 |
| Limeres, J | 1 |
| García-Caballero, L | 1 |
| Diniz-Freitas, M | 1 |
| Seoane, J | 1 |
| Diz, P | 1 |
| Xu, W | 1 |
| Sun, X | 1 |
| Wang, B | 1 |
| Guo, H | 1 |
| Cohen, A | 1 |
| Spektor, TM | 1 |
| Stampleman, L | 1 |
| Bessudo, A | 1 |
| Rosen, PJ | 1 |
| Klein, LM | 1 |
| Woliver, T | 1 |
| Flam, M | 1 |
| Eshaghian, S | 1 |
| Nassir, Y | 1 |
| Maluso, T | 1 |
| Swift, RA | 1 |
| Vescio, R | 3 |
| Berenson, JR | 1 |
| Arcaini, L | 1 |
| Lamy, T | 1 |
| Walewski, J | 1 |
| Belada, D | 1 |
| Mayer, J | 4 |
| Radford, J | 1 |
| Jurczak, W | 3 |
| Morschhauser, F | 1 |
| Alexeeva, J | 1 |
| Cabeçadas, J | 1 |
| Campo, E | 1 |
| Pileri, SA | 4 |
| Biyukov, T | 1 |
| Patturajan, M | 1 |
| Trnĕný, M | 1 |
| Fouquet, G | 2 |
| Karlin, L | 5 |
| Macro, M | 2 |
| Caillot, D | 3 |
| Roussel, M | 4 |
| Pegourie, B | 4 |
| Petillon, MO | 2 |
| Mathiot, C | 2 |
| Kolb, B | 2 |
| Stoppa, AM | 2 |
| Brechiniac, S | 1 |
| Rodon, P | 1 |
| Dib, M | 3 |
| Tiab, M | 2 |
| Richez, V | 1 |
| Araujo, C | 2 |
| Wetterwald, M | 2 |
| Garderet, L | 6 |
| Royer, B | 3 |
| Benboubker, L | 4 |
| Decaux, O | 2 |
| Escoffre-Barbe, M | 2 |
| Fermand, JP | 4 |
| Avet-Loiseau, H | 3 |
| Attal, M | 9 |
| Matsumura-Kimoto, Y | 1 |
| Kuroda, J | 3 |
| Kaneko, H | 2 |
| Kamitsuji, Y | 1 |
| Fuchida, SI | 1 |
| Nakaya, A | 1 |
| Shibayama, H | 2 |
| Uoshima, N | 2 |
| Yokota, I | 1 |
| Uchiyama, H | 2 |
| Yagi, H | 2 |
| Kosugi, S | 2 |
| Matsui, T | 1 |
| Ishikawa, J | 1 |
| Matsuda, M | 2 |
| Ohta, K | 2 |
| Iida, M | 1 |
| Tanaka, H | 2 |
| Kobayashi, M | 3 |
| Wada, K | 1 |
| Shimazaki, C | 3 |
| Nomura, S | 2 |
| Imada, K | 1 |
| Hino, M | 1 |
| Matsumura, I | 3 |
| Kanakura, Y | 2 |
| Takaori-Kondo, A | 2 |
| Gueneau, P | 1 |
| Chretien, ML | 1 |
| Cransac-Miet, A | 1 |
| Aho, LS | 1 |
| Lafon, I | 3 |
| Favennec, C | 1 |
| Guy, J | 1 |
| Boulin, M | 1 |
| Halderman, AA | 1 |
| Ryan, MW | 1 |
| Clark, C | 1 |
| Sindwani, R | 1 |
| Reh, DD | 1 |
| Poetker, DM | 1 |
| Invernizzi, R | 3 |
| Marple, BF | 1 |
| Jerkeman, M | 1 |
| Eskelund, CW | 1 |
| Hutchings, M | 1 |
| Räty, R | 1 |
| Wader, KF | 1 |
| Laurell, A | 1 |
| Toldbod, H | 1 |
| Pedersen, LB | 1 |
| Niemann, CU | 1 |
| Dahl, C | 1 |
| Kuitunen, H | 1 |
| Geisler, CH | 1 |
| Grønbæk, K | 1 |
| Kolstad, A | 1 |
| Drahy, F | 1 |
| Ingen-Housz-Oro, S | 2 |
| Grootenboer-Mignot, S | 1 |
| Wolkenstein, P | 1 |
| Chosidow, O | 2 |
| Costa, PDSS | 1 |
| Fraga, LR | 1 |
| Kowalski, TW | 1 |
| Daxbacher, ELR | 1 |
| Schuler-Faccini, L | 1 |
| Vianna, FSL | 1 |
| Iida, S | 6 |
| Wakabayashi, M | 1 |
| Tsukasaki, K | 3 |
| Miyamoto, K | 1 |
| Maruyama, D | 2 |
| Yamamoto, K | 1 |
| Takatsuka, Y | 1 |
| Kusumoto, S | 3 |
| Ando, K | 1 |
| Kikukawa, Y | 1 |
| Masaki, Y | 1 |
| Hanamura, I | 1 |
| Asai, H | 1 |
| Nagai, H | 2 |
| Shimada, K | 1 |
| Tsukamoto, N | 1 |
| Inoue, Y | 1 |
| Tobinai, K | 3 |
| Katodritou, E | 4 |
| Kyrtsonis, MC | 3 |
| Kyriakou, D | 2 |
| Symeonidis, A | 2 |
| Spanoudakis, E | 2 |
| Vasilopoulos, G | 1 |
| Anagnostopoulos, A | 2 |
| Kioumi, A | 1 |
| Zikos, P | 2 |
| Aktypi, A | 1 |
| Briasoulis, E | 2 |
| Megalakaki, A | 1 |
| Repousis, P | 1 |
| Adamopoulos, I | 1 |
| Gogos, D | 1 |
| Kotsopoulou, M | 2 |
| Pappa, V | 1 |
| Papadaki, E | 1 |
| Fotiou, D | 2 |
| Nikolaou, E | 1 |
| Giannopoulou, E | 1 |
| Hatzimichael, E | 2 |
| Giannakoulas, N | 2 |
| Douka, V | 1 |
| Kokoviadou, K | 1 |
| Timotheatou, D | 1 |
| Terpos, E | 10 |
| Dinner, S | 1 |
| Dunn, TJ | 1 |
| Price, E | 1 |
| Coutré, SE | 2 |
| Gotlib, J | 1 |
| Berube, C | 1 |
| Kaufman, GP | 1 |
| Medeiros, BC | 1 |
| Liedtke, M | 3 |
| Charlinski, G | 1 |
| Grzasko, N | 1 |
| Jurczyszyn, A | 2 |
| Janczarski, M | 1 |
| Szeremet, A | 1 |
| Waszczuk-Gajda, A | 1 |
| Bernatowicz, P | 1 |
| Swiderska, A | 1 |
| Guzicka-Kazimierczak, R | 1 |
| Lech-Maranda, E | 1 |
| Szczepaniak, A | 1 |
| Wichary, R | 1 |
| Dmoszynska, A | 4 |
| Watanabe, N | 1 |
| Kitahara, H | 1 |
| Iwao, N | 1 |
| Ohta, Y | 1 |
| Koike, M | 1 |
| Komatsu, N | 1 |
| Oka, S | 1 |
| Ono, K | 1 |
| Nohgawa, M | 1 |
| Ma, X | 1 |
| Scott, BL | 1 |
| Kiselev, P | 1 |
| Sugrue, MM | 1 |
| Swern, AS | 4 |
| Wang, YN | 1 |
| Li, XQ | 1 |
| Guo, F | 1 |
| Yang, AM | 1 |
| Qian, JM | 1 |
| Li, JN | 1 |
| Xue, HD | 1 |
| Zhou, WX | 1 |
| Ma, ZQ | 1 |
| Sivaraj, D | 1 |
| Green, MM | 1 |
| Kang, Y | 1 |
| Long, GD | 1 |
| Rizzieri, DA | 1 |
| Garrett, AH | 1 |
| McIntyre, JL | 1 |
| Chao, NJ | 1 |
| Gasparetto, C | 3 |
| Qian, X | 1 |
| Amatangelo, M | 1 |
| Bjorklund, C | 1 |
| Towfic, F | 1 |
| Flynt, E | 1 |
| Weisel, KC | 6 |
| Ocio, EM | 3 |
| Yu, X | 5 |
| Sternas, L | 5 |
| Zaki, M | 3 |
| Thakurta, A | 1 |
| Sharpley, FA | 1 |
| Manwani, R | 1 |
| Lachmann, H | 1 |
| Gilmore, J | 1 |
| Whelan, C | 1 |
| Hawkins, P | 1 |
| Soyer, N | 1 |
| Patır, P | 1 |
| Uysal, A | 1 |
| Duran, M | 1 |
| Ünal, HD | 1 |
| Durusoy, R | 1 |
| Tombuloğlu, M | 1 |
| Şahin, F | 1 |
| Töbü, M | 1 |
| Saydam, G | 1 |
| Popat, R | 2 |
| Brown, SR | 1 |
| Flanagan, L | 1 |
| Hall, A | 1 |
| Gregory, W | 1 |
| Streetly, M | 3 |
| Oakervee, H | 2 |
| Cook, G | 3 |
| Low, E | 1 |
| Cavenagh, J | 2 |
| Harrison, L | 1 |
| Kundra, A | 1 |
| Jervis, P | 1 |
| Kuhnowski, F | 1 |
| Berge, B | 1 |
| Marit, G | 2 |
| Chaleteix, C | 2 |
| Lenain, P | 1 |
| Voog, E | 1 |
| Allangba, O | 1 |
| Jourdan, E | 1 |
| Orsini-Piocelle, F | 1 |
| Brechignac, S | 1 |
| Eveillard, JR | 2 |
| Belhadj, K | 1 |
| Jaccard, A | 3 |
| Eisenmann, JC | 1 |
| Glaisner, S | 1 |
| Mohty, M | 5 |
| Loiseau, HA | 1 |
| Tavares Rodrigues, F | 1 |
| Pereira Cardozo, MR | 1 |
| da Costa Nery, JA | 1 |
| Gourd, E | 1 |
| Gong, CL | 1 |
| Studdert, AL | 1 |
| Trudel, S | 3 |
| Tessoulin, B | 2 |
| Jullien, M | 1 |
| Blin, N | 3 |
| Gastinne, T | 1 |
| Mahé, B | 2 |
| Dubruille, V | 2 |
| Bonnet, A | 1 |
| Lok, A | 1 |
| Chevallier, P | 1 |
| Peterlin, P | 2 |
| Garnier, A | 1 |
| Guillaume, T | 1 |
| Le Bourgeois, A | 1 |
| Le Gouill, S | 3 |
| Touzeau, C | 4 |
| Barwick, BG | 1 |
| Neri, P | 1 |
| Bahlis, NJ | 5 |
| Nooka, AK | 1 |
| Dhodapkar, MV | 1 |
| Jaye, DL | 1 |
| Hofmeister, CC | 4 |
| Gupta, VA | 1 |
| Auclair, D | 1 |
| Keats, JJ | 1 |
| Vertino, PM | 1 |
| Boise, LH | 1 |
| Mushtaq, A | 1 |
| Iftikhar, A | 1 |
| Hassan, H | 1 |
| Lakhani, M | 1 |
| Sagar, F | 1 |
| Kamal, A | 1 |
| Zahid, U | 1 |
| Ali, Z | 1 |
| Razzaq, F | 1 |
| Zar, MA | 1 |
| Hassan, SF | 1 |
| Safdar, A | 1 |
| Raychaudhuri, S | 1 |
| Anwer, F | 1 |
| De Luca, G | 1 |
| Cariddi, A | 1 |
| Campochiaro, C | 1 |
| Vanni, D | 1 |
| Boffini, N | 1 |
| Tomelleri, A | 1 |
| Cavalli, G | 1 |
| Dagna, L | 1 |
| Yamshon, S | 1 |
| Ruan, J | 2 |
| Blacklock, H | 2 |
| George, A | 1 |
| Goldschmidt, H | 15 |
| Chanan-Khan, A | 3 |
| Sherbenou, D | 1 |
| Avivi, I | 1 |
| Benyamini, N | 1 |
| Matsumoto, M | 2 |
| Ribrag, V | 1 |
| Usmani, SZ | 6 |
| Jagannath, S | 10 |
| San Miguel, J | 2 |
| Kher, U | 1 |
| Farooqui, M | 1 |
| Liao, J | 1 |
| Marinello, P | 1 |
| Rajkumar, SV | 10 |
| Suzuki, T | 1 |
| Yoshida, T | 2 |
| Mori, F | 1 |
| Ito, A | 2 |
| Ri, M | 2 |
| Ishida, T | 3 |
| Komatsu, H | 2 |
| Niimi, A | 1 |
| Yordanova, A | 1 |
| Hose, D | 4 |
| Neben, K | 6 |
| Witzens-Harig, M | 1 |
| Gütgemann, I | 1 |
| Raab, MS | 4 |
| Moehler, T | 3 |
| Schmidt-Wolf, IG | 2 |
| Kukreti, V | 4 |
| Young, T | 1 |
| Chu, CM | 1 |
| Chen, C | 9 |
| Jimenez-Zepeda, V | 1 |
| Skarbnik, AP | 1 |
| Smith, MR | 1 |
| Fowler, N | 2 |
| Wagner-Bartak, N | 2 |
| Romaguera, J | 3 |
| Neelapu, SS | 2 |
| Hagemeister, F | 2 |
| Fanale, M | 2 |
| Oki, Y | 1 |
| Pro, B | 2 |
| Shah, J | 1 |
| Thomas, S | 1 |
| Younes, A | 3 |
| Hosing, C | 2 |
| Newberry, KJ | 2 |
| Desai, M | 1 |
| Cheng, N | 1 |
| Bejarano, M | 2 |
| Chen, Y | 4 |
| Young, KH | 2 |
| Champlin, R | 2 |
| Kwak, L | 2 |
| Fayad, L | 2 |
| Sellner, L | 1 |
| Heiss, C | 1 |
| Benner, A | 3 |
| Hillengass, J | 3 |
| Lehners, N | 1 |
| Egerer, G | 3 |
| Ho, AD | 6 |
| Hou, W | 1 |
| Chang, MN | 1 |
| Li, Y | 2 |
| Saini, N | 1 |
| Mahindra, A | 1 |
| Wang, XY | 1 |
| Du, Q | 1 |
| Pönisch, W | 3 |
| Heyn, S | 1 |
| Beck, J | 1 |
| Wagner, I | 1 |
| Mohren, M | 1 |
| Hoffmann, FA | 2 |
| Lange, T | 1 |
| Schmalfeld, M | 1 |
| Zehrfeld, T | 2 |
| Schwarzer, A | 2 |
| Winkelmann, C | 1 |
| Edelmann, T | 1 |
| Röhrborn, R | 1 |
| Hebenstreit, K | 1 |
| Al-Ali, HK | 1 |
| Jäkel, N | 1 |
| Niederwieser, D | 3 |
| van de Donk, NW | 2 |
| Lokhorst, HM | 4 |
| Gay, F | 3 |
| Magarotto, V | 2 |
| Crippa, C | 4 |
| Pescosta, N | 2 |
| Guglielmelli, T | 7 |
| Cavallo, F | 10 |
| Pezzatti, S | 1 |
| Ferrari, S | 1 |
| Oliva, S | 2 |
| Patriarca, F | 3 |
| Offidani, M | 5 |
| Omedé, P | 2 |
| Montefusco, V | 3 |
| Petrucci, MT | 7 |
| Giuliani, N | 2 |
| Passera, R | 2 |
| Pietrantuono, G | 2 |
| Boccadoro, M | 12 |
| Corradini, P | 6 |
| Vose, JM | 5 |
| Czuczman, MS | 5 |
| Zinzani, PL | 8 |
| Pietronigro, D | 5 |
| Vadikolia, C | 1 |
| Lalagianni, C | 1 |
| Papageorgiou, G | 1 |
| Matsouka, P | 1 |
| Karras, G | 1 |
| Anagnostopoulos, N | 4 |
| Michali, E | 1 |
| Tsakiridou, A | 1 |
| Tsionos, K | 2 |
| Anargyrou, K | 1 |
| Maniatis, A | 1 |
| Bringhen, S | 7 |
| Rossi, D | 2 |
| Mina, R | 1 |
| Marcatti, M | 1 |
| La Verde, G | 1 |
| Rota-Scalabrini, D | 1 |
| Santagostino, A | 1 |
| Baldi, I | 1 |
| Carella, AM | 4 |
| Meadows, JP | 1 |
| Mark, TM | 2 |
| Christoulas, D | 4 |
| Kastritis, E | 6 |
| Papatheodorou, A | 1 |
| Pouli, A | 2 |
| Michalis, E | 1 |
| Papanikolaou, X | 1 |
| Gkotzamanidou, M | 1 |
| Koulieris, E | 1 |
| Gavriatopoulou, M | 4 |
| Zervas, K | 3 |
| Sinha, R | 2 |
| Williams, ME | 1 |
| Cicero, S | 1 |
| Haioun, C | 1 |
| Polikoff, J | 2 |
| Tilly, H | 1 |
| Prandi, K | 1 |
| Atanackovic, D | 3 |
| Schilling, G | 3 |
| Frankel, HC | 1 |
| Sharon, VR | 1 |
| Vleugels, RA | 1 |
| Merola, JF | 1 |
| Qureshi, AA | 1 |
| Zeidan, AM | 1 |
| Kharfan-Dabaja, MA | 1 |
| Komrokji, RS | 1 |
| Xie, W | 1 |
| Jakubowiak, A | 3 |
| Raje, NS | 2 |
| Alsina, M | 7 |
| Ghobrial, IM | 3 |
| Schlossman, RL | 4 |
| Munshi, NC | 4 |
| Mazumder, A | 3 |
| Vesole, DH | 3 |
| Colson, K | 1 |
| McKenney, M | 2 |
| Lunde, LE | 2 |
| Feather, J | 1 |
| Maglio, ME | 1 |
| Warren, D | 2 |
| Francis, D | 1 |
| Hideshima, T | 8 |
| Knight, R | 8 |
| Esseltine, DL | 3 |
| Mitsiades, CS | 4 |
| Weller, E | 4 |
| Anderson, KC | 15 |
| Hopfinger, G | 1 |
| Nösslinger, T | 1 |
| Lang, A | 1 |
| Linkesch, W | 1 |
| Melchardt, T | 1 |
| Weiss, L | 2 |
| Egle, A | 1 |
| Greil, R | 1 |
| Mehta, RS | 1 |
| Di Stasi, A | 1 |
| Shah, N | 2 |
| Rezvani, K | 2 |
| Alousi, A | 1 |
| O'Brien, S | 2 |
| Wierda, W | 1 |
| Keating, M | 2 |
| Shpall, EJ | 1 |
| Manabe, M | 1 |
| Okita, J | 1 |
| Tarakuwa, T | 1 |
| Harada, N | 1 |
| Aoyama, Y | 1 |
| Kumura, T | 1 |
| Ohta, T | 1 |
| Furukawa, Y | 1 |
| Mugitani, A | 1 |
| Genadieva-Stavric, S | 1 |
| Scott, LJ | 2 |
| Broccoli, A | 3 |
| Pellegrini, C | 4 |
| Celli, M | 1 |
| Argnani, L | 4 |
| Agostinelli, C | 1 |
| Pileri, S | 4 |
| Feldman, T | 1 |
| Mato, AR | 1 |
| Chow, KF | 1 |
| Protomastro, EA | 1 |
| Yannotti, KM | 1 |
| Bhattacharyya, P | 1 |
| Yang, X | 4 |
| Donato, ML | 1 |
| Rowley, SD | 1 |
| Carini, C | 1 |
| Valentinetti, M | 1 |
| Smith, J | 1 |
| Gadaleta, G | 1 |
| Bejot, C | 1 |
| Stives, S | 1 |
| Timberg, M | 1 |
| Kdiry, S | 1 |
| Pecora, AL | 1 |
| Beaven, AW | 1 |
| Coleman, M | 2 |
| Niesvizky, R | 9 |
| Baret, I | 1 |
| De Haes, P | 1 |
| Govindaraj, C | 1 |
| Madondo, M | 1 |
| Kong, YY | 1 |
| Tan, P | 1 |
| Wei, A | 1 |
| Plebanski, M | 1 |
| Yee, AJ | 1 |
| Hari, P | 1 |
| Marcheselli, R | 2 |
| Mahindra, AK | 1 |
| Cirstea, DD | 1 |
| Scullen, TA | 1 |
| Burke, JN | 1 |
| Rodig, SJ | 1 |
| Laubach, JP | 4 |
| Weller, EA | 1 |
| Kalampokis, I | 1 |
| Rabinovich, CE | 1 |
| Lane, T | 1 |
| Rannigan, L | 1 |
| Foard, D | 1 |
| Pinney, JH | 1 |
| Gibbs, SD | 1 |
| Whelan, CJ | 1 |
| Lachmann, HJ | 2 |
| Gillmore, JD | 2 |
| Hawkins, PN | 2 |
| Wechalekar, AD | 2 |
| Nair, R | 1 |
| Gheith, S | 1 |
| Popescu, D | 1 |
| Agostino, NM | 1 |
| Zago, M | 1 |
| Oehrlein, K | 2 |
| Rendl, C | 1 |
| Hahn-Ast, C | 3 |
| Kanz, L | 1 |
| Morrison, VA | 1 |
| Johnson, J | 1 |
| LaCasce, A | 1 |
| Blum, KA | 4 |
| Bartlett, NL | 3 |
| Pitcher, BN | 1 |
| Cheson, BD | 3 |
| Ise, M | 1 |
| Tsujimura, H | 1 |
| Sakai, C | 1 |
| Kumagai, K | 1 |
| Ferrero, S | 1 |
| Ladetto, M | 1 |
| Drandi, D | 1 |
| Genuardi, E | 1 |
| Urbano, M | 1 |
| Caltagirone, S | 1 |
| Grasso, M | 2 |
| Rossini, F | 1 |
| Cangialosi, C | 2 |
| Callea, V | 2 |
| Carovita, T | 1 |
| De Rosa, L | 1 |
| Pisani, F | 1 |
| Falcone, AP | 2 |
| Pregno, P | 3 |
| Terragna, C | 2 |
| Musto, P | 8 |
| João, C | 2 |
| Coelho, I | 1 |
| Costa, C | 1 |
| Esteves, S | 1 |
| Lucio, P | 1 |
| Huddleston, SM | 1 |
| Houser, KH | 1 |
| Walton, RC | 1 |
| Maddocks, K | 2 |
| Ruppert, AS | 1 |
| Browning, R | 1 |
| Jones, J | 1 |
| Flynn, J | 2 |
| Kefauver, C | 2 |
| Jiang, Y | 2 |
| Rozewski, DM | 2 |
| Poi, M | 1 |
| Phelps, MA | 4 |
| Harper, E | 1 |
| Johnson, AJ | 3 |
| Byrd, JC | 5 |
| Andritsos, LA | 2 |
| Stratton, K | 1 |
| Qu, P | 1 |
| Yaccoby, S | 1 |
| Hansen, E | 2 |
| Steward, D | 1 |
| Panozzo, S | 1 |
| Petty, N | 2 |
| Hoering, A | 2 |
| Waheed, S | 2 |
| Van Rhee, F | 3 |
| Crowley, J | 3 |
| Barlogie, B | 5 |
| Miguel, JF | 1 |
| Vij, R | 3 |
| Singla, A | 1 |
| Kumar, AK | 1 |
| Dakhil, C | 1 |
| Teeka Satyan, M | 1 |
| Haideri, N | 1 |
| Maglie, R | 1 |
| Moser, S | 1 |
| Tischer, A | 1 |
| Karpi, A | 1 |
| Schleicher, M | 1 |
| Stavjanik, S | 1 |
| Gschwantler, M | 1 |
| Hobeika, L | 1 |
| Self, SE | 1 |
| Velez, JC | 1 |
| Krawczyk, K | 1 |
| Gałązka, K | 1 |
| Gruchała, A | 1 |
| Skotnicki, AB | 2 |
| Ai, H | 3 |
| Wei, X | 3 |
| Yin, Q | 2 |
| Wang, P | 3 |
| Mi, R | 2 |
| Song, Y | 3 |
| Lau, IJ | 2 |
| Smith, D | 1 |
| Aitchison, R | 1 |
| Blesing, N | 1 |
| Roberts, P | 2 |
| Peniket, A | 1 |
| Rabin, N | 3 |
| Ramasamy, K | 3 |
| Lestang, E | 1 |
| Caristan, A | 1 |
| Néel, A | 1 |
| Graveleau, J | 1 |
| Duhamel, E | 1 |
| Masseau, A | 1 |
| Connault, J | 1 |
| Maisonneuve, H | 1 |
| Hamidou, M | 1 |
| Li, JS | 1 |
| Hussein, M | 3 |
| Nagarwala, Y | 1 |
| Baz, R | 3 |
| Kobayashi, T | 1 |
| Fuchida, S | 2 |
| Adachi, Y | 1 |
| Ishii, K | 1 |
| Nakatani, E | 1 |
| Tsudo, M | 1 |
| Taniwaki, M | 2 |
| Cai, QQ | 1 |
| Wang, C | 1 |
| Cao, XX | 1 |
| Cai, H | 1 |
| Zhou, DB | 1 |
| Morgan, G | 2 |
| Dhanasiri, S | 1 |
| Lee, D | 3 |
| Delforge, M | 4 |
| Jacques, C | 3 |
| Akehurst, R | 1 |
| Offner, F | 1 |
| Hao, Q | 1 |
| Yuan, F | 1 |
| Stewart, AK | 4 |
| Masszi, T | 5 |
| Rosiñol, L | 7 |
| Siegel, DS | 4 |
| Mihaylov, GG | 2 |
| Goranova-Marinova, V | 3 |
| Rajnics, P | 2 |
| Suvorov, A | 2 |
| Jakubowiak, AJ | 5 |
| San-Miguel, JF | 2 |
| Ludwig, H | 6 |
| Maisnar, V | 4 |
| Minarik, J | 4 |
| Bensinger, WI | 2 |
| Ben-Yehuda, D | 2 |
| Zojwalla, N | 2 |
| Tonda, ME | 1 |
| Xing, B | 2 |
| Nozzoli, C | 3 |
| Staderini, M | 2 |
| Veltroni, A | 1 |
| Longo, G | 1 |
| Bacchiarri, F | 1 |
| Donnini, I | 1 |
| Guarrera, A | 1 |
| Bosi, A | 4 |
| Takeda, Y | 1 |
| Sakaida, E | 1 |
| Nakaseko, C | 2 |
| Wei, L | 2 |
| Rozewski, D | 1 |
| Zhao, Y | 1 |
| Adusumilli, M | 1 |
| Pierceall, WE | 1 |
| Doykin, C | 1 |
| Cardone, MH | 1 |
| Jones, JA | 1 |
| Grever, MR | 3 |
| Duan, M | 1 |
| Wen, Y | 1 |
| Holstein, SA | 1 |
| McCarthy, PL | 1 |
| Rueda, A | 1 |
| García-Sanz, R | 2 |
| Pastor, M | 1 |
| Salar, A | 1 |
| Labrador, J | 1 |
| Quero-Blanco, C | 1 |
| Casanova, M | 1 |
| Provencio, M | 1 |
| Siddiqi, T | 1 |
| Rosen, ST | 1 |
| Engelen, ET | 1 |
| van Galen, KP | 1 |
| Schutgens, RE | 1 |
| Areethamsirikul, N | 1 |
| Miranda-Bautista, J | 1 |
| Fernández-Simón, A | 1 |
| Pérez-Sánchez, I | 1 |
| Menchén, L | 1 |
| Tsunemine, H | 1 |
| Yoshioka, S | 1 |
| Sakane, E | 1 |
| Akasaka, H | 1 |
| Ito, K | 1 |
| Kodaka, T | 1 |
| Takahashi, T | 1 |
| Röllig, C | 1 |
| Einsele, H | 3 |
| Wu, KL | 1 |
| Zambello, R | 3 |
| Bonaldi, L | 1 |
| Berno, T | 2 |
| Martines, A | 1 |
| Sechettin, E | 1 |
| De March, E | 2 |
| Branca, A | 1 |
| Lico, A | 2 |
| Minotto, C | 1 |
| Briani, C | 2 |
| Gurrieri, C | 1 |
| Temporin, F | 1 |
| Battistutta, C | 1 |
| Piazza, F | 1 |
| Cavraro, M | 1 |
| Trentin, L | 2 |
| Semenzato, G | 1 |
| Song, KW | 4 |
| Banos, A | 5 |
| Cavo, M | 8 |
| Ivanova, V | 2 |
| Martinez-Lopez, J | 3 |
| Renner, C | 2 |
| Teasdale, T | 1 |
| Zaki, MH | 3 |
| Rotondo, C | 1 |
| Lopalco, G | 1 |
| Iannone, F | 1 |
| Vitale, A | 1 |
| Talarico, R | 1 |
| Galeazzi, M | 1 |
| Lapadula, G | 1 |
| Cantarini, L | 1 |
| Majithia, N | 1 |
| Vincent Rajkumar, S | 1 |
| Lacy, MQ | 3 |
| Buadi, FK | 1 |
| Dispenzieri, A | 4 |
| Gertz, MA | 5 |
| Hayman, SR | 2 |
| Dingli, D | 2 |
| Kapoor, P | 1 |
| Hwa, L | 1 |
| Lust, JA | 3 |
| Russell, SJ | 1 |
| Go, RS | 2 |
| Kyle, RA | 4 |
| Kumar, SK | 2 |
| Knop, S | 1 |
| Hong, K | 3 |
| Tsukada, N | 1 |
| Shingaki, S | 1 |
| Ikeda, M | 1 |
| Miyazaki, K | 1 |
| Meshitsuka, S | 1 |
| Yoshiki, Y | 1 |
| Abe, Y | 2 |
| Guidez, S | 1 |
| Louni, C | 1 |
| Ohyba, B | 1 |
| Poulain, S | 1 |
| Herbaux, C | 1 |
| Martin, A | 1 |
| Thielemans, B | 1 |
| Brice, P | 1 |
| Choquet, S | 2 |
| Bakala, J | 1 |
| Bories, C | 1 |
| Demarquette, H | 1 |
| Nudel, M | 1 |
| Tournilhac, O | 1 |
| LeGouill, S | 1 |
| Morel, P | 2 |
| Salles, G | 1 |
| Leblond, V | 2 |
| Gupta, N | 1 |
| Goh, YT | 1 |
| Lee, JH | 1 |
| Wong, RS | 1 |
| Hanley, MJ | 1 |
| Venkatakrishnan, K | 1 |
| Hui, AM | 1 |
| Chng, WJ | 1 |
| Smolewski, P | 1 |
| Witkowska, M | 1 |
| Robak, T | 1 |
| Gooding, S | 1 |
| Sheikh, M | 1 |
| Wong, J | 1 |
| Dickens, E | 1 |
| Bullement, A | 1 |
| Elvidge, J | 2 |
| Stadtmauer, EA | 7 |
| Abonour, R | 4 |
| Cohen, AD | 2 |
| Vogl, DT | 2 |
| Gomes, CL | 1 |
| Pascucci, N | 1 |
| Smith, DD | 1 |
| Durie, BG | 1 |
| Kottler, D | 1 |
| Barète, S | 1 |
| Quéreux, G | 1 |
| Fraitag, S | 1 |
| Ortonne, N | 1 |
| Deschamps, L | 1 |
| Rybojad, M | 1 |
| Flageul, B | 2 |
| Crickx, B | 2 |
| Janin, A | 1 |
| Bagot, M | 1 |
| Battistella, M | 1 |
| Caldini, A | 1 |
| Terreni, A | 1 |
| Berardi, M | 1 |
| Biagioli, T | 1 |
| Brogi, M | 1 |
| Broijl, A | 2 |
| Kersten, MJ | 2 |
| Alemayehu, WG | 1 |
| Levin, MD | 1 |
| de Weerdt, O | 1 |
| Vellenga, E | 3 |
| Meijer, E | 2 |
| Wittebol, S | 2 |
| Tanis, BC | 1 |
| Cornelisse, PB | 1 |
| Stevens-Kroef, M | 1 |
| Bos, GM | 1 |
| Wijermans, PW | 2 |
| Lokhorst, H | 1 |
| Totani, H | 1 |
| Kato, C | 1 |
| Nakashima, T | 1 |
| Suzuki, N | 1 |
| Hagiwara, S | 1 |
| Kanamori, T | 1 |
| Murakami, S | 1 |
| Masuda, A | 1 |
| Kinoshita, S | 1 |
| Narita, T | 1 |
| Wendtner, CM | 3 |
| Hallek, M | 3 |
| Fraser, GA | 2 |
| Michallet, AS | 2 |
| Hillmen, P | 3 |
| Kalaycio, M | 2 |
| Gribben, JG | 3 |
| Stilgenbauer, S | 3 |
| Buhler, A | 3 |
| Kipps, TJ | 2 |
| Purse, B | 2 |
| Zhang, J | 5 |
| De Bedout, S | 2 |
| Mei, J | 2 |
| Chang, JE | 1 |
| Havighurst, T | 1 |
| Eickhoff, J | 1 |
| Traynor, AM | 1 |
| Kirby-Slimp, R | 1 |
| Volk, LM | 1 |
| Werndli, J | 1 |
| Weiss, M | 1 |
| Blank, J | 1 |
| Kahl, BS | 1 |
| Willenbacher, E | 1 |
| Weger, R | 1 |
| Rochau, U | 1 |
| Siebert, U | 1 |
| Willenbacher, W | 1 |
| Ogura, M | 2 |
| Imaizumi, Y | 2 |
| Uike, N | 1 |
| Asou, N | 1 |
| Utsunomiya, A | 1 |
| Aoki, T | 1 |
| Taguchi, J | 2 |
| Choi, I | 1 |
| Nosaka, K | 2 |
| Chen, N | 3 |
| Midorikawa, S | 2 |
| Ohtsu, T | 2 |
| Rassenti, L | 1 |
| Gregory, SA | 1 |
| Aurran-Schleinitz, T | 1 |
| Xing, D | 1 |
| Zhao, M | 2 |
| Yang, Y | 1 |
| Zimmerman, TM | 2 |
| Talpaz, M | 1 |
| Chanan-Khan, AA | 6 |
| Chauhan, D | 2 |
| Reich, S | 1 |
| Trikha, M | 1 |
| Richter, J | 2 |
| Biran, N | 1 |
| Duma, N | 1 |
| Siegel, D | 6 |
| De Lazzari, M | 1 |
| Fedrigo, M | 1 |
| Migliore, F | 1 |
| Cianci, A | 1 |
| Cacciavillani, L | 1 |
| Tarantini, G | 1 |
| Giorgi, B | 1 |
| Iliceto, S | 1 |
| Thiene, G | 1 |
| Valente, M | 1 |
| Angelini, A | 1 |
| Adami, F | 1 |
| Perazzolo Marra, M | 1 |
| Zu, Y | 1 |
| Zhou, J | 1 |
| Zhao, H | 1 |
| Gui, R | 1 |
| Li, M | 1 |
| Baertsch, MA | 1 |
| Schlenzka, J | 1 |
| Mai, EK | 1 |
| Merz, M | 1 |
| Hillengaß, J | 1 |
| Wuchter, P | 1 |
| Jauch, A | 2 |
| Hielscher, T | 2 |
| Kunz, C | 1 |
| Luntz, S | 1 |
| Klein, S | 1 |
| Goerner, M | 1 |
| Schmidt-Hieber, M | 1 |
| Reimer, P | 1 |
| Graeven, U | 2 |
| Fenk, R | 3 |
| Salwender, H | 1 |
| Scheid, C | 1 |
| Nogai, A | 1 |
| Haenel, M | 1 |
| Lindemann, HW | 1 |
| Martin, H | 1 |
| Noppeney, R | 1 |
| Borg, S | 1 |
| Nahi, H | 3 |
| Hansson, M | 1 |
| Persson, U | 1 |
| Gibson, CJ | 1 |
| Saunders, O | 1 |
| Sternas, LA | 1 |
| Campioni, M | 1 |
| Benedict, Á | 1 |
| Houisse, I | 1 |
| Tichy, E | 1 |
| Giannopoulou, A | 1 |
| Aggarwal, SK | 1 |
| Barber, BL | 1 |
| Panjabi, S | 1 |
| Wu, C | 1 |
| de Miranda, NF | 1 |
| Chen, L | 2 |
| Wasik, AM | 1 |
| Mansouri, L | 1 |
| Galazka, K | 1 |
| Dlugosz-Danecka, M | 1 |
| Machaczka, M | 1 |
| Zhang, H | 1 |
| Peng, R | 1 |
| Morin, RD | 1 |
| Rosenquist, R | 1 |
| Sander, B | 1 |
| Pan-Hammarström, Q | 1 |
| Migkou, M | 2 |
| Eleutherakis-Papaiakovou, E | 1 |
| Kanellias, N | 1 |
| Iakovaki, M | 1 |
| Panagiotidis, I | 1 |
| Ziogas, DC | 1 |
| Tempescul, A | 3 |
| Ianotto, JC | 3 |
| Bagacean, C | 1 |
| Salaun, PY | 1 |
| Bocsan, C | 1 |
| Zdrenghea, M | 1 |
| Bridoux, F | 1 |
| Moreau, S | 1 |
| Moumas, E | 1 |
| Abraham, J | 2 |
| Desport, E | 1 |
| Salati, M | 1 |
| Tarantino, V | 1 |
| Maiorana, A | 1 |
| Bettelli, S | 1 |
| Luminari, S | 1 |
| Liang, L | 1 |
| Zhu, YC | 1 |
| Hu, X | 1 |
| Yang, LP | 1 |
| Liu, H | 2 |
| Granell, M | 1 |
| Hernandez, MT | 2 |
| Martín, J | 1 |
| Gironella, M | 1 |
| Lynch, M | 1 |
| Paliwal, P | 1 |
| Sriskandarajah, P | 1 |
| Pawlyn, C | 1 |
| Mohammed, K | 1 |
| Dearden, CE | 1 |
| Davies, FE | 3 |
| Morgan, GJ | 4 |
| Boyd, KD | 1 |
| Kaiser, MF | 1 |
| Fonseca, R | 3 |
| Mihaylov, G | 1 |
| Bensinger, W | 3 |
| Obreja, M | 2 |
| Pozzi, S | 1 |
| Gentile, M | 1 |
| Sacchi, S | 1 |
| Cocito, F | 2 |
| Guarini, A | 1 |
| Minoia, C | 1 |
| Vincelli, I | 1 |
| Ria, R | 2 |
| Rivolti, E | 1 |
| Mele, G | 1 |
| Bari, A | 1 |
| Mazzone, C | 1 |
| Badiali, S | 1 |
| Marcheselli, L | 1 |
| Morabito, F | 3 |
| Plesner, T | 2 |
| Arkenau, HT | 1 |
| Gimsing, P | 2 |
| Krejcik, J | 1 |
| Lemech, C | 1 |
| Minnema, MC | 3 |
| Lassen, U | 1 |
| Lisby, S | 2 |
| Basse, L | 1 |
| Sasser, AK | 1 |
| Guckert, ME | 1 |
| de Boer, C | 1 |
| Yeh, H | 1 |
| Clemens, PL | 1 |
| Dalla Torre, C | 1 |
| Cacciavillani, M | 1 |
| Campagnolo, M | 1 |
| Salvalaggio, A | 1 |
| Barilà, G | 1 |
| Lucchetta, M | 1 |
| Ermani, M | 1 |
| Majer, I | 1 |
| van de Wetering, G | 1 |
| Polanyi, Z | 1 |
| Krishna, A | 1 |
| Gray, E | 1 |
| Roy, A | 1 |
| Uppuluri, R | 1 |
| Ramachandrakurup, S | 1 |
| Subburaj, D | 1 |
| Bakane, A | 1 |
| Raj, R | 1 |
| Buchanan, J | 1 |
| Cocks, K | 1 |
| Tonda, M | 1 |
| Hu, H | 1 |
| Wang, X | 1 |
| Fujiwara, H | 1 |
| Taira, N | 1 |
| Moriuchi, Y | 1 |
| Jo, T | 1 |
| Ishizawa, K | 2 |
| Ito, S | 1 |
| Yoshimitsu, M | 1 |
| Otsuka, M | 1 |
| Ruiz, W | 1 |
| Komarnicki, M | 1 |
| Ben Yehuda, D | 1 |
| O'Rourke, L | 1 |
| Qin, X | 1 |
| Guckert, M | 1 |
| Bilotti, E | 1 |
| McBride, L | 1 |
| Schmidt, L | 1 |
| Gao, Z | 1 |
| Gilani, M | 1 |
| McNeill, A | 1 |
| Bednarz, U | 1 |
| Mato, A | 1 |
| Graef, T | 2 |
| Wei, XD | 1 |
| Mi, RH | 1 |
| Yuan, FF | 1 |
| Hao, QM | 1 |
| Yin, QS | 1 |
| Song, YP | 1 |
| Kinoshita, G | 1 |
| Miyoshi, M | 1 |
| Robbins, M | 1 |
| Pandya, D | 1 |
| Chou, T | 2 |
| Rammaert, B | 1 |
| Candon, S | 1 |
| Maunoury, C | 1 |
| Bougnoux, ME | 1 |
| Jouvion, G | 1 |
| Braun, T | 1 |
| Correas, JM | 1 |
| Lortholary, O | 2 |
| Mauro, FR | 1 |
| Molica, S | 1 |
| Paoloni, F | 1 |
| Zaja, F | 2 |
| Belsito, V | 1 |
| Cortellezzi, A | 1 |
| Rizzi, R | 2 |
| Tosi, P | 3 |
| Spriano, M | 2 |
| Ferretti, A | 1 |
| Nanni, M | 1 |
| Marinelli, M | 1 |
| De Propris, MS | 1 |
| Orlando, SM | 1 |
| Vignetti, M | 1 |
| Cuneo, A | 1 |
| Guarini, AR | 1 |
| Foà, R | 3 |
| Tacchetti, P | 2 |
| Pezzi, A | 1 |
| Pantani, L | 2 |
| Rocchi, S | 1 |
| Zannetti, BA | 1 |
| Rizzello, I | 1 |
| Cabrera César, E | 1 |
| Fernández Aguirre, MC | 1 |
| González Fernández, A | 1 |
| Agarwal, A | 1 |
| Chow, E | 1 |
| Bhutani, M | 1 |
| Voorhees, PM | 1 |
| Friend, R | 1 |
| Handa, H | 1 |
| Takubo, T | 1 |
| Kase, Y | 1 |
| Boudreault, JS | 1 |
| Fernyhough, L | 1 |
| Henderson, R | 1 |
| Corbett, G | 1 |
| Baker, B | 1 |
| Browett, P | 1 |
| Forsyth, C | 1 |
| Underhill, C | 2 |
| Cannell, P | 1 |
| Trotman, J | 1 |
| Neylon, A | 1 |
| Link, E | 1 |
| Swern, A | 1 |
| Cowan, L | 1 |
| Miles Prince, H | 1 |
| Maciocia, N | 1 |
| Melville, A | 1 |
| Cheesman, S | 1 |
| Benjamin, R | 1 |
| Schey, S | 2 |
| Maciocia, P | 1 |
| D'sa, S | 2 |
| Rismani, A | 1 |
| Cerner, A | 1 |
| Aggarwal, S | 1 |
| van Beurden-Tan, CHY | 1 |
| Franken, MG | 2 |
| Blommestein, HM | 1 |
| Uyl-de Groot, CA | 2 |
| Gormley, NJ | 1 |
| Ko, CW | 1 |
| Deisseroth, A | 1 |
| Nie, L | 1 |
| Kaminskas, E | 1 |
| Kormanik, N | 1 |
| Goldberg, KB | 1 |
| Farrell, AT | 1 |
| Pazdur, R | 1 |
| Kyriakou, C | 2 |
| Vande Broek, I | 1 |
| Murphy, P | 1 |
| Bacon, P | 1 |
| Lewis, P | 1 |
| Gilet, H | 1 |
| Arnould, B | 1 |
| Ataergin, S | 1 |
| Arpaci, F | 1 |
| Demiriz, M | 1 |
| Ozet, A | 1 |
| Furkert, K | 1 |
| Hoffmann, F | 2 |
| Naumann, R | 2 |
| Bargou, R | 1 |
| Glasmacher, A | 1 |
| Serralta de Colsa, D | 1 |
| Arjona Medina, I | 1 |
| García Marín, A | 1 |
| Sanz Sánchez, M | 1 |
| Turégano Fuentes, F | 1 |
| Klein, U | 2 |
| Kosely, F | 1 |
| Hundemer, M | 1 |
| Schmitt, S | 1 |
| Srikanth, M | 2 |
| Wu, P | 1 |
| Jenner, MW | 1 |
| Ethell, ME | 1 |
| Potter, MN | 1 |
| Shaw, BE | 1 |
| Saso, RM | 1 |
| Dines, S | 1 |
| Liu, Q | 1 |
| Farley, KL | 1 |
| Muthusamy, N | 1 |
| Schaaf, LJ | 1 |
| Dalton, JT | 1 |
| Rozanski, M | 1 |
| Boldt, T | 1 |
| Ritter, U | 1 |
| Rohrberg, R | 1 |
| Schwalbe, E | 1 |
| Uhlig, J | 1 |
| Schirmer, V | 1 |
| Haas, A | 1 |
| Kreibich, U | 1 |
| Morris, TC | 1 |
| Kettle, PJ | 1 |
| Drake, M | 1 |
| Jones, FC | 1 |
| Hull, DR | 1 |
| Boyd, K | 1 |
| Morrison, A | 1 |
| Clarke, P | 1 |
| O'Reilly, P | 1 |
| Quinn, J | 1 |
| Roussou, M | 2 |
| Heath, D | 1 |
| Eleftherakis-Papaiakovou, E | 1 |
| Croucher, P | 1 |
| Alberto, SF | 1 |
| Felix, J | 1 |
| de Deus, J | 1 |
| Cibeira, MT | 5 |
| Yu, Z | 7 |
| Olesnyckyj, M | 8 |
| Zeldis, JB | 10 |
| Knight, RD | 8 |
| Giralt, S | 1 |
| Davies, F | 2 |
| Morris, C | 3 |
| Bird, J | 1 |
| Williams, C | 1 |
| Tighe, J | 1 |
| Behrens, J | 1 |
| Corvatta, L | 4 |
| Polloni, C | 4 |
| Piersantelli, MN | 2 |
| Gentili, S | 4 |
| Galieni, P | 1 |
| Visani, G | 1 |
| Alesiani, F | 2 |
| Catarini, M | 3 |
| Brunori, M | 2 |
| Samori, A | 2 |
| Burattini, M | 1 |
| Centurioni, R | 1 |
| Ferranti, M | 2 |
| Giuliodori, L | 1 |
| Candela, M | 1 |
| Mele, A | 2 |
| Marconi, M | 2 |
| Leoni, P | 4 |
| Morel, F | 1 |
| Marion, V | 1 |
| De Braekeleer, M | 1 |
| Berthou, C | 3 |
| Mileshkin, L | 5 |
| Seymour, JF | 2 |
| Milner, A | 1 |
| Ritchie, D | 1 |
| Westerman, D | 2 |
| Prince, HM | 8 |
| Justice, G | 2 |
| Wiernik, PH | 2 |
| McBride, K | 1 |
| Wride, K | 2 |
| Ervin-Haynes, A | 3 |
| Gastari, V | 1 |
| Verrou, E | 1 |
| Hadjiaggelidou, C | 1 |
| Varthaliti, M | 1 |
| Georgiadou, S | 1 |
| Laschos, K | 1 |
| Xirou, P | 1 |
| Yiannaki, E | 1 |
| Constantinou, N | 1 |
| Markala, D | 1 |
| Imai, N | 1 |
| Yagi, N | 1 |
| Konishi, T | 1 |
| Serizawa, M | 1 |
| Kobari, M | 1 |
| Prince, MH | 1 |
| Mimura, MA | 1 |
| Hirota, SK | 1 |
| Sugaya, NN | 1 |
| Sanches, JA | 1 |
| Migliari, DA | 1 |
| Zappasodi, P | 2 |
| Barbarano, L | 1 |
| Caravita, T | 5 |
| Mangiacavalli, S | 2 |
| Cafro, AM | 1 |
| Varettoni, M | 1 |
| Morra, E | 1 |
| Lazzarino, M | 1 |
| Bruzzone, A | 1 |
| Berenson, J | 1 |
| Singhal, S | 5 |
| Irwin, D | 2 |
| Williams, SF | 1 |
| Badros, AZ | 2 |
| Kenvin, L | 1 |
| Zeldis, J | 5 |
| Boccia, RV | 1 |
| Matous, J | 2 |
| Rajkumar, V | 1 |
| Lioznov, M | 1 |
| El-Cheikh, J | 1 |
| Hildebrandt, Y | 2 |
| Ayuk, F | 2 |
| Wolschke, C | 2 |
| Badbaran, A | 2 |
| Bacher, U | 2 |
| Fehse, B | 1 |
| Zander, AR | 2 |
| Blaise, D | 1 |
| Kröger, N | 2 |
| Gajraj, E | 1 |
| Chung, H | 1 |
| Boysen, M | 1 |
| Barnett, DB | 1 |
| Longson, C | 1 |
| Ford, CD | 1 |
| Asch, J | 1 |
| Konopa, K | 1 |
| Petersen, FB | 1 |
| Kaur, I | 1 |
| Dogra, S | 1 |
| Narang, T | 1 |
| De, D | 1 |
| Zagouri, F | 1 |
| Matsouka, C | 1 |
| Barbarousi, D | 1 |
| Primenou, E | 1 |
| Grapsa, I | 1 |
| Kuwabara, S | 1 |
| Kanai, K | 1 |
| Misawa, S | 1 |
| Schuster, MW | 1 |
| Harousseau, JL | 5 |
| Boral, A | 1 |
| Neuwirth, R | 1 |
| Avigan, DE | 1 |
| Doss, D | 3 |
| Warren, DL | 1 |
| Delaney, C | 1 |
| Dalton, W | 2 |
| Moore, T | 1 |
| Reeder, C | 1 |
| Cole, C | 1 |
| Kaplan, H | 1 |
| Voralia, M | 1 |
| Almadi, M | 1 |
| Ghali, PM | 1 |
| Constantin, A | 1 |
| Galipeau, J | 1 |
| Szilagyi, A | 1 |
| Eisen, T | 1 |
| Trefzer, U | 1 |
| Hamilton, A | 1 |
| Hersey, P | 1 |
| Millward, M | 1 |
| Jungnelius, JU | 1 |
| Glaspy, J | 1 |
| Böll, B | 1 |
| Borchmann, P | 1 |
| Topp, MS | 1 |
| Hänel, M | 1 |
| Reiners, KS | 1 |
| Engert, A | 1 |
| Lemaire, O | 1 |
| Bourin, P | 1 |
| Laroche, M | 1 |
| Bélard, E | 1 |
| Foss, CH | 1 |
| Christensen, LA | 1 |
| Schmidt, P | 1 |
| Nøjgaard, C | 1 |
| Krejci, M | 4 |
| Scudla, V | 3 |
| Tothova, E | 1 |
| Schutzova, M | 1 |
| Koza, V | 1 |
| Adam, Z | 5 |
| Krivanova, A | 2 |
| Buchler, T | 3 |
| Sandecka, V | 2 |
| Kralova, D | 1 |
| Zahradova, L | 4 |
| Vorlicek, J | 1 |
| Niparuck, P | 1 |
| Sorakhunpipitkul, L | 1 |
| Atichartakarn, V | 1 |
| Chuncharunee, S | 1 |
| Ungkanont, A | 1 |
| Aungchaisuksiri, P | 1 |
| Puavilai, T | 1 |
| Jootar, S | 1 |
| Sher, T | 1 |
| Miller, KC | 1 |
| Lawrence, D | 1 |
| Whitworth, A | 1 |
| Hernandez-Ilizaliturri, F | 2 |
| Miller, A | 1 |
| Lawrence, W | 1 |
| Bilgrami, SA | 1 |
| Sood, R | 1 |
| Wood, MT | 1 |
| Block, AW | 1 |
| Lee, K | 2 |
| van der Spek, E | 1 |
| Richards, T | 1 |
| Weber, D | 4 |
| Furman, RR | 2 |
| Cheung, K | 1 |
| Faye, A | 1 |
| Elstrom, R | 1 |
| Lachs, M | 1 |
| Hajjar, KA | 1 |
| Leonard, JP | 1 |
| Kneppers, E | 1 |
| Eeltink, CM | 1 |
| Huls, G | 1 |
| Koedam, J | 1 |
| van Oers, MH | 1 |
| Raymakers, RA | 1 |
| Schaafsma, MR | 1 |
| Zweegman, S | 1 |
| Ikebe, T | 1 |
| Ogata, M | 1 |
| Miyazaki, M | 1 |
| Miyazaki, Y | 1 |
| Ohtsuka, E | 1 |
| Saburi, Y | 1 |
| Goto, K | 1 |
| Ikewaki, J | 1 |
| Kohno, K | 1 |
| Uno, N | 1 |
| Imamura, T | 1 |
| Akagi, T | 1 |
| Kadota, J | 1 |
| Siniscalchi, A | 1 |
| Tendas, A | 1 |
| Cupelli, L | 1 |
| Ales, M | 1 |
| Perrotti, A | 1 |
| Niscola, P | 1 |
| de Fabritiis, P | 1 |
| Gil, H | 2 |
| Perrin, S | 1 |
| Dupond, JL | 2 |
| Meaux-Ruault, N | 1 |
| Hafsaoui, C | 1 |
| Limat, S | 1 |
| Magy-Bertrand, N | 1 |
| Hello, M | 1 |
| Barbarot, S | 1 |
| Bastuji-Garin, S | 1 |
| Revuz, J | 4 |
| Kortuem, M | 1 |
| Zonder, JA | 2 |
| de Castro, CM | 1 |
| Masliak, Z | 2 |
| Dueck, G | 1 |
| Chua, N | 1 |
| Prasad, A | 1 |
| Finch, D | 1 |
| Stewart, D | 1 |
| van der Jagt, R | 1 |
| Johnston, J | 1 |
| Reiman, T | 1 |
| Hornberger, J | 1 |
| Rickert, J | 1 |
| Dhawan, R | 1 |
| Liwing, J | 1 |
| Löthgren, M | 1 |
| Chang, H | 2 |
| Jiang, A | 1 |
| Qi, C | 1 |
| Trieu, Y | 1 |
| Blum, W | 1 |
| Klisovic, RB | 1 |
| Becker, H | 1 |
| Garzon, R | 1 |
| Walker, A | 1 |
| Chandler, JC | 1 |
| Whitman, SP | 1 |
| Curfman, J | 1 |
| Schaaf, L | 1 |
| Mickle, J | 1 |
| Devine, SM | 2 |
| Marcucci, G | 1 |
| Keizman, D | 1 |
| Zahurak, M | 1 |
| Sinibaldi, V | 1 |
| Carducci, M | 1 |
| Denmeade, S | 1 |
| Drake, C | 1 |
| Pili, R | 1 |
| Antonarakis, ES | 1 |
| Hudock, S | 1 |
| Eisenberger, M | 1 |
| Guillerm, G | 1 |
| Saglio, G | 2 |
| Laubach, J | 2 |
| Warren, KE | 1 |
| Goldman, S | 1 |
| Pollack, IF | 1 |
| Fangusaro, J | 1 |
| Schaiquevich, P | 1 |
| Stewart, CF | 1 |
| Wallace, D | 1 |
| Blaney, SM | 2 |
| Packer, R | 1 |
| Macdonald, T | 1 |
| Jakacki, R | 1 |
| Boyett, JM | 1 |
| Kun, LE | 1 |
| Berg, SL | 1 |
| Cairo, MS | 1 |
| Russell, H | 1 |
| Ayello, J | 1 |
| Ingle, AM | 1 |
| Lau, H | 1 |
| Adamson, PC | 1 |
| Armoiry, X | 1 |
| Fagnani, F | 1 |
| Aulagner, G | 1 |
| Ozaki, S | 1 |
| Harada, T | 1 |
| Fujii, S | 1 |
| Nakamura, S | 1 |
| Miki, H | 1 |
| Nakano, A | 1 |
| Kagawa, K | 1 |
| Takeuchi, K | 1 |
| Abe, M | 1 |
| Matsumoto, T | 1 |
| Aguado, B | 2 |
| Giraldo, P | 2 |
| Ríos, E | 1 |
| Cánovas, A | 1 |
| Ibáñez, Á | 1 |
| Castillo, I | 1 |
| Palomera, L | 1 |
| Rodríguez, JN | 1 |
| García, FL | 1 |
| Calvo, JM | 1 |
| Martínez-Chamorro, C | 2 |
| de la Serna, J | 1 |
| Gregora, E | 2 |
| Straub, J | 1 |
| de Larrea, CF | 1 |
| Navarro, A | 1 |
| Díaz, T | 1 |
| Fuster, D | 1 |
| Tovar, N | 1 |
| Monzó, M | 1 |
| Caraffa, P | 2 |
| Blasi, N | 1 |
| Malerba, L | 1 |
| Lyseng-Williamson, KA | 1 |
| Wäsch, R | 2 |
| Jakob, T | 1 |
| Technau, K | 1 |
| Finke, J | 1 |
| Hernandez-Ilizaliturri, FJ | 1 |
| Deeb, G | 1 |
| Malik, F | 1 |
| Macon, WR | 1 |
| Stefoni, V | 2 |
| Gandolfi, L | 2 |
| Quirini, F | 2 |
| Berti, E | 1 |
| Derenzini, E | 2 |
| Baccarani, M | 5 |
| Somlo, G | 2 |
| Lashkari, A | 1 |
| Bellamy, W | 1 |
| O'Donnell, MR | 1 |
| Mohrbacher, AF | 1 |
| Forman, SJ | 1 |
| Frankel, P | 1 |
| Chen, HX | 1 |
| Doroshow, JH | 1 |
| Gandara, DR | 1 |
| Seckinger, A | 1 |
| Russo, P | 1 |
| Lavatelli, F | 2 |
| Obici, L | 2 |
| Brugnatelli, S | 1 |
| Spina, F | 3 |
| Citro, A | 1 |
| Sammassimo, S | 1 |
| Olivero, B | 1 |
| De Muro, M | 1 |
| Ishak, J | 1 |
| Rodrigues, F | 1 |
| Buckstein, R | 1 |
| Piatkowska-Jakubas, B | 1 |
| Wolska-Smoleń, T | 2 |
| Mensah-Glanowska, P | 1 |
| Hawrylecka, D | 1 |
| Szostek, M | 1 |
| Walter, Z | 1 |
| Fukushima, T | 1 |
| Nakamura, T | 1 |
| Iwao, H | 1 |
| Umehara, H | 1 |
| Bruno, B | 4 |
| Isola, M | 1 |
| Nozza, A | 1 |
| Sperotto, A | 1 |
| Stuhler, G | 1 |
| Festuccia, M | 1 |
| Fanin, R | 3 |
| Mahadevan, D | 1 |
| Uharek, L | 1 |
| Coutré, S | 1 |
| Frankfurt, O | 1 |
| Bloor, A | 1 |
| Bosch, F | 1 |
| Kimby, E | 1 |
| Gobbi, M | 1 |
| Dreisbach, L | 1 |
| Hurd, DD | 2 |
| Ferrajoli, A | 2 |
| Shah, S | 1 |
| Moutouh-de Parseval, L | 1 |
| Heerema, NA | 1 |
| Petrucci, A | 1 |
| Perrone, G | 1 |
| Zannetti, B | 1 |
| Fehniger, TA | 1 |
| Larson, S | 1 |
| Trinkaus, K | 1 |
| Siegel, MJ | 1 |
| Cashen, AF | 1 |
| Fenske, TS | 1 |
| Schneider, SE | 1 |
| Keppel, CR | 1 |
| Wagner-Johnston, ND | 1 |
| Carson, KR | 1 |
| Tan, HH | 2 |
| Ge, ZZ | 2 |
| Gao, YJ | 2 |
| Chen, HM | 2 |
| Fang, JY | 1 |
| Chen, HY | 1 |
| Liu, WZ | 1 |
| Xiao, SD | 1 |
| Sinha, S | 1 |
| Lacy, M | 1 |
| Hayman, S | 1 |
| Buadi, F | 1 |
| Detweiler-Short, K | 1 |
| Gertz, M | 1 |
| Cortés-Hernández, J | 2 |
| Torres-Salido, M | 1 |
| Castro-Marrero, J | 1 |
| Vilardell-Tarres, M | 2 |
| Ordi-Ros, J | 2 |
| Hali, F | 1 |
| Khadir, K | 1 |
| Chiheb, S | 1 |
| Bouayad, K | 1 |
| Mikou, N | 1 |
| Benchikhi, H | 1 |
| Vega, J | 1 |
| Goecke, H | 1 |
| Rodríguez, Mde L | 1 |
| Vergara, MT | 1 |
| Kleber, M | 1 |
| Ihorst, G | 1 |
| Udi, J | 1 |
| Koch, B | 1 |
| De Luca, S | 1 |
| Vitolo, U | 1 |
| Orsucci, L | 1 |
| Levis, A | 1 |
| Salvi, F | 1 |
| Rusconi, C | 1 |
| Ravelli, E | 1 |
| Tucci, A | 1 |
| Bottelli, C | 1 |
| Balzarotti, M | 1 |
| Brusamolino, E | 1 |
| Bonfichi, M | 1 |
| Sabattini, E | 1 |
| Volpetti, S | 1 |
| Monagheddu, C | 1 |
| Vacca, A | 1 |
| Garrido Serrano, A | 1 |
| León, R | 1 |
| Sayago, M | 1 |
| Márquez, JL | 1 |
| Morita, Y | 1 |
| Shimada, T | 1 |
| Yamaguchi, T | 1 |
| Rai, S | 1 |
| Hirase, C | 1 |
| Emoto, M | 1 |
| Serizawa, K | 1 |
| Taniguchi, Y | 1 |
| Ojima, M | 1 |
| Tatsumi, Y | 1 |
| Ashida, T | 1 |
| Albani, G | 1 |
| Pascutto, C | 1 |
| Cazzola, M | 1 |
| Sibon, D | 1 |
| Cannas, G | 1 |
| Baracco, F | 1 |
| Prebet, T | 1 |
| Besson, C | 1 |
| Corm, S | 1 |
| Blanc, M | 1 |
| Slama, B | 1 |
| Perrier, H | 1 |
| Clavert, A | 1 |
| Roland, V | 1 |
| Loirat, M | 1 |
| Planche, L | 1 |
| Pennetier, M | 1 |
| Malard, F | 1 |
| Figueiredo, A | 1 |
| Martins, HF | 1 |
| Qi, CX | 1 |
| Saha, MN | 1 |
| Wolf, JL | 1 |
| Hazell, K | 1 |
| Bourquelot, PM | 1 |
| Bengoudifa, BR | 1 |
| de Magalhaes-Silverman, M | 1 |
| Oriol-Rocafiguera, A | 1 |
| Garcia-Larana, J | 1 |
| Sureda, A | 1 |
| Rosettani, B | 1 |
| Gozzetti, A | 1 |
| Defina, M | 1 |
| D'Auria, F | 2 |
| Papini, G | 1 |
| Statuto, T | 1 |
| Steduto, T | 1 |
| D'Arena, G | 1 |
| Bocchia, M | 1 |
| Ahn, JS | 1 |
| Yang, DH | 1 |
| Park, HC | 1 |
| Moon, JH | 1 |
| Sohn, SK | 1 |
| Bae, SY | 1 |
| Kim, YK | 1 |
| Kim, HJ | 1 |
| Ballanti, S | 1 |
| Pulini, S | 1 |
| Langer, C | 1 |
| Sturm, I | 1 |
| Kuhn, S | 1 |
| Hjorth, M | 1 |
| Hjertner, Ø | 1 |
| Knudsen, LM | 1 |
| Gulbrandsen, N | 1 |
| Holmberg, E | 1 |
| Pedersen, PT | 1 |
| Andersen, NF | 1 |
| Andréasson, B | 1 |
| Billström, R | 1 |
| Carlson, K | 1 |
| Carlsson, MS | 1 |
| Flogegård, M | 1 |
| Forsberg, K | 1 |
| Karlsson, T | 1 |
| Linder, O | 1 |
| Othzén, A | 1 |
| Swedin, A | 1 |
| Rehák, Z | 1 |
| Koukalová, R | 1 |
| Szturz, P | 1 |
| Moulis, M | 1 |
| Kodet, R | 1 |
| Nebeský, T | 1 |
| Brejcha, M | 1 |
| Adamová, Z | 1 |
| O'Sullivan, A | 1 |
| Kennedy, RC | 1 |
| Abbas, M | 1 |
| Dai, L | 1 |
| Pregja, SL | 1 |
| Burt, S | 1 |
| Boyiadzis, M | 1 |
| Roodman, GD | 1 |
| Mapara, MY | 1 |
| Agha, M | 1 |
| Waas, J | 1 |
| Shuai, Y | 1 |
| Normolle, D | 1 |
| Vannata, B | 1 |
| Laurenti, L | 1 |
| Chiusolo, P | 1 |
| Sorà, F | 1 |
| Balducci, M | 1 |
| Sabatelli, M | 1 |
| Luigetti, M | 1 |
| Giannotta, C | 1 |
| De Stefano, V | 1 |
| Leone, G | 1 |
| Sica, S | 1 |
| Tsao, LC | 1 |
| Westland, C | 1 |
| Singhal, AK | 1 |
| Kantarjian, H | 2 |
| Estrov, Z | 1 |
| Faderl, S | 3 |
| Ravandi, F | 1 |
| Rey, K | 1 |
| Cortes, J | 2 |
| Borthakur, G | 1 |
| Iacobelli, S | 1 |
| Fontan, J | 1 |
| Michallet, M | 2 |
| Gratwohl, A | 1 |
| Doyen, C | 2 |
| Casassus, P | 1 |
| Hertenstein, B | 1 |
| Onida, F | 1 |
| Ketterer, N | 1 |
| Koenecke, C | 1 |
| van Os, M | 1 |
| Cakana, A | 1 |
| Gorin, NC | 1 |
| de Witte, T | 1 |
| Gahrton, G | 1 |
| Barrera, LN | 1 |
| Rushworth, SA | 1 |
| Bowles, KM | 1 |
| MacEwan, DJ | 1 |
| Zimmerman, T | 1 |
| Kandarpa, M | 1 |
| Kraftson, S | 1 |
| Ross, CW | 1 |
| Harvey, C | 1 |
| Sportelli, P | 1 |
| Poradosu, E | 1 |
| Gardner, L | 1 |
| Giusti, K | 1 |
| Munoz, J | 1 |
| Janakiraman, N | 1 |
| Samaniego, F | 2 |
| McLaughlin, P | 2 |
| Cabanillas, F | 2 |
| Sun, L | 1 |
| Hartig, K | 1 |
| Byrne, C | 1 |
| Bell, N | 1 |
| Dawar, R | 1 |
| Saboo, SS | 1 |
| Fennessy, F | 1 |
| Benajiba, L | 1 |
| Borrello, I | 2 |
| Hellmann, A | 3 |
| Heuck, CJ | 1 |
| Szymonifka, J | 1 |
| Shaughnessy, JD | 1 |
| Anaissie, E | 4 |
| Nair, B | 1 |
| Alsayed, Y | 1 |
| Bailey, C | 1 |
| Epstein, J | 1 |
| Zabelina, T | 1 |
| Klyuchnikov, E | 1 |
| Kropff, M | 1 |
| Pflüger, KH | 1 |
| Burchert, A | 1 |
| Stübig, T | 1 |
| Hansen, T | 1 |
| Brunel, AS | 1 |
| Reynes, J | 1 |
| Tuaillon, E | 1 |
| Rubbo, PA | 1 |
| Montes, B | 1 |
| Le Moing, V | 1 |
| Makinson, A | 1 |
| Tiedemann, R | 1 |
| Eve, HE | 1 |
| Carey, S | 1 |
| Richardson, SJ | 1 |
| Heise, CC | 1 |
| Mamidipudi, V | 1 |
| Shi, T | 1 |
| Radford, JA | 1 |
| Auer, RL | 1 |
| Bullard, SH | 1 |
| Rule, SA | 2 |
| Zhang, Z | 1 |
| Jian, X | 1 |
| Zhang, W | 1 |
| Zhou, Q | 1 |
| Seki, JT | 1 |
| Banglawala, S | 1 |
| Lentz, EM | 1 |
| Gaultney, JG | 1 |
| Tan, SS | 1 |
| Redekop, WK | 1 |
| Huijgens, PC | 1 |
| Deng, X | 1 |
| Huang, F | 1 |
| Coman, T | 1 |
| Bachy, E | 1 |
| Socié, G | 1 |
| Uzunov, M | 1 |
| Bourhis, JH | 2 |
| Lapusan, S | 1 |
| Brebion, A | 1 |
| Vigouroux, S | 1 |
| Maury, S | 1 |
| François, S | 1 |
| Huynh, A | 1 |
| Lioure, B | 1 |
| Yakoub-Agha, I | 3 |
| Hermine, O | 3 |
| Milpied, N | 1 |
| Rubio, MT | 1 |
| Perez Botero, J | 1 |
| Burns, D | 1 |
| Thompson, CA | 1 |
| Pruthi, RK | 1 |
| Dunavin, NC | 1 |
| Elder, P | 1 |
| Phillips, GS | 1 |
| Benson, DM | 1 |
| Penza, S | 1 |
| Greenfield, C | 1 |
| Rose, KS | 1 |
| Rieser, G | 1 |
| Merritt, L | 1 |
| Ketcham, J | 1 |
| Heerema, N | 1 |
| Efebera, YA | 1 |
| Ávila, G | 1 |
| Badoux, XC | 1 |
| Keating, MJ | 1 |
| Wen, S | 1 |
| Wierda, WG | 1 |
| O'Brien, SM | 1 |
| Sargent, R | 1 |
| Burger, JA | 1 |
| Rezzonico, F | 1 |
| Farina, L | 1 |
| Murthy, V | 1 |
| Horowitz, HW | 1 |
| Pham, VP | 1 |
| Levis, WR | 1 |
| Smetana, J | 1 |
| Berankova, K | 1 |
| Zaoralova, R | 1 |
| Nemec, P | 1 |
| Greslikova, H | 1 |
| Kupska, R | 1 |
| Mikulasova, A | 1 |
| Frohlich, J | 1 |
| Sevcikova, S | 1 |
| Almasi, M | 1 |
| Kaisarova, P | 1 |
| Melicharova, H | 1 |
| Penka, M | 1 |
| Jarkovsky, J | 1 |
| Kuglik, P | 1 |
| Teixeira, A | 1 |
| Blau, IW | 1 |
| Angermund, R | 1 |
| Allietta, N | 1 |
| Broer, E | 1 |
| Mitchell, V | 1 |
| Biermann, JS | 1 |
| Devine, S | 1 |
| Djulbegovic, B | 1 |
| Faber, EA | 1 |
| Hernandez-Illizaliturri, F | 1 |
| Huff, CA | 1 |
| Kassim, A | 1 |
| Krishnan, AY | 1 |
| Meredith, R | 1 |
| Raje, N | 1 |
| Schriber, J | 1 |
| Stockerl-Goldstein, K | 1 |
| Treon, SP | 1 |
| Yahalom, J | 1 |
| Yunus, F | 1 |
| Shead, DA | 1 |
| Kumar, R | 1 |
| Merlusca, L | 1 |
| Musset, L | 1 |
| Haroche, J | 1 |
| Sebban, C | 1 |
| Galicier, L | 1 |
| Recher, C | 1 |
| Guichard, I | 1 |
| Brisseau, JM | 1 |
| Godmer, P | 1 |
| Deplanque, G | 1 |
| Asli, B | 1 |
| Marolleau, JP | 1 |
| Pérez-Encinas, M | 1 |
| Rabuñal Martínez, MJ | 1 |
| Bello López, JL | 1 |
| Greipp, PR | 3 |
| Cool, RM | 1 |
| Herrington, JD | 1 |
| Magro, L | 1 |
| Fawaz, A | 1 |
| Bauters, F | 2 |
| Wilson, EA | 1 |
| Jobanputra, S | 1 |
| Jackson, R | 1 |
| Parker, AN | 1 |
| McQuaker, IG | 1 |
| Pittini, V | 1 |
| Teti, D | 1 |
| Arrigo, C | 2 |
| Aloi, G | 2 |
| Righi, M | 1 |
| Grover, JK | 1 |
| Uppal, G | 1 |
| Raina, V | 1 |
| Kraemer, A | 1 |
| González-Porras, JR | 1 |
| González, M | 1 |
| Shaughnessy, J | 2 |
| Tian, E | 1 |
| Sawyer, J | 1 |
| McCoy, J | 1 |
| Tricot, G | 2 |
| Jacobson, J | 1 |
| Zangari, M | 2 |
| Fassas, A | 2 |
| Muwalla, F | 1 |
| Geyer, SM | 1 |
| Iturria, NL | 1 |
| Thompson, JL | 1 |
| Hansen, LA | 1 |
| Hegarty, A | 1 |
| Hodgson, T | 1 |
| Porter, S | 1 |
| Hattori, Y | 1 |
| Kulkarni, S | 1 |
| Powles, R | 1 |
| Sirohi, B | 1 |
| Treleaven, J | 1 |
| Saso, R | 1 |
| Horton, C | 1 |
| Atra, A | 1 |
| Ortin, M | 1 |
| Rudin, C | 1 |
| Goyal, S | 1 |
| Sankpal, S | 1 |
| Meller, S | 1 |
| Pinkerton, CR | 1 |
| Mehta, J | 3 |
| Huang, SY | 1 |
| Tang, JL | 1 |
| Yao, M | 1 |
| Ko, BS | 1 |
| Hong, RL | 1 |
| Tsai, W | 1 |
| Wang, CH | 1 |
| Tien, HF | 1 |
| Shen, MC | 1 |
| Chen, YC | 1 |
| Kropff, MH | 1 |
| Lang, N | 1 |
| Bisping, G | 1 |
| Dominé, N | 1 |
| Innig, G | 1 |
| Hentrich, M | 1 |
| Mitterer, M | 1 |
| Südhoff, T | 1 |
| Straka, C | 1 |
| Heinecke, A | 1 |
| Koch, OM | 1 |
| Ostermann, H | 1 |
| Berdel, WE | 1 |
| Kienast, J | 1 |
| Shetty, K | 1 |
| Kyrcz-Krzemień, S | 1 |
| Helbig, G | 1 |
| Stella-Hołowiecka, B | 1 |
| Hołowiecki, J | 1 |
| Thomas, DA | 1 |
| Estey, E | 1 |
| Giles, FJ | 1 |
| Albitar, M | 2 |
| Sarmadi, M | 1 |
| Ship, JA | 1 |
| Sayarlioglu, M | 1 |
| Kotan, MC | 1 |
| Topcu, N | 1 |
| Bayram, I | 1 |
| Arslanturk, H | 1 |
| Gul, A | 1 |
| Bauditz, J | 2 |
| Schachschal, G | 1 |
| Wedel, S | 1 |
| Lochs, H | 2 |
| Dang, NH | 1 |
| Hagemeister, FB | 1 |
| Rodriguez, MA | 1 |
| Clemons, M | 1 |
| de Carsalade, GY | 1 |
| Achirafi, A | 1 |
| Gibson, AD | 1 |
| Klem, J | 1 |
| Price, N | 1 |
| Reddy, GK | 1 |
| Cisteró, B | 1 |
| Sala, M | 1 |
| Soler, A | 1 |
| García, N | 1 |
| Segarra, M | 1 |
| Cid, MC | 1 |
| Filella, X | 1 |
| Aymerich, M | 1 |
| Rozman, M | 1 |
| Arenillas, L | 1 |
| Esteve, J | 2 |
| Montserrat, E | 1 |
| Kaufmann, H | 1 |
| Raderer, M | 1 |
| Wöhrer, S | 1 |
| Püspök, A | 1 |
| Bankier, A | 1 |
| Zielinski, C | 1 |
| Chott, A | 1 |
| Schlossman, R | 2 |
| Desikan, R | 2 |
| Blood, E | 2 |
| Mitsiades, C | 3 |
| Freeman, A | 2 |
| Bosch, J | 1 |
| Patin, J | 3 |
| Schey, SA | 1 |
| Fields, P | 1 |
| Bartlett, JB | 1 |
| Clarke, IA | 1 |
| Ashan, G | 1 |
| Dalgleish, AG | 1 |
| Maurer, T | 1 |
| Poncelet, A | 1 |
| Berger, T | 1 |
| Falco, P | 6 |
| Bertola, A | 2 |
| Hoyer, B | 1 |
| Steidl, U | 1 |
| Kondakci, M | 1 |
| Heuk, R | 1 |
| Ruf, L | 1 |
| Strupp, C | 1 |
| Neumann, F | 1 |
| Rohr, UP | 1 |
| Hildebrandt, B | 1 |
| Haas, R | 1 |
| Kobbe, G | 1 |
| Gika, D | 1 |
| Hamilos, G | 1 |
| Zomas, A | 2 |
| Zorzou, M | 1 |
| Tassidou, A | 1 |
| Anagnostou, D | 1 |
| Perfetti, V | 1 |
| Caccialanza, R | 1 |
| Comotti, B | 1 |
| Hovenga, S | 1 |
| Daenen, SM | 1 |
| de Wolf, JT | 1 |
| van Imhoff, GW | 1 |
| Kluin-Nelemans, HC | 1 |
| Sluiter, WJ | 1 |
| Micol, JB | 1 |
| Guieze, R | 1 |
| Berthon, C | 1 |
| Kuhnovsky, F | 1 |
| Terriou, L | 1 |
| Moreau, AS | 1 |
| Sharma, NL | 1 |
| Sharma, V | 1 |
| Shanker, V | 1 |
| Mahajan, VK | 1 |
| Sarin, S | 1 |
| Hussein, MA | 2 |
| del Giglio, A | 1 |
| Weinschenker, P | 1 |
| Manhani, AR | 1 |
| Carbonell, AL | 1 |
| Mitteldorf, CA | 1 |
| Letsinger, JA | 1 |
| McCarty, MA | 1 |
| Jorizzo, JL | 1 |
| Goloubeva, O | 1 |
| Rapoport, AP | 1 |
| Ratterree, B | 1 |
| Gahres, N | 2 |
| Meisenberg, B | 1 |
| Takebe, N | 1 |
| Heyman, M | 1 |
| Zwiebel, J | 1 |
| Streicher, H | 1 |
| Gocke, CD | 1 |
| Tomic, D | 1 |
| Flaws, JA | 1 |
| Zhang, B | 1 |
| Fenton, RG | 1 |
| Mattei, D | 1 |
| Mordini, N | 1 |
| Vigna Taglianti, R | 1 |
| Rapezzi, D | 1 |
| Gallamini, A | 1 |
| Thomson, K | 1 |
| Flory, A | 1 |
| Hanslip, J | 1 |
| Goldstone, AH | 1 |
| Yong, KL | 1 |
| Rahemtulla, A | 2 |
| Schmielau, J | 1 |
| Teschendorf, C | 1 |
| König, M | 1 |
| Schmiegel, W | 1 |
| Roberts, A | 1 |
| Ganju, V | 1 |
| Catalano, J | 1 |
| Bell, R | 1 |
| Simmons, PJ | 1 |
| Lillie, K | 1 |
| Milner, AD | 1 |
| Iulio, JD | 1 |
| Ramsay, R | 1 |
| Falcone, A | 2 |
| Sanpaolo, G | 1 |
| Catalano, L | 1 |
| La Sala, A | 1 |
| Mantuano, S | 1 |
| Nobile, M | 1 |
| Melillo, L | 1 |
| Scalzulli, PR | 2 |
| Dell'Olio, M | 1 |
| Bodenizza, C | 1 |
| Greco, MM | 1 |
| Merla, E | 1 |
| Cascavilla, N | 1 |
| Basu, S | 1 |
| Milne, AE | 1 |
| Rose, PE | 1 |
| Scott, GL | 1 |
| Samson, D | 1 |
| Apperley, JF | 1 |
| Ambrosini, MT | 4 |
| Ciccone, G | 1 |
| Ochiai, N | 1 |
| Yamada, N | 1 |
| Uchida, R | 1 |
| Okano, A | 1 |
| Hatsuse, M | 1 |
| Okamoto, M | 1 |
| Ashihara, E | 1 |
| Ciolli, S | 1 |
| Leoni, F | 1 |
| Gigli, F | 1 |
| Rigacci, L | 1 |
| Avonto, I | 4 |
| Rasmussen, E | 1 |
| Hollmig, K | 1 |
| Pineda-Roman, M | 1 |
| Talamo, G | 1 |
| Thertulien, R | 1 |
| Kiwan, E | 1 |
| Krishna, S | 1 |
| Fox, M | 1 |
| Badros, A | 1 |
| Gao, W | 1 |
| An, N | 1 |
| Chen, SL | 1 |
| Kirkham, SE | 1 |
| Lindley, KJ | 1 |
| Elawad, MA | 1 |
| Blanshard, C | 1 |
| Sidra, G | 1 |
| Williams, CD | 1 |
| Russell, NH | 1 |
| Zaman, S | 1 |
| Myers, B | 2 |
| Byrne, JL | 1 |
| Rus, C | 2 |
| Massaia, M | 1 |
| Capella, S | 1 |
| Zeldenrust, SR | 1 |
| Desikan, KR | 1 |
| Kelly-Colson, K | 1 |
| McKenney, ML | 1 |
| Gorelik, S | 1 |
| Rich, R | 1 |
| Wu, A | 1 |
| Dalton, WS | 1 |
| Leyvraz, S | 1 |
| Yakoub Agha, I | 1 |
| Dumontet, C | 1 |
| Renaud, M | 1 |
| Voillat, L | 1 |
| Monconduit, M | 1 |
| Grobois, B | 1 |
| Rodeghiero, F | 1 |
| Schwab, C | 1 |
| Terrier, B | 1 |
| Aouba, A | 1 |
| Diop, S | 1 |
| Clerc, J | 1 |
| Vasiliu, V | 1 |
| Munera, Y | 1 |
| Ramiro, L | 1 |
| Torrebadell, M | 1 |
| Giannopoulos, K | 1 |
| Roliński, J | 1 |
| Walker, E | 1 |
| Karam, MA | 1 |
| Choueiri, TK | 1 |
| Jawde, RA | 1 |
| Bruening, K | 1 |
| Reed, J | 1 |
| Faiman, B | 1 |
| Ellis, Y | 1 |
| Brand, C | 1 |
| Srkalovic, G | 1 |
| Andresen, S | 1 |
| Voderholzer, W | 1 |
| Cherian, G | 1 |
| Thomas, DW | 1 |
| Benevolo, G | 1 |
| Heidt, J | 1 |
| Langers, AM | 1 |
| van der Meer, FJ | 1 |
| Brouwer, RE | 1 |
| Marque, M | 1 |
| Guillot, B | 1 |
| Bessis, D | 1 |
| Ghosh, S | 1 |
| Gopal, R | 1 |
| Advani, SH | 1 |
| Fausel, C | 1 |
| Juliar, BE | 1 |
| Yiannoutsos, CT | 1 |
| Fisher, WB | 1 |
| Ansari, RH | 1 |
| Wood, LL | 1 |
| Smith, GG | 1 |
| Cripe, LD | 1 |
| Schenkel, B | 2 |
| Radocha, J | 2 |
| Adena, M | 1 |
| Smith, DK | 1 |
| Hertel, J | 1 |
| Yildirim, ND | 1 |
| Ayer, M | 1 |
| Küçükkaya, RD | 1 |
| Alpay, N | 1 |
| Mete, O | 1 |
| Yenerel, MN | 1 |
| Yavuz, AS | 1 |
| Nalçaci, M | 1 |
| Bláha, V | 1 |
| Malý, J | 1 |
| Dabak, V | 1 |
| Kuriakose, P | 1 |
| Kamboj, G | 1 |
| Shurafa, M | 1 |
| Ghobrial, I | 1 |
| Munshi, N | 2 |
| Jacob, SE | 1 |
| Weisman, RS | 1 |
| Kerdel, FA | 1 |
| Smith, SM | 1 |
| Grinblatt, D | 1 |
| Johnson, JL | 1 |
| Niedzwiecki, D | 1 |
| Rizzieri, D | 1 |
| Offer, M | 1 |
| Störk, S | 1 |
| Kneitz, C | 1 |
| Bröcker, EB | 1 |
| Hoyer, C | 1 |
| Ertl, G | 1 |
| Angermann, CE | 1 |
| Grigg, AP | 2 |
| Sasadeusz, J | 1 |
| Guariglia, R | 1 |
| Villani, O | 1 |
| Martorelli, MC | 1 |
| Zonno, A | 1 |
| Lerose, R | 1 |
| Candoni, A | 1 |
| Simeone, E | 1 |
| Zemanova, M | 1 |
| Pavlicek, P | 1 |
| Pika, T | 1 |
| Bacovsky, J | 1 |
| Jenkins, JS | 1 |
| Powell, RJ | 2 |
| Allen, BR | 1 |
| Littlewood, SM | 1 |
| Maurice, PD | 1 |
| Smith, NJ | 1 |
| Bahmer, FA | 1 |
| Zaun, H | 1 |
| Luszpinski, P | 1 |
| Moulin, G | 2 |
| Bonnet, F | 1 |
| Barrut, D | 1 |
| Franc, MP | 1 |
| Bowers, PW | 1 |
| Hasper, MF | 1 |
| Torras, H | 3 |
| Lecha, M | 3 |
| Mascaró/, JM | 1 |
| Knop, J | 1 |
| Bonsmann, G | 1 |
| Happle, R | 1 |
| Ludolph, A | 1 |
| Matz, DR | 1 |
| Mifsud, EJ | 1 |
| Macher, E | 1 |
| Mascaro, JM | 2 |
| Theophilus, S | 1 |
| Dallafior, S | 1 |
| Pugin, P | 1 |
| Cerny, T | 1 |
| Betticher, D | 1 |
| Saurat, JH | 1 |
| Hauser, C | 1 |
| Laccourreye, O | 1 |
| Fadlallah, JP | 1 |
| Pages, JC | 1 |
| Durand, H | 1 |
| Brasnu, D | 1 |
| Lowenstein, W | 1 |
| Paterson, DL | 1 |
| Georghiou, PR | 1 |
| Allworth, AM | 1 |
| Kemp, RJ | 1 |
| Menni, S | 1 |
| Imondi, D | 1 |
| Brancaleone, W | 1 |
| Croci, S | 1 |
| Ip, M | 1 |
| Gorin, MB | 1 |
| Cherouati, K | 1 |
| Claudy, A | 2 |
| Souteyrand, P | 2 |
| Cambazard, F | 1 |
| Vaillant, L | 1 |
| Lamorelle, A | 1 |
| MacPhail, L | 1 |
| Hamuryudan, V | 1 |
| Mat, C | 1 |
| Saip, S | 1 |
| Ozyazgan, Y | 1 |
| Siva, A | 1 |
| Yurdakul, S | 1 |
| Zwingenberger, K | 1 |
| Yazici, H | 1 |
| Ferrándiz, C | 1 |
| Carrascosa, JM | 1 |
| Just, M | 1 |
| Bielsa, I | 1 |
| Ribera, M | 1 |
| Lacosta Nicolás, JL | 1 |
| Martínez Iñiguez, JC | 1 |
| Jibaly, RM | 1 |
| Moallem, H | 1 |
| Fikrig, SM | 1 |
| Rabinowitz, SS | 1 |
| Lair, G | 1 |
| Marie, I | 1 |
| Cailleux, N | 1 |
| Blot, E | 1 |
| Boullié, MC | 1 |
| Courville, P | 1 |
| Lauret, P | 1 |
| Lévesque, H | 1 |
| Courtois, H | 1 |
| Engeser, P | 1 |
| Klimm, HD | 1 |
| de Wazières, B | 1 |
| Magy, N | 1 |
| Berthier, S | 1 |
| Vuitton, DA | 1 |
| Ayers, D | 1 |
| Roberson, P | 1 |
| Eddlemon, P | 1 |
| Wilson, C | 1 |
| Dhodapkar, M | 1 |
| Zeddis, J | 1 |
| Kyriakis, KP | 1 |
| Kontochristopoulos, GJ | 1 |
| Panteleos, DN | 1 |
| Federman, GL | 1 |
| Federman, DG | 1 |
| Jacobson, JM | 1 |
| Greenspan, JS | 1 |
| Spritzler, J | 1 |
| Fox, L | 1 |
| Fahey, JL | 1 |
| Jackson, JB | 1 |
| Chernoff, M | 1 |
| Wohl, DA | 1 |
| Pulvirenti, JJ | 1 |
| Hooton, TM | 1 |
| Shikuma, C | 1 |
| Amato, R | 1 |
| Kaklamani, VG | 1 |
| Kaklamanis, PG | 1 |
| Facchini, S | 1 |
| Candusso, M | 1 |
| Martelossi, S | 1 |
| Liubich, M | 1 |
| Panfili, E | 1 |
| Ventura, A | 1 |
| Hus, M | 1 |
| Soroka-Wojtaszko, M | 1 |
| Jawniak, D | 1 |
| Legiec, W | 1 |
| Ciepnuch, H | 1 |
| Skotnicki, A | 1 |
| Manko, J | 1 |
| Ronconi, S | 1 |
| Cellini, C | 1 |
| Grafone, T | 1 |
| Cangini, D | 1 |
| Tura, S | 1 |
| Manesis, DA | 1 |
| Schoeman, JF | 1 |
| Ravenscroft, A | 1 |
| Hartzenberg, HB | 1 |
| Drenth, JP | 1 |
| Vonk, AG | 1 |
| Simon, A | 1 |
| Powell, R | 1 |
| van der Meer, JW | 1 |
| Biagi, JJ | 2 |
| Taiwo, BO | 1 |
| Moehler, TM | 1 |
| Krasniqi, F | 1 |
| Westerman, DW | 1 |
| Pitini, V | 1 |
| Azzarello, D | 1 |
| La Gattuta, G | 1 |
| Curley, MJ | 1 |
| Hussein, SA | 1 |
| Hassoun, PM | 1 |
| Dolan, G | 1 |
| Nora, JJ | 1 |
| Nora, AH | 1 |
| Ramu, G | 2 |
| Girdhar, A | 1 |
| Jacobson, RR | 1 |
| Trautman, JR | 1 |
| Iyer, CG | 1 |
| Guillaume, JC | 1 |
| Janier, M | 1 |
| Hans, P | 1 |
| Marchand, C | 1 |
| Bonnetblanc, JM | 1 |
| Dallac, S | 1 |
| Klene, C | 1 |
| Radeff, B | 1 |
| Kuffer, R | 1 |
| Samson, J | 1 |
| Rustin, MH | 1 |
| Gilkes, JJ | 1 |
| Robinson, TW | 1 |
| Nicolau, DP | 1 |
| West, TE | 1 |
| Youle, M | 1 |
| Clarbour, J | 1 |
| Farthing, C | 1 |
| Connolly, M | 1 |
| Hawkins, D | 1 |
| Staughton, R | 1 |
| Gazzard, B | 1 |
| Eisenbud, L | 1 |
| Horowitz, I | 1 |
| Kay, B | 1 |
| Pinquier, L | 1 |
| Kürkçüoğlu, N | 1 |
| Atakan, N | 1 |
| Eksioğlu, M | 1 |
| Levy, L | 1 |
| Fasal, P | 1 |
| Levan, NE | 1 |
| Freedman, RI | 1 |
| Merklen, FP | 1 |
| Cottenot, F | 1 |
| Pennec, J | 1 |
| Vernant, JC | 1 |
| Buzacoux, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Open Label, Multicenter Study Assessing The Clinical Benefit Of Isatuximab Combined With Carfilzomib (Kyprolis®) And Dexamethasone Versus Carfilzomib With Dexamethasone In Patients With Relapse And/Or Refractory Multiple Myeloma Previously Tre[NCT03275285] | Phase 3 | 302 participants (Actual) | Interventional | 2017-10-25 | Active, not recruiting | ||
| A Phase 2 Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma Patients With t(11;14)[NCT06115135] | Phase 2 | 39 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure[NCT04174547] | 8,670 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With All-Transretinoic Acid in Patients With Multiple Myeloma Previously Exposed to Daratumumab-Based Regimens[NCT04700176] | Phase 2 | 43 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newly Diagnosed Transplant Eligible Multiple Myeloma[NCT05199311] | Phase 1/Phase 2 | 66 participants (Anticipated) | Interventional | 2022-05-13 | Recruiting | ||
| An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma[NCT01998971] | Phase 1 | 242 participants (Actual) | Interventional | 2014-02-18 | Active, not recruiting | ||
| A Phase 2, Multicenter, Single-Arm, Open-Label Study To Determine The Efficacy And Safety Of Single-Agent Lenalidomide (Revlimid®) In Patients With Mantel Cell NHL Who Have Relapsed Or Progressed After Treatment With Bortezomib Or Are Refractory To Bortez[NCT00737529] | Phase 2 | 134 participants (Actual) | Interventional | 2008-12-22 | Completed | ||
| A Phase 2, Multicenter, Multi-cohort, Open-label Study of Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following[NCT01946477] | Phase 2 | 186 participants (Actual) | Interventional | 2014-05-29 | Active, not recruiting | ||
| A Phase 1, Multicenter, Open Label, Dose-escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide (POM), Bortezomib (BTZ) and Low-Dose Dexamethasone (LDDEX) in Subjects With Relapsed or Refractory Multiple Myeloma (MM)[NCT01497093] | Phase 1 | 34 participants (Actual) | Interventional | 2012-02-15 | Completed | ||
| A Multicenter, Observational Study to Evaluate the Effectiveness of Lenalidomide (Revlimid®) in Subjects With Mantle Cell Lymphoma Who Have Relapsed or Progressed After Treatment With Ibrutinib or Are Refractory or Intolerant to Ibrutinib.[NCT02341781] | 30 participants (Actual) | Observational | 2015-04-30 | Completed | |||
| A Phase II Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma[NCT02460276] | Phase 2 | 50 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Observational Cohort Study Evaluating the Use and Efficacy of Pomalidomide in Patients With Multiple Myeloma in Routine Clinical Practice[NCT02902900] | 2,504 participants (Actual) | Observational | 2015-04-01 | Completed | |||
| A Phase 1 Study of Amrubicin in Combination With Lenalidomide and Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma[NCT01355705] | Phase 1/Phase 2 | 14 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| A Non-interventional Post Authorisation Registry of Patients Treated With Pomalidomide for Relapsed and Refractory Multiple Myeloma Who Have Received at Least Two Prior Treatment Regimens, Including Both Lenalidomide and Bortezomib, and Have Demonstrated [NCT02164955] | 775 participants (Actual) | Observational [Patient Registry] | 2014-06-26 | Completed | |||
| A Multi-center, Open-label Extended Access Program of Lenalidomide Plus Low-dose Dexamethasone in Chinese Subjects With Relapsed/Refactory Multiple Myeloma Who Participated in Study CC-5013-MM-021 for at Least One Year.[NCT02348528] | Phase 2 | 65 participants (Actual) | Interventional | 2012-09-11 | Completed | ||
| AZA PH GL 2003 CL 001 - Extension A Multicenter, Randomized, Open-label, Parallel-group, Phase 3 Trial of Subcutaneous Azacitidine Plus Best Supportive Care Versus Conventional Care Regimens Plus Best Supportive Care for the Treatment of Myelodysplastic S[NCT01186939] | Phase 3 | 40 participants (Actual) | Interventional | 2007-04-01 | Completed | ||
| A Multicenter, Single-arm, Open-label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma[NCT01712789] | Phase 3 | 682 participants (Actual) | Interventional | 2012-11-06 | Completed | ||
| A Multicenter, Single-Arm, Open-Label Treatment Use Protocol for Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma[NCT01632826] | 0 participants | Expanded Access | Approved for marketing | ||||
| A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial[NCT02244125] | Phase 2 | 100 participants (Actual) | Interventional | 2014-04-14 | Completed | ||
| A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)[NCT02576977] | Phase 3 | 251 participants (Actual) | Interventional | 2015-10-19 | Terminated (stopped due to The study was terminated early due to business reasons) | ||
| Multicenter Open Label Phase 2 Single Arm Study of Ixazomib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Characterized With Genomic Abnormalities of Adverse Adverse Prognostic[NCT03683277] | Phase 2 | 26 participants (Actual) | Interventional | 2019-11-03 | Terminated (stopped due to Recruitment issue, 26 patients enrolled instead of 70 initially planned) | ||
| Phase Ib Dose Finding Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma (MCL)[NCT02446236] | Phase 1 | 27 participants (Actual) | Interventional | 2015-06-18 | Active, not recruiting | ||
| National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation[NCT02340936] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| A Phase II Trial of High-dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) in the Up-front Treatment of Multiple Myeloma[NCT02416206] | Phase 2 | 65 participants (Actual) | Interventional | 2015-04-27 | Completed | ||
| A Conceptual Study of Daratumumab Intensified Treatment to Eligible Multiple Myeloma New Patients- Cyclophosphamide, Thalidomide, Dexamethasone and Daratumumab Induction, Follow by Daratumumab Consolidation and Maintenance[NCT03792620] | Phase 3 | 20 participants (Anticipated) | Interventional | 2018-11-20 | Recruiting | ||
| A Phase II Trial to Evaluate the Safety and Activity of Single-agent Lenalidomide Given as Maintenance Therapy After Response to Second-line Therapy in Patients With Relapsed DLBCL, Not Eligible for High-dose Chemotherapy and ASCT[NCT00799513] | Phase 2 | 47 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, First Line Maintenance Study Of Lenalidomide (Revlimid®) In Patients With Mantle-Cell Lymphoma[NCT01021423] | Phase 3 | 9 participants (Actual) | Interventional | 2010-04-01 | Terminated (stopped due to Terminated by sponsor due to new unpublished data that rendered the current design of the study no longer clinically relevant. There were no safety concerns.) | ||
| A Phase II Randomized Study of Lenalidomide or Lenalidomide and Rituximab as Maintenance Therapy Following Standard Chemotherapy for Patients With High/High-intermediate Risk Diffuse Large B-Cell Lymphoma[NCT00765245] | Phase 2 | 44 participants (Actual) | Interventional | 2008-10-31 | Completed | ||
| Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of Treatment With Lenalidomide Plus R-CHOP21 (LR-CHOP21) for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (DLBCL)[NCT00907348] | Phase 2 | 49 participants (Anticipated) | Interventional | 2007-10-31 | Active, not recruiting | ||
| Phase I/II Study of Lenalidomide Maintenance Following BEAM (+/- Rituximab) for Chemo-Resistant or High Risk Non-Hodgkin?s Lymphoma[NCT01035463] | Phase 1/Phase 2 | 74 participants (Actual) | Interventional | 2009-11-12 | Completed | ||
| Randomized Phase 3 Study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma. An AMN Study[NCT03143049] | Phase 3 | 120 participants (Anticipated) | Interventional | 2017-09-13 | Recruiting | ||
| A Phase I/II, Multi-center, Open Label Study of Pomalidomide, Cyclophosphamide and Prednisone (PCP) in Patients With Multiple Myeloma Relapsed and/or Refractory to Lenalidomide[NCT01166113] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Phase II, Multicenter, Single-Arm, Open-Label Study To Evaluate The Safety And Efficacy Of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma[NCT00413036] | Phase 2 | 217 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Phase I/II, Multicenter, Open Label, Clinical Trial of Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients[NCT02384083] | Phase 1/Phase 2 | 47 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Am Open-Label Phase II Study of the Safety and Efficacy of Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma[NCT00378209] | Phase 2 | 65 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With CHOP in Patients With Untreated PTCL[NCT04423926] | Phase 1/Phase 2 | 91 participants (Anticipated) | Interventional | 2020-06-10 | Recruiting | ||
| Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone (R2-GOD) in Treatment of Relapse/Refractory DLBCL:A Phase I Study[NCT03795571] | Phase 1 | 12 participants (Anticipated) | Interventional | 2019-01-01 | Recruiting | ||
| An Open-Label Phase I Study of the Safety of and Efficacy of RAD001 in Combination With Lenalidomide in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma[NCT00729638] | Phase 1 | 28 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| GEM21menos65. A Phase III Trial for NDMM Patients Who Are Candidates for ASCT Comparing Extended VRD Plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D[NCT05558319] | Phase 3 | 480 participants (Anticipated) | Interventional | 2022-10-31 | Not yet recruiting | ||
| Phase I Study of Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.[NCT00466895] | Phase 1 | 37 participants (Actual) | Interventional | 2007-04-30 | Completed | ||
| Open-label, Multi-center, Single Arm Study For The Safety And Efficacy Of Pomalidomide Monotherapy For Subjects With Refractory Or Relapsed And Refractory Multiple Myeloma. A Companion Study For Clinical Trial CC-4047-MM003[NCT01324947] | Phase 3 | 74 participants (Actual) | Interventional | 2011-03-01 | Completed | ||
| Carfilzomib and Dexamethasone in Combination With Cyclophosphamide vs. Carfilzomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: a Phase II Randomized Controlled Trial[NCT03336073] | Phase 2 | 199 participants (Actual) | Interventional | 2017-12-18 | Active, not recruiting | ||
| A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma[NCT01080391] | Phase 3 | 792 participants (Actual) | Interventional | 2010-07-14 | Completed | ||
| Real-world Evidence of Carfilzomib, Lenalidomide, Dexamethasone Combination Therapy in Korean Relapsed and/or Refractory Multiple Myeloma Patients[NCT05495620] | 300 participants (Anticipated) | Observational | 2022-08-01 | Not yet recruiting | |||
| Type 3 Von Willebrand International Registries Inhibitor Prospective Study[NCT02460458] | 265 participants (Actual) | Observational | 2012-11-05 | Active, not recruiting | |||
| Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma (MM)[NCT01239797] | Phase 3 | 646 participants (Actual) | Interventional | 2011-06-20 | Completed | ||
| A Phase 3, Muticenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone Versus High-dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma[NCT01311687] | Phase 3 | 455 participants (Actual) | Interventional | 2011-03-11 | Completed | ||
| A Multicenter Phase I/II Dose Escalation Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia[NCT02302469] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2009-03-31 | Completed | ||
| A Phase 1 Pharmacokinetic and Tolerability Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma[NCT01645930] | Phase 1 | 43 participants (Actual) | Interventional | 2012-12-17 | Completed | ||
| A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma[NCT01464034] | Phase 1/Phase 2 | 136 participants (Actual) | Interventional | 2011-11-30 | Terminated (stopped due to Lack of enrollment) | ||
| A Phase 2, Multi-Center, Randomized, Double-Blinded, Parallel Group Study of the Safety and Efficacy of Different Lenalidomide (REVLIMID®) Dose Regimens in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia[NCT00963105] | Phase 2 | 104 participants (Actual) | Interventional | 2009-10-19 | Completed | ||
| Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab and Lenalidomide in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)[NCT01754857] | Phase 2 | 36 participants (Actual) | Interventional | 2013-11-12 | Completed | ||
| A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphoma[NCT01169298] | Phase 1 | 13 participants (Actual) | Interventional | 2010-07-01 | Completed | ||
| Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma[NCT00461045] | Phase 2 | 15 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Phase I/II Multicenter, Randomized, Open Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Safety, And Efficacy Of CC-4047 Alone Or In Combination With Low-Dose Dexamethasone In Patients Wth Relapsed And Refractory Multiple Myeloma W[NCT00833833] | Phase 1/Phase 2 | 259 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| A Phase I/II Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, (BdL) for the Treatment of Patients With Relapsed Myeloma.[NCT01686386] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2010-02-28 | Recruiting | ||
| A Prospective, Multicenter, Single Arm, Phase II Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone (BiRd Regimen) in the Treatment of the First Relapsed Multiple Myeloma[NCT04063189] | Phase 2 | 100 participants (Anticipated) | Interventional | 2017-03-21 | Recruiting | ||
| An Open Label, International, Multicenter, Dose Escalating Phase I/II Trial Investigating the Safety of Daratumumab in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma[NCT01615029] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2012-06-30 | Active, not recruiting | ||
| A Phase 2, Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Efficacy of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma[NCT01724177] | Phase 2 | 26 participants (Actual) | Interventional | 2012-11-12 | Completed | ||
| Multicenter, Phase II, National and Open-label Study to Evaluate Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.[NCT05527340] | Phase 2 | 140 participants (Anticipated) | Interventional | 2022-09-30 | Not yet recruiting | ||
| Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma[NCT02076009] | Phase 3 | 569 participants (Actual) | Interventional | 2014-05-23 | Active, not recruiting | ||
| Phase 1 Multiple Ascending Dose Study of Elotuzumab (BMS-901608) in Combination With Lenalidomide/Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma in Japan[NCT01241292] | Phase 1 | 7 participants (Actual) | Interventional | 2011-01-14 | Completed | ||
| A Prospective Multicenter Pilot Trial to Evaluate the Efficacy of a Treatment With Fludarabine, Cyclophosphamide, Lenalidomide (FCL) for Advanced Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Patients.[NCT00727415] | Phase 1/Phase 2 | 42 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Phase I Study of Bendamustine in Combination With Lenalidomide (CC-5013) and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma[NCT01042704] | Phase 1 | 29 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| An Open-Label Phase I/II Study of Bendamustine, Weekly Bortezomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma[NCT01484626] | Phase 1/Phase 2 | 3 participants (Actual) | Interventional | 2011-05-05 | Terminated (stopped due to Celgene would no longer supply lenalidomide for the study) | ||
| Prospective, Open Clinical Trial of Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding[NCT04680195] | Phase 2 | 62 participants (Anticipated) | Interventional | 2020-12-14 | Not yet recruiting | ||
| The Official Title is A Multi-center, Randomized, Parallel-group, Double-blind, Placebo Controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma.[NCT00424047] | Phase 3 | 351 participants (Actual) | Interventional | 2003-01-01 | Completed | ||
| A Multicenter, Randomized, Parallel-Group, Double-blind, Placebo-controlled Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma[NCT00056160] | Phase 3 | 353 participants (Actual) | Interventional | 2003-01-01 | Completed | ||
| A Multicenter, Open-label Study to Determine the Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma[NCT00065351] | Phase 2 | 222 participants (Actual) | Interventional | 2003-07-01 | Completed | ||
| A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed/Refractory Multiple Myeloma[NCT03702725] | Phase 1 | 14 participants (Actual) | Interventional | 2019-08-29 | Active, not recruiting | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| An Open, Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple Myeloma[NCT01701076] | Phase 2 | 50 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum (MaPS in ENL[NCT03775460] | 550 participants (Anticipated) | Interventional | 2023-01-15 | Recruiting | |||
| An International, Multi-Center, Randomized, Open-Label Study of PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma[NCT00048230] | Phase 3 | 620 participants (Actual) | Interventional | 2002-06-30 | Completed | ||
| (PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older[NCT01453088] | Phase 2 | 63 participants (Actual) | Interventional | 2010-06-24 | Terminated (stopped due to Lack of Accrual) | ||
| A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma[NCT02103335] | Phase 1 | 38 participants (Actual) | Interventional | 2014-06-05 | Completed | ||
| Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma[NCT01241708] | Phase 3 | 146 participants (Actual) | Interventional | 2010-04-08 | Completed | ||
| A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®, CC-5013) in Participants With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma[NCT00179673] | Phase 2 | 43 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy[NCT02018523] | Phase 1 | 7 participants (Actual) | Interventional | 2014-06-30 | Terminated (stopped due to Study did not enroll enough subjects to make a statistically sound conclusion.) | ||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2, or IFN Based Therapy[NCT00057616] | Phase 3 | 274 participants | Interventional | 2002-10-01 | Completed | ||
| A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Hodgkin Lymphoma[NCT01207921] | Phase 1 | 28 participants (Actual) | Interventional | 2011-04-28 | Completed | ||
| Phase II Trial of Anti-Angiogenic Therapy With RT-PEPC in Patients With Relapsed Mantle Cell Lymphoma[NCT00151281] | Phase 2 | 25 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Phase I Study of CC-5013 (Lenalidomide NSC# 703813) in Pediatric Patients With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome[NCT00104962] | Phase 1 | 24 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| A Phase 2/3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of Lenalidomide (Revlimid ®) Versus Investigator's Choice in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma[NCT01197560] | Phase 2/Phase 3 | 111 participants (Actual) | Interventional | 2010-09-02 | Completed | ||
| [NCT01036399] | Phase 2 | 9 participants (Actual) | Interventional | 2008-11-30 | Terminated (stopped due to The EC withdrawn the approval becuase of possible conflicts of interests between our Institute and Supporter (Celgene)) | ||
| A Phase 1, Multi-center, Open-label Study of the Safety and Efficacy of a Stepwise Dose-escalation Schedule of Lenalidomide Monotherapy in Subjects With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia[NCT00419250] | Phase 1 | 52 participants (Actual) | Interventional | 2006-12-01 | Completed | ||
| A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma[NCT00540007] | Phase 2 | 80 participants (Actual) | Interventional | 2007-09-06 | Completed | ||
| A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Efficacy of Thalidomide for Refractory Small Intestinal Bleeding From Vascular Malformation[NCT02707484] | Phase 3 | 150 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| Salvage Treatment With Lenalidomide and Dexamethaosne(LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)[NCT00786851] | Phase 2 | 33 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma[NCT00420849] | Phase 3 | 587 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| An Open-Label Phase I Study of the Safety of Perifosine in Combination With Lenalidomide and Dexamethasone for Patients With Relapsed or Refractory Multiple Myeloma[NCT00415064] | Phase 1 | 32 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Lenalidomide and Rituximab Treatment of Relapsed Mantle Cell Lymphoma and Diffuse Large B-Cell Non-Hodgkin's Lymphoma, Transformed Large Cell Lymphoma, and/or Grade 3 Follicular Lymphoma (Follicular Cleaved Large Cell Lymphoma or Follicular Non-Cleaved La[NCT00294632] | Phase 1/Phase 2 | 54 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age[NCT01191060] | Phase 3 | 700 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS[NCT00551928] | Phase 3 | 402 participants (Actual) | Interventional | 2007-06-30 | Active, not recruiting | ||
| Phase II Study To Evaluate The Safety And Efficacy Of Lenalidomide For The Treatment Of Refractory Cutaneous Lupus[NCT01408199] | Phase 4 | 15 participants (Actual) | Interventional | 2010-01-31 | Completed | ||
| Lenalidomide in Combination With Rituximab as Treatment for Patients With Relapsed Chronic Lymphocytic Leukemia - RV-CLL-PI-0292[NCT00759603] | Phase 2 | 60 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| A Randomised, Double-blind, Placebo-controlled Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding[NCT02754960] | Phase 2 | 0 participants (Actual) | Interventional | 2010-03-31 | Withdrawn | ||
| Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation : An Open-label, Randomized, Parallel Controlled Study[NCT00964496] | Phase 2 | 55 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| The Study of the Optimal Treatment Strategy for Patients With Gastrointestinal Bleeding Due to Gastrointestinal Vascular Malformation: a Randomized, Double Blind, Placebo Controlled Study[NCT02301949] | Phase 2 | 0 participants (Actual) | Interventional | 2015-12-31 | Withdrawn | ||
| [NCT00261612] | Phase 2 | 16 participants | Interventional | 2005-01-31 | Active, not recruiting | ||
| An Open-label, Phase II Study of Cyclophosphamide, Lenalidomide and Dexamethasone (CLD) for Previously Treated Patients With AL Amyloidosis[NCT00607581] | Phase 2 | 21 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| A Phase II Study Of Genasense In Combination With Thalidomide And Dexamethasone In Relapsed And Refractory Multiple Myeloma[NCT00049374] | Phase 2 | 0 participants | Interventional | 2002-09-30 | Completed | ||
| A Phase 2, Open-label, Prospective, Multicenter Study to Evaluate the Efficacy of Intravenous Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation[NCT01923935] | Phase 2 | 105 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy[NCT00083551] | Phase 3 | 668 participants (Actual) | Interventional | 1998-08-31 | Completed | ||
| A National, Multi-Center, Open-Label Study of Velcade in Combination With Melphalan and Prednisone (V-MP) in Older Untreated Multiple Myeloma Patients.[NCT00388635] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Phase II Clinical Protocol for the Treatment of Patients With Previously Untreated CLL With Four or Six Cycles of Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide Followed by Lenalidomide Consolidation/ Maintenance[NCT01723839] | Phase 2 | 21 participants (Actual) | Interventional | 2012-02-22 | Completed | ||
| An Open-Label Study to Evaluate the Efficacy and Safety of Two CDC-501 Dose Regimens When Used Alone or in Combination With Dexamethasone for the Treatment Relapsed or Refractory Multiple Myeloma[NCT00044018] | Phase 2 | 102 participants (Actual) | Interventional | 2002-04-01 | Completed | ||
| A Phase II Trial of the Anti -PD-1 Monoclonal Antibody Pembrolizumab (MK-3475) + Lenalidomide + Dexamethasone as Post Autologous Transplant Consolidation in Patients With High-risk Multiple Myeloma[NCT02906332] | Phase 2 | 12 participants (Actual) | Interventional | 2016-12-12 | Terminated (stopped due to FDA Hold Due to Updated Risks) | ||
| QUIREDEX: A National, Open-Label, Multicenter, Randomized, Phase III Study of Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression[NCT00480363] | Phase 3 | 120 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Phase II Study of Lenalidomide, Ixazomib, Dexamethasone, and Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma[NCT04009109] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-10-21 | Recruiting | ||
| A Phase I Study of DVd +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)[NCT00091624] | Phase 1 | 77 participants (Actual) | Interventional | 2003-03-31 | Completed | ||
| Randomized Phase II Trial Evaluating the Efficiency of Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure[NCT02622906] | Phase 2 | 24 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma[NCT01297764] | Phase 1/Phase 2 | 17 participants (Actual) | Interventional | 2011-04-30 | Active, not recruiting | ||
| Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects[NCT03122431] | Phase 4 | 93 participants (Actual) | Interventional | 2017-06-05 | Completed | ||
| A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus[NCT00001680] | Phase 2 | 17 participants | Interventional | 1997-10-31 | Completed | ||
| Phase III, Prospective, Open Label, Multicenter, Randomized Trial of Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone as First Line Therapy in Myeloma Patients Aged >65.[NCT00232934] | Phase 3 | 400 participants | Interventional | 2002-01-31 | Completed | ||
| A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With VBMCP-VBAD/Velcade Versus Thalidomide / Dexamethasone Versus Velcade / Thalidomide / Dexamethasone Followed by High Dose Intensive Therapy With Autolo[NCT00461747] | Phase 3 | 390 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection[NCT00000790] | Phase 2 | 164 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
DOR: time (in months) from date of 1st IRC determined response for participants achieving PR/better to date of 1st documented PD determined by IRC/death, whichever happens 1st. If disease progression/death before analysis cut-off date was not observed, DOR was censored at date of last valid disease assessment performed prior to initiation of further anti-myeloma treatment/data cut-off date, whichever was 1st. PD (IMWG criteria): inc of >=25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute inc must be >=0.5 g/dL), serum M-protein inc >=1g/dL if lowest M component was >=5g/dL; urine M-component (absolute inc must be >=200mg/24 hour),appearance of new lesion(s), >=50% inc from nadir in SPD of >1 lesion, or >=50% inc in the longest diameter of previous lesion >1 cm in short axis. PR: >=50% reduction of serum M-protein & reduction in 24h urinary M-protein by >=90%/<200mg/24 h. Estimated by Kaplan Meier method. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | NA |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | NA |
Complete response was defined as the participants with sCR and CR. IMWG response criteria for sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates plus normal free light chain (FLC) ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates. Complete response at the time of the final analysis was assessed with hydrashift isatuximab immunofixation electrophoresis (IFE) assay, which separated immunoglobulin G (IgG) isatuximab from IgG M protein. (NCT03275285)
Timeframe: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 28.5 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 44.1 |
MRD negativity was defined as the percentage of participants for whom MRD was negative by next-generation sequencing at any timepoint after first dose of study treatment. Threshold for negativity is 10^-5. MRD status in a participant was negative if at least one result of the assessment was negative in the participant otherwise MRD was considered as positive (MRD status reported as positive, missing or unevaluable). CR: participants with sCR and CR. IMWG response criteria for sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates. Complete response at the time of the final analysis was assessed with Hydrashift isatuximab IFE assay, which separated IgG isatuximab from IgG M protein. (NCT03275285)
Timeframe: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 12.2 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 26.3 |
OR: participants with sCR, CR, VGPR & partial response (PR) as best overall response assessed by IRC using IMWG response criteria (from start of treatment until disease progression, death, initiation of further anti-myeloma treatment/cutoff date, whichever occurs 1st). sCR: negative immunofixation on serum & urine, disappearance of soft tissue plasmacytoma, <5% plasma cells in bone marrow aspirate (BMA) + normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum & urine, disappearance of soft tissue plasmacytoma, <5% plasma cells in BMA. VGPR: serum & urine M-protein detectable by immunofixation, not on electrophoresis/,>=90% reduction in serum M-protein + urine M-protein level <100mg/24h/,>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. PR:>=50% reduction of serum M-protein & decrease in 24h urinary M-protein by >=90%/<200mg/24h, if present at baseline,>=50% decrease in SPD of soft tissue plasmacytoma. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 82.9 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 86.6 |
VGPR or better: defined as participants with sCR, CR and VGPR as the best overall response (defined as best response from start of treatment until disease progression, death, initiation of further anti-myeloma treatment or cut-off date whichever occurs first) as per IRC. As per IMWG response criteria: sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in BMAs plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in BMAs. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,>=90% reduction in serum M-protein plus urine M-protein level <100mg/24h/,>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 56.1 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 72.6 |
Percentage of participants with sCR, CR and VGPR for whom MRD assessed by sequencing was negative at any time after first dose of study treatment. MRD was assessed centrally by next-generation sequencing in BM aspiration samples from participants who achieve VGPR or better, to determine depth of response at molecular level. VGPR or better: percentage of participants with sCR, CR and VGPR. sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates plus normal FLC ratio, absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in bone marrow aspirates. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,>=90% reduction in serum M-protein plus urine M-protein level <100mg/24h/,>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. (NCT03275285)
Timeframe: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 13.8 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 33.5 |
Percentage of participants with sCR, CR and VGPR for whom MRD assessed by sequencing was negative at any time after first dose of study treatment. MRD was assessed centrally by next-generation sequencing in bone marrow aspiration samples from participants who achieve VGPR or better, to determine depth of response at molecular level. VGPR or better: percentage of participants with sCR, CR and VGPR. sCR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in BMAs plus normal FLC ratio (0.26-1.65), absence of clonal cells in bone marrow biopsy. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas, <5% plasma cells in BMAs. VGPR: serum and urine M-protein detectable by immunofixation, not on electrophoresis/,>=90% reduction in serum M-protein plus urine M-protein level <100mg/24h/,>=90% decrease in SPD compared to baseline in soft tissue plasmacytoma. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 13.0 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 29.6 |
AUC was defined as area under the plasma concentration-time curve extrapolated to infinity according to the equation: AUC= AUClast + Clast/λz. AUC was calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | nanograms*hour/milliliter(ng*h/mL) (Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 784 |
AUClast was defined as area under the plasma concentration versus time curve calculated from time 0 to last quantifiable concentration. AUClast was calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | ng*h/mL (Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 779 |
Clast was defined as the last concentration observed above the lower limit of quantification. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | ng/mL (Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 3.00 |
CLss was defined as a quantitative measure of the rate at which a drug substance is removed from the body at steady state, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | Liters/hour (L/h) (Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 466 |
Cmax was defined as the maximum concentration observed after the first infusion calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 minutes (min), 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | nanogram/milliliter (ng/mL) (Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 2090 |
AUCext was defined as the percentage of the extrapolation of AUC, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | percentage of AUC (Geometric Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 0 |
T1/2 was defined as the time required for the concentration of the drug to reach half of its original value, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | hours (Median) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 0.860 |
Tlast was defined as the time of last concentration observed above the lower limit of quantification, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | hours (Median) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 4.50 |
Tmax was defined as the time to reach Cmax, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | hours (Median) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 0.54 |
Volume of Distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Vss is the apparent volume of distribution at steady-state, calculated using the non-compartmental analysis after the intravenous infusion of carfilzomib with isatuximab. (NCT03275285)
Timeframe: Cycle 1: pre-dose (0 hour), 30 min, 35 min, 45 min, 60 min, 1 hour 30 min, 2 hours 30 min and 4 hours 30 min post-dose on Day 15
| Intervention | Liters (Mean) |
|---|---|
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 453 |
Time (in months) from randomization to date of 1st documentation of progressive disease (PD)/date of death from any cause, whichever comes 1st. If PD & death are not observed before cut-off date/date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment not showing PD performed prior to initiation of further anti-myeloma treatment/cut-off date, whichever comes 1st. PD(IMWG criteria):any 1 of following:Increase(inc) of >=25% in serum M-component from nadir; serum M component inc >=1 g/dL in 2 consecutive assessment, if starting M component >=5 g/dL; and/or inc of >=25% in urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc >=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion if >1 lesion/ >=50% increase in longest diameter of previous soft tissue extramedullary disease lesion >1 cm in short axis. Estimated by Kaplan-Meier method. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (median duration of follow-up was 20.73 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 19.15 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | NA |
Time (in months) from randomization to date of 1st documentation of PD/date of death from any cause, whichever comes 1st. If PD & death are not observed before cut-off date/date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment not showing PD/cut-off date, whichever comes 1st. Progressions/deaths occurring >8 weeks after last disease assessment were censored at earliest date of last valid disease assessment not showing PD before initiation of further anti-myeloma treatment & cut-off date. PD (per IMWG criteria): meeting any 1 criteria: Inc of >=25% in serum M-component from nadir; serum M component inc >=1 g/dL in 2 consecutive assessment, if starting M component was >=5 g/dL; and/or inc of >=25% in urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc >=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion >1 cm in short axis. (NCT03275285)
Timeframe: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 20.76 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 41.66 |
Time (in months) from randomization to date of 1st PD documentation/death date, whichever is 1st. If PD & death not observed before cut-off date/date of further anti-myeloma treatment initiation, PFS censored at date of last valid disease assessment not showing PD performed prior to initiation of further anti-myeloma treatment/cut-off date, whichever was 1st. Progression/deaths occurring >8 weeks after last disease assessment censored at earliest date of last disease assessment without evidence of progression before initiation of new anti-myeloma treatment & cut-off date. PD (IMWG criteria): meeting any 1: Inc >=25% in Serum M-component from nadir; serum M component inc >=1 g/dL in 2 consecutive assessment, if starting M component >=5 g/dL; and/or inc >=25% in Urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc >=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion >1 cm short axis. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 20.27 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | NA |
PFS: time (in months) from randomization to date of first documentation of PD or date of death from any cause, whichever comes first. If PD and death are not observed before analysis cut-off date or date of initiation of further anti-myeloma treatment, PFS was censored at date of last valid disease assessment or analysis cut-off date, whichever comes first. PD as per IMWG criteria: any 1 of following: Inc of >=25% in Serum M-component from nadir; serum M component increase >=1 g/dL in 2 consecutive assessment, if starting M component was >=5 g/dL; and/or inc of >=25% in Urine M-component from nadir and/or development of new bone lesion/soft tissue extramedullary disease/inc >=50% from nadir in sum of perpendicular diameters of existing soft tissue extramedullary disease lesion if >1 lesion/ >=50% inc in longest diameter of previous soft tissue extramedullary disease lesion >1 cm in short axis. PFS estimated by Kaplan-Meier method. (NCT03275285)
Timeframe: From randomization until the final analysis data cut-off date of 14 January 2022 (the median duration of follow-up was 43.96 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 19.15 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 35.65 |
PFS2 defined as time (in months) from date of randomization to date of 1st documentation of PD (as assessed by investigator) after initiation of further anti-myeloma treatment /death from any cause, whichever comes 1st. Participants alive without progression after initiation of further anti-myeloma treatment before analysis cut-off date, PFS2 censored at date of last follow-up visit not showing disease progression after initiation of further anti-myeloma treatment /analysis cut-off date, whichever comes 1st. As per IMWG criteria, PD: defined for participants with increase of >= 25% from lowest confirmed value in any 1 of following criteria: serum M-protein (absolute increase must be >= 0.5 g/dL), serum M-protein increase >=1 g/dL if lowest M component was >=5 g/dL; urine M-component (absolute increase must be >=200 mg/24hour), appearance of new lesion(s), >=50% increase from nadir in SPD of >1 lesion, or >=50% increase in longest diameter of previous lesion >1 centimeter short axis. (NCT03275285)
Timeframe: From randomization until the final analysis data cut-off date of 14 Jan 2022 (the median duration of follow-up was 43.96 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 35.58 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 47.18 |
Time to best response was defined as time (in months) from randomization to the date of first occurrence of IRC determined as best overall response (PR or better) that is subsequently confirmed. In absence of response, participants were censored at earliest date of last valid disease assessment before disease progression/death, date of last valid disease assessment before initiation of further anti-myeloma treatment (if any)/ analysis cut-off date, whichever was 1st. PR (IMWG criteria) was defined as >=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by >=90% or to <200 mg/24 h. In addition to above listed criteria, if present at baseline, a >=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. Best Overall Response was defined as the best response, using the IRC's assessment of response, from start of treatment until disease progression, death, initiation of further anti-myeloma treatment or cut-off date, whichever occurs 1st. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 3.78 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 4.60 |
Time to first response was defined as the time (in months) from randomization to the date of first IRC determined response (PR or better) that is subsequently confirmed. In the absence of response, participants were censored at the earliest of the date of the last valid disease assessment before disease progression or death, the date of the last valid disease assessment before initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever comes first. PR per IMWG criteria was defined as >=50% reduction of serum M-protein and reduction in 24 hours urinary M-protein by >=90% or to <200 mg/24 h. In addition to the above listed criteria, if present at baseline, a >=50% reduction in the size (SPD) of soft tissue plasmacytomas was also required. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 1.12 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 1.08 |
TTP was defined as time in months from randomization to the date of first documentation of PD (as determined by the IRC). If progression was not observed before the analysis cut-off date or the date of initiation of further anti-myeloma treatment, TTP was censored at the date of the last valid disease assessment not showing disease progression performed prior to initiation of a further anti-myeloma treatment (if any) or the analysis cut-off date, whichever comes first. As per IMWG criteria, PD was defined for participants with inc of >= 25% from lowest confirmed value in any one of the following criteria: serum M-protein (the absolute inc must be >= 0.5 g/dL), serum M-protein inc >=1 g/dL if the lowest M component was >=5 g/dL; urine M-component (the absolute inc must be >=200 mg/24hour), appearance of new lesion(s), >=50% inc from nadir in SPD of >1 lesion, or >=50% inc in the longest diameter of a previous lesion >1 centimeter in short axis. (NCT03275285)
Timeframe: From randomization until the primary analysis data cut-off date of 7 Feb 2020 (the median duration of follow-up was 20.73 months)
| Intervention | months (Median) |
|---|---|
| Carfilzomib + Dexamethasone (Kd) | 20.27 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | NA |
EORTC QLQ-C30 is a cancer-specific instrument that contains 30 items & provides multidimensional assessment of HRQL. EORTC QLQ-C30 includes global health status/quality of life (GHS/QOL), functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and 6 single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from QLQ-C30 are 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale & are 7-point scale (1/Very Poor to 7/Excellent). GHS total score is calculated as ([{Q29+Q30}/2]-1)/6*100. Answers are converted into grading scale, with values between 0 (worse outcome) to100 (best outcome). High score represents a favorable outcome with best quality of life for participant. Results reported for primary analysis with data cut-off date 7-Feb-2020. (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | 1.52 | 4.17 | 3.58 | 3.60 | 3.13 | 4.22 | 3.82 | 6.60 | 4.91 | 4.34 | 8.59 | 7.08 | 9.75 | 5.26 | 6.33 | 7.27 | 8.70 | 12.40 | 10.78 | 12.50 | 17.98 | 15.56 | 14.81 | 15.00 | -6.14 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | -1.60 | 0.05 | -1.89 | -1.23 | -1.44 | -1.77 | -1.06 | -0.78 | -1.21 | -1.10 | 0.84 | -1.26 | -0.98 | 0.16 | -1.07 | 0.00 | -0.36 | -1.23 | -1.05 | -1.85 | 0.31 | 3.15 | 0.38 | 3.13 | -11.90 |
"EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of one question and scores are based on the 4-point Likert scale ranging from Not at all to Very much. Body image score is calculated as: (1 - [Q47-1]/3)*100. Scores are averaged, and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life." (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | -1.29 | 1.98 | -1.65 | -0.69 | -1.83 | -0.77 | -5.16 | -2.14 | -1.80 | -1.85 | -2.05 | -3.89 | -4.52 | 0.00 | -1.31 | -1.42 | 1.48 | 0.00 | 0.00 | -4.76 | -8.77 | -13.33 | -25.93 | -53.33 | -5.65 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | -1.27 | 1.27 | -1.10 | -2.89 | -1.60 | -3.03 | -0.25 | -1.02 | -1.33 | -0.55 | -0.55 | -2.63 | -3.24 | -2.22 | -2.94 | -1.98 | -1.77 | -3.70 | -0.76 | -3.20 | -1.85 | -5.41 | -3.03 | -8.33 | -9.36 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. Disease symptoms domain is one of the four domain scores. Disease symptoms domain consist of 6 questions and the score uses 4-point scale (1 'Not at All' to 4 'Very Much'). Disease Symptoms Domain Score is calculated as ([{Q31+Q32+Q33+Q34+Q35+Q36}/6]-1)/3*100. Scores are averaged, and transformed to 0-100 scale, where higher scores = more symptoms and lower HRQL. (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | -5.34 | -8.28 | -5.45 | -5.78 | -6.11 | -6.64 | -6.94 | -5.65 | -5.56 | -3.24 | -5.30 | -7.69 | -8.66 | -5.56 | -8.06 | -7.57 | -7.16 | -7.18 | -11.93 | -9.72 | -9.94 | -5.56 | -6.17 | -12.22 | 2.35 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | -3.40 | -7.42 | -7.46 | -6.37 | -6.16 | -4.78 | -5.47 | -5.51 | -4.98 | -7.10 | -6.89 | -5.95 | -7.08 | -5.19 | -5.77 | -4.29 | -3.78 | -3.64 | -3.54 | -3.81 | -5.35 | -6.01 | -9.60 | -14.58 | 1.75 |
"EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. It is used in conjunction with the EORTC QLQ-C30 to assess symptoms and side effects due to treatment or the disease. It consists of three questions and the scores are based on the 4-point Likert scale ranging from Not at all to Very much. Future Perspective score is calculated as (1 - ([{Q48+Q49+Q50}/3] -1)/3)*100. Scores are averaged and transformed to scale ranging from 0 to 100. A higher score represents a better quality of life." (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | 0.54 | 4.84 | 6.60 | 7.67 | 8.42 | 8.17 | 7.41 | 7.26 | 8.56 | 8.02 | 6.84 | 11.11 | 8.85 | 9.55 | 12.42 | 12.29 | 11.36 | 9.21 | 10.13 | 10.32 | 8.77 | 9.63 | 1.23 | -4.44 | -3.95 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 7.57 | 9.70 | 8.55 | 7.56 | 9.97 | 8.47 | 10.54 | 8.57 | 11.56 | 12.02 | 11.48 | 10.72 | 11.31 | 12.28 | 11.76 | 10.89 | 7.33 | 8.40 | 9.60 | 10.65 | 12.14 | 12.61 | 16.16 | 15.28 | -3.70 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. Side effects of treatment domain is one of the four domain scores. Side effects of treatment domain consists of 10 questions and the score uses a 4-point scale (1 'Not at All' to 4 'Very Much'). Side Effects of Treatment Score (MYSE) is calculated as ([{Q37+Q38+Q39+Q40+Q41+Q42+Q43+Q44+Q45+Q46}/10]-1)/3*100. Scores are averaged, and transformed to 0-100 scale, where higher scores = more side effects and lower HRQL and lower scores = less side effects and better HRQL. (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | 1.23 | 0.44 | 0.83 | 1.91 | 2.08 | 1.47 | 1.53 | 1.68 | 2.07 | 3.38 | 1.20 | 0.82 | 1.08 | 1.85 | 0.99 | 2.74 | 2.37 | 2.76 | -0.17 | 3.17 | 3.55 | 7.85 | 12.35 | 11.85 | 4.63 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 1.41 | 0.84 | 0.99 | 2.36 | 1.61 | 2.14 | 2.86 | 1.49 | 2.68 | 2.03 | 3.04 | 2.12 | 1.71 | 1.87 | 2.58 | 4.10 | 2.95 | 2.16 | 2.05 | 2.74 | 1.51 | -1.39 | -2.54 | -3.50 | 5.56 |
The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist in 2 sections a descriptive system comprising 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and Visual Analog Scale (VAS). Each dimension has a 5-level response: no problems, slight problems, moderate problems, severe problems, and extreme problems. Response options are measured with a 5-point Likert scale. The 5D-5L systems are converted into a single index utility score between 0 to 1, where higher score indicates a better health state and lower score indicate worse health state. (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | 0.05 | 0.06 | 0.02 | 0.04 | 0.03 | 0.06 | 0.06 | 0.05 | 0.06 | 0.04 | 0.03 | 0.06 | 0.06 | 0.05 | 0.06 | 0.05 | 0.02 | 0.03 | 0.06 | 0.03 | 0.05 | 0.05 | 0.04 | 0.05 | -0.03 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 0.04 | 0.05 | 0.05 | 0.04 | 0.05 | 0.04 | 0.05 | 0.04 | 0.03 | 0.05 | 0.02 | 0.03 | 0.04 | 0.05 | 0.04 | 0.03 | 0.04 | 0.03 | 0.03 | 0.02 | 0.02 | 0.00 | 0.03 | 0.04 | -0.08 |
The EQ-5D-5L is a standardized measure of health status that provides a general assessment of health utility and consist of 2 sections; descriptive system comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) and a VAS. The VAS records the respondent's self-rated health on a 20 centimeter (cm) vertical VAS; the scale went from 0 (worst imaginable health state) to 100 (best imaginable health state). This information can be used as a quantitative measure of health as judged by the individual respondents. (NCT03275285)
Timeframe: Baseline, Day 1 of each cycle (Cycle 2 to Cycle 25), at the End of Treatment visit (any day up to 114 weeks)
| Intervention | score on a scale (Mean) | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | Cycle 11 Day 1 | Cycle 12 Day 1 | Cycle 13 Day 1 | Cycle 14 Day 1 | Cycle 15 Day 1 | Cycle 16 Day 1 | Cycle 17 Day 1 | Cycle 18 Day 1 | Cycle 19 Day 1 | Cycle 20 Day 1 | Cycle 21 Day 1 | Cycle 22 Day 1 | Cycle 23 Day 1 | Cycle 24 Day 1 | Cycle 25 Day 1 | End of Treatment | |
| Carfilzomib + Dexamethasone (Kd) | 2.42 | 4.70 | 6.03 | 3.40 | 2.80 | 0.64 | 1.48 | -0.14 | 2.76 | 3.86 | 5.29 | 6.81 | 7.95 | 4.96 | 3.94 | 5.04 | 3.71 | 7.44 | 6.18 | 7.25 | 5.58 | 6.33 | 5.11 | 9.20 | -4.40 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 0.60 | 3.47 | 2.29 | 2.35 | 1.24 | 2.24 | 2.40 | 2.93 | 2.82 | 3.77 | 3.63 | 4.94 | 4.72 | 3.23 | 4.56 | 4.97 | 3.83 | 3.69 | 4.20 | 3.26 | 2.35 | 6.44 | 4.50 | 5.00 | -7.80 |
ADA were categorized as: pre-existing, treatment induced, and treatment boosted response. Pre-existing ADA was defined as ADA that were present in samples drawn during the pretreatment period (i.e., before the first isatuximab administration). Treatment-induced ADA was defined as ADA that developed at any time during the ADA on-study observation period in participants without pre-existing ADA, including participants without pretreatment samples. Treatment boosted ADA was defined as pre-existing ADA with an increase in titer during the ADA on-study observation period. (NCT03275285)
Timeframe: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: 111 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Pre-existing ADA | Treatment induced ADA | Treatment boosted ADA | |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 0 | 0 | 0 |
RR comprises of complete RR (CR renal), partial RR (PR renal) & minor RR (MR renal). CR renal was defined as an improvement in estimated glomerular filtration rate (eGFR) from <50 mL/min/1.73m^2 at Baseline to >=60 mL/min/1.73m^2 in at least 1 assessment during the treatment period (time from first dose of study treatment up to 30 days after last dose of study treatment); PR renal was defined as improvement in eGFR from <15 mL/min/1.73m^2 at baseline to at least 1 assessment in the range of 30 to 60 mL/min/1.73m^2 during the on-treatment-period and MR renal was defined as an improvement in eGFR from <15 mL/min/1.73m^2 at Baseline to at least 1 assessment in the range of 15 to 30 mL/min/1.73m^2 during the on-treatment-period or from 15 to 30 mL/min/1.73m^2 at Baseline to at least 1 assessment in the range of 30 to 60 mL/min/1.73m^2 during the on-treatment-period. (NCT03275285)
Timeframe: From the first dose of study treatment to 30 days following the last administration of study treatment (maximum duration: up to 114 weeks)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| CR Renal | MR Renal | |
| Carfilzomib + Dexamethasone (Kd) | 4 | 1 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 13 | 4 |
Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily had a causal relationship with the treatment. TEAEs were defined as AEs that developed, worsened, or became serious during the treatment period (time from the first dose of study treatments up to 30 days after last dose of study treatments). An SAE was any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability / incapacity, was a congenital anomaly/birth defect, was a medically important event. (NCT03275285)
Timeframe: From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: up to 208 weeks for Kd arm and 215 weeks for IKd arm)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any TEAE | Any treatment emergent SAE | |
| Carfilzomib + Dexamethasone (Kd) | 119 | 73 |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 175 | 124 |
Ceoi is the plasma concentration observed at the end of intravenous infusion. (NCT03275285)
Timeframe: End of infusion on Cycle 1 Day 1 and Cycle 1 Day 15; Cycle 2 Day 1
| Intervention | microgram/milliliter (mcg/mL) (Mean) | ||
|---|---|---|---|
| Cycle 1 Day 1 | Cycle 1 Day 15 | Cycle 2 Day 1 | |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 274.01 | 380.28 | 522.74 |
Ctrough was the plasma concentration observed just before treatment administration during repeated dosing. (NCT03275285)
Timeframe: Pre-infusion on Cycle 1 Day 1, Day 8, Day 15 and Day 22, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 5 Day 1, Cycle 6 Day 1, Cycle 7 Day 1, Cycle 8 Day 1, Cycle 9 Day 1 and Cycle 10 Day 1
| Intervention | mcg/mL (Mean) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 | Cycle 1 Day 8 | Cycle 1 Day 15 | Cycle 1 Day 22 | Cycle 2 Day 1 | Cycle 3 Day 1 | Cycle 4 Day 1 | Cycle 5 Day 1 | Cycle 6 Day 1 | Cycle 7 Day 1 | Cycle 8 Day 1 | Cycle 9 Day 1 | Cycle 10 Day 1 | |
| Isatuximab + Carfilzomib + Dexamethasone (IKd) | 3.66 | 82.14 | 180.02 | 252.63 | 324.28 | 295.78 | 342.48 | 389.25 | 427.16 | 433.22 | 490.51 | 486.07 | 490.08 |
Kaplan Meier estimates for the duration of CR/CRu was calculated from the date of the first occurrence of CR/CRu to the date of documented disease progression or death (without documented progression) for participants who obtained a CR/CRu; participants who had not progressed (or died) were censored at the last valid assessment. (NCT00737529)
Timeframe: From Day 1 of study drug to progression or early discontinuation; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 24.43 |
Kaplan Meier estimate for the duration of response (DoR) was calculated from the date of the first occurrence of initial response for responders (demonstrating evidence of at least a PR) to the date of first documented disease progression (any new lesion or increase by ≥ 50% of previously involved sites from nadir) or death (without documented progression) for participants who responded; participants who had not progressed (or died) were censored at the last valid assessment. (NCT00737529)
Timeframe: From Day 1 of study drug to progression or early treatment discontinuation; up to data cut-off date of 06 April 2016; Median duration of treatment was 94.5 days.
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 16.64 |
Kaplan Meier estimate of time to progression was calculated as time from the start of the study drug therapy to the first observation of disease progression. Participants who died without progression were censored at the date of death; otherwise, the censoring rules presented above for PFS applied to the analysis of TTP. Progressive Disease(PD): Appearance of new lesion or increase by ≥50% from previously involved sites from nadir (NCT00737529)
Timeframe: From Day 1 of study drug to first documented time of progression; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 5.46 |
Kaplan Meier estimates of PFS was defined as the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever comes first. If a participant had not progressed or died, PFS was censored at the time of last adequate assessment when the participant was known not to have progressed. For participants who received other anti-lymphoma therapy with no evidence of progression, PFS was censored at time of last adequate tumor assessment with no evidence of progression prior to the start of new anti-lymphoma treatment. (NCT00737529)
Timeframe: From Day 1 of study drug to first documented date of disease progression; up to data cut-off date of 06 April 2016; median time in follow-up was 16.34 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 4.01 |
Time to treatment failure (TTF) was calculated from the start of study drug therapy to early discontinuation from treatment due to any cause, including disease progression, toxicity, or death and was based on site-reported data. (NCT00737529)
Timeframe: From Day 1 of study drug to first documented time of treatment failure; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 3.75 |
Kaplan Meier estimate of overall survival was calculated from the time the first dose of study drug to death from any cause. Participants who had not died were censored at the last date the participant was known to be alive. (NCT00737529)
Timeframe: From Day 1 of study drug to first documented date of progressive disease or death; up to the final data cut-off date of 30 March 2017; median duration of follow-up for surviving participants was 62.94 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 19.50 |
Overall Response Rate (ORR) was defined as the percentage of participants whose best response was Complete Response, Complete Response unconfirmed or Partial Response. Participants who had discontinued before any response has been observed, or changed to other anti-lymphoma treatments before response had been observed, were considered as non-responders. Tumor Response was assessed by a modification of the International Lymphoma Workshop Response Criteria, IWRC, Cheson, 1999); CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow; PR = is defined ≥50% decrease in 6 largest nodes or nodal masses. (NCT00737529)
Timeframe: From Day 1 of study treatment to progession or early treatment discontinuation; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days.
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 29.9 |
The percentage of participants whose best response was CR or CRu. Participants who had discontinued before CR/CRu was observed, or changed to other anti-lymphoma treatments before a CR/CRu response had been observed, were considered as non-responders. CR is defined as the disappearance of all clinical and radiographic evidence of disease; CRu is defined as a CR, with a 1) residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters (SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2) indeterminate bone marrow. (NCT00737529)
Timeframe: From Day 1 of study drug to progression or early treatment discontinuation; up to data cut-off date of 06 April 2016; Median duration of treatment was 94.5 days
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 9.0 |
Time to Complete Response (CR+CRu) was defined as the time from the first dose of study drug to the date of the first occurrence of at least CRu and was calculated only for participants with CR or CRu. (NCT00737529)
Timeframe: From Day 1 of study drug to first documented CR/CRu or better; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 3.9 |
Time to Response was defined as the time from first dose of study drug to the date of the first response (having at least a PR) and was calculated only for responding participants. (NCT00737529)
Timeframe: From Day 1 of study drug to time of first documented PR or better; up to data cut-off date of 06 April 2016; median duration of treatment was 94.5 days
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 3.5 |
Adverse events were assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3: according to the following scale: Grade 1 = Mild Adverse Event (AE), Grade 2 = Moderate AE, Grade 3 = Severe and Undesirable AE, Grade 4 = Life-threatening or Disabling AE, and Grade 5 = Death; Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. after the first dose of study drug and within 28 days after the last dose. A TEAE is defined as any AE occurring or worsening on or after the first dose of study drug and within 28 days after the last dose of study drug. (NCT00737529)
Timeframe: From the first dose of lenalidomide through 28 days after the last dose during the follow-up phase; median (minimum, maximum) duration of treatment was 94.0 (1.0, 1950 days)
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAE | Any TEAE Related to Investigational Product (IP) | Any TEAE Grade 3-5 AE | Any TEAE Grade 3 AE | Any TEAE Grade 4 AE | Any TEAE Grade 5 AE | Any Grade 3-5 AE Related to IP | Any Grade 3 AE Related to IP | Any Grade 4 AE Related to IP | Any Grade 5 AE Related to IP | Any TEAE Serious Adverse Event (SAE) | Any SAE Related to IP | Any TEAE Leading to Stopping of IP | Any Treatment Related AE Leading to Stopping IP | Any AE Leading to Dose Reduction | Any AE Leading to IP Interruption | Any Treatment Related AE Leading to Dose Reduction | Treatment Related AE Leading to IP Interruption | |
| Lenalidomide | 132 | 118 | 106 | 101 | 57 | 18 | 90 | 88 | 41 | 2 | 70 | 30 | 28 | 16 | 55 | 81 | 52 | 66 |
(NCT01355705)
Timeframe: 140 days
| Intervention | days (Median) |
|---|---|
| Amrubicin + Lenalidomide + Dexamethasone | 133 |
"Progression-free survival (PFS) is alive and free from progression, per the modified International Myeloma Working Group Uniform Response Criteria, defined as any of:~Serum monoclonal protein ≥ 125% baseline and/or ≥ +0.5 g/dL from baseline,~Urine monoclonal protein ≥ 125% baseline and/or ≥ +200 mg/24 hour from baseline~New or increased bone lesions or plasmacytomas~Serum calcium > 11.5 mg/dL (attributed to increased plasma cells)" (NCT01355705)
Timeframe: 9 months
| Intervention | days (Median) |
|---|---|
| Amrubicin + Lenalidomide + Dexamethasone | 96 |
(NCT01355705)
Timeframe: 9 months
| Intervention | days (Median) |
|---|---|
| Amrubicin + Lenalidomide + Dexamethasone | 92 |
"Modified International Myeloma Working Group Uniform Response Criteria:~Complete (CR)=~Negative for monoclonal protein (MP) in urine (U) and serum (S) +~No tissue plasmacytomas (PC) +~<5% plasma cells (PCs) in marrow (M)~Stringent CR (sCR)= CR with normal light chain ratio+ no PCs in M~Near CR (nCR)= CR, except MP persists in U and S~Partial (PR)= S MP ≤50%, + U MP ≤90% or <200 mg/24 hours (hr)~Very Good PR (VGPR)= in S MP ≤90%, + U MP <100 mg/24 hr~Minimal (MR)=~S MP ≤51-75%, +~If light chain is excreted, reduced 50-89%/24 hr that is also >200 mg/24 hr, +~No increase in lytic bone lesions~Progressive disease (PD)= any of:~S MP ≥125% and/or ≥+0.5 g/dL,~U MP ≥125% and/or ≥+200 mg/24 hr~New or increased bone lesions/PC~S calcium >11.5 mg/dL (attributed to increased PCs)~PD after CR/sCR=~Reappearance of S or U MP~≥5% clonal PCs in M~New PC, lytic bone lesions, hypercalcemia~Stable Disease (SD)= Not CR, VGPR, MR, PR, or PD" (NCT01355705)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) rate | Very Good Partial Response (VGPR) Rate | Total CR + VGPR | Partial Response (PR) Rate | Overall Response Rate (ORR = CR + VGPR + PR) | |
| Amrubicin + Lenalidomide + Dexamethasone | 0 | 7.6 | 7.6 | 15.4 | 23 |
Participant counts for a variety of subsets of treatment emergent adverse events (TEAEs)during the extension study period (43-68 months). Subsets include participants counts for serious TEAEs, serious TEAEs that the investigator evaluated as releated to treatment, TEAEs leading to discontinuation of therapy, or a dose reduction, or a dose interruption. (NCT01186939)
Timeframe: 43- 68 months
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Participants with >=1 treatment emergent AE (TEAE) | Participants with >=1 treatment related TEAE | Participants with >=1 serious TEAE | Participants with >=1 serious trtment related TEAE | Participants w TEAE leading to discontinued treat | Participants w TEAE leading to dose reduction | Participants w TEAE leading to dose interruption | |
| Azacitidine | 39 | 27 | 20 | 5 | 15 | 4 | 15 |
Duration of response, calculated for responders only, was defined as time from the initial documented response (SCR, CR, VGPR or PR) to the first confirmed disease progression, or death if no disease progression was recorded. Participants without a documented progression were censored at the time of their last tumor assessment. (NCT01712789)
Timeframe: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
| Intervention | Months (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 7.9 |
Overall survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until death due to any cause. Participants who did not have death data at the time of study end/analysis were censored at the time they were last known to be alive. (NCT01712789)
Timeframe: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
| Intervention | Months (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 11.9 |
Progression free survival was calculated as the time from study enrollment, defined as the IVRS enrollment date, until either PD or death (any cause). Participants without an event (either a documented PD or death) at the time of study end were censored at the time of their last documented disease assessment or at the IVRS enrollment date if no disease assessment was conducted. (NCT01712789)
Timeframe: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
| Intervention | Months (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 4.6 |
Time to progression was calculated as the time from study enrollment until first recorded disease progression as determined by the site investigator based on the IMWG criteria, or until death due to progression. Participants not experiencing a documented progression were censored at the time of their last tumor assessment (or at the time of trial enrollment if no assessment was conducted). (NCT01712789)
Timeframe: From enrollment to the end of follow-up; median time on follow-up was 10.9 (range 0 - 81) months
| Intervention | Months (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 4.8 |
Overall response rate (ORR) was defined as the percentage of participants with a stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR) according to the International Myeloma Working Group uniform response criteria (IMWG URC) assessed by the Investigator. Responses must have been confirmed at at least 2 consecutive assessments before the institution of any new therapy with no known evidence of progressive or new bone lesions (NCT01712789)
Timeframe: Response was assessed at each treatment cycle and at treatment discontinuation; median duration of treatment with pomalidomide and LD-dex was 21.4 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 33.4 |
Pharmacokinetic (PK) parameters are derived from pomalidomide concentration versus time data. (NCT01712789)
Timeframe: Cycles 1, 2, 3, 4, 5, 6
| Intervention | Liters/hour (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 6.02 |
Pharmacokinetic (PK) parameters are derived from Pomalidomide concentration versus time data. (NCT01712789)
Timeframe: Cycles 1, 2, 3, 4, 5, 6
| Intervention | Liters (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 75.10 |
Time to response was defined as the time from treatment enrollment to the first documentation of response (sCR, CR, VGPR or PR) based on IMWG criteria. (NCT01712789)
Timeframe: Response was assessed at each treatment cycle and at treatment discontinuation; median duration of treatment with pomalidomide and LD-dex was 21.4 weeks
| Intervention | Weeks (Median) |
|---|---|
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 8.1 |
"An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, regardless of etiology. Any worsening (i.e., any significant adverse change in the frequency or intensity of a pre- existing condition) was considered an AE. The severity of AEs were graded based on the symptoms according to version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events. Second primary malignancies were monitored as events of interest and considered as part of the assessment of AEs.~A SAE = AE occurring at any dose that:~Results in death;~Is life-threatening~Requires inpatient hospitalization or prolongation of existing hospitalization~Results in persistent or significant disability/incapacity~Is a congenital anomaly/birth defect" (NCT01712789)
Timeframe: From the first dose of study treatment up to 28 days following the last dose of study treatment. The median duration of treatment with pomalidomide and LD-dex was 21.4 weeks.
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ TEAE | ≥ 1 TEAE Related to Pomalidomide (POM) | ≥ 1 TEAE Related to LD-Dex | ≥ 1 TEAE Related to Either POM or LD-Dex | ≥ 1 Grade (Gr) 3 or 4 TEAE | ≥ 1 Gr 3 or 4 TEAE Related to (R/T) POM | ≥ 1 Gr 3 or 4 TEAE R/T LD-Dex | ≥ 1 Gr 3 or 4 TEAE R/T Either POM or LD-Dex | ≥ 1 Grade 5 TEAE | ≥ 1 Grade 5 TEAE R/T POM | ≥ 1 Grade 5 TEAE R/T LD-Dex | ≥ 1 Grade 5 TEAE R/T either POM or LD-Dex | ≥ 1 Serious TEAE | ≥ 1 Serious TEAE R/T POM | ≥ 1 Serious TEAE R/T LD-Dex | ≥ 1 Serious TEAE R/T Either POM or LD-Dex | ≥ 1 Serious TEAE Leading to (L/T)Stopping of POM | ≥ 1 Serious TEAE L/T Stopping of LD-Dex | ≥1 Serious TEAE L/T Stopping either POM or LD-Dex | ≥ 1 TEAE L/T to Stopping of POM | ≥ 1 TEAE L/T to Stopping of LD-DEX | ≥ 1 TEAE L/T to Stopping of Either POM or LD-DEX | ≥1 Study Drug Related TEAE (L/T) Stopping POM | ≥1 Study Drug Related TEAE L/T Stopping LD-Dex | ≥1 Drug Related TEAE L/T Stopping LD-Dex or POM | ≥ 1 TEAE L/T to Reduction (R/D) of POM | ≥ 1 TEAE L/T to R/D of LD-DEX | ≥ 1 TEAE L/T to R/D of Either POM or LD-DEX | ≥ 1 Study Drug Related TEAE L/T to R/D of POM | ≥ 1 Study Drug Related TEAE L/T to R/D of LD-DEX | ≥1 StudyDrug Related TEAE L/T to R/D POM or LD-DEX | ≥ 1 TEAE L/T to Interruption (I/R) of POM | ≥ 1 TEAE L/T to I/R of LD-DEX | ≥ 1 TEAE L/T to I/R of either POM or LD-DEX | ≥ 1 Study Drug Related TEAE L/T to I/R of POM | ≥ 1 Study Drug Related TEAE L/T to I/R of LD-DEX | ≥1 StudyDrug Related TEAE L/T to I/R POM or LD-DEX | |
| Pomalidomide Plus Low Dose Dexamethasone (LD-Dex) | 673 | 527 | 448 | 575 | 606 | 417 | 226 | 448 | 127 | 14 | 16 | 18 | 448 | 187 | 146 | 215 | 36 | 34 | 37 | 54 | 61 | 63 | 30 | 19 | 38 | 164 | 150 | 244 | 142 | 135 | 224 | 455 | 434 | 470 | 294 | 185 | 333 |
Disease control rate was the percentage of participants who achieved confirmed sCR, CR, VGPR, PR, minimal response (MR) or have demonstrated stable disease (SD) for at least 12 weeks prior to any evidence of progression. PD was development of or an increase in the size of bone lesions or soft tissue plasmacytomas. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum FLC assay ratio and absence of clonal cells in bone marrow by immunohistochemistry/fluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component <100 mg/24 hr; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg/24 hours. The data cutoff date was July 9, 2018. (NCT02576977)
Timeframe: Up to approximately 30 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 88.1 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 84.8 |
ORR was defined as the percentage of the participants in the analysis population who achieved at least a partial response (stringent complete response [sCR]+complete response [CR]+very good partial response [VGPR]+partial response [PR]) according to the IMWG. CR = negative immunofixation of serum and urine AND disappearance of any soft tissue plasmacytomas AND <5% plasmacytomas in the bone marrow; sCR=stringent complete response, CR as above PLUS normal serum free light-chain (FLC) assay ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; VGPR = serum and urine M-component detectable by immunofixation but not on electrophoresis OR ≥ 90% reduction in serum M-component plus urine M-component <100 mg/24 hr; PR = ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg/24 hours. The database cutoff date was July 9, 2018. (NCT02576977)
Timeframe: Up to approximately 30 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 37.3 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 42.4 |
Overall survival is defined as the time from randomization to death due to any cause. Participants without documented death at the time of the final analysis were censored at the date of the last follow-up. Median overall survival was calculated from the product-limit (Kaplan-Meier) method for censored data. The database cutoff date was August 3, 2020. (NCT02576977)
Timeframe: Up to approximately 54 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 21.0 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 39.6 |
An adverse event was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Database cutoff was August 3, 2020. (NCT02576977)
Timeframe: Up to approximately 54 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 26 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 10 |
An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Database cutoff was August 3, 2020. (NCT02576977)
Timeframe: Up to approximately 54 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 122 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 119 |
Progression free survival was defined as the time from randomization to the first documented disease progression, or death due to any cause, whichever occurred first. PFS was assessed by CAC blinded central review according to the IMWG criteria based on the development of new bone lesions or soft tissue plasmacytomas or on a definite increase in the size of existing bone lesions or soft tissue plasmacytomas. Median PFS was calculated from the product-limit (Kaplan-Meier) method for censored data. The database cutoff date was July 9, 2018. (NCT02576977)
Timeframe: Up to approximately 30 months
| Intervention | Months (Median) |
|---|---|
| Pembrolizumab+Pomalidomide+Dexamethasone | 5.7 |
| Standard of Care (SOC) Pomalidomide+Dexamethasone | 7.4 |
(NCT02416206)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| BeEAM | 28 |
(NCT02416206)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| BeEAM | 60 |
(NCT02416206)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| BeEAM | 37 |
"Participants with treatment-emergent adverse events (TEAEs) during the treatment period plus 30 days. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator.~The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE." (NCT01021423)
Timeframe: up to 9 months
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| At least one TEAE | At least one TEAE related to study drug | At least one NCI CTC grade 3-4 TEAE | At least one NCI CTC grade 3-4 related to drug | At least one serious TEAE | At least one serious TEAE related to drug | TEAE leading to discontinuation of drug | Related TEAE leading to discontinuation of drug | TEAE leading to dose reduction or interruption | Related TEAE - dose reduction or interruption | |
| Lenalidomide | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Placebo | 4 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 |
Disease-free survival is the time from on-treatment to first relapse or death (whichever comes first). Those who are alive and without relapse are censored at the last date known alive. (NCT00765245)
Timeframe: From on-treatment date to disease recurrence, up to 1 year
| Intervention | years (Mean) |
|---|---|
| Arm I: Lenalidomide | 0.818 |
| Arm II: Lenalidomide and Rituximab IV | 0.90 |
Disease-free survival is the estimated probable duration of life from on-study date to date of death from any cause, using the Kaplan-Meier method where death is an event, with censoring for non-expired patients at last known date alive. (NCT00765245)
Timeframe: From on-treatment date to disease recurrence, up to 2 years
| Intervention | years (Median) |
|---|---|
| Arm I: Lenalidomide | 0.818 |
| Arm II: Lenalidomide and Rituximab IV | 0.757 |
Count of patients according to the worst-grade toxicity experienced by each, where worst-grade toxicity is per NCI common toxicity criteria: grade 1, mild; grade 2, moderate; grade 3, severe; grade 4, life-threatening; grade 5, death. Toxicities present at baseline and continuing without change in grade are excluded when considering worst-grade toxicity. (NCT00765245)
Timeframe: 30 days after completing treatment, for up to 13 months
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Number of patients with WGT=1 | Number of patients with WGT=2 | Number of patients with WGT=3 | Number of patients with WGT=4 | Number of patients with WGT=5 | |
| Arm I: Lenalidomide | 2 | 6 | 6 | 5 | 0 |
| Arm II: Lenalidomide and Rituximab IV | 0 | 8 | 8 | 5 | 0 |
The Kaplan-Meier method will be used to estimate the event-free survival distribution. (NCT01035463)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| All Phase I Participants | 84 |
| All Phase II Participants | 87 |
The Maximum Tolerated Dose (MTD) is defined to be the dose cohort below which 3 out of 6 subjects experience dose limiting toxicities during cycle 1. Dose limiting toxicities graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCT01035463)
Timeframe: Cycle 1, 28 days
| Intervention | milligrams PO daily (Number) |
|---|---|
| Treatment (Stem Cell Transplantation) | 10 |
The Kaplan-Meier method will be used to estimate the overall survival distribution. This outcome only reports data as it pertains to overall survival at one year. All-cause mortality includes survival for follow up for all subjects on the study. (NCT01035463)
Timeframe: 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| All Phase I Participants | 100 |
| All Phase II Participants | 95 |
"Kaplan-Meier estimates for the duration of response were calculated for responders and defined as the time from at least a partial response (PR) to progression of disease (PD) or death due to Non-Hodgkin's lymphoma.~For response assessment criteria (per Cheson, 1999) see the primary outcome measure in this results posting." (NCT00413036)
Timeframe: Up to 1459 days
| Intervention | Months (Median) |
|---|---|
| Lenalidomide | 18.4 |
"Kaplan-Meier estimate of progression-free survival is defined as start of study drug therapy to the first observation of progressive disease or death due to any cause, whichever comes first.~Response assessed according to Cheson, Journal of Clinical Oncology, 1999. Full definition of progressive disease, refer to Cheson article.~Progressive Disease(PD): Appearance of new lesion during/end of therapy; >=50% increase from lowest measurement in SPD." (NCT00413036)
Timeframe: Up to 1459 days
| Intervention | Months (Median) |
|---|---|
| Lenalidomide | 4.5 |
"Kaplan-Meier estimate of time-to-progression is calculated as time from the start of study drug therapy to the first observation of disease progression.~Response assessed according to Cheson, Journal of Clinical Oncology, 1999. Full definition of progressive disease, refer to Cheson article.~Progressive Disease(PD): Appearance of new lesion during/end of therapy; >=50% increase from lowest measurement in SPD." (NCT00413036)
Timeframe: Up to 1459 days
| Intervention | Months (Median) |
|---|---|
| Lenalidomide | 4.5 |
"Response assessed according to Cheson, Journal of Clinical Oncology, 1999. Full definitions, refer to Cheson article.~Complete Response(CR): Complete disappearance of all detectable disease and disease-related symptoms if present before therapy; normalization of lab abnormalities assignable to NHL. If bone marrow involved before treatment, must be cleared on repeat biopsy.~Complete Response Unconfirmed(CRu): CR, with one of the following: 1)residual lymph node mass >1.5 cm that has decreased by 75% in the sum of the product of the diameters(SPD). Individual nodes previously confluent decreased by more than 75% in the SPD compared with original mass; 2)indeterminate bone marrow.~Partial Response(PR): >50% decrease in 6 largest nodes or nodal masses. Nodes selected according to Cheson.~Stable Disease(SD): Less than PR, but not progressive disease.~Progressive Disease(PD): Appearance of new lesion during/end of therapy; >=50% increase from lowest measurement in SPD." (NCT00413036)
Timeframe: Up to 1459 days
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Complete Response Unconfirmed (CRu) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease | |
| Lenalidomide | 7 | 21 | 40 | 71 | 78 |
Duration of response will be measured as the time from initiation of a response to first documentation of disease progression or death, or date last known progression-free and alive for those who have not progressed or died. (NCT00378209)
Timeframe: Assessed at a median follow-up of 44 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Dexamethasone, Bortezomib Combination | 8.7 |
"Response assessed by the European Group for Blood and Marrow Transplant (EBMT) criteria, modified to include nCR and VGPR from the international uniform response criteria (IMWG).~Objective response was defined by the achievement of at least Partial Response (PR) or better (CR-complete response, nCR-near complete response, and VGPR-very good partial response)." (NCT00378209)
Timeframe: Assessed every cycle for up to 8 cycles and best response was reported
| Intervention | percentage of treated patients (Number) |
|---|---|
| Lenalidomide, Dexamethasone, Bortezomib Combination | 64 |
defined as time from treatment initiation to death, or last known to be alive for those who had not died (NCT00378209)
Timeframe: assesed at a median follow-up of 44 months
| Intervention | month (Median) |
|---|---|
| Lenalidomide, Dexamethasone, Bortezomib Combination | 30 |
Progression-free survival is defined as the time from registration to the disease progression or death from any cause, censored at date last known progression-free for those who have not progressed or died. (NCT00378209)
Timeframe: aassesed at a median follow-up of 44 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Dexamethasone, Bortezomib Combination | 9.5 |
"Response assessed by the European Group for Blood and Marrow Transplant (EBMT) criteria, modified to include nCR and VGPR from the international uniform response criteria (IMWG).~Progressive disease (PD) required one or more of the following:~>25% increased in serum monoclonal paraprotein (must also be an absolute increase of at least 5 g/L and confirmed on a repeat investigation) >25% increased in 24-hour urinary light chain excretion (must also be an absolute increase of at least 200 mg/24 h and confirmed on a repeat investigation) >25% increased in plasma cells in a bone marrow aspirate or on trephine biopsy (must also be an absolute increase of at least 10%) Definite increase in the size of existing lytic bone lesions or soft tissue plasmacytomas.~Development of new bone lesions or soft tissue plasmacytomas (not including compression fracture).~Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.8 mmol/L not attributable to any other cause)." (NCT00378209)
Timeframe: 6 months after therapy
| Intervention | percentage of treated patients (Number) |
|---|---|
| Lenalidomide, Dexamethasone, Bortezomib Combination | 75 |
"Progression-free survival was calculated as the time from randomization to disease progression as determined by the Investigator based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier.~Progressive disease requires 1 of the following:~Increase of ≥ 25% from nadir in:~Serum M-component (absolute increase ≥ 0.5 g/dl)~Urine M-component (absolute increase ≥ 200 mg/24 hours)~In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase > 100 mg/dl)~Bone marrow plasma cell percentage (absolute % ≥ 10%)~Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas." (NCT01324947)
Timeframe: From randomization through the follow-up phase; Maximum duration of follow-up for PFS was 90.3 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide | 16.0 |
Duration of Response (calculated for responders only) is defined as the time from the initial documented response (partial response or better) to confirmed disease progression by the investigator based on IMWG criteria. (NCT01324947)
Timeframe: From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum duration of response follow-up was 90.3 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide | 28.3 |
Overall survival was calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01324947)
Timeframe: From randomization through the follow-up phase; Maximum time on follow-up was 141.1 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide | 33.6 |
"Time to progression (TTP) was calculated as the time from randomization to the first documented progression confirmed by the investigator and based on the International Myeloma Working Group Uniform Response criteria (IMWG).~Progressive disease requires 1 of the following:~Increase of ≥ 25% from nadir in:~Serum M-component (absolute increase ≥ 0.5 g/dl)~Urine M-component (absolute increase ≥ 200 mg/24 hours)~In patients without measurable serum and urine M-protein levels the difference between involved and uninvolved free light chain (FLC) levels (absolute increase > 100 mg/dl)~Bone marrow plasma cell percentage (absolute % ≥ 10%)~Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas.~Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease." (NCT01324947)
Timeframe: From randomization through the follow-up phase; up to the data-cut off of 31 July 2014; Maximum time to progression follow-up was 90.3 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide | 19.0 |
"Objective response defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) based on Investigator Assessment.~SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein and urine M-protein level <100 mg/24 hours; PR: ≥50% reduction of serum M-Protein and reduction in urinary M-protein by ≥90% or to <200 mg/24 hours. A ≥50% decrease in the difference between involved and uninvolved FLC levels in place of the M-protein criteria or a ≥50% reduction in plasma cells in place of M-protein if baseline was ≥30%. If present at baseline a ≥50% reduction in size of soft tissue plasmacytomas." (NCT01324947)
Timeframe: From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Pomalidomide | 23.0 |
"Objective response defined as a best overall response of complete response (CR) or partial response (PR) based on the CR and requires all of the following:~Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days.~<5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed.~No increase in size or number of lytic bone lesions.~Disappearance of soft tissue plasmacytomas.~PR requires all of the following:~≥50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days.~Reduction in 24-hour urinary light chain extraction by ≥90% or to <200 mg, maintained at least 42 days.~For patients with non-secretory myeloma, ≥50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days." (NCT01324947)
Timeframe: From randomization through the study follow-up phase; up to the data cut-off of 31 July 2014; Maximum time on follow-up was 141.1 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Pomalidomide | 20.3 |
Time to Response was calculated as the time from enrollment to the initial response (PR or better) based on IMWG and assessed by the investigator. (NCT01324947)
Timeframe: From randomization through the follow-up phase; up to the data-cut off of 31 July 2014; Maximum time to response was 23.1 weeks
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide | 8.3 |
"An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE is any AE occurring at any dose that:~Results in death;~Is life-threatening;~Requires or prolongs existing inpatient hospitalization;~Results in persistent or significant disability/incapacity;~Is a congenital anomaly/birth defect;~Constitutes an important medical event.~The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0):~Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required);-Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death" (NCT01324947)
Timeframe: From first dose of study drug through to 30 days after the last dose, until the data cut-off date of 31 July 2014. Maximum time on treatment was 94.1 weeks.
| Intervention | participants (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | Grade 3-4 adverse event | AE related to pomalidomide | Grade 3-4 AE related to pomalidomide | Grade 5 AE | ≥1 Serious AE (SAE) | ≥1 SAE related to pomalidomide | ≥1 SAE leading to stopping pomalidomide | ≥AE leading to discontinuation of pomalidomide | ≥1 study drug related AE leading to stopping POM | ≥1 AE leading to reduction of pomalidomide | ≥1 study drug related AE leading to reducing POM | ≥1 AE leading to interruption of pomalidomide | ≥ 1 study drug related interruption of POM | |
| Pomalidomide | 73 | 64 | 51 | 33 | 19 | 52 | 15 | 6 | 8 | 1 | 11 | 9 | 41 | 25 |
Disease control rate was defined as the percentage of participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), partial response (PR), minimal response (MR), or stable disease (SD) lasting ≥ 8 weeks according to International Myeloma Working Group - Uniform Response Criteria (IMWG-URC) (MR was determined using European Group for Blood and Marrow Transplantation criteria). (NCT01080391)
Timeframe: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Dexamethasone (Rd) | 87.1 |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 92.7 |
Duration of disease control (DDC) was calculated for participants who achieved disease control. DDC was defined as the time in months from randomization to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS. (NCT01080391)
Timeframe: From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 46 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Dexamethasone (Rd) | 18.9 |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 28.7 |
Duration of response (DOR) was calculated for participants who achieved a best response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR). Duration of response was defined as the time in months from the initial start of response (PR or better) to the earlier of documented progressive disease (PD) or death due to any cause. Participants who had not progressed or died were censored according to the censoring rules defined previously for PFS. (NCT01080391)
Timeframe: From randomization through the data cutoff date of 16 June 2014. Longest follow-up time was approximately 42 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Dexamethasone (Rd) | 21.2 |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 28.6 |
Overall response rate is defined as the percentage of participants who achieved either a confirmed stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) as their best response based on the Independent Review Committee (IRC) assessed response outcome. Response was determined using the International Myeloma Working Group - Uniform Response Criteria (IMWG-URC). (NCT01080391)
Timeframe: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide and Dexamethasone (Rd) | 66.7 |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 87.1 |
Overall survival (OS) was defined as the duration from randomization to death due to any cause. Participants who were still alive were censored at the date when the participant was last known to be alive or the data cutoff date, whichever occurred earlier. (NCT01080391)
Timeframe: From randomization through the data cutoff date of 28 April 2017 for the final analysis of overall survival; median follow up time was 67.1 months in each treatment group.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Dexamethasone (Rd) | 40.4 |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 48.3 |
Kaplan-Meier estimate of median time from randomization to progressive disease (PD) or all-cause death. PD was assessed using International Myeloma Working Group-Uniform Response Criteria (IMWG-URC). One or more conditions were required to meet PD: 2 consecutive rising serum or urine M-protein from central lab; documented new bone lesion(s) or soft tissue plasmacytoma(s) or increased size of existing bone lesion(s) or plasmacytoma(s); or confirmed hypercalcemia due solely to plasma cell proliferative disorder (local lab greater than 11.5 mg/dL on 2 separate occasions). Censoring conditions (censoring dates) were: no post-baseline disease assessment (DA) (randomization date); started non-protocol systemic anticancer treatment before PD or death (last DA date before such treatment); died or had PD after more than 1 missed DA (last DA date without PD before the first missed visit); or were alive and without documentation of PD, including lost to follow-up without PD (last DA date). (NCT01080391)
Timeframe: From randomization through the data cutoff date of 16 June 2014. Median follow-up time was approximately 31 months.
| Intervention | months (Median) |
|---|---|
| Lenalidomide and Dexamethasone (Rd) | 17.6 |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 26.3 |
Health-related quality of life was assessed with the use of the European Organization for Research and Treatment of Cancer Quality of Life Core Module (QLQ-C30) questionnaire, a validated instrument in multiple myeloma patients. Scores range from 0 to 100, with higher scores indicating better health related quality of life. (NCT01080391)
Timeframe: Cycle 1 Day 1 (Baseline), Day 1 of Cycles 3, 6, 12, 18
| Intervention | scores on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 1 Day 1 (Baseline) | Cycle 3, Day 1 | Cycle 6, Day 1 | Cycle 12, Day 1 | Cycle 18, Day 1 | |
| Carfilzomib, Lenalidomide, and Dexamethasone (CRd) | 58.3 | 59.9 | 62.5 | 62.7 | 64.3 |
| Lenalidomide and Dexamethasone (Rd) | 58.1 | 56.8 | 58.9 | 57.3 | 59.9 |
Measurement of Factor VIII (FVIII) Amidolytic Activity (FVIII:Am) in the blood through chromogenic test. Only patients with FVIII:Am less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.63 |
Measurement of the amount of Factor VIII (FVIII) protein in the blood through FVIII:Ag test. Only patients with FVIII:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 3.64 |
Measurement of the Factor VIII (FVIII) Procoagulant Activity (FVIII:C) in the blood through one-stage clotting test. Only patients with FVIII:C less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 2.43 |
Measurement of Von Willebrand Factor (VWF) Propeptide levels in the blood through VWF Propeptide test. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 7.3 |
Measurement of the amount of Von Willebrand Factor (VWF) protein in the blood through Von Willebrand Factor Antigen (VWF:Ag) test. Only patients with VWF:Ag less or equal to 5 IU/dL were considered for the analysis. (NCT02460458)
Timeframe: 12 months (confirmatory phase)
| Intervention | IU/dL (Mean) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 1.29 |
"Number of patients for who the following tests have been performed:~Hemoglobin (mmol/L), Hemagglutination Titer (HT) (%), Mean Corpuscular Volume (MVC) (fl), Leucocytes (E9/L), Neutrophils (%), Basophils (%), Eosinophils (%), Lymphocytes (%), Platelet Count (E9/L), Mean Platelet Volume (MPV) (fl), Prothrombin Time (sec), Partial Thromboplastin Time (PTT) (sec), Partial Thromboplastin Time Mix 50:50 (PTT mix 50:50) (sec), Ferritin (ug/l), Bleeding Time (min:sec), Closure Time (sec), Collagen/ADP (sec), Collagen/Epinephrine (sec); Factor VIII Procoagulant Activity (FVIII:C) (IU/mL), Von Willebrand Factor Ristocetin Cofactor (VWF:RCo) (IU/mL), Won Willebrand Factor Antigen (VWF:Ag) (IU/mL)." (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 265 |
Evaluation of the titre of Anti-Von Willebrand Factor (anti-VWF) Antibodies through Bethesda Test. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 4 |
Record of any allergic and anaphylactic reactions occurred in the past due to the use of any Von Willebrand Factor (VWF) concentrate and the date of onset. (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) |
|---|---|
| Type 3 Von Willebrand's Disease (VWD3) | 41 |
Record of any product used during the retrospective phase (collected type of blood products/Von Willebrand Factor (VWF) concentrate, year of first exposure, units used). (NCT02460458)
Timeframe: 24 months (retrospective phase)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Packed red cells | Cryoprecipitates | Fresh frozen plasma | Platelet concentrates | |
| Type 3 Von Willebrand's Disease (VWD3) | 24 | 123 | 10 | 1 |
"The change from baseline of the mean score of pain interference at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 (No pain, No interference) to 10 (Pain as bad as you can imagine, Highest imaginable interference) numeric rating scale." (NCT01239797)
Timeframe: From baseline up to approximately 38 months
| Intervention | Score on a scale (Mean) |
|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 0.95 |
| Lenalidomide + Dexamethasone | 0.48 |
"The change from baseline of the mean score of pain severity at the end of treatment using the Brief Pain Inventory-Short Form (BPI-SF). The BPI-SF is a self administered questionnaire developed to assess the severity of pain (the sensory dimension) as well as the degree to which pain interferes with function (the reactive dimension). The BPI-SF uses 0 (No pain, No interference) to 10 (Pain as bad as you can imagine, Highest imaginable interference) numeric rating scale." (NCT01239797)
Timeframe: From baseline up to approximately 38 months
| Intervention | Score on a scale (Mean) |
|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 0.52 |
| Lenalidomide + Dexamethasone | -0.04 |
"Overall survival is defined as the time from randomization to the date of death from any cause. If a subject has not died, their survival time will be censored at the date of last contact (last known alive date). A subject will be censored at the date of randomization if they were randomized but had no follow-up. (Based on Kaplan Meier estimates)" (NCT01239797)
Timeframe: Randomization to the date of death from any cause (up to approximately 9 years)
| Intervention | Months (Median) |
|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 48.30 |
| Lenalidomide + Dexamethasone | 39.62 |
Primary definition of Progression-free survival (PFS) defined as the time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. The primary analysis of PFS was based on the primary definition using the Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria. Tumor assessments were made every 4 weeks (±1 week) relative to the first dose of study medication. (NCT01239797)
Timeframe: From randomization up to 326 events (up to approximately 38 months)
| Intervention | Months (Median) |
|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 19.35 |
| Lenalidomide + Dexamethasone | 14.85 |
"The time from randomization to the date of first documented tumor progression or death due to any cause. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Tumor assessments were made every 4 weeks (±1 week) relative to the first dose of study medication based on Independent Review Committee (IRC) tumor assessment using the European Group for Blood and Bone Marrow Transplant (EBMT) criteria.~Note: This outcome measure represents an updated version of the primary endpoint to include additional data collection that has occurred after the primary completion date. (Assessments were made until 06-Jul-2018)" (NCT01239797)
Timeframe: From randomization up to to the date of first documented tumor progression or death (up to approximately 85 months)
| Intervention | Months (Median) |
|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 19.42 |
| Lenalidomide + Dexamethasone | 14.92 |
Objective response rate (ORR) defined as the percentage of participants with a best response on-study of partial response (PR) or better (stringent CR [sCR], complete response [CR], very good partial response [VGPR], and partial response [PR]) based on the Independent Review Committee (IRC) assessment of best response using the European Group for Blood and Bone Marrow Transplant (EBMT) assessment criteria. Participants were censored at the last adequate assessment prior to the start of any subsequent systemic-therapy or at the last adequate assessment prior to 2 missing assessments (> 10 weeks). Participants who died more than 10 weeks after the randomization date and had no on-treatment assessment were censored at the randomization date. Clinical deterioration was not considered progression. Assessments were made every 4 weeks. (NCT01239797)
Timeframe: From randomization up to approximately 38 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Lenalidomide + Dexamethasone + Elotuzumab | 78.5 |
| Lenalidomide + Dexamethasone | 65.5 |
Duration of response (calculated for responders only) is defined as time from the initial documented response (partial response or better) to confirmed disease progression, based on IMWG criteria assessed by the Independent Response Adjudication Committee. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 35.1 |
| High-Dose Dexamethasone | 28.1 |
Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 07 September 2012. Maximum time on follow-up for survival was 70 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | NA |
| High-Dose Dexamethasone | 34.0 |
Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 29 August 2017. Maximum time on follow-up for survival was 324 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 56.1 |
| High-Dose Dexamethasone | 35.3 |
Overall survival is calculated as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up for survival was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 54.0 |
| High-Dose Dexamethasone | 34.9 |
Objective response is defined as a best overall response of stringent complete response (SCR), complete response (CR), very good partial response (VGPR) or partial response (PR) based on the Independent Response Adjudication Committee: SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. In addition to the above, if present at baseline a ≥ 50% reduction in the size of soft tissue plasmacytomas is also required. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 23.5 |
| High-Dose Dexamethasone | 3.9 |
Objective response defined as a best overall response of complete response (CR) or partial response (PR) based on the Independent Response Adjudication Committee: CR requires all of the following: - Absence of original monoclonal paraprotein in serum and urine by immunofixation maintained at least 42 days. - <5% plasma cell in bone marrow aspirate and on bone marrow biopsy, if performed. - No increase in size or number of lytic bone lesions. - Disappearance of soft tissue plasmacytomas. PR requires all of the following: - ≥ 50% reduction in level of serum monoclonal paraprotein, maintained at least 42 days. - Reduction in 24-hour urinary light chain extraction by ≥ 90% or to < 200 mg, maintained at least 42 days. - For patients with non-secretory myeloma, ≥ 50% reduction in plasma cells in bone marrow aspirate and on biopsy, if performed, for at least 42 days. - ≥ 50% reduction in the size of soft tissue plasmacytomas. - No increase in size or number of lytic bone lesions. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 22.2 |
| High-Dose Dexamethasone | 3.3 |
Progression-free survival was calculated as the time from randomization to disease progression as determined by the Independent Response Adjudication Committee based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier. Progressive disease required 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 07 September 2012. Maximum duration of follow-up for PFS assessments was 57 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 15.7 |
| High-Dose Dexamethasone | 8.0 |
Progression-free survival was calculated as the time from randomization to disease progression as determined by the Independent Response Adjudication Committee based on the International Myeloma Working Group Uniform Response criteria (IMWG), or death on study, whichever occurred earlier. Progressive disease requires 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum duration of follow-up for PFS assessments was 74 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 16.0 |
| High-Dose Dexamethasone | 8.1 |
"Time to improvement in bone pain is defined as the time from randomization to at least one category improvement from Baseline in bone pain category. Bone pain was categorized (from best to worst) according to answers to the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire for patients with Multiple Myeloma Module (QLQ-MY20), Question 1, Have you had bone aches or pain?: 1) Not at all, 2) A little, 3) Quite a bit, or 4) Very much." (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 5.7 |
| High-Dose Dexamethasone | 4.1 |
Time to improvement in ECOG performance status defined as the time from randomization until at least a one category improvement from Baseline in ECOG performance status score. The categories of the ECOG Performance Status Scale are as follows: -0: Fully active, able to carry on all pre-disease performance without restriction; -1: Restricted in physically strenuous activity but ambulatory and able to carry our work of a light or sedentary nature, e.g., light housework, office work; -2: Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. Patients with a score of 3, 4 or 5 were excluded from participating in the study. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 8.1 |
| High-Dose Dexamethasone | 4.3 |
Time to improvement in renal function is defined as the time from randomization to at least one category improvement from Baseline in renal function. Renal Function was categorized as (from best to worst): - Normal: creatinine clearance ≥80 mL/min; - Grade 1: creatinine clearance ≥60 to <80 mL/min; - Grade 2 : creatinine clearance ≥45 to < 60 mL/min. Participants with creatinine clearance < 45 mL/min at baseline were excluded from the study. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 4.6 |
| High-Dose Dexamethasone | 4.1 |
Time to progression (TTP) is calculated as the time from randomization to the first documented progression confirmed by a blinded, independent Response Adjudication Committee and based on the International Myeloma Working Group Uniform Response criteria (IMWG). Progressive disease requires 1 of the following: • Increase of ≥ 25% from nadir in: o Serum M-component (absolute increase ≥ 0.5 g/dl); o Urine M-component (absolute increase ≥ 200 mg/24 hours); o Bone marrow plasma cell percentage (absolute % ≥ 10%); • Development of new or increase in the size of existing bone lesions or soft tissue plasmacytomas; • Development of hypercalcemia (corrected serum calcium > 11.5 mg/dl) attributed solely to plasma cell proliferative disease. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 20.0 |
| High-Dose Dexamethasone | 9.0 |
Time to response is calculated as the time from randomization to the initial documented response (partial response or better) based on IMWG criteria. SCR: CR and normal free light chain (FLC) ratio and no clonal cells in bone marrow; CR: Negative serum and urine on immunofixation, disappearance of any soft tissue plasmacytomas and ≤ 5% plasma cells in bone marrow; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥ 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours; PR: ≥ 50% reduction of serum M-Protein and reduction in urinary M-protein by ≥ 90% or to < 200 mg/24 hours. If present at baseline a ≥ 50% reduction in size of soft tissue plasmacytomas is also required. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 8.1 |
| High-Dose Dexamethasone | 10.5 |
Time to increased hemoglobin, defined as the time from randomization to at least one category improvement from Baseline in common terminology criteria for adverse events (CTCAE) grade for hemoglobin level. Hemoglobin categories are: 1) Normal; 2) CTCAE Grade 1: < lower limit of normal (LLN) to 10.0 g/dL; 3) CTCAE Grade 2: < 10.0 to <8.0 g/dL. Participants with CTCAE Grade 3 anemia or worse at Baseline were excluded from the study. (NCT01311687)
Timeframe: From randomization until the data cut-off date of 01 March 2013. Maximum time on follow-up was 93 weeks.
| Intervention | weeks (Median) |
|---|---|
| Pomalidomide Plus Low-Dose Dexamethasone | 3.4 |
| High-Dose Dexamethasone | 1.3 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Emotional Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -2.87 | -5.66 | -6.31 | -8.64 | -4.17 |
| Pomalidomide Plus Low-Dose Dexamethasone | 1.22 | 2.40 | 2.44 | 1.91 | 0.19 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Fatigue Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reduction in fatigue (i.e. improvement in symptom) and positive values indicate increases in fatigue (i.e. worsening of symptom). (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | 4.03 | 7.76 | 9.43 | 9.47 | 10.49 |
| Pomalidomide Plus Low-Dose Dexamethasone | 2.43 | 3.26 | 1.71 | 0.21 | 0.99 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Pain Scale is scored between 0 and 100, with a high score indicating a higher level of symptoms. Negative change from Baseline values indicate reductions in pain (i.e. improvement in symptom) and positive values indicate increases in pain (i.e. worsening of symptom). (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | 0.36 | 2.83 | 3.03 | 2.47 | 10.19 |
| Pomalidomide Plus Low-Dose Dexamethasone | -2.70 | -3.58 | -2.41 | -1.64 | -2.40 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used in clinical research to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Physical Functioning Scale is scored between 0 and 100, with a high score indicating better functioning/support. Negative change from Baseline values indicate deterioration in functioning and positive values indicate improvement. (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -3.96 | -9.69 | -8.08 | -5.43 | -4.81 |
| Pomalidomide Plus Low-Dose Dexamethasone | -2.32 | -0.56 | 0.17 | 0.91 | 0.54 |
The European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients with Multiple Myeloma (EORTC QLQ-MY20) is a 20-question tool used in clinical research to assess health-related quality of life in multiple myeloma patients. The QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). The EORTC QLQ-MY20 Side Effects Scale is scored between 0 and 100, with a high score reflecting a higher level of symptoms. Negative change from Baseline values indicate reduction in side effects (i.e.improvement in symptom) and positive values indicate increase in side effects (i.e. worsening of symptom). (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | 2.61 | 5.35 | 7.46 | 6.89 | 7.30 |
| Pomalidomide Plus Low-Dose Dexamethasone | 2.71 | 3.26 | 3.73 | 4.74 | 4.55 |
The European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life (QOL) questionnaire (EORTC QLQ-C30) is a 30-question tool used to assess the overall quality of life in cancer patients. It consists of 15 domains: 1 global health status (GHS) scale, 5 functional scales (Physical, Role, Cognitive, Emotional, Social), and 9 symptom scales/items (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Sleep Disturbance, Appetite Loss, Constipation, Diarrhea, Financial Impact). The EORTC QLQ-C30 Global Health Status/QOL scale is scored between 0 and 100, with a high score indicating better Global Health Status/QOL. Negative change from Baseline values indicate deterioration in QOL or functioning and positive values indicate improvement. (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -3.75 | -2.36 | -3.03 | 0.00 | -0.93 |
| Pomalidomide Plus Low-Dose Dexamethasone | 0.52 | 2.67 | 0.80 | 0.51 | -2.51 |
The European Organization for Research and Treatment of Cancer QoL Questionnaire for Patients with Multiple Myeloma (EORTC QLQ-MY20) is a 20-question tool used in clinical research to assess health-related quality of life in multiple myeloma patients. The QLQ-MY20 includes four domains (Disease Symptoms, Side-Effects of Treatment, Body Image and Future Perspective). The EORTC QLQ-MY20 Disease Symptoms Scale is scored between 0 and 100, with a high score reflecting a higher level of symptoms. Negative change from Baseline values indicate reduction (i.e. improvement) in symptoms and positive values indicate increase (i.e. worsening) of symptoms. (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5 Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -1.07 | 0.97 | 1.35 | 1.48 | 2.12 |
| Pomalidomide Plus Low-Dose Dexamethasone | -0.50 | -1.36 | -1.15 | -0.53 | 0.60 |
"EQ-5D is a self-administered questionnaire that assesses health-related quality of life (QOL). The EQ-5D descriptive health profile comprises five dimensions of health (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 levels of response: No problem (1), some problems (2), and extreme problems (3). A unique EQ-5D health state is defined by combining one level from each of the five dimensions into a single utility index score. EQ-5D index values range from -0.59 to 1.00 where an EQ-5D score of 1.00 equals perfect health, a score of 0 equals death and a score of -0.59 equals worst imaginable health state. A positive change from Baseline score indicates improvement in health status. A negative change from Baseline score indicates worsening in health status. Negative scores represent the possible though unlikely situation that a patient's QOL is worse than death, i.e. they would rather be dead than living with that QOL" (NCT01311687)
Timeframe: Day 1 of Cycle 1 (Baseline), and Day 1 of Cycles 2, 3, 4, 5 and 6
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Cycle 2, Day 1 | Cycle 3, Day 1 | Cycle 4, Day 1 | Cycle 5, Day 1 | Cycle 6, Day 1 | |
| High-Dose Dexamethasone | -0.02 | -0.06 | -0.07 | -0.04 | -0.12 |
| Pomalidomide Plus Low-Dose Dexamethasone | -0.03 | 0.01 | 0.04 | 0.01 | 0.03 |
An adverse event is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. A serious AE is any AE occurring at any dose that: • Results in death; • Is life-threatening; • Requires or prolongs existing inpatient hospitalization; • Results in persistent or significant disability/incapacity; • Is a congenital anomaly/birth defect; • Constitutes an important medical event. The Investigator assessed the relationship of each AE to study drug and graded the severity according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death. (NCT01311687)
Timeframe: From first dose of study drug through to 30 days after the last dose as of the end of the study (29 August 2017); maximum time on treatment was 297, 269, and 239 weeks in the Pomalidomide + LD-Dex, HD-Dex, and cross-over groups respectively.
| Intervention | Participants (Count of Participants) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse event | Grade 3-4 adverse events | AE related to pomalidomide | AE related to dexamethasone | AE related to either study drug | Grade 3-4 AE related to pomalidomide | Grade 3-4 AE related to dexamethasone | Grade 3-4 AE related to either study drug | Grade 5 adverse events | Serious adverse events (SAEs) | SAE related to pomalidomide | SAE related to dexamethasone | SAE related to either study drug | SAE leading to discontinuation of pomalidomide | SAE leading to discontinuation of dexamethasone | SAE leading to discontinuation of either study dru | AE leading to discontinuation of pomalidomide | AE leading to discontinuation of dexamethasone | AE leading to discontinuation of either study drug | |
| HD-Dex / Pomalidomide | 11 | 8 | 11 | 5 | 11 | 6 | 2 | 6 | 1 | 4 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| High-Dose Dexamethasone | 149 | 127 | 0 | 115 | 115 | 0 | 70 | 70 | 21 | 80 | 0 | 36 | 36 | 0 | 14 | 14 | 0 | 16 | 16 |
| Pomalidomide Plus Low-Dose Dexamethasone | 298 | 266 | 251 | 205 | 271 | 199 | 114 | 212 | 46 | 195 | 89 | 73 | 98 | 20 | 20 | 23 | 30 | 34 | 38 |
Time to worsening in quality of life domains was calculated as the time from Baseline to the first worsened minimally important difference (MID), defined as the smallest change in a QOL score considered important to patients that would lead the patient or clinician to consider a change in therapy. MID thresholds were calculated in Standard Error of Measurement (SEM) units using the Baseline QOL data. Based on the MID, participants were classified as worsened according to the following: For the EORTC QLQ-C30 global health status and functional scales and the EQ-5D health utility score, participants were classified as worsened if their change from Baseline score was less than -1 SEM. For the EORTC QLQ-C30 symptom scores (fatigue and pain) and EORTC QLQ-MY20 disease symptoms and side effects scales, participants were classified as worsened if their change from Baseline score was greater than 1 SEM. See previous outcome measures for definitions of each scale. (NCT01311687)
Timeframe: Assessed on Day 1 of the first 6 treatment cycles.
| Intervention | days (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Global Health Status | Physical Functioning | Emotional Functioning | Fatigue | Pain | Disease Symptoms | Side Effects of Treatment | Health Utility | |
| High-Dose Dexamethasone | 57 | 67 | 85 | 57 | 85 | 106 | 85 | 162 |
| Pomalidomide Plus Low-Dose Dexamethasone | 71 | 128 | 146 | 58 | 92 | 127 | 90 | 225 |
(NCT01645930)
Timeframe: Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose
| Intervention | hr*ng/mL (Mean) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 685.9 |
(NCT01645930)
Timeframe: Cycle 1, Day 15 pre-dose and multiple time-points (up to 336 hours) post-dose
| Intervention | hr*ng/mL (Mean) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 1746.0 |
(NCT01645930)
Timeframe: Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose
| Intervention | ng/mL (Mean) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 37.57 |
(NCT01645930)
Timeframe: Cycle 1, Day 15 pre-dose and multiple time-points (up to 336 hours) post-dose
| Intervention | ng/mL (Mean) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 57.57 |
DOR was defined as the length of time between the date of first documented response (PR, VGPR, or CR) and the date of first documented progressive disease (PD). According to IMWG criteria: CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level <100 mg per 24 hour. (NCT01645930)
Timeframe: From date of documentation of a confirmed response to date of progressive disease, (approximately 20 months)
| Intervention | months (Median) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 12.9 |
DLT was defined as any of the following AEs that were considered by investigator to be possibly related to therapy: 1. Grade 4 neutropenia lasting at least 7 consecutive days; 2. Grade 3 neutropenia with fever and/or infection; 3. Grade 4 thrombocytopenia at least 7 consecutive days; 4. Grade 3 thrombocytopenia with clinically significant bleeding; 5. Platelet count <10,000/mm^3; 6. Grade 2 peripheral neuropathy with pain or ≥Grade 3 peripheral neuropathy; 7. Grade 3 or greater nausea and / or emesis despite the use of optimal anti-emetic prophylaxis; 8. Grade 3 or greater diarrhea that occurred despite maximal supportive therapy; 9. Any other Grade 3 or greater nonhematologic toxicity with the following exceptions: Grade 3 arthralgia/myalgia, <1 week Grade 3 fatigue; 10. A delay of >2 weeks in the subsequent cycle of treatment; 11. Other combination study drug-related nonhematologic toxicities ≥Grade 2 that, in the opinion of the investigator, required discontinuation of study drug. (NCT01645930)
Timeframe: Cycle 1 (up to Day 28)
| Intervention | participants (Number) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 2 |
Percentage of participants who achieve or maintain any best response category during the treatment period were reported. Best response includes complete response (CR), very good partial response (VGPR), and partial response (PR). Response was assessed according to IMWG criteria. CR: negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow; PR: ≥50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to <200 mg per 24 hours. VGPR: serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level <100 mg per 24 hour. (NCT01645930)
Timeframe: From Cycle 1, Day 1 to Cycle 3, Day 1 until disease progression (approximately 20 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 53.5 |
(NCT01645930)
Timeframe: Cycle 1, Day 1 pre-dose and multiple time-points (up to 168 hours) post-dose
| Intervention | hours (Median) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 1.5 |
(NCT01645930)
Timeframe: Cycle 1, Day 15 pre-dose and multiple time-points (up to 336 hours) post-dose
| Intervention | hours (Median) |
|---|---|
| Ixazomib+Lenalidomide+Dexamethasone | 2.0 |
An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is defined as any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or was a medically important event. (NCT01645930)
Timeframe: From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)
| Intervention | participants (Number) | |
|---|---|---|
| AEs | SAEs | |
| Ixazomib+Lenalidomide+Dexamethasone | 43 | 18 |
Clinically significant laboratory abnormalities were defined as any test results which were observed beyond the clinically acceptable limits as per the discretion of investigator. Clinical laboratory tests included chemistry, hematology and urinalysis tests. (NCT01645930)
Timeframe: From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alanine Aminotransferase Increased | Aspartate Aminotransferase Increased | Blood Creatinine Increased | Haemoglobin Decreased | Neutrophil Count Decreased | Platelet Count Decreased | Anaemia | Febrile Neutropenia | Neutropenia | Thrombocytopenia | Hyperglycaemia | Hypocalcaemia | Hypokalaemia | Hypomagnesaemia | Hyponatraemia | Hypophosphataemia | |
| Ixazomib+Lenalidomide+Dexamethasone | 2 | 1 | 1 | 1 | 2 | 4 | 6 | 1 | 12 | 8 | 1 | 3 | 5 | 1 | 1 | 2 |
The number of participants who meet markedly abnormal criteria for vital signs, included diastolic and systolic blood pressure, heart rate, oral temperature, respiratory rate, and body weight. (NCT01645930)
Timeframe: From the first dose of study drug through 30 days after the last dose of study drug (up to 577 days)
| Intervention | participants (Number) | |
|---|---|---|
| Grade 1 or 2 Hypertension | Grade 2 Hypotension | |
| Ixazomib+Lenalidomide+Dexamethasone | 4 | 1 |
Duration of response (DOR) was defined as the time from the first visit where PR, CRi, or CR was documented to progressive disease (PD). Duration of response was censored at the last date that the participant was known to be progression-free for participants who had not progressed at the time of analysis or who withdrew consent or were lost to follow-up prior to documentation of progression. (NCT00963105)
Timeframe: Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide 5 mg | 101.1 |
| Lenalidomide 10 mg | 35.1 |
| Lenalidomide 15 mg | 88.8 |
Event-free survival (EFS) is the interval between the start of treatment to the first sign of disease progression, or treatment for relapse or death (whichever occurred first). If withdrawal of consent or loss to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression. (NCT00963105)
Timeframe: From randomization until the end of the study; maximum time on study was 91 months.
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide 5 mg | 25.6 |
| Lenalidomide 10 mg | 31.9 |
| Lenalidomide 15 mg | 24.1 |
Overall survival (OS) was defined as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who had withdrawn consent or were lost to follow-up before death was documented. (NCT00963105)
Timeframe: From randomization until the end of the study; maximum time on study was 91 months.
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide 5 mg | 161.0 |
| Lenalidomide 10 mg | 106.7 |
| Lenalidomide 15 mg | 154.6 |
Progression-free survival (PFS) was calculated as the time from randomization to the first documented progression or death due to any cause during or after the treatment period, whichever occurred first. The progression date was assigned to the earliest time when any progression is observed without prior missing assessments. If withdrawal of consent or loss to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression. (NCT00963105)
Timeframe: From randomization until the end of the study; maximum time on study was 91 months.
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide 5 mg | 31.4 |
| Lenalidomide 10 mg | 45.1 |
| Lenalidomide 15 mg | 66.3 |
Time to progression (TTP) was defined as the time from randomization to the first documented progression. For participants who did not progress during the study, TTP was censored at the last adequate response assessment showing evidence of no disease progression. (NCT00963105)
Timeframe: From randomization until the end of the study; maximum time on study was 91 months.
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide 5 mg | 96.3 |
| Lenalidomide 10 mg | 47.6 |
| Lenalidomide 15 mg | 66.3 |
ORR was defined as the percentage of patients with a complete response (CR), CR with incomplete bone marrow (BM) recovery (CRi) or partial response (PR) during treatment. Response was assessed according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines. Per the guidelines, a CR required peripheral blood lymphocytes below 4 x 10^9/L, absence of lymphadenopathy, no hepatomegaly or splenomegaly, absence of disease and blood counts neutrophils >1.5 x 10^9/L, platelets >100 x 10^9/L, hemoglobin (hgb) >11g/dL) and BM at least normocellular for age. CRi = CR with incomplete BM recovery. PR = required at least 2 months from end of treatment, a ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value and either a ≥ 50% reduction in lymphadenopathy or ≥50% reduction of liver enlargement or ≥50% reduction of spleen enlargement plus neutrophils >1.5 x 10^9/ or ≥50% increase, platelets >100 x 10^9/L or ≥50% increase, hgb 11 g/dL. (NCT00963105)
Timeframe: Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide 5 mg | 47.1 |
| Lenalidomide 10 mg | 37.1 |
| Lenalidomide 15 mg | 40.0 |
Time to response (TTR) was calculated as the time from randomization to the first documented date of response (PR, CRi or CR) based on iwCLL guidelines for participants with an objective response during the treatment period. (NCT00963105)
Timeframe: Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide 5 mg | 16.9 |
| Lenalidomide 10 mg | 12.6 |
| Lenalidomide 15 mg | 12.7 |
Adverse events (AEs) were graded for severity by the investigator according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 with the exceptions of hematologic toxicities and tumor lysis syndrome, according to the following scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening or disabling AE Grade 5 = Death The investigator determined the relationship of each AE to study drug based on the timing of the AE and whether other medications, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the observed event. (NCT00963105)
Timeframe: From first dose of study drug to 30 days after the last dose; the maximum duration of treatment was 251, 265, and 267 weeks in the 5 mg, 10 mg, and 15 mg treatment groups respectively.
| Intervention | Participants (Count of Participants) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any adverse events | Treatment-related adverse events (TRAE) | Grade 3/4 adverse events | Treatment-related Grade 3/4 adverse events | Grade 5 adverse events | Treatment-related Grade 5 adverse events | Serious adverse events | Treatment-related serious adverse events | AE leading to discontinuation of study drug | TRAE leading to discontinuation of study drug | AE leading to study drug dose reduction only | AE leading to study drug dose interruption only | AE leading to study drug interruption & reduction | |
| Lenalidomide 10 mg | 34 | 34 | 32 | 32 | 4 | 2 | 24 | 13 | 17 | 14 | 6 | 24 | 26 |
| Lenalidomide 15 mg | 35 | 32 | 34 | 30 | 3 | 0 | 27 | 20 | 16 | 13 | 5 | 25 | 19 |
| Lenalidomide 5 mg | 34 | 33 | 33 | 31 | 4 | 2 | 24 | 15 | 21 | 16 | 8 | 25 | 18 |
The primary objective is progression-free survival (PFS). Tumor measurements and disease assessments will be performed at the time of screening, following cycles 3 and 6 of induction chemotherapy, every 4 cycles during the maintenance portion of treatment, and at the end of treatment (EOT). Subjects with clinical evidence of progression prior to a planned disease assessment will be evaluated at the time of clinically suspected progression. Follow-up visits for disease assessment will occur every 3 months after the EOT visit until PD, initiation of alternate anti-neoplastic therapy, decision by the subject to withdraw from the study, or death. The follow-up period will begin after the EOT visit, and all subjects will be followed for at least 2 years after completion of therapy or until death or progression and until the last patient has been followed for at least 1 year following completion of therapy. (NCT01754857)
Timeframe: At least 24 months following completion of therapy, an average of 5 years
| Intervention | years (Median) |
|---|---|
| Bendamustine, Rituximab, Lenalidomide | 4.76 |
To determine toxicities observed with induction chemotherapy and maintenance therapy. Safety evaluations will be based on the incidence, intensity, and type of adverse events (AEs) and clinical laboratory results. Drug doses will be modified as required based on toxicity as assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 4.0. (NCT01754857)
Timeframe: Up to 30 months
| Intervention | toxicity related events (Number) | |
|---|---|---|
| Serious Adverse Events due to toxicities | Adverse Events due to toxicities | |
| Bendamustine, Rituximab, Lenalidomide | 41 | 167 |
Duration of treatment is defined as the last dose date minus the first dose date of the dose cohort plus 1 expressed in weeks. (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | weeks (Mean) |
|---|---|
| MRZ 0.5 mg/m^2 | 6.09 |
(NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | cycles (Mean) |
|---|---|
| MRZ 0.5 mg/m^2 | 2.6 |
Disease response and progression were determined by the investigator using the International Myeloma Working Group Uniform Response Criteria (IMWG-URC). Overall response rate includes patients with a best response of PR of better. Stringent complete response (CR) includes immunophenotypic CR and molecular CR in addition to stringent CR. (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Stringent Complete Response (sCR) or better | Complete Response (CR) | Very Good Partial Response (VGPR) | Partial Response (PR) | Minimal Response (MR) | Stable Disease (SD) | Progressive Disease (PD) | Not Evaluated | |
| MRZ 0.5 mg/m^2 | 0 | 0 | 0 | 0 | 0 | 4 | 9 | 2 |
A patient was counted in a cycle if the patient received at least one dose of study drug during the cycle. (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Cycle 1 | Cycle 2 | Cycle 3 | Cycle 4 | Cycle 5 | Cycle 6 | |
| MRZ 0.5 mg/m^2 | 15 | 12 | 6 | 3 | 2 | 1 |
"Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug.~Treatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship." (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| At least one TEAE | At least one treatment related TEAE | At least one NPI-0052 related TEAE | At least one grade ≥3 TEAE | At least one treatment related grade ≥3 TEAE | At least one NPI-0052 related grade ≥3 TEAE | At least one serious TEAE | At least one treatment related serious TEAE | At least one NPI-0052 related serious TEAE | |
| MRZ 0.5 mg/m^2 | 15 | 14 | 13 | 12 | 8 | 5 | 7 | 4 | 1 |
"Adverse events were graded using NCI-CTCAE (version 4.3). TEAEs are defined as any adverse event with an onset date between the date of first dose and 30 days after the date of last dose of any study drug.~Treatment-related adverse events are adverse events considered related to at least one study drug by the investigator (NPI-002, dexamethasone), including those with unknown relationship." (NCT00461045)
Timeframe: Through study completion, an average of 6.09 weeks.
| Intervention | TEAEs (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Number of TEAEs | Number of treatment related TEAEs | Number of NPI-0052 related TEAEs | Number of grade ≥3 TEAEs | Number of treatment related grade ≥3 TEAEs | Number of NPI-0052 realted grade ≥3 TEAEs | Number of serious TEAEs | Number of treatment related serious TEAEs | Number of NPI-0052 related serious TEAEs | |
| MRZ 0.5 mg/m^2 | 149 | 73 | 50 | 41 | 16 | 9 | 21 | 5 | 1 |
"The maximum tolerated dose was defined as the highest dose level at which no more than 1 of 6 participants experiences a DLT within the first 28-day cycle.~DLTs were defined as:~Grade 4 neutropenia or thrombocytopenia~Febrile neutropenia~Grade 3 or 4 nausea, vomiting or diarrhea despite optimal symptomatic treatment~Serum transaminase > 20 * upper limit of normal (ULN)~Serum transaminase > 5 * ULN for >= 7 days~Delay of the start of cycle 2 by >7 days due to pomalidomide-related adverse event" (NCT00833833)
Timeframe: Up to Day 28 (Cycle 1)
| Intervention | participants (Number) |
|---|---|
| Phase 1: 2 mg Pomalidomide | 1 |
| Phase 1: 3 mg Pomalidomide | 1 |
| Phase 1: 4 mg Pomalidomide | 2 |
| Phase 1: 5 mg Pomalidomide | 4 |
"Duration of myeloma response is defined as the time from when the response criteria are first met for partial response (PR) or better, until the first date the response criteria are met for progressive disease (PD) or until the participant dies from any cause, whichever occurs first. Duration of response for participants last known to be alive with no progression after a complete response (CR) or PR was censored at the date of last adequate response assessment. Participants with confirmed responses that occur after receiving any other anti-myeloma therapy (except for adding dexamethasone to the pomalidomide treatment arm), including radiation therapy initiated after baseline, was censored at the last adequate assessment prior to the initiation of such treatment.~Response was assessed by the Independent Response Adjudication Committee (IRAC) using European Group for Blood and Bone Marrow Transplant (EBMT) criteria as described in the previous outcome." (NCT00833833)
Timeframe: up to 70 weeks
| Intervention | weeks (Median) |
|---|---|
| Phase 2: Pomalidomide + Dexamethasone | 32.1 |
| Phase 2: Pomalidomide | NA |
"Overall survival was defined as the time between randomization and death. Participants who die, regardless of the cause of the death, were considered to have had an event. All participants who were lost to follow-up prior to the end of the trial or who were withdrawn from the trial were censored at the time of last contact. Participants who were still being treated were censored at the last available date the subject was known to be alive, or clinical cut-off date if it was earlier.~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: up to 70 weeks
| Intervention | weeks (Median) |
|---|---|
| Phase 2: Pomalidomide + Dexamethasone | 62.6 |
| Phase 2: Pomalidomide | 59.3 |
"Progression free survival (PFS) is the time from randomization to the first documentation of disease progression or death from any cause during study, whichever occurs earlier. Disease progression was assessed by the Independent Response Adjudication Committee (IRAC).~For the primary PFS analysis, participants who withdrew for any reason or received another antimyeloma therapy (except adding dexamethasone to the Phase 2: Pomalidomide arm) without documented PD (as determined by the IRAC review) were censored on the date of their last adequate response assessment, prior to receiving any other anti-myeloma therapy. Subjects who were still active at the time of the data cut-off date without PD (as determined by the IRAC) were censored on the date of their last adequate response assessment.~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: up to 67 weeks
| Intervention | weeks (Median) |
|---|---|
| Phase 2: Pomalidomide + Dexamethasone | 16.6 |
| Phase 2: Pomalidomide | 10.7 |
"Percentage of participants with the progression-free survival events: disease progression and death. Disease progression was assessed by the Independent Response Adjudication Committee (IRAC).~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: up to 67 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Phase 2: Pomalidomide + Dexamethasone | 76.1 |
| Phase 2: Pomalidomide | 75.0 |
"Time to myeloma response is defined as the time from randomization to the time the response criteria for complete response (CR) or partial response (PR) are first met.~Response was assessed by the Independent Response Adjudication Committee (IRAC) using European Group for Blood and Bone Marrow Transplant (EBMT) criteria as described previously.~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: up to 70 weeks
| Intervention | weeks (Median) |
|---|---|
| Phase 2: Pomalidomide + Dexamethasone | 8.1 |
| Phase 2: Pomalidomide | 8.9 |
"TEAEs that occurred during Phase 1 after dexamethasone was added to pomalidomide treatment.~Relation to study drug was assessed by the Investigator as either suspected or not suspected. Counts represent the suspected relationship. Severity was assessed using National Cancer Institute Common Toxicity Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0): 1= Mild 2= Moderate 3= Severe 4= Life-threatening and 5= Death related to AE. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: Up to week 126
| Intervention | percentage of participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 or more (1+) AE | 1+ AE related to pomalidomide | 1+ AE related to dexamethasone | 1+ severity grade 3-4 AE | 1+ severity grade 3-4 AE related to pomalidomide | 1+ severity grade 3-4 AE related to dexamethasone | 1+ serious AE (SAE) | 1+ SAE related to pomalidomide | 1+ SAE related to dexamethasone | 1+ AE leading to discontinuation of pomalidomide | 1+ AE -- discontinuation of dexamethasone | 1+AE -dose reduction/interruption of pomalidomide | 1+ AE-dose reduction/interruption of dexamethasone | 1+related AE-reduction/interruption of pomalidomid | 1+related AE-reduction/interruption of dexamethaso | |
| Phase 1: 2 mg Pomalidomide | 100.0 | 100.0 | 100.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Phase 1: 3 mg Pomalidomide | 100.0 | 75.0 | 75.0 | 75.0 | 75.0 | 75.0 | 75.0 | 25.0 | 50.0 | 25.0 | 25.0 | 50.0 | 75.0 | 25.0 | 75.0 |
| Phase 1: 4 mg Pomalidomide | 90.0 | 80.0 | 70.0 | 70.0 | 20.0 | 20.0 | 40.0 | 20.0 | 10.0 | 20.0 | 20.0 | 40.0 | 60.0 | 20.0 | 20.0 |
| Phase 1: 5 mg Pomalidomide | 100.0 | 100.0 | 85.7 | 57.1 | 42.9 | 0.0 | 28.6 | 0.0 | 0.0 | 0.0 | 0.0 | 71.4 | 71.4 | 57.1 | 42.9 |
"Relation to study drug was assessed by the Investigator as either suspected or not suspected. Counts represent the suspected relationship. Severity was assessed using National Cancer Institute Common Toxicity Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0): 1= Mild 2= Moderate 3= Severe 4= Life-threatening and 5= Death related to AE. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: Up to week 104
| Intervention | percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 or more (1+) AE | 1+ AE related to pomalidomide | 1+ severity grade 3-4 AE | 1+ severity grade 3-4 AE related to pomalidomide | 1+ serious AE (SAE) | 1+ SAE related to pomalidomide | 1+ AE leading to discontinuation of pomalidomide | 1+AE-dose reduction/interruption of pomalidomide | 1+related AE-reduction/interruption of pomalidomid | |
| Phase 1: 2 mg Pomalidomide | 100.0 | 66.7 | 83.3 | 33.3 | 50.0 | 0.0 | 16.7 | 16.7 | 0.0 |
| Phase 1: 3 mg Pomalidomide | 100.0 | 75.0 | 37.5 | 25.0 | 12.5 | 12.5 | 0.0 | 75.0 | 37.5 |
| Phase 1: 4 mg Pomalidomide | 100.0 | 85.7 | 78.6 | 42.9 | 42.9 | 7.1 | 21.4 | 42.9 | 28.6 |
| Phase 1: 5 mg Pomalidomide | 100.0 | 100.0 | 80.0 | 70.0 | 30.0 | 10.0 | 0.0 | 80.0 | 70.0 |
"Relation to study drug was assessed by the Investigator as either suspected or not suspected. Counts represent the suspected relationship. Severity was assessed using National Cancer Institute Common Toxicity Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE v3.0): 1= Mild 2= Moderate 3= Severe 4= Life-threatening and 5= Death related to AE. Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: Up to week 70
| Intervention | percentage of participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 or more (1+) AE | 1+ AE related to pomalidomide | 1+ severity grade 3-4 AE | 1+ severity grade 3-4 AE related to pomalidomide | 1+ serious AE (SAE) | 1+ SAE related to pomalidomide | 1+ AE leading to discontinuation of pomalidomide | 1+related AE --discontinuation of pomalidomide | 1+AE - reduction of pomalidomide | 1+ AE - interruption of pomalidomide | 1+ related AE - interruption of pomalidomide | 1+related AE - reduction of pomalidomide | |
| Phase 2: Pomalidomide (Overall) | 100.0 | 88.8 | 89.7 | 67.3 | 67.3 | 20.6 | 12.1 | 3.7 | 29.9 | 58.9 | 32.7 | 24.3 |
| Phase 2: Pomalidomide (Pom + Dex Only) | 93.4 | 68.9 | 70.5 | 44.3 | 47.5 | 19.7 | 3.3 | 1.6 | 9.8 | 36.1 | 21.3 | 8.2 |
| Phase 2: Pomalidomide (Pom Only) | 99.1 | 87.9 | 84.1 | 58.9 | 46.7 | 9.3 | 10.3 | 2.8 | 25.2 | 47.7 | 24.3 | 20.6 |
| Phase 2: Pomalidomide + Dexamethasone | 100.0 | 89.3 | 88.4 | 62.5 | 61.6 | 17.9 | 8.0 | 1.8 | 20.5 | 63.4 | 27.7 | 17.9 |
"IRAC used EBMT criteria to assess myeloma response:~Complete Response (CR)-absence of serum and urine monoclonal paraprotein for 6 weeks, plus no increase in size or number of lytic bone lesions, plus other factors)~Partial Response (PR)-not all CR criteria, plus >=50% reduction in serum monoclonal paraprotein plus others~Minimal Response (MR)- 25-49% reduction in serum monoclonal paraprotein plus others~Stable Disease (SD)- not MR or progressive disease (PD)~Progressive Disease (PD)- reappearance of monoclonal paraprotein, lytic bone lesions, other~Not Evaluable (NE).~Data collection is ongoing and future data results will be included as available." (NCT00833833)
Timeframe: up to 70 weeks
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Complete response (CR) | Partial response (PR) | Minimal response (MR) | Stable disease (SD) | Progressive disease (PD) | Not evaluable | |
| Phase 2: Pomalidomide | 0.0 | 9.3 | 15.7 | 46.3 | 15.7 | 13.0 |
| Phase 2: Pomalidomide + Dexamethasone | 0.9 | 29.2 | 15.0 | 35.4 | 6.2 | 13.3 |
ORR is defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). International Myeloma Working Group (IMWG) criteria- CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and less than (<) 5 percentage (%) plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immuno fluorescence; PR: greater than equal to (>=) 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by >= 90 percentage (%) or to <200 mg/24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level <100 mg per 24 hour. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 1: 2 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 100.0 |
| Phase 1: 4 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 100.0 |
| Phase 1: 8 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 75.0 |
| Phase 1: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 66.7 |
Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the International Myeloma Working Group (IMWG) criteria. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Months (Median) |
|---|---|
| Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | NA |
Overall Survival (OS) was defined as the number of days from administration of the first infusion (Day 1) to date of death. Median Overall Survival was estimated by using the Kaplan Meier method. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Months (Median) |
|---|---|
| Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | NA |
ORR is defined as percentage of participants who achieved stringent complete response (sCR), complete response (CR), very good partial response (VGPR) or partial response (PR). IMWG criteria- CR: Negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and less than (<) 5 percentage (%) plasma cells in bone marrow; sCR: CR+Normal free light chain ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; PR: greater than eqaul to (>=) 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by >= 90 percentage (%) or to <200 mg/24 hours; VGPR: Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level <100 mg per 24 hour. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Percentage of participants (Number) |
|---|---|
| Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 81.3 |
Progression free survival (PFS) was defined as the time between the date of first dose of daratumumab and either disease progression or death, whichever occurs first. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Months (Median) |
|---|---|
| Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | NA |
TTP was defined as the number of days from the date of first infusion (Day 1) to the date of first record of disease progression. Disease progression (IMWG criteria): increase of >=25 percent (%) from lowest response level in Serum M-component and/or (the absolute increase must be >=0.5 g/dL) Urine M-component and/or (the absolute increase must be >=200 mg/24 hour; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels. The absolute increase must be >10 mg/dL; Bone marrow plasma cell percentage: the absolute % must be >=10 %; Definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL or 2.65 mmol/L) that can be attributed solely to the plasma cell proliferative disorder. Median TTP was estimated by using the Kaplan-Meier method. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Months (Median) |
|---|---|
| Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | NA |
Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Months (Mean) | |
|---|---|---|
| Time to first response | Time to best response | |
| Phase 1: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 2.25 | 5.47 |
| Phase 1: 2 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 0.83 | 3.12 |
| Phase 1: 4 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 1.14 | 12.54 |
| Phase 1: 8 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 1.27 | 9.75 |
Time to first response was defined as the time from the date of first dose of daratumumab to the date of initial documentation of a response (PR or better). Time to best response was defined as the time between the date of first dose of daratumumab and the date of the initial evaluation of the best response (PR or better) to treatment. (NCT01615029)
Timeframe: Up to 3 years
| Intervention | Months (Mean) | |
|---|---|---|
| Time to first response | Time to best response | |
| Phase 2: 16 mg/kg Daratumumab + Lenalidomide and Dexamethasone | 1.55 | 5.60 |
PFS was defined as the time from the first dose of study treatment to progressive disease (PD) or death due to any cause on study or within 28 days after study discontinuation, whichever occurred earlier. (NCT01724177)
Timeframe: From day 1 of study treatment to the date of disease progression; up to data cut date of date of 19 May 2017; maximum study duration was 134.1 weeks
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide | 16.30 |
Overall Survival was defined as the time from the start of study treatment to the death due to any cause. For participants who were still alive at the time of the data cutoff, survival data were censored at the latest available date the participant was known to be alive. (NCT01724177)
Timeframe: From Day 1 of study treatment to disease progression or death; up to final data cut-off date of 19 May 2017; maximum surivival time was 197.9 weeks
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide | 88.10 |
The response duration in participants with an objective response was measured from the date of the first Complete Response or Complete Response unconfirmed or Partial Response to the first date of Relapsed Disease or Progressive Disease (PD). For participants who did not progress during the study, DOR was censored at the last adequate response assessment not showing evidence of PD. (NCT01724177)
Timeframe: From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; Maximum study duration was 134.1 Weeks
| Intervention | weeks (Number) |
|---|---|
| Lenalidomide | 24.10 |
Time to progression was calculated as the time from the first dosing of study treatment to the first documented PD and assessed by the ESEC (NCT01724177)
Timeframe: From day 1 of study treatment to the date of disease progression; up to data cut date of 19 May 2017; maximum study duration was 134.1 weeks
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide | 16.30 |
The tumor control rate was measured for those with a response of Complete Remission, + CRu, + PR + Stable Disease (SD) in the EE population based on the best response. (NCT01724177)
Timeframe: From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 73.1 |
"ORR is a Complete Response (CR) + Complete Response unconfirmed (CRu) + Partial Response (PR). A CR requires that target lesions have regressed to normal; nodal non-target lesions have regressed to normal; extranodal non-target lesions have disappeared; hepatomegaly/splenomegaly has disappeared; skin findings are GR 0; peripheral blood is normal; Bone marrow (BM) infiltration is negative and no new lesions. A CRu requires the sum of the product diameters (SPD) of target lesions have decreased by at least 75% from baseline; nodal non-target lesions have regressed to normal size; extranodal non-target lesions have disappeared; hepatomegaly/splenomegaly has disappeared; skin findings are Grade 0; peripheral blood is normal; BM infiltration is negative and no new lesions. A PR requires the SPD of target lesions has decreased by at least 50% from baseline; all nodal non-target lesions have regressed to normal or show no increase in size; all extranodal non-target lesions have disappeared" (NCT01724177)
Timeframe: From day 1 of study treatment to date of first documented CR, CRU or PR; Up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 42.3 |
Time to Response was defined as the time from the first dose of study treatment to the initial documented response (CR or CRu, or PR) (NCT01724177)
Timeframe: From day 1 of study treatment to first documented response; up to data cut-off date of 19 May 2017; maximum study duration was 134.1 weeks
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide | 8.10 |
Treatment Emergent Adverse Event (TEAE) was defined as any AE occurring on or after the start of study treatment and within 28 days after the last dose. Severity was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0): Grade 1= Mild Grade 2= Moderate Grade 3= Severe Grade 4= Life-threatening and Grade 5= Death related to AE. Serious AEs (SAEs) were those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above. (NCT01724177)
Timeframe: From the date of the first dose of study drug up to 28 days after the last dose of study drug; up to data cutoff date of 19 May 2017; maximum treatment duration was 130.1 weeks
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 TEAE | ≥ 1 TEAE Related to Lenalidomide | ≥ 1 NCI CTCAE Grade (GR) 3 or Greater TEAE | ≥ 1 NCI CTCAE ≥ GR 3 TEAE Related to Lenalidomide | ≥ 1 Serious TEAE | ≥ 1 Serious TEAE Related to Lenalidomide | ≥ 1 TEAE Leading to Discontinuation | ≥ 1 Related TEAE Leading to Discontinuation | ≥ 1 TEAE Leading to Dose Reduction/Interruption | ≥ 1 related TEAE Leading to Decrease/Interruption | ≥ 1 TEAE Resulting in Death | |
| Lenalidomide | 26 | 26 | 25 | 25 | 11 | 9 | 8 | 8 | 17 | 17 | 0 |
DOR was defined for participants with confirmed response (PR or better) as time between first documentation of response and disease progression/death due to PD, whichever occurs first. PD was defined as meeting any one of following criteria: Increase of >=25% in level of serum M-protein from lowest response value and absolute increase must be >=0.5g/dL; Increase of >=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be >=200mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of >=25% in difference between involved and uninvolved FLC levels from lowest response value and absolute increase must be >10mg/dL; Definite increase in size of existing bone lesions/soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5mg/dL) that can be attributed solely to PC proliferative disorder. (NCT02076009)
Timeframe: From randomization to the date of first documented evidence of PD (up to 21 months)
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 17.4 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | NA |
Overall response rate was defined as the percentage of participants who achieved a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria, during or after study treatment. IMWG criteria for PR: >=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by >=90% or to <200 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of >=50% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria, in addition to the above criteria, if present at baseline, a >=50% reduction in the size of soft tissue plasmacytomas is also required. (NCT02076009)
Timeframe: From randomization to disease progression (up to 21 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 76.4 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | 92.9 |
Overall survival was measured from the date of randomization to the date of the participant's death. (NCT02076009)
Timeframe: From randomization to date of death due to any cause (up to 87.5 months)
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 51.84 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | 67.58 |
VGPR or better is defined as the percentage of participants who achieved VGPR, complete response (CR) and stringent complete response (sCR) according to the International Myeloma Working Group criteria (IMWG). IMWG criteria for VGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis, or >=90% reduction in serum M-protein plus urine M-protein <100 mg/24 hours, if the serum and urine M-protein are not measurable, a decrease of >90% in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria. In addition to the above criteria, if present at baseline, a >=50% reduction in the size of soft tissue plasmacytomas is also required; CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry. (NCT02076009)
Timeframe: From randomization to disease progression (up to 21 months)
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 44.2 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | 75.8 |
PFS: duration from date of randomization to either progressive disease (PD)/death, whichever occurred first. PD: defined as meeting any 1 of following criteria: Increase of greater than equal to (>=)25 percent(%) in level of serum M-protein from lowest response value and absolute increase must be >=0.5 gram per deciliter (g/dL); Increase of >=25% in 24-hours(h) urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be >=200 mg/24h; Only in participants without measurable serum and urine M-protein levels: increase of >=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be >10 mg/dL; Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) attributed solely to plasma cell (PC) proliferative disorder. (NCT02076009)
Timeframe: From randomization to either disease progression or death whichever occurs first (up to 21 months)
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 18.43 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | NA |
TTP was defined as time from date of randomization to date of first documented evidence of progressive disease (PD). PD was defined as meeting any one of following criteria: Increase of >=25% in level of serum M-protein from lowest response value and absolute increase must be >=0.5 g/dL; Increase of >=25% in 24-hour urinary light chain excretion (urine M-protein) from lowest response value and absolute increase must be >=200 mg/24hours; Only in participants without measurable serum and urine M-protein levels: increase of >=25% in difference between involved and uninvolved free light chain (FLC) levels from lowest response value and absolute increase must be >10 milligram per deciliter (mg/dL); Definite increase in size of existing bone lesions or soft tissue plasmacytomas; Definite development of new bone lesions or soft tissue plasmacytomas; Development of hypercalcemia (corrected serum calcium >11.5 mg/dL) that can be attributed solely to plasma cell (PC) proliferative disorder. (NCT02076009)
Timeframe: From randomization to disease progression (up to 21 months)
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 18.43 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | NA |
Time to response was defined as the time between the date of randomization and the first efficacy evaluation that the participant met all criteria for partial response (PR) or better. (NCT02076009)
Timeframe: From randomization up to first documented CR or PR (up to 21 months)
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 1.3 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | 1.0 |
Time to subsequent anticancer treatment was defined as the time from randomization to the start of subsequent anticancer treatment or death due to progressive disease (PD), whichever occurs first. (NCT02076009)
Timeframe: From randomization to date of start of subsequent anticancer treatment or death due to PD, whichever occured first (up to 87.5 months)
| Intervention | months (Median) |
|---|---|
| Lenalidomide, Low-dose Dexamethasone (Rd) | 23.1 |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | 69.3 |
Minimal residual disease was assessed for all participants who achieved a complete response (CR) or stringent complete response (sCR). CR: Negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas, and <5% PCs in bone marrow; sCR: CR and normal FLC ratio, absence of clonal PCs by immunohistochemistry, immunofluorescence or 2- to 4 color flow cytometry. The MRD negativity rate was defined as the percentage of participants who had negative MRD assessment at any time point after the first dose of study drugs by evaluation of bone marrow aspirates or whole blood at 10^ minus (-) 4, 10^-5, 10^-6 threshold. (NCT02076009)
Timeframe: From randomization to the date of first documented evidence of PD (up to 87.5 months)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| MRD negative rate (10^-4) | MRD negative rate (10^-5) | MRD negative rate (10^-6) | |
| Daratumumab, Lenalidomide, Low-dose Dexamethasone (DRd) | 40.6 | 33.2 | 13.3 |
| Lenalidomide, Low-dose Dexamethasone (Rd) | 10.2 | 6.7 | 1.8 |
The detection of anti-elotuzumab anti-drug antibodies (ADAs) in human serum was performed using a validated bridging electrochemiluminescence immunoassay (ECLA) on the Meso Scale Discovery (MSD) platform. Sample collection was performed prior to administration of elotuzumab at Day 1 of each cycle. (NCT01241292)
Timeframe: First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) |
|---|---|
| Elotuzumab 10 mg/kg | 3 |
| Elotuzumab 20 mg/kg | 0 |
Vital signs (body temperature, seated blood pressure, heart rate, and respiration rate) were recorded at screening on Days 1, 8, 15, and 22 of Cycles 1 and 2, on Days 1 and 15 of Cycle 3, and at the end of treatment. Blood pressure (Diastolic and Systolic) and heart rate were recorded after the participant sat quietly for at least 5 minutes. Clinical relevance of vital sign data was determined by the investigator. (NCT01241292)
Timeframe: First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) |
|---|---|
| Elotuzumab 10 mg/kg | 0 |
| Elotuzumab 20 mg/kg | 0 |
The quantification of elotuzumab in human serum was performed using a validated enzyme-linked immunosorbent assay (ELISA). Cmax was measured in micrograms per milliliter (µg/mL). Samples of serum were obtained at: Cycle 1, Day 1: 0 hour (h), 30 minutes (min) 2 h post dose; Day 8: 0h, 2 h; Day 15: 0h, 30 min; Day 22: 0h, 30min, 2h. Cycle 2, Day 1, 22 0h, 2h. Cycle 3, Day 1: 0h, 30h, 2h; Day 15: 0h. (NCT01241292)
Timeframe: Days 1, 8, 15 and 22 of cycle 1, Days 1 and 22 of cycle 2, Days 1 and 15 of cycle 3
| Intervention | µg/mL (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 1 (n=3,3) | Cycle 1 Day 8 (n=3,3) | Cycle 1 Day 15 (n=3,3) | Cycle 1 Day 22 (n=3,2) | Cycle 2 Day 1 (n=3,3) | Cycle 2 Day 22 (n=3,3) | Cycle 3 Day 1 (n=3,3) | |
| Elotuzumab 10 mg/kg | 173 | 237 | 297 | 234 | 240 | 270 | 286 |
| Elotuzumab 20 mg/kg | 376 | 549 | 652 | 724 | 671 | 844 | 972 |
The quantification of elotuzumab in human serum was performed using a validated enzyme-linked immunosorbent assay (ELISA). Cmin was measured in micrograms per milliliter (µg/mL). Samples of serum were obtained at: Cycle 1, Day 1: 0 hour (h), 30 minutes (min) 2 h post dose; Day 8: 0h, 2 h; Day 15: 0h, 30 min; Day 22: 0h, 30min, 2h. Cycle 2, Day 1, 22 0h, 2h. Cycle 3, Day 1: 0h, 30h, 2h; Day 15: 0h. (NCT01241292)
Timeframe: Days 8, 15 and 22 of cycle 1, Days 1 and 22 of cycle 2, Days 1 and 15 of cycle 3
| Intervention | µg/mL (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Cycle 1 Day 8 (n=3,3) | Cycle 1 Day 15 (n=3,3) | Cycle 1 Day 22 (n=3,2) | Cycle 2 Day 1 (n=3,2) | Cycle 2 Day 22 (n=3,3) | Cycle 3 Day 1 (n=3,3) | Cycle 3 Day 15 (n=3,3) | |
| Elotuzumab 10 mg/kg | 59.1 | 97.0 | 24.6 | 25.8 | 57.8 | 77.2 | 59.4 |
| Elotuzumab 20 mg/kg | 165 | 252 | 280 | 389 | 547 | 579 | 466 |
Complete response (CR) and Partial Response (PR) were based on the European Group for Blood and Bone Marrow Transplant (EBMT) Criteria. Very Good Partial response was derived from the International Myeloma Working Group (IMWG) criteria. Participants who had a reduction in M-protein or plasmacytoma but did not meet the EBMT criteria for PR were classified as minimal response (MR). Hematologic, radiologic and/or clinical assessments were done every cycle starting with cycle 2. Each cycle is 4 weeks in length (Day 1, Day 8, Day 15, Day 22). Cycle 2 began on study Day 29. CR=negative immunofixation 6 weeks, <5% plasma cells, no increase in size or number of lytic lesions, complete disappearance of extramedullary plasmacytoma. PR=≥50%reduction in M-protein for 6 weeks, ≥90% reduction of urinary light chain excretion or < 200 mg/24hours for 6 weeks, ≥50% reduction in size of extramedullary plasmacytoma present at baseline, no increase in size or number of lytic lesions. (NCT01241292)
Timeframe: Cycle 2 (Study Day 29) to last dose (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete Response | Very Good Partial Response | Partial Response | Minimal Response | |
| Elotuzumab 10 mg/kg | 0 | 1 | 1 | 1 |
| Elotuzumab 20 mg/kg | 1 | 2 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug. Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4= Potentially Life-threatening or disabling. Data cut-off February 2014. (NCT01241292)
Timeframe: First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All SAEs Any Grade | Grade 3-4 SAEs | AEs Leading to Discontinuation | Grade 3-4 AEs | Deaths | |
| Elotuzumab 10 mg/kg | 2 | 1 | 0 | 3 | 0 |
| Elotuzumab 20 mg/kg | 3 | 3 | 1 | 3 | 0 |
NCI CTCAE, version 3.0 was used to measure toxicity scale. Sodium high (H) Gr 1:>ULN - 150; Gr 2: >150 - 155; Gr 3: >155 - 160; Gr 4: >160 mmol/L; Sodium low(L) Gr 1:
Timeframe: First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Potassium High, Any Grade | Potassium High, Grade 3-4 | Potassium Low, Any Grade | Potassium Low, Grade 3-4 | Sodium High, Any Grade | Sodium High, Grade 3-4 | Sodium Low, Any Grade | Sodium Low, Grade 3-4 | |
| Elotuzumab 10 mg/kg | 0 | 0 | 3 | 0 | 1 | 0 | 2 | 0 |
| Elotuzumab 20 mg/kg | 2 | 0 | 2 | 1 | 2 | 0 | 3 | 0 |
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 was used to measure toxicity scale. Lower Limits of Normal (LLN). Hemoglobin Gr 1:
Timeframe: First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin Any Grade | Hemoglobin Grade 3-4 | Lymphocytes Any Grade | Lymphocytes Grade 3-4 | Neutrophils Any Grade | Neutrophils Grade 3-4 | Platelet Count Any Grade | Platelet Count Grade 3-4 | Leukocytes Any Grade | Leukocytes Grade 3-4 | |
| Elotuzumab 10 mg/kg | 3 | 0 | 3 | 3 | 3 | 2 | 3 | 1 | 3 | 2 |
| Elotuzumab 20 mg/kg | 3 | 1 | 3 | 3 | 3 | 3 | 2 | 0 | 3 | 1 |
National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0 was used to measure toxicity scale. Lower Limits of Normal (LLN). Upper Limits of Normal (ULN). Alanine transaminase (ALT); Aspartate aminotransferase (AST); Alkaline phosphatase (ALP). ALT Grade (Gr)1:>1.0 to 2.5*ULN; Gr 2: >2.5 to 5.0*ULN; Gr 3: >5.0 to 20.0*ULN; Gr 4: >20.0*ULN. AST Gr 1: >1.0 to 2.5*ULN; Gr 2: >2.5 to 5.0*ULN; Gr 3: >5.0 to 20.0*ULN; Gr 4: >20.0*ULN. Total bilirubin Gr 1: >1.0 to 1.5*ULN; Gr 2: >1.5 to 3.0*ULN; Gr 3: >3.0 to 10..0*ULN; Gr 4: >10.0.0*ULN. ALP (U/L) Gr1:>1.0 to 2.5*ULN, Gr2:>2.5 to 5.0*ULN, Gr3:>5.0 to 20.0*ULN, Gr4:>20.0*ULN. Albumin (low) Gr 1:
Timeframe: First dose (Day 1) to last dose plus 60 days (assessed up to January 2017, approximately 71 months)
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Albumin Any Grade | Albumin Grade 3-4 | ALP Any Grade | ALP Grade 3-4 | ALT Any Grade | ALT Grade 3-4 | AST Any Grade | AST Grade 3-4 | Creatinine Any Grade | Creatinine Grade 3-4 | Bilirubin Total Any Grade | Bilirubin Total Grade 3-4 | |
| Elotuzumab 10 mg/kg | 3 | 0 | 1 | 0 | 2 | 1 | 1 | 1 | 0 | 0 | 1 | 0 |
| Elotuzumab 20 mg/kg | 3 | 0 | 2 | 0 | 2 | 1 | 2 | 1 | 2 | 0 | 0 | 0 |
Response will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy, radiographic evaluation. Response will be evaluated at three different levels: clinical, cytometric and molecular. (NCT00727415)
Timeframe: After 6 months from study entry (end of treatment)
| Intervention | percentage of participants on DFS (Number) |
|---|---|
| Phase I-II Lenalidomide | 35.33 |
Severe infection requiring more than 2 weeks of antibiotic therapy. (NCT00727415)
Timeframe: At 24 months from study entry (end of follow-up)
| Intervention | participants with severe infecitons (Number) |
|---|---|
| Phase I-II Lenalidomide | 2 |
Response will be assessed by clinical examination, peripheral blood, bone marrow aspirate and biopsy, radiographic evaluation. Response will be evaluated at three different levels: clinical, cytometric and molecular. (NCT00727415)
Timeframe: After 6 months from study entry (end of treatment).
| Intervention | percentage of patients in CR (Number) |
|---|---|
| Phase I-II Lenalidomide | 22.5 |
Data from all subjects who receive any study drug will be included in the safety analyses. (NCT00727415)
Timeframe: At 24 months from study entry (end of follow-up)
| Intervention | Participants who died during the study (Number) |
|---|---|
| Phase I-II Lenalidomide | 14 |
(NCT00727415)
Timeframe: After 6 months from study entry (end of treatment).
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| CR according to IgHV mutated | CR according to CD19+/CD38+, <30% | CR according to CD19+/CD38+, >30% | CR according to deletion 11q and 17p, absent | |
| Phase I-II Lenalidomide | 28.00 | 33.33 | 16.67 | 31.82 |
Maximum tolerated dose of lenalidomide given in combination with fludarabine. (NCT00727415)
Timeframe: The MTD of Lenalinomide will be evaluated during the two courses given with the escalated dose of Lenalinomide defined by the respective dose level.
| Intervention | number of patients without DLT (Number) | |
|---|---|---|
| Dose level 1 - 5 mg | Dose level 2 - 10 mg | |
| Phase I-II Lenalidomide | 6 | 1 |
Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression. (NCT00424047)
Timeframe: Up to data cut off of 03 August 2005; up to 24 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 67.6 |
| Placebo Plus Dexamethasone | 33.3 |
Duration of response was calculated for responders and defined as the time from the first observation of a response (e.g., the first time that the appropriate decrease in M-protein level was observed for confirmed responders) to the first documented progression or relapse. Response duration was censored at the last adequate assessment showing evidence of no progression. (NCT00424047)
Timeframe: Up to data cut off of 03 Mar 2008; up to 51 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 68.1 |
| Placebo Plus Dexamethasone | 33.3 |
OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT00424047)
Timeframe: Randomization to data cut off of 03 August 2005; up to 24 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | NA |
| Placebo Plus Dexamethasone | NA |
OS was calculated as the time from randomization to death from any cause. OS was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who were lost to follow-up before death was documented. (NCT00424047)
Timeframe: Randomization to data cut off of 02 March 2008; up to 51 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 161.9 |
| Placebo Plus Dexamethasone | 133.3 |
Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia. (NCT00424047)
Timeframe: From randomization up to cut-off date of 03 August 2005; up to 24 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 52.1 |
| Placebo Plus Dexamethasone | 20.1 |
Time to progression was calculated as the time from randomization to the first occurrence of disease progression, as determined by a detailed review of all the myeloma response assessment data using the Bladé criteria (Bladé, 1998). Disease progression was also based on bone marrow findings, worsening lytic bone disease, progressively enlarging extramedullary plasmacytomas, or hypercalcemia. (NCT00424047)
Timeframe: From randomization up to cut-off date of 02 March 2008; up to 51 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 52.4 |
| Placebo Plus Dexamethasone | 20.1 |
Time from randomization to the date of the first occurrence of a symptomatic SRE (clinical need for radiotherapy or surgery to bone). (NCT00424047)
Timeframe: Up to unblinding data cut off of 03 August 2005; up to 24 months
| Intervention | participants (Number) |
|---|---|
| Lenalidomide Plus Dexamethasone | NA |
| Placebo Plus Dexamethasone | NA |
The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented. (NCT00424047)
Timeframe: Randomization to cut off date of 03 August 2005; up to 24 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 10.1 |
| Placebo Plus Dexamethasone | 12.3 |
The time to first worsening of the ECOG performance status was calculated as the time from randomization to the date of the first worsening compared with the last ECOG evaluation obtained prior to randomization. Data were censored at the last date that the participant was known to be unchanged or improved from before randomization for the participants who had not had worsened at the time of the analysis and for the patients who were lost to follow-up before worsening in the ECOG performance status was documented. (NCT00424047)
Timeframe: Randomization to cut off date of 02 March 2008; up to 51 months
| Intervention | weeks (Median) |
|---|---|
| Lenalidomide Plus Dexamethasone | 10.1 |
| Placebo Plus Dexamethasone | 12.3 |
Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma. (NCT00424047)
Timeframe: Randomization to data cut-off of 02 Mar 2008; up to 51 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Not Evaluable (NE) those without response data | |
| Lenalidomide Plus Dexamethasone | 17.0 | 42.6 | 28.4 | 3.4 | 8.5 |
| Placebo Plus Dexamethasone | 4.0 | 19.4 | 56.6 | 14.3 | 5.7 |
"An AE is any sign, symptom, illness, or diagnosis that appears or worsens during the course of the study. Treatment-emergent AEs (TEAEs) are any AE occurring or worsening on or after the first treatment of the study drug and within 30 days after the last cycle end date of study drug. A serious AE = any AE which results in death; is life-threatening; requires or prolongs existing inpatient hospitalization; results in persistent or significant disability is a congenital anomaly/birth defect; constitutes an important medical event.~The severity of AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE, Version 2.0): Grade 1 = Mild (no limitation in activity or intervention required); Grade 2 = Moderate (some limitation in activity; no/minimal medical intervention required); Grade 3 = Severe (marked limitation in activity; medical intervention required, hospitalization possible); Grade 4 = Life-threatening; Grade 5 = Death." (NCT00424047)
Timeframe: From first dose of study drug through to 30 days after the last dose, until the data cut-off date of 25 June 2013; up to 90 months
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| ≥ 1 Adverse Event | ≥ 1 Serious Adverse Event | ≥ 1 AE leading to study drug discontinuation | ≥ 1 AE leading to dose reduction or interruption | ≥ 1 Drug-Related Adverse Event | ≥ 1 Drug-Related Serious Adverse Event | ≥Death within ≤ 30 days of last dose of study drug | ≥ 1 Grade 1 or Higher Adverse Event | ≥ 1 Grade 2 or Higher Adverse Event | ≥ 1 Grade 3 or Higher Adverse Event | ≥ 1 Grade 4 or Higher Adverse Event | |
| Lenalidomide Plus Dexamethasone | 176 | 105 | 46 | 137 | 160 | 54 | 17 | 176 | 168 | 146 | 52 |
| Placebo Plus Dexamethasone | 175 | 79 | 31 | 100 | 151 | 30 | 20 | 175 | 167 | 119 | 37 |
Complete Response (CR): Disappearance of monoclonal paraprotein and maintained for ≥ 6 weeks . Remission Response (RR):75-99% reduction in the level of the serum monoclonal paraprotein compared to baseline; 90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR): 50-74% reduction in the level of monoclonal paraprotein compared to baseline; 50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD): Criteria for PR or PD have not been met. Plateau Phase: If PR, stable monoclonal paraprotein values (within 25% above or below nadir)/stable soft tissue plasmacytomas maintained for at least 3 months. Progressive Disease (PD): Reappearance of serum or urinary monoclonal paraprotein on immunofixation or electrophoresis on two consecutive occasions at least one week apart. Increase of percentage of plasma cells in bone marrow aspirate or biopsy to ≥ 5%. Development of at least one new lytic bone lesion or soft tissue plasmacytoma. (NCT00424047)
Timeframe: Randomization to 03 August 2005; up to 24 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Complete Response (CR) | Partial Response (PR) | Stable Disease (SD) | Progressive Disease (PD) | Not Evaluable (NE) those without response data | |
| Lenalidomide Plus Dexamethasone | 15.3 | 43.8 | 29.0 | 2.8 | 9.1 |
| Placebo Plus Dexamethasone | 4.0 | 19.4 | 56.6 | 14.3 | 5.7 |
The overall confirmed response that was maintained for ≥6 weeks. Complete Response (CR):Disappearance of monoclonal paraprotein. Remission Response (RR):75-99% reduction in monoclonal paraprotein/90-99% reduction in 24-hr urinary light chain excretion. Partial Response (PR):50-74% reduction in monoclonal paraprotein/50-89% reduction in 24-hr urinary light chain excretion. Stable Disease (SD):Criteria for PR or PD not met. Plateau Phase:If PR, stable monoclonal paraprotein (within 25% above or below nadir)/stable soft tissue plasmacytomas. Progressive Disease (PD):Disease worsens. (NCT00056160)
Timeframe: Up to Unblinding (07 Jun 2005)
| Intervention | Participants (Number) |
|---|---|
| CC-5013/Dex | 107 |
| Placebo/Dex | 34 |
Overall survival was calculated as the time from randomization to death from any cause. (NCT00056160)
Timeframe: 170 weeks (median overall survival of CC-5013/Dex treatment group)
| Intervention | Weeks (Median) |
|---|---|
| CC-5013/Dex | 170.1 |
| Placebo/Dex | 136.4 |
The time to first worsening on the ECOG Performance Scale was calculated as the time from randomization to the date of the first worsening compared to the last ECOG evaluation obtained prior to randomization. (NCT00056160)
Timeframe: 30 weeks (mean time to first worsening of ECOG performance status for CC-5013/Dex treatment group)
| Intervention | Weeks (Mean) |
|---|---|
| CC-5013/Dex | 29.9 |
| Placebo/Dex | 15.0 |
Time to progression (TTP) was calculated as the time from randomization to the first documentation of progressive disease based on the myeloma response determination criteria developed by Bladé et. al., Br J Haematol 1998; 102:1115-1123. (NCT00056160)
Timeframe: 60 weeks (median Time To Progression of CC-5013/Dex treatment group)
| Intervention | Weeks (Median) |
|---|---|
| CC-5013/Dex | 60.1 |
| Placebo/Dex | 20.1 |
(NCT01453088)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 27 |
| Auto Transplant High Dose Melphalan+Bortezomib | 27 |
Progression free survival of elderly patients with multiple myeloma treated with either high-dose melphalan versus high-dose melphalan and bortezomib at 3 years (NCT01453088)
Timeframe: Participants will be followed post transplant for a minimum of 3 years, and after that may be monitored as part of the study indefinitely
| Intervention | Participants (Count of Participants) |
|---|---|
| Auto Transplant High Dose Melphalan | 13 |
| Auto Transplant High Dose Melphalan+Bortezomib | 11 |
"Response was defined as participants with a complete response (CR), unconfirmed complete response (Cru) or partial response (PR), assessed using the International Workshop Lymphoma Response Criteria (IWLRC) and based on best responses as determined by the investigator. CR: Complete disappearance of all detectable clinical and radiographic evidence of disease, disappearance of any disease-related symptoms, and normalization of biochemical abnormalities.~Cru: Criteria for CR above but with 1 or more of the following:~A residual lymph node mass > 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of diameters (SPD)~Indeterminate bone marrow (increased number or size of aggregates without cytologic or architectural atypia).~PR: ≥ 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD." (NCT00179673)
Timeframe: From enrollment through study completion. Median duration on study was 4.4 months with a maximum of 32 months
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 23.3 |
"Tumor control was defined as participants with a complete response, unconfirmed complete response, partial response or stable disease (SD), assessed using the International Workshop Lymphoma Response Criteria (IWLRC) and based on best responses as determined by the investigator.~SD was defined as a response less than a PR (see above) but not Progressive Disease (PD).~PD was defined as~≥ 50 % increase from nadir in the SPD of any previously identified abnormal node for partial responders or non-responders.~Appearance of any new lesion during or at the end of therapy." (NCT00179673)
Timeframe: From enrollment through study completion. Median duration on study was 4.4 months with a maximum of 32 months
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 60.5 |
Progression-free survival was defined as the time from the start of study drug therapy to the first observation of disease progression or death due to any cause, whichever came first. Participants who withdrew for any reason or received another NHL therapy including stem cell transplantation without documented progressive disease were censored on the date of their last adequate response assessment indicating no progression (or last adequate assessment prior to receiving other NHL therapy). Participants who were still active without progressive disease at the time of the data cut-off date were censored on the date of their last adequate response assessment. (NCT00179673)
Timeframe: From enrollment through study completion. Median duration on study was 4.4 months with a maximum of 32 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide | 4.4 |
The duration of response was calculated as the first response assessment demonstrating evidence of at least a partial response to the first documentation of progressive disease (as determined by computed tomography scan) or death due to NHL, whichever occurred first. For participants without documentation of progression, the duration of response was censored at the last date of tumor assessment indicating no progression. Median was based on the Kaplan-Meier estimate. (NCT00179673)
Timeframe: From enrollment through study completion. Median duration on study was 4.4 months with a maximum of 32 months
| Intervention | months (Median) |
|---|---|
| Lenalidomide | NA |
"The Investigator determined the relationship between the administration of study drug and the occurrence of an AE as suspected if the temporal relationship of the adverse event to study drug administration made a causal relationship possible, and other drugs, therapeutic interventions, or underlying conditions did not provide a sufficient explanation for the observed event.~The Investigator graded the severity of AEs according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) criteria and the following scale:~Grade 1 = Mild~Grade 2 = Moderate~Grade 3 = Severe~Grade 4 = Life threatening~Grade 5 = Death~A Serious AE is defined as any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or constitutes an important medical event." (NCT00179673)
Timeframe: From the start of study drug through 30 days after the last dose of study drug. Maximum time on study drug was 13.8 months.
| Intervention | participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| At least one Adverse Event (AE) | ≥ 1 AE related to study drug | Grade (GR) 3-5 AE | Grade 3-5 AE related to study drug | Serious adverse event (SAE) | SAE related to study drug | AE leading to discontinuation of study drug | Related AE leading to study drug discontinuation | AE leading to dose reduction or interruption | |
| Lenalidomide | 42 | 37 | 27 | 24 | 18 | 10 | 9 | 5 | 27 |
Stromal angiogenesis was assessed using blood vascular and perivascular markers, including VEGFR-1, VEGFR-2, CD34, and a-SMA, as well as lymphatic vascular markers ofVEGFR-3, podoplanin, and Lyve-1. (NCT00151281)
Timeframe: 38 months
| Intervention | pg/mL (Median) |
|---|---|
| RT-PEPC Drug Therapy | 109.5 |
measured by overall Response Rate (ORR), which includes Complete response and partial response. (NCT00151281)
Timeframe: 38 months
| Intervention | percentage of patients (Number) |
|---|---|
| Study Treatment Arm | 73 |
Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0. (NCT00151281)
Timeframe: 38 months
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Grade 3 or 4 neutropenia | Anemia | Thrombocytopenia | Fatigue | Constipation | Cough | Nausea | Neuropathy | Dyspnea | Rash | |
| RT-PEPC Drug Therapy | 14 | 1 | 4 | 22 | 14 | 14 | 13 | 13 | 11 | 10 |
"QoL assessments were obtained with version 3 of the Functional Assessment of Cancer Therapy-General (FACT-G) instrument. The FACT-G is comprised of four subscales: physical well-being (7-items, score range 0-28), social/family well-being (7-items, score range 0-28), emotional well-being (6-items, score range 0-24), and functional well-being (7-items, score range 0-28). Users of the FACT-G are able to generate an overall score and four subscale scores with ranges and distributions that are sample-specific. All questions in the FACT-G use a 5-point rating scale (0 = Not at all to 4 = Very much) A higher number indicates a better Quality of Life, and has a possible range of 0-108 points.~ANOVA was used to compare the difference in the means of total score among the different time points (baseline, every 2M until 6M, and every 6M until PD). The mean of the total FACT-G scores at baseline and mean of total score at all timepoints (using ANOVA) are reported below." (NCT00151281)
Timeframe: baseline, every 2 months until Month 6, and every 6 months until disease progression
| Intervention | FACT-G score (Mean) | |
|---|---|---|
| Mean FACT-G Score at baseline | Mean Total FACT-G Score between all time points | |
| RT-PEPC Drug Therapy | 83.3 | 89.4 |
Duration of complete response was defined as the time from the first documented complete response (CR + CRu) until the first disease progression or death for participants who had a CR. (NCT01197560)
Timeframe: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
| Intervention | Weeks (Median) |
|---|---|
| Lenalidomide | 66.4 |
| Investigators Choice (Control Arm) | 179.3 |
Duration of overall response was calculated as the time of initial response (CR+CRu+PR) until documented disease progression determinted by computerized scan CT scan or MRI or death due to lymphoma, whichever occurred earlier, for participants who responded. (NCT01197560)
Timeframe: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
| Intervention | Weeks (Median) |
|---|---|
| Lenalidomide | 64.7 |
| Investigators Choice (Control Arm) | 63.1 |
Overall survival was defined as time from randomization until death of any cause. (NCT01197560)
Timeframe: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
| Intervention | Weeks (Median) |
|---|---|
| Lenalidomide | 31.0 |
| Investigators Choice (IC) | 24.6 |
Progression-free survival was defined as the time from randomization to the first documented disease progression or death due to any cause. (NCT01197560)
Timeframe: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
| Intervention | Weeks (Median) |
|---|---|
| Lenalidomide | 9.6 |
| Investigators Choice (IC) | 7.1 |
A complete response was defined as participants with a complete response (CR), or unconfirmed complete response (CRu) based on IWG 1999 Response Criteria for NHL as assessed by the investigator. A CR is a complete disappearance of all disease with the exception of nodes. No new lesions. Previously enlarged organs must have regressed and not be palpable. Bone marrow must be negative if positive at baseline. Normalization of markers. CR Unconfirmed (CRu) does not qualify for CR above, due to a residual nodal mass or an indeterminate BM. (NCT01197560)
Timeframe: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide | 13.7 |
| Investigators Choice (IC) | 3.9 |
Durable overall response rate was defined as the percentage of participants who maintained a response for at least 16 weeks after initial response. (NCT01197560)
Timeframe: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
| Intervention | percentage of participants (Median) |
|---|---|
| Lenalidomide | 23.5 |
| Investigators Choice (Control Arm) | 9.8 |
Response was defined as having a CR, CRu or PR, based on IWG 1999 Response Criteria for NHL as evaluated by the investigators. CR = complete disappearance of disease and disease related symptoms. All lymph nodes and nodal masses regressed on computed tomography to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes > 1.5 cm prior to therapy and ≤ 1.0 cm in their short axis for nodes 1.1-1.5 cm in their long axis and > 1.0 cm in their short axis prior to therapy). Spleen and/or liver not palpable on physical exam, normal size by imaging, and absence of nodules related to lymphoma. If BM was involved prior to therapy, infiltrate must have cleared on repeat biopsy. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in the other nodes, liver, or spleen. Splenic and hepatic nodules regressed by ≥ 50% in their SPD or, for single nodules, in the greatest transverse diameter. No new disease. (NCT01197560)
Timeframe: From the date of randomization to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
| Intervention | Percentage of participants (Number) |
|---|---|
| Lenalidomide | 29.4 |
| Investigators Choice (IC) | 13.7 |
"A TEAE was defined as an AE that begins or worsens in intensity of frequency on or after the first dose of study drug through 28 days after last dose of study drug.~A serious adverse event (SAE) is any:~Death;~Life-threatening event;~Any inpatient hospitalization or prolongation of existing hospitalization;~Persistent or significant disability or incapacity;~Congenital anomaly or birth defect;~Any other important medical event The investigator determined the relationship of an AE to study drug based on the timing of the AE relative to drug administration and whether or not other drugs, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the event.The severity of an AE was evaluated by the investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (Version 4.03) where Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death" (NCT01197560)
Timeframe: From first dose of study drug to the final data cut-off date of 18 May 2018; median study duration was 27.0 and 19.7 weeks, respectively.
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any TEAEs | Any Treatment Related TEAE | Any TEAE Grade ≥ 3 | Any TEAE Grade ≥ 4 | Any TEAE Grade 5 | Any TEAE Grade 3 or 4 | Any Treatment Related TEAE Grade ≥ 3 | Any Treatment Related TEAEs Grade ≥ 4 | Any Treatment Related TEAE Grade 5 | Any Treatment Related TEAE Grade 3 or 4 | Any Serious Adverse Events (SAEs) | Any Treated Related SAEs | Any AE leading to stopping of study drug | Any drug related AE leading to halt of study drug | Any AE leading to dose interruption/reduct | Any drug related AE leading to interruption/reduct | |
| Investigators Choice (IC) | 55 | 45 | 53 | 36 | 18 | 52 | 39 | 21 | 2 | 39 | 42 | 21 | 17 | 4 | 34 | 30 |
| Lenalidomide | 54 | 49 | 43 | 29 | 9 | 42 | 30 | 15 | 0 | 30 | 31 | 14 | 11 | 5 | 32 | 27 |
An overall response is a complete response (CR), unconfirmed complete response (CRu) or partial response (PR) and was evaluated by the IRAC. A CR = complete disappearance of disease and related symptoms. Lymph nodes and nodal masses regressed on computed tomography to normal size (≤ 1.5 cm in their greatest transverse diameter for nodes > 1.5 cm prior to therapy and ≤ 1.0 cm in their short axis for nodes 1.1-1.5 cm in their long axis and > 1.0 cm in their short axis prior to therapy). Spleen and/or liver not palpable on exam, normal size by imaging, and absence of nodules related to lymphoma. If bone marrow was involved prior to therapy, infiltrate must have cleared on repeat biopsy. PR = ≥ 50% decrease in sum of the product of the diameters (SPD) of up to 6 of the largest dominant nodes or nodal masses. No increase in other nodes, liver, or spleen. Splenic and hepatic nodules regressed by ≥ 50% in their SPD or for single nodules, in the greatest transverse diameter;no new disease. (NCT01197560)
Timeframe: From the date of randomization to the data cut-off of 4 July 2013; when all patients reached the scheduled 16-week assessment or had progressed/died before the scheduled 16-week assessment); the median study duration was 27.0 and 19.7 weeks, respectively.
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| ORR for All Participants | GCB Subtype | Non-GCB | |
| Investigators Choice (IC) | 11.8 | 12.0 | 11.5 |
| Lenalidomide | 27.5 | 26.1 | 28.6 |
"Cytostatic overall response rate = CR + PR + SD greater than or equal to 6 months~Definitions per 2007 Cheson Lymphoma Response Criteria" (NCT00540007)
Timeframe: From 6 months through 3.5 years after study entry
| Intervention | Participants (Count of Participants) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 15 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 18 |
-Duration of response: defined as the interval from the date of response (CR or PR) is documented to the date of progression, taking as reference the smallest measurements recorded since the treatment started (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.68 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 4.08 |
-Event-free survival (time to treatment failure) is measured from the time from study entry to any treatment failure including disease progression, or discontinuation of treatment for any reason (eg, disease progression, toxicity, patient preference, initiation of new treatment without documented progression, or death). (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.78 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 3.93 |
"Overall response rate = CR + PR~Definitions per 2007 Cheson Lymphoma Response Criteria" (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | percentage of participants (Number) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 21.0 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 28.6 |
Overall survival is defined as the time from entry onto the clinical trial until death as a result of any cause. (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 17.434 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 23.717 |
(NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.78 |
| Cohort 2 - Lenalidomide Daily on Days 1-28 | 3.93 |
-Time to progression (TTP) is defined as the time from study entry until documented lymphoma progression or death as a result of lymphoma. (NCT00540007)
Timeframe: Through 3.5 years from study entry or until disease progression
| Intervention | months (Median) |
|---|---|
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 3.68 |
| Cohort 2 | 4.08 |
"Adverse events were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0~The higher the grade the worse the adverse event was considered" (NCT00540007)
Timeframe: 30 days following the completion of treatment
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | Leukopenia | Anemia | Lymphopenia | Thrombocytopenia | Fatigue | AST | ALT | Bilirubin | Sensory neuropathy | Dehydration | Infection without neutropenia | Infection with neutropenia | Edema | Dyspnea | Pleural effusion | Alkaline phosphatase | Abdominal pain | Low potassium | Low sodium | Low albumin | Low calcium | High calcium | Low phosphorus | Hearing loss | Thrombosis/embolism | Rash | Febrile neutropenia | Pneumonia | High potassium | Hyperuricemia | Confusion | Dizziness | Speech impairment | Chest pain | Extremity pain | Muscle pain | Secondary malignancy - MDS | |
| Cohort 1 - Lenalidomide Daily on Days 1-21 | 18 | 11 | 10 | 9 | 7 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 2 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cohort 2 | 20 | 13 | 4 | 10 | 8 | 2 | 1 | 1 | 2 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the appetite loss scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 0.4 |
| Lenalidomide - Subpopulation From UK + Ireland | 3.3 |
| Lenalidomide - Subpopulation From Spain | -4.5 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of cognitive functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -1.9 |
| Lenalidomide - Subpopulation From UK + Ireland | -4.9 |
| Lenalidomide - Subpopulation From Spain | 3.5 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the constipation scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 1.1 |
| Lenalidomide - Subpopulation From UK + Ireland | 7.9 |
| Lenalidomide - Subpopulation From Spain | 2.6 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the diarrhea scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 8.6 |
| Lenalidomide - Subpopulation From UK + Ireland | 8.1 |
| Lenalidomide - Subpopulation From Spain | 9.0 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the dyspnoea scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 2.7 |
| Lenalidomide - Subpopulation From UK + Ireland | 2.7 |
| Lenalidomide - Subpopulation From Spain | -0.9 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of emotional functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -0.2 |
| Lenalidomide - Subpopulation From UK + Ireland | -4.0 |
| Lenalidomide - Subpopulation From Spain | -0.7 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 2.6 |
| Lenalidomide - Subpopulation From UK + Ireland | 5.3 |
| Lenalidomide - Subpopulation From Spain | 1.0 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a problem scale like the financial problems scale = higher level of financial problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 2.0 |
| Lenalidomide - Subpopulation From UK + Ireland | 0.8 |
| Lenalidomide - Subpopulation From Spain | 0.9 |
EORTQ QLC-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better quality of life. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 1.1 |
| Lenalidomide - Subpopulation From UK + Ireland | -1.8 |
| Lenalidomide - Subpopulation From Spain | -2.2 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the insomnia scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -3.8 |
| Lenalidomide - Subpopulation From UK + Ireland | 2.2 |
| Lenalidomide - Subpopulation From Spain | -1.8 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the nausea/vomiting scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 1.0 |
| Lenalidomide - Subpopulation From UK + Ireland | 0.1 |
| Lenalidomide - Subpopulation From Spain | -2.2 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the pain scale = higher level of symptomatology/problems. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -3.9 |
| Lenalidomide - Subpopulation From UK + Ireland | -5.2 |
| Lenalidomide - Subpopulation From Spain | -6.6 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. EORTC QLQ-C30 includes functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting), and other (dyspnoea, appetite loss, insomnia, constipation/diarrhea, and financial difficulties). Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of physical functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -3.6 |
| Lenalidomide - Subpopulation From UK + Ireland | -2.9 |
| Lenalidomide - Subpopulation From Spain | -1.8 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score=better level of role functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -2.4 |
| Lenalidomide - Subpopulation From UK + Ireland | -1.5 |
| Lenalidomide - Subpopulation From Spain | -2.6 |
EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer patients. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score = better level of social functioning. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -5.2 |
| Lenalidomide - Subpopulation From UK + Ireland | -5.3 |
| Lenalidomide - Subpopulation From Spain | -3.1 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the body image scale, higher scores = better body image. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -4.3 |
| Lenalidomide - Subpopulation From UK + Ireland | -2.0 |
| Lenalidomide - Subpopulation From Spain | -5.3 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. EORTC QLQ-MY20 includes four scales: disease symptoms, treatment side-effects, future perspective, and body image. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the disease symptoms scale = higher level of symptomatology. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | -2.4 |
| Lenalidomide - Subpopulation From UK + Ireland | -1.2 |
| Lenalidomide - Subpopulation From Spain | -3.9 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale. For the future perspective scale, higher score = better perspective of the future. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 5.8 |
| Lenalidomide - Subpopulation From UK + Ireland | 3.4 |
| Lenalidomide - Subpopulation From Spain | 4.4 |
EORTC QLQ-MY20 is a validated questionnaire to assess the overall quality of life in patients with multiple myeloma. Questions used 4-point scale (1 'Not at All' to 4 'Very Much'). Scores are averaged, and transformed to 0-100 scale; higher score for the side effects scale = higher level of symptomatology. (NCT00420849)
Timeframe: Baseline (Day 0), Week 24
| Intervention | units on a scale (Mean) |
|---|---|
| Lenalidomide - Subpopulation From Austria + Australia | 4.9 |
| Lenalidomide - Subpopulation From UK + Ireland | 4.7 |
| Lenalidomide - Subpopulation From Spain | 2.0 |
Time between first dose and when a TEAE for peripheral neuropathy was reported. The mean is the univariate mean without adjusting for censoring. The treatment duration was used for censored participants. (NCT00420849)
Timeframe: up to 124 weeks
| Intervention | weeks (Mean) |
|---|---|
| Lenalidomide Plus Dexamethasone | 25.6 |
Time between first dose and when a TEAE for venous thromboembolic event was reported. The mean is the univariate mean without adjusting for censoring. The treatment duration was used for censored participants. (NCT00420849)
Timeframe: up to 124 weeks
| Intervention | weeks (Mean) |
|---|---|
| Lenalidomide Plus Dexamethasone | 26.5 |
"Counts of study participants who had treatment-emergent adverse events (TEAEs) defined as any reported AE that started on or after the first day of study drug dosing. A participant with multiple occurrences of an adverse event within a category is counted only once in that category.~National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) was used by investigators to assess TEAEs. Severity scale ranges from 0 (none) to 5 (death). Grade 3=severe AE; Grade 4=life threatening or disabling AE; Grade 5=death." (NCT00420849)
Timeframe: up to 123 weeks
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| At least one treatment-emergent AE (TEAE) | At least one TEAE related to study drug | At least one TEAE with severity grade of 3 or 4 | At least one serious AE (SAE) | |
| Lenalidomide Plus Dexamethasone | 586 | 519 | 471 | 340 |
Number of participants with at least one peripheral neuropathy treatment-emergent adverse event (TEAE), and number of participants reporting AEs coded to preferred terms that comprise the search terms for peripheral neuropathy in MedDRA version 9.0 are listed. A participant with multiple occurrences of a TEAE was counted only once for that category. (NCT00420849)
Timeframe: up to 124 weeks
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| At least one TEAE of peripheral neuropathy | Neuropathy peripheral | Peripheral sensory neuropathy | Neuralgia | Peripheral motor neuropathy | Polyneuropathy | Sensory disturbance | |
| Lenalidomide Plus Dexamethasone | 84 | 46 | 33 | 5 | 2 | 2 | 1 |
Number of participants with at least one venous thromboembolic treatment-emergent adverse event (TEAE), and number of participants reporting AEs coded to preferred terms that comprise the search terms for venous thromboembolic events in MedDRA version 9.0 are listed. A participant with multiple occurrences of a TEAE was counted only once for that category. (NCT00420849)
Timeframe: up to 124 weeks
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| At least one venous thromboembolic event | Deep vein thrombosis | Pulmonary embolism | Thrombophlebitis | Venous thrombosis limb | |
| Lenalidomide Plus Dexamethasone | 60 | 38 | 23 | 7 | 1 |
MTD is defined as the highest dose level in which 1 or fewer participants experienced a dose limiting toxicity (DLT) in 6 participants treated. DLT is any grade III or IV toxicity during the first 28 days (first cycle) of therapy. (NCT00294632)
Timeframe: 28 days of cycle 1
| Intervention | mg (Number) |
|---|---|
| Phase I: Lenalidomide + Rituximab | 20 |
Objective response rate defined as percentage of participants with complete or partial response after 2 cycles of therapy maintained for one month. Objective response monitored using Simon's optimal 2-stage design. (NCT00294632)
Timeframe: 56 days
| Intervention | percentage of participants (Number) |
|---|---|
| Lenalidomide + Rituximab | 57 |
Complete response: Absence lymphadenopathy, hepatomegaly or splenomegaly & constitutional symptoms; Normal complete blood count (CBC) exhibited by polymorphonuclear leukocytes>1500/µL, platelets>100,000/µL, hemoglobin>11.0 g/dL (untransfused); lymphocyte count <5,000/µL; Bone marrow aspirate & biopsy normocellular for age with <30% nucleated cells lymphocytes; Absence Lymphoid nodules. Fulfillment CR criteria after induction with exception of treatment related persistent cytopenia & bone marrow lymphoid nodules both considered partial response; Partial response: Requires 50% decrease in peripheral lymphocytes from pre-treatment, 50% reduction in lymphadenopathy, &/or 50% reduction in splenomegaly/hepatomegaly for 2+ months from therapy completion. Additionally one following from pre-treatment: Polymorphonuclear leukocytes 1,500/µL or 50% improvement; Platelets>100,000/µL or 50% improvement; Hemoglobin>11.0 g/dL (untransfused) or 50% improvement. (NCT00759603)
Timeframe: Responses assessed after 12 cycles, up to 48 weeks with interim assessments performed after 3, 6 and 12 cycles.
| Intervention | Percentage of Participants (Number) |
|---|---|
| Lenalidomide + Rituximab | 66 |
The cessation of bleeding was defined as repeated negative faecal occult blood test (FOBT) (monoclonal colloidal gold color technology) during our observation period. Rebleeding was defined based on a positive FOBT at any visit after treatment. (NCT00964496)
Timeframe: 52 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 13 |
| Iron-controlled Group | 0 |
The change from baseline in bleeding duration at 12 months (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | days (Mean) |
|---|---|
| Thalidomide Group | 5.2 |
| Iron-controlled Group | 0.8 |
The Change from baseline in bleeding episodes at 12 months (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | bleeding episodes (Mean) |
|---|---|
| Thalidomide Group | -9.36 |
| Iron-controlled Group | 1.41 |
The change from baseline in average hemoglobin (Hb) level(tested every month) at 12 months. (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | g/L (Mean) |
|---|---|
| Thalidomide Group | 3.06 |
| Iron-controlled Group | -0.01 |
Change of total transfused red cell requirements at 12 months after randomization from one year before baseline in transfusion dependent patients (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | milliliter (Mean) |
|---|---|
| Thalidomide Group | -1585.71 |
| Iron-controlled Group | -28.57 |
Numbers of participants dependent on blood transfusions (NCT00964496)
Timeframe: 52 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 3 |
| Iron-controlled Group | 13 |
The primary end point was defined as the patients whose rebleeds decreased from baseline by ≥ 50% at 12 months. Reduction of rebleeds = [(total bleeding episode at 12 months - total bleeding episodes at a year before randomization)/total bleeding episodes at a year before randomization(baseline)]*100%. Rebleeding was defined based on a positive fecal occult blood test (FOBT) (monoclonal colloidal gold color technology) at any visit after treatment. (NCT00964496)
Timeframe: baseline and 12 months
| Intervention | participants (Number) |
|---|---|
| Thalidomide Group | 20 |
| Iron-controlled Group | 1 |
Overall Survival at six years after initiating protocol therapy (NCT00083551)
Timeframe: 6 Years
| Intervention | percentage of participants (Number) |
|---|---|
| Thalidomide | 65 |
| No Thalidomide | 58 |
Analysis of the Primary Endpoint: The complete responses will be estimated by the number of patients with CR divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 4 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 45 |
Analysis of the other Secondary Endpoints: The overall response rate will be estimated by the number of patients with complete and partial responses divided by the total number of evaluable patients. (NCT01723839)
Timeframe: 28 day cycle, up to 6 cycles
| Intervention | Percentage of Participants (Number) |
|---|---|
| FCR With Lenalidomide | 95 |
Assessed by the investigator per International Myeloma Working Group criteria(IMWG) uniform response criteria. Result reflects number of participants whose best overall response qualified as sCR, CR, or VGPR in 2 year follow up period. (NCT02906332)
Timeframe: Every 3 weeks (day 1 of every 21-day treatment cycle +/- 7 days) through 12 weeks.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 11 |
Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received pembrolizumab (MK-3475), lenalidomide and dexamethasone, including serious adverse events (SAEs). Result reflects count of participants who experienced an SAE. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 1 |
Assessed at 12 months; Subjects without documented PD or death will be censored at the last disease assessment date. Those who died without documented PD will be censored at the time of death. Result reflects count of participants who had progressed at 12 months. (NCT02906332)
Timeframe: Time from Day 0 (transplant) and date of enrollment to study completion (through 12 weeks) by investigator assessment.
| Intervention | Participants (Count of Participants) |
|---|---|
| Pembrolizumab + Lenalidomide | 10 |
PFS will be assessed from the date of ASCT, with day 0 defined as date of stem cell infusion (if tandem transplant the 2nd of 2 transplants will be used) until the date of progression, defined as the date at which the patient starts the next line of therapy or the date of death. (NCT02906332)
Timeframe: Up to 3 years
| Intervention | months (Median) |
|---|---|
| Pembrolizumab + Lenalidomide | 27.6 |
Serum levels of hydroxycloroquine by LCMS (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| Inactive SLE With Standard Dose of HCQ | 991.6 |
| Inactive SLE With Reduced Dose of HCQ | 569.0 |
Serum levels of thalidomide by liquid chromatography and tandem mass spectrometry (HPLC-MS/MS) (NCT03122431)
Timeframe: 12 months
| Intervention | ng/mL (Mean) |
|---|---|
| SLE/Cutaneous Lupus With Thalidomide | 415.1 |
88 reviews available for thalidomide and Recrudescence
| Article | Year |
|---|---|
Nonresectable Thoracic Rosai-Dorfman Disease: A Case Report and Review of the Literature.
Topics: Adult; Histiocytosis, Sinus; Humans; Immunosuppressive Agents; Low Back Pain; Lower Extremity; Male; | 2019 |
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Ag | 2020 |
Lenalidomide in the treatment of chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B- | 2017 |
Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2017 |
Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: A systematic review and meta-analysis.
Topics: Humans; Immunosuppressive Agents; Lupus Erythematosus, Cutaneous; Peripheral Nervous System Diseases | 2018 |
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethas | 2018 |
Pomalidomide: A Review in Relapsed and Refractory Multiple Myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Dose-Re | 2017 |
Daratumumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal; Bortezomib; Dexamethasone; Disease-Free Survival; Drug Administration Schedu | 2017 |
Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Drug Administr | 2018 |
Management of multiple myeloma in the relapsed/refractory patient.
Topics: Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Humans; Immuno | 2017 |
Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review.
Topics: Administration, Oral; Administration, Topical; Angiogenesis Inhibitors; Epistaxis; Estriol; Estrogen | 2018 |
Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition.
Topics: Anti-Inflammatory Agents; Erythema Nodosum; Glucocorticoids; Humans; Inflammation; Leprostatic Agent | 2018 |
The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review.
Topics: Angiogenesis Inhibitors; Epistaxis; Humans; Recurrence; Telangiectasia, Hereditary Hemorrhagic; Thal | 2018 |
Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 2019 |
IMiDs New and Old.
Topics: Animals; Antineoplastic Agents; Biomarkers; Disease Susceptibility; Drug Resistance, Neoplasm; Hemat | 2019 |
Therapies for mantle cell lymphoma: current challenges and a brighter future.
Topics: Antibodies; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Cyclin D1; E | 2013 |
Therapeutic strategies for the treatment of multiple myeloma.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytokines; Gene Expression | 2013 |
Management of double-refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron | 2013 |
Second autologous transplant as salvage therapy in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 2013 |
Novel generation of agents with proven clinical activity in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Immunologic Factor | 2013 |
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA Methylation; | 2014 |
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases.
Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combi | 2014 |
New approaches to management of multiple myeloma.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Boron Compounds; Boronic Ac | 2014 |
Pomalidomide: a review of its use in patients with recurrent multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Pro | 2014 |
Preclinical and clinical results with pomalidomide in the treatment of relapsed/refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; H | 2014 |
Current challenges in the management of patients with relapsed/refractory multiple myeloma.
Topics: Boronic Acids; Bortezomib; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple M | 2011 |
Treatment-related adverse events in patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Kidney; Multiple Myeloma; Nervous System D | 2011 |
Current advances in non-proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Histone Deacetylase Inhibitors; Humans; Lenalidomide; Multiple Myeloma; Recu | 2011 |
[Thalidomide in combination with interferon and interleukin 2 in the induction therapy for relapsed refractory acute myeloid leukemia: two case report and literature review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Interferons; Interleukin-2; Leukemia, Myeloi | 2014 |
Novel drug combinations for the management of relapsed/refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Management; Disease | 2014 |
[Successful treatment with melphalan, dexamethasone and thalidomide for relapsed idiopathic light chain deposit disease: a case report and literature review].
Topics: Dexamethasone; Humans; Melphalan; Multiple Myeloma; Recurrence; Thalidomide | 2015 |
Management of relapsed multiple myeloma after autologous stem cell transplant.
Topics: Autografts; Dexamethasone; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple My | 2015 |
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
Topics: Aniline Compounds; Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunomodulation; Immuno | 2015 |
Thalidomide for treatment of gastrointestinal bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review of the literature.
Topics: Aged; Angiodysplasia; Databases, Factual; Epistaxis; Female; Gastrointestinal Hemorrhage; Humans; Me | 2015 |
The risk of secondary primary malignancies after therapy for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr | 2015 |
[Successful treatment of relapsed and refractory multiple myeloma by using clarithromycin-lenalidomide, low-dose dexamethasone(BiRd), and melphalan-prednisolone(MP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethasone; Female; Humans; | 2015 |
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives.
Topics: Anti-Bacterial Agents; Azathioprine; Behcet Syndrome; Colchicine; Dapsone; Humans; Interferon-alpha; | 2015 |
Treatment options for mantle cell lymphoma.
Topics: Adenine; Antineoplastic Agents; Drug Resistance, Neoplasm; Hematopoietic Stem Cell Transplantation; | 2015 |
The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
Topics: Angiogenesis Inhibitors; Bevacizumab; Glioblastoma; Humans; Recurrence; Salvage Therapy; Thalidomide | 2016 |
Treatment of relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; H | 2016 |
Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Prot | 2016 |
Practical Considerations in Managing Relapsed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2017 |
Practical Considerations in Managing Relapsed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2017 |
Practical Considerations in Managing Relapsed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2017 |
Practical Considerations in Managing Relapsed Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Hematopoietic Stem Cell T | 2017 |
Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Human | 2017 |
Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, | 2017 |
Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bort | 2017 |
A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Constipation; De | 2008 |
[Treatment for multiple myeloma: current status and future strategy in Japan].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Boronic Acids; Bor | 2008 |
United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Humans; Imm | 2009 |
Recurrent obscure gastrointestinal bleeding: dilemmas and success with pharmacological therapies. Case series and review.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Angiography; Animals; Antifibrinol | 2009 |
New developments in the treatment of patients with multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Boronic A | 2010 |
Advances in treatment for relapses and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Multiple Myeloma; | 2010 |
Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Synergism; Histone Deacetylase Inhibitors; Hu | 2010 |
The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials, Phase II | 2010 |
Multiple myeloma.
Topics: Anemia; Bone Diseases; Boronic Acids; Bortezomib; Clinical Trials as Topic; Cysteine Proteinase Inhi | 2011 |
Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as | 2011 |
Treatment options for relapsed and refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2011 |
Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ce | 2011 |
New agents in follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; B-Lymphocytes; Be | 2011 |
Advantageous use of lenalidomide in multiple myeloma: discussion of three case studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Male; Mul | 2012 |
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy | 2012 |
The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clini | 2012 |
Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Disease Prog | 2012 |
Current therapeutic strategy for multiple myeloma.
Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone | 2013 |
Current therapy for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Therapy, Combination | 2002 |
Thalidomide for the treatment of relapsed and refractory multiple myeloma.
Topics: Cell Division; Clinical Trials as Topic; Dexamethasone; Drug Therapy, Combination; Humans; Multiple | 2002 |
Multiple myeloma: how far have we come?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Diagnosis, Differential; Humans; Multip | 2003 |
Thalidomide dosing in patients with relapsed or refractory multiple myeloma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Multiple | 2003 |
[Thalidomide treatment in multiple myeloma].
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Clinical Trials, Phase | 2003 |
[Thalidomide: mechanisms of action and new insights in hematology].
Topics: Amyloidosis; Angiogenesis Inhibitors; Clinical Trials as Topic; Cytokines; Follow-Up Studies; Foreca | 2005 |
Thalidomide: present and future in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; H | 2005 |
Complex aphthosis: a large case series with evaluation algorithm and therapeutic ladder from topicals to thalidomide.
Topics: Adult; Algorithms; Behcet Syndrome; Diagnosis, Differential; Female; Humans; Male; Recurrence; Stoma | 2005 |
Current treatment options for myeloma.
Topics: Age Factors; Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone | 2005 |
Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, | 2005 |
Novel treatment approaches for patients with multiple myeloma.
Topics: Angiogenesis Inhibitors; Boronic Acids; Bortezomib; Cell Proliferation; Clinical Trials, Phase I as | 2006 |
The role of thalidomide in multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dex | 2006 |
An analysis of clinical trials assessing the efficacy and safety of single-agent thalidomide in patients with relapsed or refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Biomarkers, Tumor; Clinical Trials as Topic; Disease-Free Survival; Drug Re | 2007 |
The emerging role of novel therapies for the treatment of relapsed myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Drug Ther | 2007 |
Pegylated liposomal doxorubicin and immunomodulatory drug combinations in multiple myeloma: rationale and clinical experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Drug-Related | 2007 |
Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
Topics: Animals; Blood Proteins; Boronic Acids; Bortezomib; Cell Transplantation; Humans; Immunoglobulins; M | 2007 |
Lenalidomide in myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Multipl | 2007 |
The treatment of relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Humans; Lenalidomide; Multiple Myeloma; Pyrazines; | 2007 |
An update on drug combinations for treatment of myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; | 2008 |
[Adamantiades-Behçet's disease. Clinical review].
Topics: Adult; Age Factors; Behcet Syndrome; Child; Colchicine; Female; Humans; Immunosuppressive Agents; In | 2008 |
Sutton's disease (periadenitis mucosa necrotica recurrens).
Topics: Adult; Colchicine; Diagnosis, Differential; Humans; Male; Recurrence; Stomatitis, Aphthous; Thalidom | 1995 |
Topical and systemic therapy for recurrent aphthous stomatitis.
Topics: Adjuvants, Immunologic; Administration, Topical; Adrenal Cortex Hormones; Analgesics; Anti-Inflammat | 1997 |
[Treatment of recurrent aphthous stomatitis. A bibliographic review].
Topics: Adrenal Cortex Hormones; Adult; Calcium Phosphates; Dinoprostone; Female; Glycopeptides; Humans; Imm | 1998 |
Thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; D | 2000 |
The evolution of specific genetic and environmental counseling in congenital heart diseases.
Topics: Chromosomes; Counseling; Ductus Arteriosus, Patent; Environmental Health; Heart Defects, Congenital; | 1978 |
171 trials available for thalidomide and Recrudescence
| Article | Year |
|---|---|
3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dex | 2021 |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; | 2022 |
A Randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis.
Topics: Double-Blind Method; Humans; Pain; Recurrence; Stomatitis, Aphthous; Thalidomide | 2022 |
Thalidomide for Recurrent Bleeding Due to Small-Intestinal Angiodysplasia.
Topics: Administration, Oral; Angiodysplasia; China; Double-Blind Method; Gastrointestinal Hemorrhage; Hemat | 2023 |
A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2019 |
The efficacy and safety of thalidomide on the recurrence interval of continuous recurrent aphthous ulceration: A randomized controlled clinical trial.
Topics: Double-Blind Method; Humans; Quality of Life; Recurrence; Stomatitis, Aphthous; Thalidomide | 2020 |
Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2020 |
OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Dexamethasone; | 2020 |
Phase I/II study of high dose pomalidomide with G-CSF support and dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free | 2020 |
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dexa | 2021 |
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dexa | 2021 |
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dexa | 2021 |
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Intravenous; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Dexa | 2021 |
Circularly permuted TRAIL plus thalidomide and dexamethasone versus thalidomide and dexamethasone for relapsed/refractory multiple myeloma: a phase 2 study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemoth | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protoco | 2017 |
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethaso | 2017 |
Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Disease-Free Su | 2017 |
Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxor | 2018 |
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Follow-Up Studies | 2018 |
Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; | 2018 |
Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Dexameth | 2018 |
Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Immunoglobulin Light-chain Am | 2018 |
Extended follow-up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi-centre phase I/II Clinical Trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Fe | 2019 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2018 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2018 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2018 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 2018 |
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2019 |
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2013 |
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine | 2013 |
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine | 2013 |
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine | 2013 |
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antine | 2013 |
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2013 |
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dise | 2013 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2013 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2013 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2013 |
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 2013 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Borte | 2013 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Borte | 2013 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Borte | 2013 |
Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Borte | 2013 |
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Drug-Related Si | 2013 |
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Drug-Related Si | 2013 |
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Drug-Related Si | 2013 |
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Drug-Related Si | 2013 |
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2014 |
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy | 2014 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Drug Therapy, Combination; Gene Expression; Humans; Im | 2014 |
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Gene Expression Pro | 2014 |
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease- | 2015 |
Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2015 |
A dose escalation feasibility study of lenalidomide for treatment of symptomatic, relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Feasibility St | 2014 |
Phase II study of pomalidomide in high-risk relapsed and refractory multiple myeloma.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Recurrence; Thalidomide; Treatment Outcome | 2014 |
Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studies; Huma | 2014 |
Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bias; Cross-Over Studies; Dexamethasone; Dose- | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Reduced occurrence of tumor flare with flavopiridol followed by combined flavopiridol and lenalidomide in patients with relapsed chronic lymphocytic leukemia (CLL).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cohort S | 2015 |
A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma.
Topics: Administration, Metronomic; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2015 |
Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Foll | 2015 |
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberratio | 2015 |
Lenalidomide is safe and active in Waldenström macroglobulinemia.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Drug Administration Sc | 2015 |
Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Agents; Asia; Boron Compounds; Dexamethasone; Female; Glycine; Humans; L | 2015 |
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Male; Ma | 2015 |
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; | 2016 |
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cohort Studies; Dexamethasone; Dru | 2016 |
Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Im | 2016 |
Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; | 2016 |
Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.
Topics: Adult; Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-C | 2016 |
Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Follow-Up Studies | 2016 |
Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2016 |
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantatio
Topics: Adult; Aged; Dexamethasone; Disease-Free Survival; Female; Humans; Lenalidomide; Male; Middle Aged; | 2016 |
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resista | 2016 |
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resista | 2016 |
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resista | 2016 |
Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resista | 2016 |
Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Creatinine; Dexamethasone; D | 2016 |
Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2016 |
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free | 2016 |
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2017 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Demography; Dexamethas | 2016 |
Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Adminis | 2016 |
Multicenter Phase II Study of Lenalidomide in Relapsed or Recurrent Adult T-Cell Leukemia/Lymphoma: ATLL-002.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Endpoin | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease | 2016 |
Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Dexamethasone; Drug Therapy, Combination; Female; Humans; L | 2017 |
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cyclophosphamide; Drug | 2017 |
Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Boron Compounds; Dexamethasone; | 2017 |
Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc | 2017 |
Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamet | 2017 |
Development and validation of a highly sensitive liquid chromatography/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma.
Topics: Chromatography, Liquid; Flavonoids; Humans; Lenalidomide; Multiple Myeloma; Piperidines; Recurrence; | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Combined Modality | 2008 |
Clarithromycin with low dose dexamethasone and thalidomide is effective therapy in relapsed/refractory myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clarithromycin; Dexamethaso | 2008 |
The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; | 2008 |
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Topics: Adult; Aged; Aged, 80 and over; Chi-Square Distribution; Dexamethasone; Disease-Free Survival; Drug | 2009 |
Predicting durable remissions following thalidomide therapy for relapsed myeloma.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Follow-Up Studies; Humans; Male; Middle | 2009 |
Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Drug Ad | 2009 |
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; M | 2009 |
Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial.
Topics: Adolescent; Adult; Aged; Child; Colchicine; Dapsone; Drug Administration Schedule; Female; Follow-Up | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations | 2009 |
Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Dosage Calculations | 2009 |
Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Erythem | 2009 |
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boro | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2009 |
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Constipation; Diarrhea; | 2009 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma.
Topics: Adult; Antineoplastic Agents; Female; Hodgkin Disease; Humans; Lenalidomide; Male; Middle Aged; Neop | 2010 |
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, H | 2010 |
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2010 |
Safety and efficacy of a combination therapy with Revlimid, Adriamycin and dexamethasone (RAD) in relapsed/refractory multiple myeloma (MM): a single-centre experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorubicin; Drug Resistance, N | 2011 |
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2010 |
Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; | 2010 |
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplas | 2010 |
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease Progressi | 2010 |
Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Sch | 2011 |
Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Area Under Curve; Central Nervous System Ne | 2011 |
Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Humans | 2011 |
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Compassionate Use Trials; Cross-Sectional Stu | 2011 |
Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; DNA Repair; Drug Resistance, Neoplasm; Fema | 2011 |
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2011 |
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Dr | 2011 |
Phase II randomized trial of bevacizumab versus bevacizumab and thalidomide for relapsed/refractory multiple myeloma: a California Cancer Consortium trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplast | 2011 |
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Kaplan-Mei | 2011 |
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2011 |
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic | 2012 |
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineopla | 2012 |
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.
Topics: Adult; Antineoplastic Agents; Cell Line, Tumor; Chemokine CCL17; Chemokine CCL22; Disease-Free Survi | 2011 |
Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; | 2012 |
Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma.
Topics: Antineoplastic Agents; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration | 2012 |
Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Chromosome Deletion; Chrom | 2012 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Admi | 2012 |
Efficacy, safety and quality-of-life associated with lenalidomide plus dexamethasone for the treatment of relapsed or refractory multiple myeloma: the Spanish experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2012 |
Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose | 2012 |
Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydroch | 2012 |
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother | 2012 |
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.
Topics: Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pai | 2012 |
Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 Randomi
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethason | 2012 |
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationsh | 2012 |
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2012 |
Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.
Topics: Aged; Biomarkers, Pharmacological; Disease-Free Survival; Female; Gene Expression Regulation, Neopla | 2012 |
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Topics: Adolescent; Adult; Aged; Angiogenesis Inhibitors; Disease-Free Survival; Female; Humans; Lenalidomid | 2013 |
Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences.
Topics: Adiponectin; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; | 2012 |
Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept.
Topics: Adolescent; Adult; C-Reactive Protein; Etanercept; Follow-Up Studies; Humans; Immunoglobulin G; Midd | 2013 |
Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus.
Topics: Administration, Oral; Adult; Diarrhea; Drug Resistance; Female; Humans; Immunologic Factors; Lenalid | 2012 |
Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chem | 2013 |
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2013 |
Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; beta 2-Microglobulin; Body Height; Body Weight; C-Reactive | 2002 |
Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Ischem | 2003 |
[Preliminary results of monotherapy with thalidomide in recurrent and treatment resistant cases of multiple myeloma].
Topics: Adult; Aged; Drug Resistance; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Stem | 2003 |
[Pentoxifylline in the treatment of erythema nodosum leprosum: results of an open study].
Topics: Adolescent; Adult; Erythema Nodosum; Female; Follow-Up Studies; Glucocorticoids; Humans; Immunosuppr | 2003 |
Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease | 2004 |
Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
Topics: Disease Progression; Disease-Free Survival; Female; Humans; Intercellular Adhesion Molecule-1; Inter | 2004 |
Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma.
Topics: Administration, Oral; Aged; Cytokines; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mu | 2004 |
Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy.
Topics: Administration, Oral; Adult; Aged; Drug Administration Schedule; Female; HIV Infections; Humans; Imm | 2004 |
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL).
Topics: Adult; Aged; Amyloidosis; Anti-Inflammatory Agents; Dexamethasone; Drug Therapy, Combination; Female | 2005 |
Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Dose- | 2005 |
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Dexamethasone; Femal | 2005 |
Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2005 |
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; An | 2005 |
Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Bortezomib; Female; Huma | 2006 |
Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma.
Topics: Aged; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protoc | 2005 |
Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Dose | 2006 |
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pr | 2006 |
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free | 2006 |
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free | 2006 |
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free | 2006 |
Thalidomide and hematopoietic-cell transplantation for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free | 2006 |
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Combined Modality Therapy | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalido | 2006 |
Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Diseases; Diphosphonates; Disease-Free Su | 2006 |
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Lenalidomide; Mal | 2006 |
Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Drug Toleran | 2007 |
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclo | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2007 |
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Female; Humans; | 2008 |
Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Evaluati | 2008 |
Thalidomide in severe orogenital ulceration.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Genital Diseases, Fe | 1984 |
[Treatment of Jessner-Kanof disease with thalidomide].
Topics: Adult; Clinical Trials as Topic; Diagnosis, Differential; Female; Humans; Lupus Erythematosus, Disco | 1983 |
Thalidomide treatment of recurrent necrotic giant mucocutaneous aphthae and aphthosis.
Topics: Behcet Syndrome; Humans; Recurrence; Skin Ulcer; Thalidomide | 1982 |
Thalidomide as treatment of refractory aphthous ulceration related to human immunodeficiency virus infection.
Topics: Adult; HIV Infections; HIV-1; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Stomatit | 1995 |
Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Behcet Syndrome; Double-Blind Method; Drug Administration Schedule; Follow-Up Stu | 1998 |
Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis.
Topics: Administration, Oral; Adult; Age Factors; Chronic Disease; Combined Modality Therapy; Female; Follow | 1997 |
[Treatment of recurrent ulceration with low doses of thalidomide. Pilot study in 17 patients].
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Dose-Response Relationship, Drug; Female; Genital Disea | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Antitumor activity of thalidomide in refractory multiple myeloma.
Topics: Angiogenesis Inhibitors; Bence Jones Protein; Bone Marrow; Bone Marrow Examination; Disease Progress | 1999 |
Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus.
Topics: Adult; Appetite; Constipation; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; | 2000 |
Thalidomide in low intermittent doses does not prevent recurrence of human immunodeficiency virus-associated aphthous ulcers.
Topics: Anti-HIV Agents; Double-Blind Method; HIV Infections; Humans; Immunosuppressive Agents; Recurrence; | 2001 |
Thalidomide treatment of resistant or relapsed multiple myeloma patients.
Topics: Adult; Aged; Angiogenesis Inhibitors; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; | 2001 |
Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.
Topics: Adult; Angiogenesis Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Middl | 2001 |
Thalidomide: an alternative therapy for treatment of apthous ulcers (canker sores).
Topics: CD4 Lymphocyte Count; Double-Blind Method; HIV Infections; Humans; Placebos; Randomized Controlled T | 1995 |
Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: a randomized, double-blind, placebo-controlled trial.
Topics: Acute-Phase Reaction; Adult; Cross-Over Studies; Cytokines; DNA Mutational Analysis; Double-Blind Me | 2001 |
Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Randomized Controlle | 1990 |
284 other studies available for thalidomide and Recrudescence
| Article | Year |
|---|---|
Pomalidomide combinations are a safe and effective option after daratumumab failure.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Dru | 2023 |
Maintenance therapy with a combination of azacitidine, danazol, and thalidomide after intensive chemotherapy in patients with acute myeloid leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Azacitidine; Danazol; Female; Hematopoietic Stem Cell | 2023 |
Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy.
Topics: Angiogenesis Inhibitors; Female; Hematopoietic Stem Cell Transplantation; Humans; Magnetic Resonance | 2019 |
Long-term outcomes of thalidomide in pediatric Crohn's disease.
Topics: Age Factors; Child; Child, Preschool; Cohort Studies; Crohn Disease; Female; Humans; Infant; Male; M | 2020 |
[Pomalidomide/cyclophosphamide/dexamethasone combination therapy for relapsed/refractory multiple myeloma accompanied by extramedullary lesions].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Hematopoietic Stem | 2020 |
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients.
Topics: Aged; Anti-Inflammatory Agents; Dexamethasone; Drug Resistance; Europe; Female; Follow-Up Studies; H | 2020 |
[Thalidomide in refractory Crohn's disease: long-term efficacy and safety].
Topics: Crohn Disease; Drug-Related Side Effects and Adverse Reactions; Humans; Immunosuppressive Agents; Re | 2020 |
Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; An | 2020 |
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2021 |
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplasti | 2021 |
Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds | 2021 |
Apremilast for treatment of recurrent erythema multiforme.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Erythema Multiforme; Female; Humans; Male; Mo | 2017 |
Resolution of psoriasis after tonsillectomy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Facial Dermatoses; Female; Glucocorticoids; Humans; Pharyng | 2017 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; | 2017 |
Anti-CD138 chimeric antigen receptor-modified T cell therapy for multiple myeloma with extensive extramedullary involvement.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 2017 |
Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Combined Modality Therapy; Cy | 2017 |
Lenalidomide as a treatment for relapsed AL amyloidosis in an HIV-positive patient.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; HI | 2017 |
Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Circulating MicroRNA; Dexamethasone; Drug Resistance | 2017 |
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexam | 2017 |
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexam | 2017 |
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexam | 2017 |
Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexam | 2017 |
'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Drug Resistance, Neoplasm; Humans; Immuno | 2018 |
Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004).
Topics: Adenine; Aged; Aged, 80 and over; Disease Progression; Female; Humans; Lenalidomide; Lymphoma, Mantl | 2017 |
Presentation and outcome with second-line treatment in AL amyloidosis previously sensitive to nontransplant therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Chemotherapy, Adjuvant; Dexametha | 2018 |
A Dramatic Case of Odynophagia.
Topics: Aged; Humans; Immunosuppressive Agents; Male; Pain; Recurrence; Stomatitis, Aphthous; Thalidomide | 2018 |
Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disea | 2018 |
Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combinati | 2018 |
Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme.
Topics: Adult; Chronic Disease; Drug Substitution; Erythema Multiforme; Female; Humans; Immunologic Factors; | 2018 |
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C | 2018 |
The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Retroperitoneal relapse in an older patient with multiple myeloma during pomalidomide and dexamethasone treatment.
Topics: Aged; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Immunologic Factors; Multiple | 2018 |
Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Humans; Lenalidomide; | 2018 |
Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
Topics: Aged; Aged, 80 and over; Anemia; Azacitidine; Databases, Factual; Decitabine; Electronic Health Reco | 2018 |
[The 465th case: intestinal obstruction, gastrointestinal hemorrhage and duodenal fistula].
Topics: Anastomosis, Surgical; Colon; Crohn Disease; Cutaneous Fistula; Digestive System Surgical Procedures | 2018 |
Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; | 2018 |
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Computation | 2019 |
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Computation | 2019 |
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Computation | 2019 |
Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Computation | 2019 |
Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/\
refractory multiple myeloma: a real-life experience
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Widespread Dermatophytosis in a Patient Treated for Leprosy Type II Reactional State after MDT/WHO-MB Release.
Topics: Antifungal Agents; Brazil; Dapsone; Erythema Nodosum; Humans; Leprostatic Agents; Leprosy, Lepromato | 2018 |
Combination therapy for first relapse of multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide | 2018 |
Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexam | 2019 |
Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexametha | 2019 |
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Topics: Antineoplastic Agents; DNA Copy Number Variations; Drug Resistance, Neoplasm; Enhancer Elements, Gen | 2019 |
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Dose-Response Relationship, Drug; F | 2020 |
Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamet | 2013 |
Successful salvage therapy using lenalidomide in a patient with relapsed multiple myeloma after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; M | 2013 |
Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2013 |
Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease-Free | 2013 |
Designs for randomized phase II clinical trials with two treatment arms.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bias; Clinical Trials, Phase II as To | 2013 |
Successful treatment of thalidomide for recurrent bleeding due to gastric angiodysplasia in hereditary hemorrhagic telangiectasia.
Topics: Aged; Angiodysplasia; Gastrointestinal Hemorrhage; Humans; Male; Recurrence; Stomach Diseases; Telan | 2013 |
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Humans; Multiple Myeloma; Oligopeptides; Proteasome I | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluatio | 2013 |
"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dex | 2014 |
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bone Rem | 2014 |
Lower-dose thalidomide therapy effectively treats cutaneous lupus erythematosus but is limited by neuropathic toxicity.
Topics: Adult; Aged; Female; Humans; Immunosuppressive Agents; Lupus Erythematosus, Discoid; Male; Middle Ag | 2013 |
Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant.
Topics: Aged; Bone Marrow; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Immuno | 2014 |
Single-agent lenalidomide is effective in the treatment of a heavily pretreated and refractory angioimmunoblastic T-cell lymphoma patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cycl | 2014 |
Thalidomide: Still an important second-line treatment in refractory cutaneous lupus erythematosus?
Topics: Adult; Aged; Female; Humans; Lupus Erythematosus, Cutaneous; Male; Middle Aged; Recurrence; Retrospe | 2015 |
Successful management of refractory pediatric-onset complex aphthosis with lenalidomide.
Topics: Adolescent; Diagnosis, Differential; Humans; Immunologic Factors; Lenalidomide; Male; Recurrence; St | 2014 |
Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens.
Topics: Aged; Amyloidosis; Boronic Acids; Bortezomib; Cohort Studies; Dexamethasone; Drug Therapy, Combinati | 2014 |
A rare case of acute lymphoblastic leukemia in a patient with light chain (AL) amyloidosis treated with lenalidomide.
Topics: Aged; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Birefringence | 2014 |
Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2014 |
Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Topics: Aneuploidy; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; | 2014 |
Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Follow-Up Studie | 2015 |
Thalidomide for recalcitrant nodular scleritis in sarcoidosis.
Topics: Female; Humans; Immunosuppressive Agents; Middle Aged; Recurrence; Sarcoidosis; Scleritis; Thalidomi | 2014 |
Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biopsy; Boroni | 2014 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustin | 2016 |
Evidence that thalidomide is effective in recurrent bleeding from watermelon stomach associated with liver cirrhosis.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Gastric Antral Vascular Ectasia; Gastrointestina | 2014 |
Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic | 2014 |
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2014 |
Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; | 2015 |
Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients.
Topics: Aged; Angiogenesis Inhibitors; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combinatio | 2015 |
Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Femal | 2015 |
Efficacy and safety of low-dose lenalidomide plus dexamethasone in patients with relapsed or refractory POEMS syndrome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethason | 2015 |
[Thalidomide combined with interferon in 12 cases of relapsed or refractory mantle cell lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Interferons; Lymphoma, Mantle-Cell; Recurren | 2014 |
Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2015 |
[Treatment of multiple myeloma with lenalidomide and bortezomib combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Mul | 2015 |
Weber-Christian disease with ileocolonic involvement successfully treated with infliximab.
Topics: Adult; Anti-Infective Agents; Biopsy; Colonic Diseases; Female; Humans; Ileal Diseases; Infliximab; | 2015 |
Pomalidomide. A last-line treatment option for multiple myeloma.
Topics: Antineoplastic Agents; Humans; Multiple Myeloma; Recurrence; Thalidomide | 2014 |
Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Banding; | 2015 |
Outcomes of primary refractory multiple myeloma and the impact of novel therapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezom | 2015 |
[Graft-versus-host disease associated with lenalidomide maintenance after allogeneic transplantation for relapsed/refractory multiple myeloma].
Topics: Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalid | 2015 |
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.
Topics: Aged; Antineoplastic Agents; Bortezomib; Cost-Benefit Analysis; Female; Humans; Lenalidomide; Male; | 2015 |
Retrospective Multicentric Study of 25 Kimura Disease Patients: Emphasis on Therapeutics and Shared Features with Cutaneous IgG4-Related Disease.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Angiolymphoid Hyperplasia with | 2015 |
New patterns of relapse in multiple myeloma: a case of "light chain escape" in which FLC predicted relapse earlier than urine and serum immunofixation.
Topics: Bence Jones Protein; Bendamustine Hydrochloride; Blood Protein Electrophoresis; Bortezomib; Dexameth | 2016 |
Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Bortezomib; Female; Hematopoietic Ste | 2016 |
Safety and tolerability of pomalidomide-based regimens (pomalidomide-carfilzomib-dexamethasone with or without cyclophosphamide) in relapsed/refractory multiple myeloma and severe renal dysfunction: a case series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female | 2017 |
Nonamyloidotic Light Chain Cardiomyopathy: The Arrhythmogenic Magnetic Resonance Pattern.
Topics: Bortezomib; Cardiomyopathies; Combined Modality Therapy; Defibrillators, Implantable; Dexamethasone; | 2016 |
[Efficacy analysis of CAG priming regimen combined with talidomide, interferon and interleukin 2 as the induction therapy for relapsed refractory acute myeloid leukemia].
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulat | 2016 |
Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit An | 2016 |
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Dexamethasone; Disease-Free S | 2016 |
Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations.
Topics: Adenine; CARD Signaling Adaptor Proteins; Drug Resistance, Neoplasm; Genetic Heterogeneity; Guanylat | 2016 |
Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol | 2016 |
Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide.
Topics: Aged; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Recurrence; Remission Induct | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2016 |
Durable remission in a patient with leptomeningeal relapse of a MYC/BCL6-positive double-hit DLBCL treated with lenalidomide monotherapy.
Topics: Aged; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Recurrence; Survival Rate; Thalid | 2017 |
The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Combined Modality Therapy; Drug Resistance, Neoplasm | 2017 |
Lenalidomide long-term neurotoxicity: Clinical and neurophysiologic prospective study.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Drug Resi | 2016 |
Panobinostat Plus Bortezomib Versus Lenalidomide in Patients with Relapsed and/or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Treatment Comparison of Survival Outcomes using Patient-level Data.
Topics: Antineoplastic Agents; Bortezomib; Drug Therapy, Combination; Female; Humans; Hydroxamic Acids; Indo | 2017 |
Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Child, Preschool; Dexamethasone; Drug Resistance; | 2017 |
Thalidomide induces mucosal healing in postoperative Crohn disease endoscopic recurrence: Case report and literature review.
Topics: Capsule Endoscopy; Colonoscopy; Crohn Disease; Female; Humans; Immunosuppressive Agents; Intestinal | 2016 |
Vorinostat in Combination With Lenalidomide and Dexamethasone in Lenalidomide-Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Humans; Hy | 2016 |
[Thalidomide combined with interferon and interleukin-2 in treatment of relapsed or refractory acute myelogenous leukemia].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interf | 2016 |
Thalidomide for steroid-dependent chronic disseminated candidiasis after stem cell transplantation: A case report.
Topics: Antifungal Agents; Bone Marrow Transplantation; Candida albicans; Candidiasis; Chronic Disease; Fluc | 2017 |
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Bortezomib; Disease Progression; Gene Expression; Humans; | 2017 |
Lung Toxicity after Lenalidomide Treatment in a Patient with Multiple Myeloma.
Topics: Dexamethasone; Glucocorticoids; Humans; Immunologic Factors; Lenalidomide; Lung Diseases, Interstiti | 2017 |
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexameth | 2017 |
FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, | 2017 |
Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Comorbid | 2017 |
Transient efficacy of double high-dose chemotherapy and autologous peripheral stem cell transplantation, immunoglobulin, thalidomide, and bortezomib in the treatment of scleromyxedema.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Therapy, Combination; Humans; Immunogl | 2008 |
[Invalidating and recurrent gastrointestinal bleeding caused by intestinal angiodysplasia: treatment with thalidomide].
Topics: Aged; Angiodysplasia; Gastrointestinal Hemorrhage; Humans; Male; Recurrence; Severity of Illness Ind | 2008 |
Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; F | 2009 |
Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethas | 2008 |
Thalidomide for the treatment of severe intestinal bleeding.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Gastrointestinal Hemorrhage | 2008 |
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III a | 2008 |
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III a | 2008 |
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III a | 2008 |
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III a | 2008 |
The current landscape of multiple myeloma treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2008 |
Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Recurrence; Remiss | 2009 |
Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
Topics: Aged; Aged, 80 and over; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myelo | 2009 |
Relapse of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome without increased level of vascular endothelial growth factor following successful autologous peripheral blood stem cell transplantation.
Topics: Antibiotics, Antineoplastic; Biomarkers; Blood Transfusion, Autologous; Dexamethasone; Diuretics; Do | 2009 |
Long-term outcome in relapsed and refractory multiple myeloma treated with thalidomide. Balancing efficacy and side-effects.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Ret | 2009 |
Hematology: Lenalidomide plus dexamethasone is effective in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III a | 2009 |
Unusual myeloma relapse after thalidomide therapy: the dark side of the moon?
Topics: Humans; Immunophenotyping; Multiple Myeloma; Recurrence; Thalidomide | 2009 |
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug | 2009 |
Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
Topics: Hematopoietic Stem Cell Transplantation; HLA-DR Antigens; Humans; Killer Cells, Natural; Lenalidomid | 2010 |
Lenalidomide for the treatment of relapsed multiple myeloma.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Health Care Rationing; Humans; Lenalidomide; Multiple | 2009 |
CR with lenalidomide in del(5)(q13q33) AML relapsing after allogeneic hematopoietic SCT.
Topics: Aged; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Graft vs Host | 2010 |
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Tri | 2009 |
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Tri | 2009 |
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Tri | 2009 |
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Tri | 2009 |
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2009 |
Relapse of POEMS syndrome without increased level of VEGF.
Topics: Humans; Immunosuppressive Agents; Neural Conduction; Platelet Count; POEMS Syndrome; Recurrence; Tha | 2009 |
Relapse/Refractory myeloma patient: potential treatment guidelines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Lenalidomide; Mul | 2009 |
DKK1 correlates with response and predicts rapid relapse after autologous stem cell transplantation in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combin | 2010 |
[Thalidomide therapy for gastrointestinal angiodysplasia].
Topics: Angiodysplasia; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Middle Aged; R | 2009 |
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
Topics: Adult; Aged; Boronic Acids; Bortezomib; Disease Progression; Hematopoietic Stem Cell Transplantation | 2009 |
Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Huma | 2010 |
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Clinical Trials as Topic; Compassionate U | 2010 |
[Retrospective analysis of thalidomide therapy in patients with relapsed/refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Dexamethasone; Disease-Free Survival; Drug Therapy, Combination; Fem | 2010 |
[Recurrent aphthosis: safety of low dose thalidomide].
Topics: Adult; Aged; Aged, 80 and over; Behcet Syndrome; Female; Humans; Immunosuppressive Agents; Male; Mid | 2010 |
Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis.
Topics: Adolescent; Adult; Aged; Cohort Studies; Drug Tolerance; Drug-Related Side Effects and Adverse React | 2010 |
Lenalidomide-induced hypersensitivity pneumonitis.
Topics: Adrenal Cortex Hormones; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Antineoplastic | 2010 |
Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberratio | 2010 |
ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Hematopoiet | 2011 |
Lenalidomide: an update on evidence from clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Dexamethasone; Disease Pro | 2010 |
Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezom | 2011 |
Transient inflammatory reaction during lenalidomide plus reduced-dose dexamethasone therapy in two patients with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Inflam | 2011 |
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combi | 2011 |
Stevens-Johnson/toxic epidermal necrolysis overlap syndrome following lenalidomide treatment for multiple myeloma relapse after allogeneic transplantation.
Topics: Antineoplastic Agents; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Recurrence; Stevens-John | 2012 |
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Germinal Cent | 2011 |
Chromosomal aberrations +1q21 and del(17p13) predict survival in patients with recurrent multiple myeloma treated with lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberratio | 2011 |
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
Topics: Adult; Aged; Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bor | 2012 |
Lenalidomide can induce long-term responses in patients with multiple myeloma relapsing after multiple chemotherapy lines, in particular after allogeneic transplant.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cytogenetics; Dexamethasone; Humans; Immunogl | 2011 |
Cost effectiveness of treatments for relapsed/refractory multiple myeloma: response to a methodology. RE: Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swed
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Kapl | 2011 |
Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma.
Topics: Antineoplastic Agents; Dexamethasone; Disease Progression; Dose-Response Relationship, Drug; Humans; | 2011 |
[High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma patients--single center experience].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Ma | 2011 |
Rapid response of plasmacytomas to lenalidomide plus low-dose dexamethasone therapy in a patient with relapsed multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Middle | 2011 |
Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease-Free Survival; Graft vs Host | 2012 |
The role of HIF-1, angiopoietin-2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide-associated actions: a pilot in vivo study.
Topics: Adaptor Proteins, Signal Transducing; Angiopoietin-2; Calcium-Binding Proteins; Gastrointestinal Hem | 2011 |
Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hematopoietic Stem Cell Transplantati | 2012 |
Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome.
Topics: Adult; Chronic Disease; Dermatologic Agents; Female; Humans; Long-Term Care; Lupus Erythematosus, Cu | 2012 |
[Pyoderma gangrenosum and Behçet's disease: a study of two pediatric cases].
Topics: Adolescent; Behcet Syndrome; Child; Dermatologic Agents; Drug Therapy, Combination; Fatal Outcome; F | 2011 |
[Thalidomide for recurrent gastrointestinal bleeding caused by angiodysplasia: report of one case].
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Gastrointestinal Hemorrhage; Humans; Intestines; Male | 2011 |
Prognostic risk factor evaluation in patients with relapsed or refractory multiple myeloma receiving lenalidomide treatment: analysis of renal function by eGFR and of additional comorbidities by comorbidity appraisal.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Dep | 2012 |
Thalidomide treatment in cirrhotic patients with severe anemia secondary to vascular malformations.
Topics: Aged; Anemia; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; | 2012 |
Cytokine profiles in relapsed multiple myeloma patients undergoing febrile reactions to lenalidomide.
Topics: Aged; Antineoplastic Agents; Cytokines; Female; Fever; Humans; Lenalidomide; Male; Middle Aged; Mult | 2011 |
Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Prog | 2012 |
p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
Topics: Adult; Aged; Antineoplastic Agents; Canada; Cell Nucleus; Chromosomes, Human, Pair 17; Dexamethasone | 2012 |
Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Fata | 2012 |
A comparison of bortezomib, cyclophosphamide, and dexamethasone (Vel-CD) chemotherapy without and with thalidomide (Vel-CTD) for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Borte | 2012 |
Successful treatment of patients with multiple myeloma and impaired renal function with lenalidomide: results of 4 German centers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Female; Humans; Lenalidomide; | 2012 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality The | 2012 |
Efficacy of lenalidomide plus dexamethasone for POEMS syndrome relapsed after autologous peripheral stem-cell transplantation.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined | 2012 |
Bortezomib induces heme oxygenase-1 expression in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; Heme Oxygena | 2012 |
Relapse of liver amyloidosis 6 years after autologous stem cell transplantation.
Topics: Adult; Amyloidosis; Female; Humans; Lenalidomide; Liver Diseases; Magnetic Resonance Imaging; Periph | 2012 |
Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Cyclophos | 2012 |
Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease Prog | 2012 |
Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiretroviral The | 2012 |
Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexa | 2013 |
Recurrent aortic aneurysm due to Behcet's disease: a case report from China.
Topics: Adult; Anticoagulants; Aortic Aneurysm; Aortography; Aspirin; Behcet Syndrome; China; Glucocorticoid | 2013 |
Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
Topics: Antineoplastic Agents; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Lenalidomide; Ma | 2013 |
Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; | 2013 |
Successful treatment with thalidomide for a patient with recurrent gastrointestinal bleeding due to angiodysplasia diagnosed by capsule endoscopy.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Capsule Endoscopy; Female; Gastrointestinal Hemorrhag | 2013 |
Lenalidomide as salvage treatment for multiple myeloma relapsing after allogeneic hematopoietic stem cell transplantation: a report from the French Society of Bone Marrow and Cellular Therapy.
Topics: Adult; Antineoplastic Agents; Female; France; Graft vs Host Disease; Hematopoietic Stem Cell Transpl | 2013 |
Successful treatment with thalidomide of a patient with congenital factor V deficiency and factor V inhibitor with recurrent gastrointestinal bleeding from small bowel arteriovenous malformations.
Topics: Aged; Angiogenesis Inhibitors; Arteriovenous Malformations; Blood Coagulation Factor Inhibitors; Blo | 2013 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hema | 2013 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hema | 2013 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hema | 2013 |
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hema | 2013 |
Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Agents; Complementarity Determining Regions; Gene Rearrangement, B-Lymphocyte, | 2013 |
Giant PPD reaction with positive QuantiFERON-TB Gold in a patient with lepromatous leprosy.
Topics: Adult; Erythema Nodosum; Humans; Interferon-gamma Release Tests; Latent Tuberculosis; Leprosy, Lepro | 2012 |
Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Chromosome Aberrat | 2013 |
Multiple myeloma, version 1.2013.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; B | 2013 |
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients.
Topics: Adult; Aged; Antineoplastic Agents; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combi | 2013 |
Is thalidomide effective for the treatment of gastrointestinal bleeding in hereditary hemorrhagic telangiectasia?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Electrocoagulation; Gastrointestinal Hemorrhag | 2002 |
Efficacy of a low dose of thalidomide in advanced multiple myeloma.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2002 |
Response to thalidomide in chemotherapy-resistant mantle cell lymphoma: a case report.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Drug Resistance, Neoplasm; Fatal Outcome; Huma | 2002 |
Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF.
Topics: Angiogenesis Inhibitors; Endothelial Growth Factors; Fibroblast Growth Factor 2; Humans; Intercellul | 2002 |
The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma.
Topics: Adult; Aged; Constipation; Dose-Response Relationship, Drug; Fatigue; Female; Humans; Immunosuppress | 2002 |
Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clavicle; Cyclophosphamide; Dexamethasone; Dru | 2002 |
Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, P | 2003 |
Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration | 2003 |
Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis.
Topics: Adolescent; Child; Crohn Disease; Female; Follow-Up Studies; Granuloma; Humans; Immunosuppressive Ag | 2003 |
Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Adult; Child; Child, Preschool; Chronic Disease; | 2003 |
Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma.
Topics: Aged; Dexamethasone; Drug Interactions; Female; Glucocorticoids; Humans; Leukocyte Count; Male; Midd | 2003 |
Thalidomide for recurrent aphthous ulcerations.
Topics: AIDS-Related Opportunistic Infections; Humans; Recurrence; Stomatitis, Aphthous; Thalidomide | 2003 |
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers; Fibroblast Growt | 2003 |
Refractory major aphthous stomatitis managed with systemic immunosuppressants: a case report.
Topics: Adult; Clinical Protocols; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Patient Educat | 2004 |
Treatment of recurrent perforating intestinal ulcers with thalidomide in Behçet's disease.
Topics: Adjuvants, Immunologic; Adult; Behcet Syndrome; Female; Humans; Intestinal Perforation; Recurrence; | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for treatment of severe intestinal bleeding.
Topics: Adult; Aged; Angiogenesis Inhibitors; Crohn Disease; Female; Gastrointestinal Hemorrhage; Humans; Ma | 2004 |
Thalidomide for patients with recurrent lymphoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Cytokines; Humans; Lymphoma; Middle Aged; Recurrence; Salvage | 2004 |
45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2004 |
[Thalidomide in the treatment of recurrent plasmocitomas in an HIV-infected patient].
Topics: HIV Infections; Humans; Male; Middle Aged; Plasmacytoma; Recurrence; Thalidomide | 2004 |
Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Angiogenic Proteins; Cytokines; Female; Human | 2004 |
Successful management of immune thrombocytopenic purpura with thalidomide in a patient with multiple myeloma.
Topics: Antineoplastic Agents; Combined Modality Therapy; Drug Resistance; Humans; Immunoglobulins, Intraven | 2004 |
Single-agent thalidomide for treatment of first relapse following high-dose chemotherapy in patients with multiple myeloma.
Topics: Antineoplastic Agents; Dose-Response Relationship, Drug; Humans; Multiple Myeloma; Recurrence; Thali | 2005 |
Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: identification of prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Angiogenesis Inhibitors; beta 2-Microglobulin; Clinical Tr | 2004 |
Deep vein thrombosis: a rare complication of thalidomide therapy in recurrent erythema nodosum leprosum.
Topics: Adult; Cyclophosphamide; Dexamethasone; Drug Therapy, Combination; Erythema Nodosum; Female; Glucoco | 2004 |
Hepatic plasmacytosis as a manifestation of relapse in multiple myeloma treated with thalidomide.
Topics: Antineoplastic Agents; Asthenia; Biopsy; Bone Marrow Cells; Boronic Acids; Bortezomib; Female; Human | 2005 |
Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Combined Modality Therapy; Female; Hematopoietic S | 2005 |
Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Disease-Fr | 2005 |
Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clone Cells; Disease Progression; Dose-Respons | 2005 |
Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Evaluation; Female; | 2005 |
The changing landscape of myeloma therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Hematopoietic Stem Cell T | 2006 |
Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Humans; Ma | 2005 |
[The effect of cyclophosphamide, thalidomide and dexamethasone combination therapy in relapsed/refractory multiple myeloma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Drug Administ | 2006 |
Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide.
Topics: Angiodysplasia; Angiogenesis Inhibitors; Angiography; Blood Transfusion; Capsule Endoscopy; Child; C | 2006 |
Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Humans; Multiple My | 2006 |
Very low doses of thalidomide as single agent in relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Dexamethasone; Female; Humans; Immunosuppressive | 2006 |
Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Enoxapari | 2006 |
Thyroid gland plasmacytoma with a dramatic and persistent complete response under thalidomide and dexamethasone-associated treatment.
Topics: Aged; Antineoplastic Agents, Hormonal; Dexamethasone; Female; Humans; Immunosuppressive Agents; Mult | 2006 |
Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Boronic Acids; Borte | 2006 |
Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pretreated patients with chronic lymphocytic leukemia.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose-Respons | 2007 |
Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide.
Topics: Aged; Aged, 80 and over; Angiodysplasia; Angiogenesis Inhibitors; Capsule Endoscopy; Disease Progres | 2006 |
The efficacy of low dose thalidomide in refractory/relapsed myeloma: a retrospective audit.
Topics: Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Multip | 2006 |
Thalidomide as treatment for digestive tract angiodysplasias.
Topics: Aged, 80 and over; Angiodysplasia; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Humans; L | 2006 |
Thalidomide for treatment of PFAPA syndrome.
Topics: Adult; Fever; Humans; Immunosuppressive Agents; Lymphadenitis; Male; Periodicity; Pharyngitis; Recur | 2007 |
Myelomatous pleural effusion.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Doxorub | 2006 |
Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Dexam | 2007 |
Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Clinical Trials as Topic; Multiple Myeloma; Pyrazi | 2007 |
48th annual meeting of the American Society of Hematology December 9-12, 2006, Orlando, FL.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortez | 2007 |
[Low-dose thalidomide in refractory and relapsing multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multipl | 2007 |
Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Hu | 2007 |
Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment.
Topics: Aged; Aged, 80 and over; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Myelo | 2007 |
A pilot study of thalidomide in recurrent GI bleeding due to angiodysplasias.
Topics: Aged; Angiodysplasia; Angiogenesis Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Male; Pi | 2008 |
Pyoderma gangrenosum--rebel without a cure?
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibo | 2008 |
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease.
Topics: Amyloidosis; Anti-Inflammatory Agents; Boronic Acids; Bortezomib; Dexamethasone; Disease-Free Surviv | 2008 |
Hepatitis B reactivation after thalidomide.
Topics: Amyloidosis; Female; Hepatitis B; Humans; Immunosuppressive Agents; Kidney Diseases; Middle Aged; Re | 2008 |
Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Immunologic Factors; Le | 2008 |
Extramedullary progression of multiple myeloma under thalidomide therapy despite concomitant response of medullary disease.
Topics: Disease Progression; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Thalidomide | 2008 |
Thalidomide treatment of recurrent erythema multiforme.
Topics: Adult; Erythema Multiforme; Humans; Male; Neurologic Examination; Recurrence; Thalidomide | 1982 |
Effect of thalidomide on orogenital ulceration.
Topics: Adult; Female; Genital Diseases, Female; Genital Diseases, Male; Humans; Male; Recurrence; Stomatiti | 1983 |
Chronic cutaneous lupus erythematosus. Thalidomide treatment of 11 patients.
Topics: Adult; Aged; Drug Administration Schedule; Female; Humans; Lupus Erythematosus, Discoid; Male; Middl | 1983 |
[Thalidomide in the treatment of aphthosis and Behçet's disease. 4 years' experience].
Topics: Adolescent; Adult; Aged; Behcet Syndrome; Drug Evaluation; Female; Humans; Male; Middle Aged; Necros | 1982 |
Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus.
Topics: Chronic Disease; Female; Follow-Up Studies; Humans; Lupus Erythematosus, Discoid; Male; Nervous Syst | 1983 |
Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus.
Topics: Chronic Disease; Female; Follow-Up Studies; Humans; Lupus Erythematosus, Discoid; Male; Nervous Syst | 1983 |
Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus.
Topics: Chronic Disease; Female; Follow-Up Studies; Humans; Lupus Erythematosus, Discoid; Male; Nervous Syst | 1983 |
Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus.
Topics: Chronic Disease; Female; Follow-Up Studies; Humans; Lupus Erythematosus, Discoid; Male; Nervous Syst | 1983 |
Treatment with thalidomide in steroid dependency and neuritis.
Topics: Adrenal Cortex Hormones; Erythema Nodosum; Humans; Leprosy; Male; Neuritis; Recurrence; Thalidomide | 1980 |
[Successful treatment of a case of cutaneous Langerhans cell granulomatosis with 2-chlorodeoxyadenosine and thalidomide].
Topics: Aged; Cladribine; Drug Therapy, Combination; Female; Histiocytosis, Langerhans-Cell; Humans; Immunos | 1995 |
Recurrent giant aphthous ulcers in a child: protracted treatment with thalidomide.
Topics: Child; Humans; Recurrence; Stomatitis, Aphthous; Thalidomide | 1993 |
Recurrence of a choroidal neovascular membrane in a patient with punctate inner choroidopathy treated with daily doses of thalidomide.
Topics: Adult; Choroid; Choroid Diseases; Female; Fluorescein Angiography; Fundus Oculi; Humans; Immunosuppr | 1996 |
[Treatment by thalidomide of chronic multiforme erythema: its recurrent and continuous variants. A retrospective study of 26 patients].
Topics: Adolescent; Adult; Aged; Chronic Disease; Erythema Multiforme; Female; Humans; Immunosuppressive Age | 1996 |
Steroid-resistant idiopathic esophageal ulcer in a child with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Candidiasis; Child, Preschool; Drug Resistance; Esophageal Disea | 1998 |
[Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide].
Topics: Adult; Dermatologic Agents; Female; Histiocytosis, Langerhans-Cell; Humans; Patient Compliance; Recu | 1998 |
[Therapy of recurrent exudative erythema multiforme. Effectiveness of thalidomide--report of a case].
Topics: Aged; Dermatologic Agents; Erythema Multiforme; Female; Humans; Recurrence; Thalidomide; Treatment O | 1999 |
Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 2000 |
Recalcitrant pyoderma gangrenosum treated with thalidomide.
Topics: Anti-Inflammatory Agents; Dermatologic Agents; Humans; Male; Methylprednisolone; Middle Aged; Pyoder | 2000 |
Thalidomide in the treatment of relapsed multiple myeloma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Connectin; Disease-Free Surv | 2000 |
Thalidomide for recurrent renal-cell cancer in a 40-year-old man.
Topics: Adenocarcinoma, Clear Cell; Adult; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Drug Therapy, Com | 2000 |
[Discoid lupus, recurrent aphthosis. New indications for thalidomide?].
Topics: Humans; Immunosuppressive Agents; Lupus Erythematosus, Discoid; Recurrence; Stomatitis, Aphthous; Th | 2001 |
Treatment of Behçet's disease--an update.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Behcet Syndrome; Chl | 2001 |
Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results.
Topics: Adolescent; Adult; Crohn Disease; Humans; Immunosuppressive Agents; Male; Recurrence; Remission Indu | 2001 |
Possible role of adjunctive thalidomide therapy in the resolution of a massive intracranial tuberculous abscess.
Topics: Antitubercular Agents; Combined Modality Therapy; Drug Therapy, Combination; Humans; Infant; Magneti | 2001 |
Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation.
Topics: Angiogenesis Inhibitors; Bone Marrow Transplantation; Humans; Multiple Myeloma; Recurrence; Thalidom | 2001 |
Use of thalidomide in HIV infection.
Topics: Adrenal Cortex Hormones; AIDS-Related Opportunistic Infections; HIV Infections; Humans; Recurrence; | 2001 |
Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Etoposide; Female; | 2001 |
Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
Topics: Adult; Antineoplastic Agents; Bone Marrow Transplantation; Female; Graft vs Host Disease; Humans; In | 2001 |
Diabetic foot disease in a patient with multiple myeloma receiving thalidomide.
Topics: Angiogenesis Inhibitors; Collateral Circulation; Combined Modality Therapy; Diabetes Mellitus, Type | 2002 |
Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma.
Topics: Angiogenesis Inhibitors; Female; Herpes Simplex; Herpes Zoster; Humans; Middle Aged; Multiple Myelom | 2002 |
Analysis of durability of response to thalidomide treatment for relapsed myeloma patients.
Topics: Aged; Aged, 80 and over; Dexamethasone; Drug Therapy, Combination; Female; Follow-Up Studies; Humans | 2002 |
Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis.
Topics: Adult; Behcet Syndrome; Humans; Male; Recurrence; Skin Ulcer; Stomatitis, Aphthous; Thalidomide | 1979 |
Workshop on "chemotherapy of leprosy" at the Central Leprosy Teaching and Research Institute, Chengalpattu (Tamil Nadu) on 21 January 1978.
Topics: Clofazimine; Dapsone; Humans; India; Leprosy; Recurrence; Rifampin; Thalidomide | 1979 |
Treatment of steroid dependant cases of recurrent lepra reaction with a combination of thalidomide and clofazimine.
Topics: Adult; Clofazimine; Dapsone; Drug Therapy, Combination; Humans; Leprosy; Male; Recurrence; Steroids; | 1979 |
The diagnosis and treatment of leprosy.
Topics: Biopsy; Clofazimine; Dapsone; Erythema Nodosum; Humans; Immunotherapy; Leprosy; Recurrence; Rifampin | 1976 |
An open trial with clofazimine in the management of recurrent lepra reaction using thalidomide as a control drug.
Topics: Adolescent; Adult; Clofazimine; Humans; Leprosy; Male; Middle Aged; Recurrence; Thalidomide | 1976 |
Recurrent aphthous ulcer in patient infected with human immunodeficiency virus: successful treatment with thalidomide.
Topics: Administration, Topical; HIV Infections; Homosexuality; Humans; Male; Middle Aged; Mouth Mucosa; Rec | 1990 |
Pyoderma gangrenosum associated with Behçet's disease: treatment with thalidomide.
Topics: Adult; Behcet Syndrome; Gangrene; Humans; Leg Ulcer; Male; Prednisolone; Pyoderma; Recurrence; Thali | 1990 |
Thalidomide: treatment of severe recurrent aphthous stomatitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Humans; Male; Recurrence; Stomatitis, Aphthous; T | 1990 |
Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody.
Topics: Adult; Female; HIV Seropositivity; Humans; Male; Recurrence; Stomatitis, Aphthous; Thalidomide | 1989 |
Recurrent aphthous stomatitis of the Behçet's type: successful treatment with thalidomide.
Topics: Behcet Syndrome; Humans; Male; Middle Aged; Recurrence; Stomatitis, Aphthous; Thalidomide | 1987 |
[Treatment of recurrent buccal aphthosis].
Topics: Colchicine; Humans; Levamisole; Recurrence; Stomatitis, Aphthous; Thalidomide | 1987 |
Thalidomide in the treatment of recurrent necrotic mucocutaneous aphthae.
Topics: Humans; Recurrence; Stomatitis, Aphthous; Thalidomide | 1985 |
Treatment of erythema nodosum leprosum with thalidomide.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Erythema Nodosum; Female; Humans; Leprosy; Male; Recu | 1973 |
[Quadriplegia, in lepromatous leprosy previously cleared-up, diffuse polyneuritis which appeared in spite of 6 years of follow-up consolidating treatment with Sultirene alone].
Topics: Adolescent; Adult; Child; Follow-Up Studies; Humans; Leprosy; Male; Polyneuropathies; Quadriplegia; | 1971 |